Age,Answer,Education,Gender,Qualification,Question,Tagging,Topic,WorkerId,branch,doggos_crowd,doggos_text,level,node_id
,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes , as compared with tamoxifen , in postmenopausal women with hormone-receptor -- positive breast cancer .

In two phase 3 trials , we randomly assigned premenopausal women with hormone-receptor -- positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years . Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin , oophorectomy , or ovarian irradiation . The primary analysis combined data from 4690 patients in the two trials .

After a median follow-up of 68 months , disease-free survival at 5 years was 91.1 % in the exemestane -- ovarian suppression group and 87.3 % in the tamoxifen -- ovarian suppression group ( hazard ratio for disease recurrence , second invasive cancer , or death , 0.72 ; 95 % confidence interval ( CI ) , 0.60 to 0.85 ; P ( 0.001 ) . The rate of freedom from breast cancer at 5 years was 92.8 % in the exemestane -- ovarian suppression group , as compared with 88.8 % in the tamoxifen -- ovarian suppression group ( hazard ratio for recurrence , 0.66 ; 95 % CI , 0.55 to 0.80 ; P ( 0.001 ) . With 194 deaths ( 4.1 % of the patients ) , overall survival did not differ significantly between the two groups ( hazard ratio for death in the exemestane -- ovarian suppression group , 1.14 ; 95 % CI , 0.86 to 1.51 ; P = 0.37 ) . Selected adverse events of grade 3 or 4 were reported for 30.6 % of the patients in the exemestane -- ovarian suppression group and 29.4 % of those in the tamoxifen -- ovarian suppression group , with profiles similar to those for postmenopausal women .

In premenopausal women with hormone-receptor -- positive early breast cancer , adjuvant treatment with exemestane plus ovarian suppression , as compared with tamoxifen plus ovarian suppression , significantly reduced recurrence . ( Funded by Pfizer and others ; TEXT and SOFT ClinicalTrials . gov numbers ,  NCT00066703  and  NCT00066690  , respectively . )

",,,,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, 'early breast cancer': {'Participants'}, '5 year': {'Intervention'}, '92.8 %': {'Outcomes'}, '88.8 %': {'Outcomes'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}, 'adverse event': {'Outcomes'}, '30.6 %': {'Outcomes'}, '29.4 %': {'Outcomes'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, 'early breast cancer': {'Condition'}, '5 year': {'Duration'}, '92.8 %': {'Effect-strength'}, '88.8 %': {'Effect-strength'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}, 'adverse event': {'Adverse-effects'}, '30.6 %': {'Adverse-effects'}, '29.4 %': {'Adverse-effects'}}}",breast,,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': [], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The participants were women.', 'Condition': 'The participants were premenopausal and had hormone-receptor positive early breast cancer.', 'Sample-size': 'There were 4690 patients.', 'Intervention-general': 'The study assessed the impact of exemestane with ovarian suppression.', 'Duration': 'Participants received the intervention for a period of 5 years.', 'Control': 'A comparison group was assigned tamoxifen plus ovarian suppression.', 'Outcomes-general': 'The study assessed the recurrence of breast cancer and the survival of patients.', 'Effect-strength': 'The rate of freedom from breast cancer at 5 years was 92.8% in the examestane group, and 88.8% in the tamoxifen group. The disease-free survival at 5 years was 91.1% in the examestane group and 87.3% in the tamoxifen group. Overall survival did not differ significantly between the two groups.', 'Adverse-effects': 'Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the examestane group and 29.4% of the tamoxifen group.', 'Conclusion-general': 'In pre-menopausal women with hormone-receptor early breast cancer, treatment with examestane plus ovarian suppression significantly reduced the recurrence of cancer when compared with treatment with tamoxifen with ovarian suppression.'}",0,NEJMoa1404037
,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality , screening must detect life-threatening disease at an earlier , more curable stage . Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage .

We used Surveillance , Epidemiology , and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer ( ductal carcinoma in situ and localized disease ) and late-stage breast cancer ( regional and distant disease ) among women 40 years of age or older .

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year , from 112 to 234 cases per 100,000 women -- an absolute increase of 122 cases per 100,000 women . Concomitantly , the rate at which women present with late-stage cancer has decreased by 8 % , from 102 to 94 cases per 100,000 women -- an absolute decrease of 8 cases per 100,000 women . With the assumption of a constant underlying disease burden , only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease . After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age , we estimated that breast cancer was overdiagnosed ( i.e. , tumors were detected on screening that would never have led to clinical symptoms ) in 1.3 million U.S. women in the past 30 years . We estimated that in 2008 , breast cancer was overdiagnosed in more than 70,000 women ; this accounted for 31 % of all breast cancers diagnosed .

Despite substantial increases in the number of cases of early-stage breast cancer detected , screening mammography has only marginally reduced the rate at which women present with advanced cancer . Although it is not certain which women have been affected , the imbalance suggests that there is substantial overdiagnosis , accounting for nearly a third of all newly diagnosed breast cancers , and that screening is having , at best , only a small effect on the rate of death from breast cancer .

",,,,NEJMoa1206809,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'three decade': {'Intervention'}, '1976 through 2008': {'Intervention'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, 'united states': {'Participants'}, '8 %': {'Outcomes'}, '8 case per 100,000': {'Outcomes'}, 'double': {'Outcomes'}, '102 to 94': {'Outcomes'}, '112 to 234': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'three decade': {'Duration'}, '1976 through 2008': {'Duration'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, 'united states': {'Location'}, '8 %': {'Effect-strength'}, '8 case per 100,000': {'Effect-strength'}, 'double': {'Effect-strength'}, '102 to 94': {'Effect-strength'}, '112 to 234': {'Effect-strength'}}}",breast,,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': [], 'Location': ['A'], 'Sample-size': [], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The participants were women.', 'Age': 'The participants were 40 years of age or older.', 'Location': 'The participants were from the United States.', 'Intervention-general': 'The study assessed the impact of screening mammography.', 'Duration': 'The screening mammography was offered for three decades (from 1976 to 2008).', 'Outcomes-general': 'The study measured the occurrences of early and late-stage breast cancers.', 'Effect-strength': 'The introduction of screening mammography was associated with a doubling in the number of cases of early stage breast cancer (from 112 to 234 cases per 100,000 women). The rate at which women present with late-stage breast cancer decreased by 8% (an absolute decrease of 8 cases per 100,000 women).', 'Conclusion-general': 'Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. This imbalance suggests that there is a substantial overdiagnosis.'}",0,NEJMoa1206809
,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups . The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment .

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years . Women between the ages of 50 and 69 years were offered screening mammography every 2 years . We compared the incidence-based rates of death from breast cancer in four groups : two groups of women who from 1996 through 2005 were living in counties with screening ( screening group ) or without screening ( nonscreening group ) ; and two historical-comparison groups that from 1986 through 1995 mirrored the current groups .

We analyzed data from 40,075 women with breast cancer . The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group ( rate ratio , 0.72 ; 95 % confidence interval ( CI ) , 0.63 to 0.81 ) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group ( rate ratio , 0.82 ; 95 % CI , 0.71 to 0.93 ; P ( 0.001 for both comparisons ) , for a relative reduction in mortality of 10 % in the screening group ( P = 0.13 ) . Thus , the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years , or a third of the total reduction of 7.2 deaths .

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer , but the screening itself accounted for only about a third of the total reduction . ( Funded by the Cancer Registry of Norway and the Research Council of Norway . )

",,,,NEJMoa1000727,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer mortality': {'Outcomes'}, 'norway': {'Participants'}, '50 and 69': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '40,075': {'Participants'}, '7.2': {'Outcomes'}, '4.8': {'Outcomes'}, '10 %': {'Outcomes'}, 'rate of death from breast cancer': {'Outcomes'}, '1996 through 2005': {'Intervention'}, 'nonscreen': {'Intervention'}, '2.4': {'Outcomes'}, 'a third': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer mortality': {'Outcomes-general'}, 'norway': {'Location'}, '50 and 69': {'Age'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '40,075': {'Sample-size'}, '7.2': {'Effect-strength'}, '4.8': {'Effect-strength'}, '10 %': {'Effect-strength'}, 'rate of death from breast cancer': {'Outcomes-general'}, '1996 through 2005': {'Duration'}, 'nonscreen': {'Control'}, '2.4': {'Effect-strength'}, 'a third': {'Effect-strength'}, 'historical': {'Control'}}}",breast,,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': [], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The study was performed on women.', 'Age': 'The participants were between the ages of 50 and 69 years.', 'Location': 'The participants were from Norway.', 'Sample-size': 'The study analyzed data from 40075 participants.', 'Intervention-general': 'The study assessed the impact of screening mammography.', 'Duration': 'Participants were offered screening mammography every 2 years from 1996 to 2005.', 'Control': 'Participants in counties with screening were compared to participants in counties without screening, and with two historical groups.', 'Outcomes-general': 'The studied measure deaths from breast cancer.', 'Effect-strength': 'The relative reduction in mortality in the screening group was of 10%. The effect of screening in the reduction of deaths, when comparing with the historical groups, was of about a third of the total reduction (7.2 per 100,000 vs 4.8 per 100,000 person-years).', 'Conclusion-general': 'The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction'}",0,NEJMoa1000727
,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer . Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer .

In a randomized , placebo-controlled , double-blind trial of exemestane designed to detect a 65 % relative reduction in invasive breast cancer , eligible postmenopausal women 35 years of age or older had at least one of the following risk factors : 60 years of age or older ; Gail 5-year risk score greater than 1.66 % ( chances in 100 of invasive breast cancer developing within 5 years ) ; prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ ; or ductal carcinoma in situ with mastectomy . Toxic effects and health-related and menopause-specific qualities of life were measured .

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3 % were randomly assigned to either exemestane or placebo . At a median follow-up of 35 months , 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo , with a 65 % relative reduction in the annual incidence of invasive breast cancer ( 0.19 % vs. 0.55 % ; hazard ratio , 0.35 ; 95 % confidence interval ( CI ) , 0.18 to 0.70 ; P = 0.002 ) . The annual incidence of invasive plus noninvasive ( ductal carcinoma in situ ) breast cancers was 0.35 % on exemestane and 0.77 % on placebo ( hazard ratio , 0.47 ; 95 % CI , 0.27 to 0.79 ; P = 0.004 ) . Adverse events occurred in 88 % of the exemestane group and 85 % of the placebo group ( P = 0.003 ) , with no significant differences between the two groups in terms of skeletal fractures , cardiovascular events , other cancers , or treatment-related deaths . Minimal quality-of-life differences were observed .

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer . During a median follow-up period of 3 years , exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life . ( Funded by Pfizer and others ; NCIC CTG MAP .3 ClinicalTrials . gov number ,  NCT00083174  . )

",,,,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, '35 year': {'Participants'}, '60 year': {'Participants'}, 'gail 5-year risk score': {'Participants'}, 'atypical ductal': {'Participants'}, 'lobular hyperplasia': {'Participants'}, 'lobular carcinoma in situ': {'Participants'}, 'ductal carcinoma in situ with mastectomy': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '65 %': {'Outcomes'}, '0.35 %': {'Outcomes'}, '0.77 %': {'Outcomes'}, '88 %': {'Outcomes'}, 'adverse event': {'Outcomes'}, '85 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, '35 year': {'Age'}, '60 year': {'Condition'}, 'gail 5-year risk score': {'Condition'}, 'atypical ductal': {'Condition'}, 'lobular hyperplasia': {'Condition'}, 'lobular carcinoma in situ': {'Condition'}, 'ductal carcinoma in situ with mastectomy': {'Condition'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '65 %': {'Effect-strength'}, '0.35 %': {'Effect-strength'}, '0.77 %': {'Effect-strength'}, '88 %': {'Adverse-effects'}, 'adverse event': {'Adverse-effects'}, '85 %': {'Adverse-effects'}}}",breast,,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The study was performed on women.', 'Age': 'The participants were 35 years old or older.', 'Condition': 'The participants were postmenopausal, and had one of the following risk factors: 60 years of age or older; Gail 5-year risk score greater than 1.66%; prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy', 'Sample-size': 'The study had 4560 participants.', 'Intervention-general': 'The study assessed the impact of examestane.', 'Duration': 'The median follow-up was of 35 months.', 'Control': 'Some of the participants were randomly assigned to a control group.', 'Outcomes-general': 'The study measured the occurrence of breast cancers.', 'Effect-strength': 'There was a 65% relative reduction in the annual incidence of invasive breast cancer in the group given examestane. The annual incidence for invasive and non-invasive breast cancers was 0.35% (11) on the examestane group and 0.77% (32) on the placebo group.', 'Adverse-effects': 'Adverse effects occurred in 88% of the examestane group and 85% of the placebo group.', 'Conclusion-general': 'Examestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer.'}",0,NEJMoa1103507
,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure , a risk factor for cardiovascular disease , but the effects of sodium intake on global cardiovascular mortality are uncertain .

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries ( accounting for 74.1 % of adults throughout the world ) , and we used these data to quantify the global consumption of sodium according to age , sex , and country . The effects of sodium on blood pressure , according to age , race , and the presence or absence of hypertension , were calculated from data in a new meta-analysis of 107 randomized interventions , and the effects of blood pressure on cardiovascular mortality , according to age , were calculated from a meta-analysis of cohorts . Cause-specific mortality was derived from the Global Burden of Disease Study 2010 . Using comparative risk assessment , we estimated the cardiovascular effects of current sodium intake , as compared with a reference intake of 2.0 g of sodium per day , according to age , sex , and country .

In 2010 , the estimated mean level of global sodium consumption was 3.95 g per day , and regional mean levels ranged from 2.18 to 5.51 g per day . Globally , 1.65 million annual deaths from cardiovascular causes ( 95 % uncertainty interval ( confidence interval ) , 1.10 million to 2.22 million ) were attributed to sodium intake above the reference level ; 61.9 % of these deaths occurred in men and 38.1 % occurred in women . These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes ( 9.5 % ) . Four of every 5 deaths ( 84.3 % ) occurred in low - and middle-income countries , and 2 of every 5 deaths ( 40.4 % ) were premature ( before 70 years of age ) . The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya .

In this modeling study , 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day . ( Funded by the Bill and Melinda Gates Foundation . )

",,,,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '66 country': {'Participants'}, '74.1 %': {'Participants'}, '1.65 million': {'Outcomes'}, '1 of every 10': {'Outcomes'}, '9.5 %': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '66 country': {'Location'}, '74.1 %': {'Sample-size'}, '1.65 million': {'Effect-strength'}, '1 of every 10': {'Effect-strength'}, '9.5 %': {'Effect-strength'}}}",cardio,,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'A'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': [], 'Condition': [], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': [], 'Intensity': [], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Location': 'Participants were from 66 different countries', 'Sample-size': 'The data used accounted for 74.1% of the adults throughout the world.', 'Intervention-general': 'The study assessed the impact of sodium consumption.', 'Outcomes-general': 'The study measured death from cardiovascular causes.', 'Effect-strength': 'Sodium consumption was associated with 1.65 million deaths from cardiovascular disease, which represent 9.5% or 1 of every 10 deaths of cardiovascular causes', 'Conclusion-general': 'Sodium consumption above a reference level of 2.0g a day was associated with 1.65 million deaths from cardiovascular diseases.'}",0,NEJMoa1304127
,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death , azithromycin is thought to have minimal cardiotoxicity . However , published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death .

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication , excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization . The cohort included patients who took azithromycin ( 347,795 prescriptions ) , propensity-score -- matched persons who took no antibiotics ( 1,391,180 control periods ) , and patients who took amoxicillin ( 1,348,672 prescriptions ) , ciprofloxacin ( 264,626 prescriptions ) , or levofloxacin ( 193,906 prescriptions ) .

During 5 days of therapy , patients taking azithromycin , as compared with those who took no antibiotics , had an increased risk of cardiovascular death ( hazard ratio , 2.88 ; 95 % confidence interval ( CI ) , 1.79 to 4.63 ; P ( 0.001 ) and death from any cause ( hazard ratio , 1.85 ; 95 % CI , 1.25 to 2.75 ; P = 0.002 ) . Patients who took amoxicillin had no increase in the risk of death during this period . Relative to amoxicillin , azithromycin was associated with an increased risk of cardiovascular death ( hazard ratio , 2.49 ; 95 % CI , 1.38 to 4.50 ; P = 0.002 ) and death from any cause ( hazard ratio , 2.02 ; 95 % CI , 1.24 to 3.30 ; P = 0.005 ) , with an estimated 47 additional cardiovascular deaths per 1 million courses ; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses . The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin .

During 5 days of azithromycin therapy , there was a small absolute increase in cardiovascular deaths , which was most pronounced among patients with a high baseline risk of cardiovascular disease . ( Funded by the National Heart , Lung , and Blood Institute and the Agency for Healthcare Quality and Research Centers for Education and Research on Therapeutics . )

",,,,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'death from any because': {'Outcomes'}, 'tennessee': {'Participants'}, 'noncardiovascular illness': {'Participants'}, '347,795': {'Participants'}, '1,391,180': {'Participants'}, '1,348,672': {'Participants'}, '264,626': {'Participants'}, '193,906': {'Participants'}, 'no antibiotic': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '245': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'death from any because': {'Outcomes-general'}, 'tennessee': {'Location'}, 'noncardiovascular illness': {'Condition'}, '347,795': {'Sample-size'}, '1,391,180': {'Sample-size'}, '1,348,672': {'Sample-size'}, '264,626': {'Sample-size'}, '193,906': {'Sample-size'}, 'no antibiotic': {'Control'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '245': {'Effect-strength'}, '5': {'Duration'}}}",cardio,,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': [], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Condition': 'Individuals with serious noncardiovascular illnesses were discarded.', 'Location': 'The participants were from Tennesse.', 'Sample-size': 'The study looked at patients with 347,795 prescriptions of azithromycin, 1,348,672 prescriptions of amoxicillin, 265,626 prescriptions of ciprofloxacin, and 193,906 prescriptions of levofloxacin. ', 'Intervention-general': 'The study assessed the impact of azithromycin.', 'Duration': 'The study considered the treatment of patients during 5 days.', 'Control': 'The study considered matched individuals who took no antibiotics, as well as individuals who took other drugs such as amoxicillin, ciprofloxacin and levofloxacin.', 'Outcomes-general': 'The study measured the risk of cardiovascular death and the risk of death from any cause.', 'Effect-strength': 'Relative to amoxicillin , azithromycin caused an estimated 47 additional cardiovascular deaths per 1 million courses; In high risk patients ithere were 245 additional (estimated) cardiovascular deaths per 1 million courses', 'Conclusion-general': 'During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, most pronounced among patients with a high baseline risk of cardiovascular disease.'}",0,NEJMoa1003833
,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established .

We enrolled in our study 10,744 overweight or obese subjects , 55 years of age or older , with preexisting cardiovascular disease , type 2 diabetes mellitus , or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events . All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week , single-blind , lead-in period , after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine ( 4906 subjects ) or placebo ( 4898 subjects ) . The primary end point was the time from randomization to the first occurrence of a primary outcome event ( nonfatal myocardial infarction , nonfatal stroke , resuscitation after cardiac arrest , or cardiovascular death ) .

The mean duration of treatment was 3.4 years . The mean weight loss during the lead-in period was 2.6 kg ; after randomization , the subjects in the sibutramine group achieved and maintained further weight reduction ( mean , 1.7 kg ) . The mean blood pressure decreased in both groups , with greater reductions in the placebo group than in the sibutramine group ( mean difference , 1.2 \/ 1.4 mm Hg ) . The risk of a primary outcome event was 11.4 % in the sibutramine group as compared with 10.0 % in the placebo group ( hazard ratio , 1.16 ; 95 % confidence interval ( CI ) , 1.03 to 1.31 ; P = 0.02 ) . The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1 % and 2.6 % in the sibutramine group and 3.2 % and 1.9 % in the placebo group , respectively ( hazard ratio for nonfatal myocardial infarction , 1.28 ; 95 % CI , 1.04 to 1.57 ; P = 0.02 ; hazard ratio for nonfatal stroke , 1.36 ; 95 % CI , 1.04 to 1.77 ; P = 0.03 ) . The rates of cardiovascular death and death from any cause were not increased .

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause . ( Funded by Abbott ; ClinicalTrials . gov number ,  NCT00234832  . )

",,,,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'cardiovascular outcome': {'Outcomes'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, '55 year': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'type 2 diabete': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, 'overweight or obese subject': {'Participants'}, '11.4 %': {'Outcomes'}, '3.4 year': {'Intervention'}, '10.0 %': {'Outcomes'}, 'placebo': {'Intervention'}, '1.16': {'Outcomes'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'cardiovascular outcome': {'Outcomes-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, '55 year': {'Age'}, 'preexist cardiovascular disease': {'Condition'}, 'type 2 diabete': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, 'overweight or obese subject': {'Condition'}, '11.4 %': {'Effect-strength'}, '3.4 year': {'Duration'}, '10.0 %': {'Effect-strength'}, 'placebo': {'Control'}, '1.16': {'Effect-strength'}}}",cardio,,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'Participants were 55 years or older.', 'Condition': 'Participants were obese or overweight, and had either preexisting cardiovascular disease, type 2 diabetes, or both.', 'Sample-size': 'There were 10,744 participants enrolled in the study, which was carried in 9804 subjects.', 'Intervention-general': 'The study assessed the effect of Sibutramine.', 'Duration': 'The treatment lasted in average 3.4 years.', 'Control': 'Some of the participants were assigned to a control group were they received a placebo.', 'Outcomes-general': 'The study assessed the risk of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, as well as the risk of cardiovascular death or death from any cause).', 'Effect-strength': 'The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group, (hazard ration 1.16).', 'Conclusion-general': 'Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and of nonfatal stroke, but nor of cardiovascular death or death from any cause.'}",0,NEJMoa1003114
,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus , but its effect on cardiovascular morbidity and mortality has not been determined .

We conducted searches of the published literature , the Web site of the Food and Drug Administration , and a clinical-trials registry maintained by the drug manufacturer ( GlaxoSmithKline ) . Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks , the use of a randomized control group not receiving rosiglitazone , and the availability of outcome data for myocardial infarction and death from cardiovascular causes . Of 116 potentially relevant studies , 42 trials met the inclusion criteria . We tabulated all occurrences of myocardial infarction and death from cardiovascular causes .

Data were combined by means of a fixed-effects model . In the 42 trials , the mean age of the subjects was approximately 56 years , and the mean baseline glycated hemoglobin level was approximately 8.2 % . In the rosiglitazone group , as compared with the control group , the odds ratio for myocardial infarction was 1.43 ( 95 % confidence interval ( CI ) , 1.03 to 1.98 ; P = 0.03 ) , and the odds ratio for death from cardiovascular causes was 1.64 ( 95 % CI , 0.98 to 2.74 ; P = 0.06 ) .

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance . Our study was limited by a lack of access to original source data , which would have enabled time-to-event analysis . Despite these limitations , patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes .

",,,,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '56 year': {'Participants'}, '1.43': {'Outcomes'}, '1.64': {'Outcomes'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '56 year': {'Age'}, '1.43': {'Effect-strength'}, '1.64': {'Effect-strength'}, '24 week': {'Duration'}, 'control group': {'Control'}, '42 trial': {'Sample-size'}}}",cardio,,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The mean age of the subjects was of 56 years.', 'Condition': 'Patients had type 2 diabetes mellitus.', 'Sample-size': '42 trials were analyzed in this study.', 'Intervention-general': 'The study assessed the effect of Rosiglitazone.', 'Duration': 'Studies included in the analysis lasted for more than 24 weeks.', 'Control': 'Studies included in the analysis had a control group not receiving rosiglitazone.', 'Outcomes-general': 'The study measured the myocardial infarction and deaths from cardiovascular causes.', 'Effect-strength': 'In the rosiglitazone group, as compared with the control group, the odds ratio of myocardial infarction was 1.43, and for death  from cardiovascular causes it was 1.64.', 'Conclusion-general': 'Rosiglitazone was associated with a significant increase in the risk of myocardial infarction, and of death from cardiovascular causes.'}",0,NEJMoa072761
,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain .

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline , with follow-up periods from 1986 to 2006 , 1991 to 2003 , and 1986 to 2006 . The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals , with multivariable adjustments made for age , baseline body-mass index for each period , and all lifestyle factors simultaneously . Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance -- weighted meta-analysis .

Within each 4-year period , participants gained an average of 3.35 lb ( 5th to 95th percentile , − 4.1 to 12.4 ) . On the basis of increased daily servings of individual dietary components , 4-year weight change was most strongly associated with the intake of potato chips ( 1.69 lb ) , potatoes ( 1.28 lb ) , sugar-sweetened beverages ( 1.00 lb ) , unprocessed red meats ( 0.95 lb ) , and processed meats ( 0.93 lb ) and was inversely associated with the intake of vegetables ( − 0.22 lb ) , whole grains ( − 0.37 lb ) , fruits ( − 0.49 lb ) , nuts ( − 0.57 lb ) , and yogurt ( − 0.82 lb ) ( P ≤ 0.005 for each comparison ) . Aggregate dietary changes were associated with substantial differences in weight change ( 3.93 lb across quintiles of dietary change ) . Other lifestyle factors were also independently associated with weight change ( P ( 0.001 ) , including physical activity ( − 1.76 lb across quintiles ) ; alcohol use ( 0.41 lb per drink per day ) , smoking ( new quitters , 5.17 lb ; former smokers , 0.14 lb ) , sleep ( more weight gain with ( 6 or ) 8 hours of sleep ) , and television watching ( 0.31 lb per hour per day ) .

Specific dietary and lifestyle factors are independently associated with long-term weight gain , with a substantial aggregate effect and implications for strategies to prevent obesity . ( Funded by the National Institutes of Health and others . )

",,,,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}, 'u.s.': {'Participants'}, 'free of chronic disease': {'Participants'}, 'not obese': {'Participants'}, '4-year': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}, 'u.s.': {'Location'}, 'free of chronic disease': {'Condition'}, 'not obese': {'Condition'}, '4-year': {'Duration'}}}",diet,,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': [], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': [], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The study was performed in women and men.', 'Condition': 'The participants were free of chronic diseases and not obese at the beginning of the study.', 'Location': 'The participants were from the United States of America.', 'Sample-size': 'There were 120,877 participants.', 'Intervention-general': 'The study assessed the impact of different dietary and life style factors.', 'Duration': 'The effects were evaluated at 4 year intervals.', 'Outcomes-general': 'The study measured long-term weight loss.', 'Conclusion-general': 'Specific dietary lifestyle factors are independently associated with long-term weight gain.'}",0,NEJMoa1014296
,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk . We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events .

In a multicenter trial in Spain , we randomly assigned participants who were at high cardiovascular risk , but with no cardiovascular disease at enrollment , to one of three diets : a Mediterranean diet supplemented with extra-virgin olive oil , a Mediterranean diet supplemented with mixed nuts , or a control diet ( advice to reduce dietary fat ) . Participants received quarterly individual and group educational sessions and , depending on group assignment , free provision of extra-virgin olive oil , mixed nuts , or small nonfood gifts . The primary end point was the rate of major cardiovascular events ( myocardial infarction , stroke , or death from cardiovascular causes ) . On the basis of the results of an interim analysis , the trial was stopped after a median follow-up of 4.8 years .

A total of 7447 persons were enrolled ( age range , 55 to 80 years ) ; 57 % were women . The two Mediterranean-diet groups had good adherence to the intervention , according to self-reported intake and biomarker analyses . A primary end-point event occurred in 288 participants . The multivariable-adjusted hazard ratios were 0.70 ( 95 % confidence interval ( CI ) , 0.54 to 0.92 ) and 0.72 ( 95 % CI , 0.54 to 0.96 ) for the group assigned to a Mediterranean diet with extra-virgin olive oil ( 96 events ) and the group assigned to a Mediterranean diet with nuts ( 83 events ) , respectively , versus the control group ( 109 events ) . No diet-related adverse effects were reported .

Among persons at high cardiovascular risk , a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events . ( Funded by the Spanish government 's Instituto de Salud Carlos III and others ; Controlled-Trials . com number ,  ISRCTN35739639  . )

",,,,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'high cardiovascular risk': {'Participants'}, 'no cardiovascular disease': {'Participants'}, '7447': {'Participants'}, '55 to 80 year': {'Participants'}, '57 %': {'Participants'}, '0.70': {'Outcomes'}, '0.72': {'Outcomes'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'adverse effect': {'Outcomes'}, 'control': {'Intervention'}, 'fat': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'high cardiovascular risk': {'Condition'}, 'no cardiovascular disease': {'Condition'}, '7447': {'Sample-size'}, '55 to 80 year': {'Age'}, '57 %': {'Sex'}, '0.70': {'Effect-strength'}, '0.72': {'Effect-strength'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'adverse effect': {'Adverse-effects'}, 'control': {'Control'}, 'fat': {'Control'}, '109': {'Effect-strength'}}}",diet,,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The study was performed in women and men. 57% of the participants were woman.', 'Age': 'The participants were between 55 to 80 years of age at baseline.', 'Condition': 'Participants enrolled were at high cardiovascular risk, but with no cardiovascular disease at enrollment.', 'Location': 'The study was performed in Spain.', 'Sample-size': 'There were 7,447 participants enrolled.', 'Intervention-general': 'The study assessed the impact of a mediterranean diet.', 'Duration': 'The effects were evaluated after a median follow-up of 4.8 years.', 'Control': 'The studied involved a control diet (advice to reduce dietary fat).', 'Outcomes-general': 'The study measured the occurrence of cardiovascular events.', 'Effect-strength': 'Adjusted hazard ratios (versus the control group) for the group assigned to a mediterranean diet with olive oil were 0.70 (96 events vs. 109 control) and for the group assigned to a mediterranean diet with mixed nuts were 0.72 (83 events vs. 109 control).', 'Adverse-effects': 'No adverse effects were reported.', 'Conclusion-general': 'Among individuals at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.'}",0,NEJMoa1200303
,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages , but the association between coffee consumption and the risk of death remains unclear .

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health -- AARP Diet and Health Study who were 50 to 71 years of age at baseline . Participants with cancer , heart disease , and stroke were excluded . Coffee consumption was assessed once at baseline .

During 5,148,760 person-years of follow-up between 1995 and 2008 , a total of 33,731 men and 18,784 women died . In age-adjusted models , the risk of death was increased among coffee drinkers . However , coffee drinkers were also more likely to smoke , and , after adjustment for tobacco-smoking status and other potential confounders , there was a significant inverse association between coffee consumption and mortality . Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows : 0.99 ( 95 % confidence interval ( CI ) , 0.95 to 1.04 ) for drinking less than 1 cup per day , 0.94 ( 95 % CI , 0.90 to 0.99 ) for 1 cup , 0.90 ( 95 % CI , 0.86 to 0.93 ) for 2 or 3 cups , 0.88 ( 95 % CI , 0.84 to 0.93 ) for 4 or 5 cups , and 0.90 ( 95 % CI , 0.85 to 0.96 ) for 6 or more cups of coffee per day ( P ( 0.001 for trend ) ; the respective hazard ratios among women were 1.01 ( 95 % CI , 0.96 to 1.07 ) , 0.95 ( 95 % CI , 0.90 to 1.01 ) , 0.87 ( 95 % CI , 0.83 to 0.92 ) , 0.84 ( 95 % CI , 0.79 to 0.90 ) , and 0.85 ( 95 % CI , 0.78 to 0.93 ) ( P ( 0.001 for trend ) . Inverse associations were observed for deaths due to heart disease , respiratory disease , stroke , injuries and accidents , diabetes , and infections , but not for deaths due to cancer . Results were similar in subgroups , including persons who had never smoked and persons who reported very good to excellent health at baseline .

In this large prospective study , coffee consumption was inversely associated with total and cause-specific mortality . Whether this was a causal or associational finding can not be determined from our data . ( Funded by the Intramural Research Program of the National Institutes of Health , National Cancer Institute , Division of Cancer Epidemiology and Genetics . )

",,,,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, '50 to 71': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, '50 to 71': {'Age'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': [], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Sex': 'The study was performed in women and men.', 'Age': 'The participants were between 50 to 71 years of age at baseline.', 'Condition': 'Participants with cancer, heart disease and stroke were excluded.', 'Sample-size': 'There were 229,119 men and 173,141 women among the participants.', 'Intervention-general': 'The study assessed the impact of coffee consumption.', 'Duration': 'The study followed up individuals between 1995 and 2008.', 'Outcomes-general': 'The study measured long-term total and cause-specific mortality.', 'Conclusion-general': 'Coffee consumption was inversely associated with total and cause-specific mortality in non-smokers.'}",0,NEJMoa1112010
,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein , fat , or carbohydrates has not been established , and there are few studies that extend beyond 1 year .

We randomly assigned 811 overweight adults to one of four diets ; the targeted percentages of energy derived from fat , protein , and carbohydrates in the four diets were 20 , 15 , and 65 % ; 20 , 25 , and 55 % ; 40 , 15 , and 45 % ; and 40 , 25 , and 35 % . The diets consisted of similar foods and met guidelines for cardiovascular health . The participants were offered group and individual instructional sessions for 2 years . The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content .

At 6 months , participants assigned to each diet had lost an average of 6 kg , which represented 7 % of their initial weight ; they began to regain weight after 12 months . By 2 years , weight loss remained similar in those who were assigned to a diet with 15 % protein and those assigned to a diet with 25 % protein ( 3.0 and 3.6 kg , respectively ) ; in those assigned to a diet with 20 % fat and those assigned to a diet with 40 % fat ( 3.3 kg for both groups ) ; and in those assigned to a diet with 65 % carbohydrates and those assigned to a diet with 35 % carbohydrates ( 2.9 and 3.4 kg , respectively ) ( P ) 0.20 for all comparisons ) . Among the 80 % of participants who completed the trial , the average weight loss was 4 kg ; 14 to 15 % of the participants had a reduction of at least 10 % of their initial body weight . Satiety , hunger , satisfaction with the diet , and attendance at group sessions were similar for all diets ; attendance was strongly associated with weight loss ( 0.2 kg per session attended ) . The diets improved lipid-related risk factors and fasting insulin levels .

 Reduced-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize .  ( ClinicalTrials . gov number ,  NCT00072995  . )

",,,,NEJMoa0804748,"{'Coarse': {'lipid relate risk factor': {'Outcomes'}, 'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '3.6': {'Outcomes'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '3.3': {'Outcomes'}, '3.4': {'Outcomes'}, '2.9': {'Outcomes'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '3.6': {'Effect-strength'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '3.3': {'Effect-strength'}, '3.4': {'Effect-strength'}, '2.9': {'Effect-strength'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': ['A'], 'Location': [], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The study was performed in adults.', 'Condition': 'The individuals in which the study was performed were overweight.', 'Sample-size': 'The study was performed in 811 individuals.', 'Intervention-general': 'The participants were assigned to one of four diets, with energy derived from different percentages of fat, carbs and protein.', 'Duration': 'The intervention was assessed after 6 months and after two years.', 'Intensity': 'The targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20 , 15 , and 65%; 20, 25, and 55%; 40, 15, and 45% ; and 40, 25, and 35%.', 'Outcomes-general': 'The study measured weight loss.', 'Effect-strength': 'Weight loss remained similar in those who were assigned diets with more and less protein (3.0 vs. 3.6 kg), fat (3.3 vs 3.3 kg), and carbs (2.9 vs 3.4 kg).', 'Conclusion-general': 'Reduced calorie diets result in clinically meaningful weight loss regardless of which macro-nutrients they emphasize.'}",0,NEJMoa0804748
,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy , safety , and immunogenicity of candidate malaria vaccine RTS , S\/AS01 is being conducted in seven African countries .

From March 2009 through January 2011 , we enrolled 15,460 children in two age categories -- 6 to 12 weeks of age and 5 to 17 months of age -- for vaccination with either RTS , S\/AS01 or a non-malaria comparator vaccine . The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol . After 250 children had an episode of severe malaria , we evaluated vaccine efficacy against severe malaria in both age categories .

In the 14 months after the first dose of vaccine , the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS , S\/AS01 group and 0.55 episodes per person-year in the control group , for an efficacy of 50.4 % ( 95 % confidence interval ( CI ) , 45.8 to 54.6 ) in the intention-to-treat population and 55.8 % ( 97.5 % CI , 50.6 to 60.4 ) in the per-protocol population . Vaccine efficacy against severe malaria was 45.1 % ( 95 % CI , 23.8 to 60.5 ) in the intention-to-treat population and 47.3 % ( 95 % CI , 22.4 to 64.2 ) in the per-protocol population . Vaccine efficacy against severe malaria in the combined age categories was 34.8 % ( 95 % CI , 16.2 to 49.2 ) in the per-protocol population during an average follow-up of 11 months . Serious adverse events occurred with a similar frequency in the two study groups . Among children in the older age category , the rate of generalized convulsive seizures after RTS , S\/AS01 vaccination was 1.04 per 1000 doses ( 95 % CI , 0.62 to 1.64 ) .

The RTS , S\/AS01 vaccine provided protection against both clinical and severe malaria in African children . ( Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative ; RTS , S ClinicalTrials . gov number ,  NCT00866619  . )

",,,,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 's / as01': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'march 2009 through january 2011': {'Intervention'}, '15,460': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'non malaria comparator vaccine': {'Intervention'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '34.8 %': {'Outcomes'}, 'serious adverse event': {'Outcomes'}, 'three dos': {'Intervention'}, '12 month': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 's / as01': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'march 2009 through january 2011': {'Duration'}, '15,460': {'Sample-size'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'non malaria comparator vaccine': {'Control'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '34.8 %': {'Effect-strength'}, 'serious adverse event': {'Adverse-effects'}, 'three dos': {'Intensity'}, '12 month': {'Duration'}}}",immunization,,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': [], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The participants were children in two age categories: 6 to 12 weeks of age and 5 to 17 months of age.', 'Location': 'The participants were from Africa.', 'Sample-size': 'There were 15,460 patients in the study.', 'Intervention-general': 'The study assessed the RTS,S/AS01 vaccine.', 'Duration': 'The study assessed patients after 11 to 14 months of the first dose of the vaccine. Participants were enrolled in the study from March 2009 through January 2011', 'Intensity': 'Participants received all three doses of the vaccine.', 'Control': 'A non-malaria comparator vaccine was administered to a control group.', 'Outcomes-general': 'The study measured episodes of clinical and severe malaria.', 'Effect-strength': 'In the older age category, the efficacy of the vaccine for clinical malaria was 50.4% intention-to-treat/55.8% per-protocol, and for severe malaria, it was 45.1% intention-to-treat/47.3% per-protocol. In the combined age categories, the efficacy of the vaccine against severe malaria was 34.8% per-protocol.', 'Adverse-effects': 'Serious adverse events, such as seizures, occurred with a similar frequency in the two study groups.', 'Conclusion-general': 'The RTS,S/AS01 vaccine provided protection against both clinical and severe malaria.'}",0,NEJMoa1102287
,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A ( H1N1 ) virus is responsible for the first influenza pandemic in 41 years . A safe and effective vaccine is needed . A randomized , observer-blind , parallel-group trial evaluating two doses of an inactivated , split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia .

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses , administered 21 days apart . A total of 240 subjects , equally divided into two age groups ( ( 50 years and ≥ 50 years ) , were enrolled and underwent randomization to receive either 15 μg or 30 μg of hemagglutinin antigen by intramuscular injection . We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination . The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay , the proportion of subjects with either seroconversion or a significant increase in antibody titer , and the factor increase in the geometric mean titer .

By day 21 after the first dose , antibody titers of 1:40 or more were observed in 114 of 120 subjects ( 95.0 % ) who received the 15-μg dose and in 106 of 119 subjects ( 89.1 % ) who received the 30-μg dose . A similar result was observed after the second dose of vaccine . No deaths , serious adverse events , or adverse events of special interest were reported . Local discomfort ( e.g. , injection-site tenderness or pain ) was reported by 56.3 % of subjects , and systemic symptoms ( e.g. , headache ) by 53.8 % of subjects after each dose . Nearly all events were mild to moderate in intensity .

A single 15-μg dose of 2009 H1N1 vaccine was immunogenic in adults , with mild-to-moderate vaccine-associated reactions . ( ClinicalTrials . gov number ,  NCT00938639  . )

",,,,NEJMoa0907413,"{'Coarse': {'hemagglutinin antigen by intramuscular injection': {'Intervention'}, 'immunogenicity': {'Outcomes'}, '15 μg': {'Intervention'}, '30 μg': {'Intervention'}, '240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '18 and 64': {'Participants'}, '21': {'Intervention'}, '114 of 120': {'Outcomes'}, '95.0 %': {'Outcomes'}, '106 of 119': {'Outcomes'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '15 μg': {'Intensity'}, '30 μg': {'Intensity'}, '240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '18 and 64': {'Age'}, '21': {'Duration'}, '114 of 120': {'Effect-strength'}, '95.0 %': {'Effect-strength'}, '106 of 119': {'Effect-strength'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': [], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The study was performed on adults between the ages of 18 and 64.', 'Condition': 'The study was performed in healthy participants.', 'Location': 'The study was performed at a single site in Australia.', 'Sample-size': 'There were a total of 240 participants.', 'Intervention-general': 'The study assessed the 2009 H1N1 vaccine.', 'Duration': 'Effects were assessed 21 days after.', 'Intensity': 'Subjects were randomized to receive two dosages of vaccines with either 15 μg or 30 μg of hemagglutinin antigen by intramuscular injection.', 'Outcomes-general': 'The study measured the immunogenicity H1N1 vaccine.', 'Effect-strength': 'Antibody titers of 1:40 or more were observed in 114 of 120 (or 95%) of the subjects who received the 15 μg dose and in 106 of 119  (or 89%)  of the subject who received the 30 μg dose.', 'Adverse-effects': 'Local discomfort was reported by 56.3% of the subjects and systemic symptoms by 53.8% after each dose.', 'Conclusion-general': 'A single 15 μg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine associated reactions.'}",0,NEJMoa0907413
,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles , mumps , and rubella ( MMR ) is a cause of autism .

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998 . The cohort was selected on the basis of data from the Danish Civil Registration System , which assigns a unique identification number to every live-born infant and new resident in Denmark . MMR-vaccination status was obtained from the Danish National Board of Health . Information on the children 's autism status was obtained from the Danish Psychiatric Central Register , which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark . We obtained information on potential confounders from the Danish Medical Birth Registry , the National Hospital Registry , and Statistics Denmark .

Of the 537,303 children in the cohort ( representing 2,129,864 person-years ) , 440,655 ( 82.0 percent ) had received the MMR vaccine . We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders . After adjustment for potential confounders , the relative risk of autistic disorder in the group of vaccinated children , as compared with the unvaccinated group , was 0.92 ( 95 percent confidence interval , 0.68 to 1.24 ) , and the relative risk of another autistic-spectrum disorder was 0.83 ( 95 percent confidence interval , 0.65 to 1.07 ) . There was no association between the age at the time of vaccination , the time since vaccination , or the date of vaccination and the development of autistic disorder .

This study provides strong evidence against the hypothesis that MMR vaccination causes autism .

",,,,NEJMoa021134,"{'Coarse': {'measle , mumps , and rubella vaccination': {'Intervention'}, 'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, 'january 1991 through december 1998': {'Intervention'}, '537,303': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'measle , mumps , and rubella vaccination': {'Intervention-general'}, 'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, 'january 1991 through december 1998': {'Duration'}, '537,303': {'Sample-size'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}, 'unvaccinated': {'Control'}}}",immunization,,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': [], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The study was performed in children.', 'Location': 'The study was performed with individuals born in Denmark.', 'Sample-size': 'The study had a cohort with 537,303 individuals.', 'Intervention-general': 'The study assessed the impact of Measles, Mumps, and Rubella (MMR) vaccination.', 'Duration': 'The study assessed children born from January 1991 through December 1998.', 'Control': 'Vaccinated children were compared to an unvaccinated group.', 'Outcomes-general': 'The study measured the occurrence of autistic disorders and autistic-spectrum disorders', 'Effect-strength': 'The relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group was 0.92 (316 children had autistic disorder), and for other autistic-spectrum disorders 0.83 (422 children had autistic-spectrum disorder).', 'Conclusion-general': 'The study provides strong evidence against the hypothesis that MMR vaccination causes autism.'}",0,NEJMoa021134
,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States , children receive five doses of diphtheria , tetanus , and acellular pertussis ( DTaP ) vaccine before 7 years of age . The duration of protection after five doses of DTaP is unknown .

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011 . This period included a large outbreak in 2010 . We conducted a case -- control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age . We compared children with pertussis confirmed by a positive polymerase-chain-reaction ( PCR ) assay with two sets of controls : those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members . We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose . Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded .

We compared 277 children , 4 to 12 years of age , who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls . PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls ( P ( 0.001 ) or matched controls ( P = 0.005 ) . Comparison with PCR-negative controls yielded an odds ratio of 1.42 ( 95 % confidence interval , 1.21 to 1.66 ) , indicating that after the fifth dose of DTaP , the odds of acquiring pertussis increased by an average of 42 % per year .

Protection against pertussis waned during the 5 years after the fifth dose of DTaP . ( Funded by Kaiser Permanente ) .

",,,,NEJMoa1200850,"{'Coarse': {'acellular pertussis vaccine': {'Intervention'}, 'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, '2006 to 2011': {'Intervention'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, 'health plan member': {'Intervention'}, '277': {'Participants'}, '4 to 12': {'Participants'}, '3318': {'Participants'}, '6086': {'Participants'}, '42 %': {'Outcomes'}, 'united states': {'Participants'}}, 'Fine': {'acellular pertussis vaccine': {'Intervention-general'}, 'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, '2006 to 2011': {'Duration'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, 'health plan member': {'Control'}, '277': {'Sample-size'}, '4 to 12': {'Age'}, '3318': {'Sample-size'}, '6086': {'Sample-size'}, '42 %': {'Effect-strength'}, 'united states': {'Location'}}}",immunization,,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': [], 'Age': ['A'], 'Condition': [], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': [], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': [], 'Conclusion-general': ['A']}, 'Count': 1}","{'Age': 'The study was performed in children from 4 to 12 years old.', 'Location': 'The study was performed in California, in the USA.', 'Sample-size': 'The study compared 277 children with confirmed pertussis (PCR-positive) with 3318 children without confirmed pertussis (PCR-negative) and 6086 matched controls from the general population.', 'Intervention-general': 'The study assessed  the diphtheria, tetanus, and acellular pertussis vaccine (DTaP)', 'Duration': 'The study assessed subjects from 2006 to 2011.', 'Control': 'There were two control groups: a group closely matched from the general population of health-plan members, and another group were the subjects were PCR-negative for pertussis.', 'Outcomes-general': 'The study assessed the occurrence of PCR-positive pertussis.', 'Effect-strength': 'Children with confirmed pertussis were more likely to have received the fifth DTaP dose earlier. After the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.', 'Conclusion-general': 'The protection against pertussis granted by the diphtheria, tetanus, and acellular pertussis vaccine (DTaP) decreases after its fifth dose.'}",0,NEJMoa1200850
40-60,"Pre-menopausal women with hormone-receptor positive (HRP) breast cancer have another promising treatment available to them to reduce recurrence of the disease.  Adjuvant Exemestane with an aromatase inhibitor, or hormone receptor, is shown to improve outcomes, as compared to tamoxifen plus ovarian suppression. A five-year follow-up in the  Exemestane group showed a disease-free survival rate at 91.1 % compared to the Tamoxifen group with a 87.3% survival rate. The rate of freedom from cancer at five years was at nearly 93% in the Exemestane group as compared to about 89% in the Tamoxifen group. In the study of 4690 patients, there were 194 deaths. The overall survival rate did not differ significantly between the two groups. Adverse reactions were similar in both groups. This is great news for women looking for an alternative treatment to suppress the chance of HRP breast cancer returning.",College,female,0.7692307692307693,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A2KROBPV0YPE4A,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'b'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['b'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK
24-39,"In premenopausal breast cancer (specifically the early, hormone receptor positive kind), treatment with a therapy called aromatase inhibitor is better than another drug called tamoxifen. They found this by studying the clinical trial data from 4690 patients from two separate trials. The 5 year survival rate was 91% for aromatase inhibitor and 87% for tamoxifen. The researchers had a fairly high confidence in that result. However, the group that was treated with the aromatase inhibitor had a slightly elevated risk for adverse side effects as opposed to those treated with the tamoxifen. In summary, the research found that women treated with adjuvant treatment with exemstane plus ovarian suppression medication were more likely to stay in remission after their breast cancer had been treated, as opposed to the tamoxifen group. This study was paid for by Pfizer and is publicly available online.",College,female,0.8461538461538461,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,A2WNTEVRT68JXT,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP
40-60,"This study found that in postmenopausal women with hormone receptor-positive breast cancer and when compared to tamofoxifen, that adjuvant therapy with an aromatase inhibitor improves outcomes. During two phase 3 trials the primary analysis used data from 4690 patients. Ovarian estrogen production was achieved with the use of the gonadotropin releasing hormone agoinsts triptorellin, oophoroectomy, or ovarian irraditation. Findings concluded that in premenopausal women  with hormone receptor -positive breast cancer that tamoxifen plus ovarian suppression and adjuvant treatment with exemestane plus ovarian suppression ended up significantly reducing recurrence. A median follow up of 68 months disease free survival was 91.1%.The rate of freedom from breast cancer at five years was 92.8% for this group of women involved. A well executed study for the cancer researchers involved. Postmenopausal women achieved the same outcomes thus proving pre or post menopause did not matter.",College,female,0.7692307692307693,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, '92.8 %': {'Outcomes'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, '92.8 %': {'Effect-strength'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,1,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA
40-60,"In 2 phase 3 trials, randomly assigned premenopausal women w/ hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or taxoifen plus ovarian suppression for a 5-year period. Suppression of ovarian estrogen production was achieved with using gonadotropin-releasing-hormone agonist triptorelin, oophorectomy or ovarian irradiation. The primary analysis combined data from 4690 patients in 2 trials. After a median f/u of 68 months, disease-free  survival at 5 years was 91.1% in exemestane group & 87.3% in tamoxifen group. The rate of no breast cancer at 5 years was 92.8% in the exemestane group & 88.8% in the tamoxifen group. With 194 deaths, overall survival did not differ much between the 2 groups. Selected adverse events of grade 3 or 4 were reported for 30.6% of patients in the exemestane grp & 29.4% in the tamoxifen group, similar to those for postmenopausal women. In premenopausal women with hormone-receptor, positive early breast cancer adjuvant treatment w/ exemestane plus ovarian suprression significantly reduced recurrence. ",Some College,female,1.0,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, 'early breast cancer': {'Participants'}, '5 year': {'Intervention'}, '92.8 %': {'Outcomes'}, '88.8 %': {'Outcomes'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}, 'adverse event': {'Outcomes'}, '30.6 %': {'Outcomes'}, '29.4 %': {'Outcomes'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, 'early breast cancer': {'Condition'}, '5 year': {'Duration'}, '92.8 %': {'Effect-strength'}, '88.8 %': {'Effect-strength'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}, 'adverse event': {'Adverse-effects'}, '30.6 %': {'Adverse-effects'}, '29.4 %': {'Adverse-effects'}}}",breast,A98E8M4QLI9RS,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM
24-39,"Testing over several years has proven that an aromatase inhibitor (exemestane) improves outcomes for post-menopausal women with hormone-receptor positive breast cancer. The women all went through ovarian suppression via different methods, but survival rate after five and a half years was higher for those who went through ovarian suppression while taking exemestane than those who went through it taking tamoxifen. In addition, more women were free from breast cancer after five years that had been taking the exemestane as opposed to those who took tamoxifen. The treatment was also found to be helpful for pre-menopausal women with hormone-receptor positive early breast cancer. 4690 patients were tested during these trials over more than five years, and the results indicate that the aromatase inhibitor exemestane was overall the more successful drug treatment when compared to tamoxifen and combined with suppression of ovarian estrogen production. ",Some College,female,0.46153846153846156,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, 'early breast cancer': {'Participants'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, 'early breast cancer': {'Condition'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,AUPHYAKC58LPA,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE
24-39,"Adjuvant therapy with an aromatase inhibitor improves outcomes when compared to tamokifen, in postmenopausal women with hormone-receptor positive breast cancer. Trials were done in which women with hormone receptor positive early breast cancer were assigned to one of two groups, those with the aromatase inhibitor or those with tamokifen. These trials lasted for a period of five years. A total of 4,690 patients were studied in two trials that contained three phases per trial. At the 68 month follow up, disease free survival was found to be higher in the aromatase inhibitor group over the tamokifen group with a confidence interval of 95%. The rate of freedom from breast cancer was higher in the aromatase inhibitor group than the tamokifen group. With a death rate of 4.1%, overall survival did not differ significantly between the two groups. Adverse events were reported at a higher rate in the group with the aromatase inhibitor than the group with tamokifen.",College,female,0.6153846153846154,NEJMoa1404037,"{'Coarse': {'early breast cancer': {'Participants'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'adverse event': {'Outcomes'}}, 'Fine': {'early breast cancer': {'Condition'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'adverse event': {'Adverse-effects'}}}",breast,AWCD7E12GSX2Z,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'D', 'A'], 'Intervention': ['C', 'A', 'B'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ
24-39,"Studies have shown improved patient outcomes in postmenopausal women with hormone-receptor positive breast cancer who received adjuvant therapy with an aromatase inhibitor as compared to tamoxifen. In two phase 3 randomized controlled trials of nearly 4700 premenopausal women with hormone-receptor positive breast cancer, adjuvant therapy with exemestane in combination with ovarian suppression showed significantly higher rates of disease-free survival at 5 years and freedom from breast cancer at 5 years as compared to tamoxifen in combination with ovarian suppression. The rates of overall survival as well as grade 3 or 4 adverse effects were not significantly different among the two groups. The results of these two trials in premenopausal women support those of previously published studies examining the effects of adjuvant aromatase inhibitors compared to tamoxifen in postmenopausal women with hormone-receptor positive breast cancer.",College,male,1.0,NEJMoa1404037,"{'Coarse': {'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A3K7OKFT05A073,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX
40-60,"We have an extraordinary study of the benefits of using Adjuvant Exemestane with ovarian suppression in premenopausal breast cancer compared to patients using Tamoxifen with ovarian suppression. In the study, primary analysis combined data from 4690 patients in two trials.  In 2 phase 3 trials,  randomly assigned premenopausal women (a woman usually in her 40s have menstrual irregularity experience menopause symptoms)  with hormone-receptor early breast cancer to the aromatase inhibitor exemestan plus ovarian suppression or tamoxifen plus ovarian suppression, suppression of the ovarian estrogen was achieved with the used of gonadotropin-releasing hormone agonist triptorelin, oophorectomy or ovarian irradiation.In the follow up of 5 years, we had disease-free survival of exemestane 91.1% compared to tamoxifen 87.3%. The freedom of breast cancer at 5yrs, exemestane was 92.8% compared to tamoxifen 88.8%. With deaths of 4.1%, there wasn't much difference between the two groups.  In conclusion, patients using exemestane had significantly reduced recurrence compared to tamoxifen.",College,female,0.5384615384615384,NEJMoa1404037,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, 'early breast cancer': {'Participants'}, '5 year': {'Intervention'}, '92.8 %': {'Outcomes'}, '88.8 %': {'Outcomes'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, 'early breast cancer': {'Condition'}, '5 year': {'Duration'}, '92.8 %': {'Effect-strength'}, '88.8 %': {'Effect-strength'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A3MV3MK1DR9MNZ,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO
40-60,"Mammography screening doesn't seem to have much affect on the breast cancer mortality rate in Norway. The challenge in quantifying the effects of mammograms on mortality was conducted in a nine year comparison study of over 40- thousand women aged 50 to 69 with breast cancer. They looked at the incidence in rates of death from the disease among those who had and had not been screened for breast cancer. The women were all offered a mammogram every two years. The data was analyzed between the two groups and showed the death rate was reduced by 7 deaths per 100,000 among those women in the screened group, and nearly 5 deaths in the non-screened group. This resulted in a relative reduction in mortality of 10% in the screening group. The differences suggest that the availability of screening was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for about a third of the total reduction. ",College,female,0.7692307692307693,NEJMoa1000727,"{'Coarse': {'breast cancer mortality': {'Outcomes'}, 'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '10 %': {'Outcomes'}, 'rate of death from breast cancer': {'Outcomes'}, 'a third': {'Outcomes'}}, 'Fine': {'breast cancer mortality': {'Outcomes-general'}, 'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '10 %': {'Effect-strength'}, 'rate of death from breast cancer': {'Outcomes-general'}, 'a third': {'Effect-strength'}}}",breast,A2KROBPV0YPE4A,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L
40-60,"This study was about the effects on screening mammography on breast cancer in Norway. The availability of screening mammography  which was offered a mammography screening every two years and has been associated with a reduction in the rate of death from breast cancer. The historical use of control subjects does not take into account chronologic trends associated with advances in breast cancer. The chronologic trends associated with a reduction in the rate of death from breast cancer, but the studys screening itself accounted for only about a third of the total reduction.  The program was started in 1996 in Norway and expanded in following years to other countries. There were approximately 40,000 aged between fifty through sixty nine women who took part in this study. The rate of death dropped by 7.2 per 100,000 people for the final result. This project was funded by the Cancer Registry of Norway and the research council of Norway.",College,female,0.7692307692307693,NEJMoa1000727,"{'Coarse': {'screen mammography': {'Intervention'}, 'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}, 'rate of death from breast cancer': {'Outcomes'}, 'a third': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}, 'rate of death from breast cancer': {'Outcomes-general'}, 'a third': {'Effect-strength'}, 'historical': {'Control'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15
15-24,"Screening mammography's usefulness in preventing breast cancer deaths is hard to gauge because it's hard to find good comparison groups. You can compare to older study groups but that wouldn't account for changes in technology that might affect mortality rates decreasing. The Norwegian breast cancer screening program started and grew, leading to women from 50-69 years old getting access to mammogram screenings every two years. They compared four groups made up of 40,075 women total with breast cancer. Two groups were from 1996-2005. One group received screening and one did not. The other two groups were from 1986 through 1995 and again, one received screening and the other didn't. The rate of death decreased by 7.2 deaths per 100,000 person-years in the 1996-2005 group compared to the 1986-1995 group. In women that didn't get screened, there was still a reduction of 4.8 deaths per 100,000 person-years. This concludes that screening did help reduce deaths but other factors helped with reduction of breast cancer deaths. ",Some College,female,0.8461538461538461,NEJMoa1000727,"{'Coarse': {'screen mammography': {'Intervention'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '40,075': {'Participants'}, '7.2': {'Outcomes'}, '4.8': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '40,075': {'Sample-size'}, '7.2': {'Effect-strength'}, '4.8': {'Effect-strength'}}}",breast,A1UI0SM8QV5IZ8,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3
40-60,"A Norwegian breast-cancer screening program that started in 1996 was expanded geographically during a subsequent 9 years. Women ages 50 to 69 yrs were offered screening mammograms every 2 yrs. They compared incidence-based rates of death from breast cancer in  2 group of women who from 1996 thru 2005 were living in counties w/ screening (screening group) or w/out (nonscreening group) and 2 historical-comparison groups that from 1986 thru 1995 mirrored the current group. Data was analyzed from 40075 women w/ breast cancer. The death rate was reduced by 7.2 deaths per 100,000 person-years in the nonscreen group as compared with the historical nonscreen group), for a relative reduction in mortality of 10% in the screening group. The difference in the reduction of mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years. The availability of screening mammograms was associated w/ reducing the rate of death from breast cancer. The screening itself accounted for about 1/3 of the total reduction.",Some College,female,1.0,NEJMoa1000727,"{'Coarse': {'woman': {'Participants'}, '7.2': {'Outcomes'}, '10 %': {'Outcomes'}, 'rate of death from breast cancer': {'Outcomes'}, 'nonscreen': {'Intervention'}, '2.4': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'woman': {'Sex'}, '7.2': {'Effect-strength'}, '10 %': {'Effect-strength'}, 'rate of death from breast cancer': {'Outcomes-general'}, 'nonscreen': {'Control'}, '2.4': {'Effect-strength'}, 'historical': {'Control'}}}",breast,A98E8M4QLI9RS,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE
40-60,"A study was performed in Norway to see if screening mammography would reduce the incidence of death from breast cancer.  Women between the ages of 50 and 69 years old were included in the study. They were screened every 2 years. The owmen were separated into 4 different groups. One group of women who lived in a countries with screening between 1996 and 2005, and a group of women who did not have screening in their country. Another study was performed on women that mirrored that study from 1986 to 1995. 40,075 women who had breast cancer were analyzed. Using screening methods the incidence of death from breast cancer was only 7.2 deaths per 100,00 person years.  This means that 2.4 women were saved from death by these screening procedures. Having mammography screening available to women was a major factor in reducing the incidence of breast cancer in women. The study showed that in Norway the reduction accounted for a 1/3 reduction in death.",Some College,female,0.8461538461538461,NEJMoa1000727,"{'Coarse': {'screen mammography': {'Intervention'}, 'norway': {'Participants'}, '50 and 69': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '40,075': {'Participants'}, '7.2': {'Outcomes'}, '2.4': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'norway': {'Location'}, '50 and 69': {'Age'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '40,075': {'Sample-size'}, '7.2': {'Effect-strength'}, '2.4': {'Effect-strength'}}}",breast,A2LTOS0AZ3B28A,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP
40-60,"The breast cancer screening program in Norway was started in 1996 to counteract the challenge of determining the efficacy of mammograms in terms of death from the disease on equal groups. Using past data was never helpful as it did not take into account things like then-current advances in breast cancer treatment and awareness. The Norwegian program offered women between the ages of 50 and 69 a mammogram every two years. They compared the results with similar groups of women who lived in other countries that provided screening, similar groups of women who lived in countries without screening and two historical groups that had similar experiences with screenings. They analyzed data from over 40,000 women with cancer of the breast. In all women who had screenings, the mortality rate was reduced by 7.2 deaths per 100,000 people. This reduced the death rate by 10%. This showed that screening does reduce the risk of death. ",College,female,0.8461538461538461,NEJMoa1000727,"{'Coarse': {'norway': {'Participants'}, '50 and 69': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}, '10 %': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'norway': {'Location'}, '50 and 69': {'Age'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}, '10 %': {'Effect-strength'}, 'historical': {'Control'}}}",breast,A3HEDIGLDT2NF3,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T
24-39,"A study that took place in Norway found that making mammography screening available to women between the ages of 50 and 90 every two years had an impact on the rate of breast cancer deaths. To verify the data, it was compared to women who lived in a place where no mammography screening was available, and then compared to older data from both types of groups (women who lived where screening was available and those who did not). The total reduction of deaths from the recent group who lived in an area when mammography screening was made available was 7.2 less deaths per year. Unfortunately the overall comparison revealed that the availability of screening alone only contributed to 2.4 less deaths per year.  Although the impact of having mammography screening available to residents of a country makes only a slight impact on the number of breast cancer deaths per year, it is still an impact, and should not be discounted. ",Some College,female,0.46153846153846156,NEJMoa1000727,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}, '2.4': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}, '2.4': {'Effect-strength'}}}",breast,AUPHYAKC58LPA,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'D', 'A', 'C'], 'Intervention': ['B', 'B', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['D'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC
24-39,"A breast-cancer screening program in Norway has published its results on the effect of breast-cancer screening on mortality rates of breast cancer. This study was deemed necessary as there is some difficulty in finding comparison groups. The study began in 1996 and expanded in the coming 9 years. During this time, women fitting certain criteria were offered screening every two years and four comparison groups were formed. They were women who lived in counties where screening had been offered and not offered during the trial period, and two similar groups that were formed ten years previous to the forming of these groups. Data from 40, 075 women was analyzed and it was found among both the current and historical group that those offered breast cancer screening saw a decrease in mortality rates of about a third. This was a reduction of about 2.4 people in every 100,000. This has shown that offering breast cancer screening can impact the mortality rate of breast cancer.",Some College,male,0.8461538461538461,NEJMoa1000727,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '2.4': {'Outcomes'}, 'a third': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '2.4': {'Effect-strength'}, 'a third': {'Effect-strength'}, 'historical': {'Control'}}}",breast,A1TMWYZL6USNIF,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29
40-60,"While mammography is the preferred choice in detecting an early incidence of breast cancer in women, a study performed over three decades is showing some dramatic results. Effective cancer screening programs show both a substantial increase in the number of cases detected in early stages, and a decrease in cancer presenting itself at a later stage.  Since mammography was introduced in the U.S., the number of early stage cancer cases detected had doubled in just one year, while late stage cases declined.  Based on variables such as hormone-replacement therapy and other adjusted trends, the study concluded that breast cancer was overdiagnosed in 1.3 million women in the U.S. in the past 30 years. This has led researchers to believe that while screening is important, it has only marginally reduced the rate at which women are diagnosed with advanced cancer.  The imbalance suggests that overdiagnosis accounts for nearly a third of all newly diagnosed breast cancers. Screening has only a small effect on the death rate from the disease.",College,female,0.7692307692307693,NEJMoa1206809,"{'Coarse': {'breast cancer': {'Outcomes'}, 'three decade': {'Intervention'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'three decade': {'Duration'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, 'double': {'Effect-strength'}}}",breast,A2KROBPV0YPE4A,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z
40-60,"Effective cancer-screening programs increase the incidence of cancer detection at an early stage and decrease the incidence of cancer presenting at a late stage. Surveillance, Epidemiology and end results data among women 40 yrs or older was used to examine trends from 1976 thru 2008 in the incidence of early-state breast cancer (ductal carcinoma in situ and localized) and late-stage breast cancer (regional and distant). The introduction of screening mammography in the US has been linked with doubling the number of cases of early-state breast cancer that are detected each yr, from 112 to 234 cases per 100,000 women. The rate women present w/ late-state cancer has decreased by 8%, from 102 to 94 cases per 100,000. It was estimated that breast cancer was overdiagnosed in 1.3 million US women in the past 30 yrs. In 2008, breast cancer was overdiagnosed in more than 70000 women, that is 31% of all breast cancers diagnosed. Despite increases in the number of early-state breast cancer found, screening mammograms has only marginally reduced the rate where women present with advance cancer. ",Some College,female,1.0,NEJMoa1206809,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, '8 %': {'Outcomes'}, 'double': {'Outcomes'}, '102 to 94': {'Outcomes'}, '112 to 234': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, '8 %': {'Effect-strength'}, 'double': {'Effect-strength'}, '102 to 94': {'Effect-strength'}, '112 to 234': {'Effect-strength'}}}",breast,A98E8M4QLI9RS,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT
24-39,"A study was conducted over thirty-two years with the object of comparing the rate of early and late stage breast cancer in women over 40. It was discovered that since mammography screening began in the United States there was a larger number of early stage breast cancer diagnoses. Unfortunately, it was also discovered that a great portion of those diagnoses were actually lumps or tumors that would never have developed into advanced stage breast cancer. This significantly cuts the success rate of mammography screening in the prevention of advanced stage breast cancer. It was estimated that in 2008 alone, that 31 percent of all breast cancer diagnoses were over diagnosed  in this manner. The overall data accumulated from this study indicates that mammography screening has only a very slight impact on the total death rate attributed to breast cancer, and because of over diagnosing, is actually driving the numbers of early stage breast cancer detected higher than it is. ",Some College,female,0.46153846153846156,NEJMoa1206809,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, 'united states': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, 'united states': {'Location'}}}",breast,AUPHYAKC58LPA,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF
24-39,"For breast cancer treatment to be the most effective, it is necessary for breast cancer to be found at earlier stages. To help further this, research has been done into this topic. The focus of the systematic review was that of trends in detecting breast cancer early, through mammography, from 1976 to 2008. While studies have shown that mammography has been effective at detecting breast cancer in the earlier stages, there were other things the study found as well that give less optimistic results. Taking into account certain trends in overdiagnosis and excesses due to hormone-replacement therapy, it was found that around 31% of breast cancer cases diagnosed in 2008 were overdiagnosed and around 1.3 million cases followed suit in the past 30 years. The researchers in these studies came to the conclusion that screening mammography has not had a large impact on the number of cases that advance to further stages of breast cancer, and consequently little effect on the mortality rate of breast cancer.",Some College,male,0.8461538461538461,NEJMoa1206809,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}}}",breast,A1TMWYZL6USNIF,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8
40-60,"Thirty years of academic study have shown that breast cancer screening programs do not reduce the rate with which women develop advanced cancer. Effective screening must not only increase cancer detection in early stages, but also decrease the incidence of patients developing cancer later. The study used three types of cancer detection data gathered between the years of 1976 and 2008. Early evidence was promising. Screening mammography in the US has doubled the number of early stage breast cancer patients detected per year. Also, the rate of late stage cancers reported has dropped 8%. However, the incidence of overdiagnosis - for example the finding of non symptomatic tumors - was high, with researchers estimating at least 1.3 million overdiagnosises have occurred in the past 30 years. In 2008 alone, it was estimated that 31% of all breast cancer diagnosises were overdiagnosed. This new information suggests that mammography screening is having a limited effect on the rate of fatal breast cancers. ",College,female,0.7692307692307693,NEJMoa1206809,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '8 %': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '8 %': {'Effect-strength'}, 'double': {'Effect-strength'}}}",breast,A1SXNLUT6WM90L,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9
24-39,"An analysis of the incidence of early-stage and late-stage breast cancer among women aged 40 years or older over three decades (from 1976 to 2008) found that breast cancer was overdiagnosed in nearly one-third of all new cases. This equates to roughly 1.3 million women in the United States over the past three decades and more than 70,000 in 2008 alone. The overdiagnosis of breast cancer, defined as the presence of tumors upon screening that would not have led to the presentation of clinical symptoms, is thought to be due, in large part, to the increased use of mammography in clinical practice. While the introduction of mammography within cancer-screening programs in the United States has undoubtedly led to an increase in the detection of early-stage breast cancer, minimal effects have been seen with their use on the rates of advanced breast cancer presentations and mortality attributed to the disease.",College,male,1.0,NEJMoa1206809,"{'Coarse': {'breast cancer': {'Outcomes'}, 'three decade': {'Intervention'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, 'united states': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'three decade': {'Duration'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, 'united states': {'Location'}}}",breast,A3K7OKFT05A073,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ
24-39,"To decrease the likelihood of death breast cancer screens should be done early in life so as to catch the disease in the early stages. If done so the breast cancer screen will increase the likelihood that cancer will be detected at earlier ages, but will decrease the prevalence of finding cancer at later more difficult to treat stages. Studies were done on breast cancer screens from 1976 to 2008 among women over 40 years of age. Introduction of mammography in the US has resulted in a increase in detection of breast cancer in women by double, but decreased the number of these detections in the later stage of the disease overall. The rate of decrease in dectections at the later stage of breast cancer was 8%. Excluding data associated with hormone-replacement therapy and data from women diagnosed who were younger than age 40, lead to the finding that breast cancer is over diagnosed in 1.3 million women in the past 30 years.",College,female,0.6153846153846154,NEJMoa1206809,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, '8 %': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, '8 %': {'Effect-strength'}, 'double': {'Effect-strength'}}}",breast,AWCD7E12GSX2Z,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S
24-39,"Cancer screening programs are vital for early detection which is vital for reducing lives lost to breast cancer. They are constantly researching cancer and studying from the past 40 years to help eradicate breast cancer. They are constantly seeking knowledge in order to find more ways to stop cancer. Mammograms have significantly increased the early detection rates, which is a good thing. The rate at which women present with late stage breast cancer has decreased quite a bit. While there is still no cure, women are being treated earlier and thus are becoming cancer free and living at higher rates, than in previous years. Breast cancer has been commonly misdiagnosed because of the presence of benign tumors and similar issues, some caused by hormone replacement therapy. So the statistics about diagnoses, are not as accurate as they may seem at first glance. There is still a long way to go to lower the rate of late stage detection. Screening only has a small effect on the death rate. ",Some College,female,0.6923076923076923,NEJMoa1206809,"{'Coarse': {'breast cancer': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}}}",breast,AHYXP6QIMYJLD,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'D'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,1,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB
40-60,"A study has been completed showing promising results for the drug Exemestane for breast cancer prevention in post-menopausal women. Aromatase inhibitors, like Exemestane, are shown to prevent more types of breast cancer and with fewer side effects than Tamoxifen and Raloxifene in patients with early-stage breast cancer. In the study, 4560 women with a median age of 62.5 and with various risk factors, were assigned to a group and given either Exemestane or a placebo. Results showed Exemestane significantly reduced invasive breast cancers in post-menopausal women who were in the moderate risk group for developing the cancer. There were also no significant differences between the two groups in developing adverse reactions like fractures, cardiovascular events and other treatment-related problems. A median follow-up three years later showed no serious toxic effects and only minimal changes in health-related quality of life after using Exemestane.",College,female,0.7692307692307693,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, 'placebo': {'Control'}}}",breast,A2KROBPV0YPE4A,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU
24-39,"A randomized, placebo-controlled trial was completed to test the invasive breast cancer reduction percentage of exemestane, by taking 4560 women and splitting them into two groups. One group would receive exemestane, while the other would receive a placebo. The group of women had a median age of 62.5 years and median score of 2.3% for a Gail risk score.The first check in was at a median time of 35 months. There were 11 cases of invasive breast cancers in the group that was given exemestane, while there were 32 cases in the group that received the placebo. Adverse events occured in 88% of the exemestane group and 85% of the placebo group. These events could be bone fractures, heart attacks, other cancers, or treatment releated death. There were minimal quality-of-life differences between the groups. Another follow up was completed after 3 years, that showed no association between exemestane and serious toxic effects.",Some College,male,0.5384615384615384,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '88 %': {'Outcomes'}, 'adverse event': {'Outcomes'}, '85 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '88 %': {'Adverse-effects'}, 'adverse event': {'Adverse-effects'}, '85 %': {'Adverse-effects'}}}",breast,A2WP9EC483LJY4,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['B']}}",,1,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR
15-24,"Exemestane has been studied for use in Postmenopausal women for Breast Cancer prevention. The study was conducted on postmenopausal women who were at increased risk for breast cancer with a median Gail risk of 2.3%. 62.5 years old was the median age of the 4560 women participating in the study. The participants were randomly placed into two groups, one being the placebo group, and the other being the Exemestane group. After following up with participants within a median time frame of 35 months, invasive breast cancers were found in only 11 of the participants in the Exemestane group in contrast with 32 participants in the placebo group. The yearly occurrence of both non invasive and invasive breast cancers when using Exemestane was 0.35%, where as the yearly occurrence not using Exemestane clocked in at 0.77%. No significant negative side effects occurred more often in the Exemestane group then the placebo group. Exemestane was found to have no effects of toxicity and had very small changes in quality of life in relation to health.",Some College,female,0.9230769230769231,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '0.35 %': {'Outcomes'}, '0.77 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '0.35 %': {'Effect-strength'}, '0.77 %': {'Effect-strength'}}}",breast,ADGH08WUP68ZF,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR
40-60,"In a random, placebo-controlled double-blind trial of exemestane made to detect a 65% reduction in invasive breast cancer, eligible postmenopausal women 35 years or older having one or more of the following risk factors: 60 yrs or older; Gail 5-yr risk score greater than 1.66% (chances in 100 of invasive breast cancer within 5 yrs); prior atypical ductal or lobular hyperplaisa or lobular carcinoma in situ; or ductal carcinoma in situ w/ mastectomy. Toxic effects and health-related and menopause specific qualities of life were measured. A total of 4560 women whose median age was 62.5 yrs and median Gail risk was 2.3% were randomly assigned exemestane or placebo. Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life. (Funded by Pfizer and others)",Some College,female,1.0,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, '35 year': {'Participants'}, 'atypical ductal': {'Participants'}, 'lobular carcinoma in situ': {'Participants'}, '4560': {'Participants'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, '35 year': {'Age'}, 'atypical ductal': {'Condition'}, 'lobular carcinoma in situ': {'Condition'}, '4560': {'Sample-size'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A98E8M4QLI9RS,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B
40-60,"A study of 4560 women aged 62.5 years and the median Gail risk score of 2.3% were given the drug exemestane or a placebo to see which drug helped the most. After about 35 months a follow up was done. 11 breast cancers were detected in women who used Exemestane and 32 in those given the placebo. This study showed that by giving women who previously had breast cancer the drug Exemestane had a 65% relative reduction in invasive breast cancer. Exemestane really reduced the incidence of recurring breast cancer in post menopausal women. Especially when they were at an increased risk of recurring breast cancer. After a follow up with these women 3 years later, it was found that Exemestane also had no serious toxic side effects, made no difference in incidences of heart attacks or other cardiovascular events and also helped the women maintain their quality of life after breast cancer. It would seem that this drug is very good at preventing a return of breast cancer for many women who have experienced it before. ",Some College,female,0.8461538461538461,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '65 %': {'Effect-strength'}}}",breast,A2LTOS0AZ3B28A,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7
40-60,"In a recent study on 4560 postmenopausal women, the drug exemestane was tested. The women were randomly given either the drug or a placebo. Eleven of the women given exemestane had invasive breast cancer. Thirty-two given the placebo had the same condition. The yearly rate of invasive breast cancer, as opposed to non-invasive, in the women given the drug was .35%. The group given the placebo had a rate of .77%. 88% of the postmenopausal women who were given the drug experienced adverse events. In the group given the placebo, 85% experienced these adverse events, including skeletal fractures, cardiovascular events, other types of cancers and treatment-induced deaths. There was not a clinically significant difference between the two groups in terms of adverse events. Exemestane was shown to significantly decrease breast cancer that was invasive for older women who were at a moderate risk for breast cancer.",College,female,0.8461538461538461,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, '4560': {'Participants'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '88 %': {'Outcomes'}, 'adverse event': {'Outcomes'}, '85 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '88 %': {'Adverse-effects'}, 'adverse event': {'Adverse-effects'}, '85 %': {'Adverse-effects'}}}",breast,A3HEDIGLDT2NF3,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'B', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA
24-39,"Aromatase inhibitors are better to use in the treatment of breast cancer than tamoxifen or raloxifene. A recent study found that one of these, exemestane was particularly effective in reducing invasive breast cancers in the subjects of the study. Compared to individuals given a placebo, it was found that there was a 65% reduction in incidence of these invasive breast cancers. The study found that there were only very slightly more adverse effects in the group receiving the treatment as opposed to those simply receiving a placebo. This shows that exemestane effected quality of life about as much as those who did not receive medication. It was found, in a 3 year follow-up, that the treatment had no serious toxic effects and effected quality of life minimally. To qualify for this study, the women involved were all post-menopausal and had an increased risk of developing invasive breast cancer. ",Some College,male,0.8461538461538461,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A1TMWYZL6USNIF,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'B', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F
40-60,"A number drugs are used for preventing breast cancer, including tamoxifen and raloxifene. These can also be used by breast cancer patients. Aromatase inhibitors are preferred by patients due to their low side effects, as compared to tamoxifen. In an academic study - controlled to be double-blind and placebo controlled - exmestane was very effective, showing a 65% reduction of invasive breast cancer. The 4560 participants were menopausal women age 35 or higher, who also had a risk factor for breast cancer. Risks included being over 60 and testing highly on an instrument used to rate breast cancer risk. The study looked at quality of life, specifically how it was impacted by treatment. Participants were given either the drug extemestane or a placebo. In follow up testing about three years later there were 11 breast cancers in the patients given the drug and 32 in patients who took the placebo. Otherwise, there were no significant differences in the group in terms of quality of life.The study proves that exemestane does reduce the incidence of breast cancer in menopausal women.",College,female,0.7692307692307693,NEJMoa1103507,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '65 %': {'Effect-strength'}}}",breast,A1SXNLUT6WM90L,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,1,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU
24-39,"Azithromycin is an macrolide antibiotic medication that has a close link with sudden cardiac death. This medication is thought to have the least toxicity to the heart. A study was done using a Tennessee Medicaid group that monitored effects of short term effects of medication on the heart. It excluded patients that had serious non cardiac illnesses. The medications tested were azithromycin, amoxicillin, ciprofloxacin and levofloxacin. The patients took the medications for 5 days. The ones that took azithromycin were more likely to die from cardiac risk than those who did not take any medications. Those who took amoxicillin had no increase in risk of death. The results for levofloxacin were almost the same where as the results for risk of death were slightly lower with the drug ciprofloxacin. The patients that had a high baseline risk of cardiovascular disease were in more danger of death from the antibiotic. ",Some College,male,0.9230769230769231,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A39GH5GG2B7KA1,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K
24-39,"The risk of cardiovascular death in relation to Azithromycin. Thought to have minimal cardiotoxicity, azithromycin may increase risk of cardiovascular death based off of published reports of arrhythmias. A study was done on a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious non-cardiovascular illness and person-time during and not long after hospitalization. The cohort included patients who took amoxicillin, ciprofloxacin, or levofloxacin. Those who took azithromycin compared to those who took no antibiotics had an increased risk of cardiovascular death and death from any cause during the 5 days of therapy. Patients taking amoxicillin had no increase in risk. An estimated 47 additional cardiovascular deaths per 1 million courses. Though patients in the highest decile of risk had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of death was higher with zithromycin than with ciproflaxacin but did not differ much from levofloxacin.",College,male,1.0,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'death from any because': {'Outcomes'}, 'tennessee': {'Participants'}, 'no antibiotic': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '245': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'death from any because': {'Outcomes-general'}, 'tennessee': {'Location'}, 'no antibiotic': {'Control'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '245': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A2ELH7YDLFNJUZ,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,1,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9
40-60,"A Tennessee Medicaid cohort study was designed to detect an increase risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347795), propensity-score - matched persons who took no antibiotics (1391180 control periods) and patients who took amoxicillin (1348672 prescriptions), ciprofloxacin (264626) or levofloxacin (193906). During 5 days of therapy, patients taking azithromycin as compared to those who took no antibiotics has an increased risk of cardiovascular death and death from any cause. Patients who took amoxicillin had no increase in the risk of death during this period. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ much from that with levofloxacin. With 5 days of azithromycin, there was a small absolute increase in cardiovascular death which was most pronounced w/ patients with a high baseline risk of cardiovascular disease. ",Some College,female,0.8461538461538461,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'death from any because': {'Outcomes'}, 'tennessee': {'Participants'}, 'noncardiovascular illness': {'Participants'}, 'no antibiotic': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'death from any because': {'Outcomes-general'}, 'tennessee': {'Location'}, 'noncardiovascular illness': {'Condition'}, 'no antibiotic': {'Control'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A98E8M4QLI9RS,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T
24-39,Azithromycin is thought to have minimal cardiotoxicity. However reports of arrthyimas suggest that azithromycin may increase risk of cardiovascular death. A cohort was designed to detect a risk of death related to short term cardiac affections of this medication. The cohort excluded patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. During 5 days of therapy the patients taking azithromycin as compared to those who took no antibiotics had an increased risk of cardiovascular death and death from any cause. Patients who took amoxicillen had no increase in risk of death during this period. Azithromycin was associated with an increased risk of cardiovascular death and death from any cause with an estimated 47 additional cardiovascular deaths per 1 million courses. Death was significantly greater with this medication then any other but did not differ significantly with that of levofloxacin.  ,High School,female,0.7692307692307693,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'death from any because': {'Outcomes'}, 'noncardiovascular illness': {'Participants'}, 'no antibiotic': {'Intervention'}, 'levofloxacin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'death from any because': {'Outcomes-general'}, 'noncardiovascular illness': {'Condition'}, 'no antibiotic': {'Control'}, 'levofloxacin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A2YUCJ28XANFOX,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['B', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA
24-39,"Some antibiotics are linked to an increased risk of cardiac death. There was a study on a Medicaid cohort in Tennessee, that was designed to detect an increased risk of death that is related to cardiac side effects from medication. It excluded patients with non cardiovascular conditions and those recently hospitalized. It included the medication Azithromycin, and matched with those who didn't take any antibiotics; and also those who took: Amoxicillin, Ciprofloxacin, and Levofloxacin. A 5 day treatment cycle of Azithromycin, was found to have an increased risk of a cardiac related death. A 5 day treatment cycle of Amoxicillin was found to have no increased risk of cardiac related death. So, The results showed that Azithromycin, Ciprofloxacin and Levofloxacin were found to increase the risk of cardiac death, while Amoxicillin was not found to increase the risk of cardiac death. This increased risk, was the most high in those who already had an increased risk of a cardiac related death.",Some College,female,0.6923076923076923,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,AHYXP6QIMYJLD,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1
15-24,"Some macrolides cause arrhythmias and can lead to cardiac death. It is believed that azithromycin is less harmful to the heart than most macrolides, but reports do exist that suggest it still increases risk of cardiovascular death. A study was done on Tennessee Medicaid patients to assess risk of cardiac-related death due to medication. This included patients taking azithromycin, amoxicillin, ciprofloxacin, or levofloxacin, as well as a control group taking no medication.Patients in the azithromycin group had a higher risk of cardiovascular-related death, and a higher risk of death from any cause than the amoxicillin group. The azithromycin group also had a significantly higher risk of cardiovascular death than the ciprofloxacin group. There was no significant difference in risk of death between azithromycin and levofloxacin groups. In conclusion, azithromycin treatment led to slightly increased risk of cardiovascular death. Patients with a high baseline risk of cardiovascular disease showed the highest increase in incidence of cardiovascular death.",College,female,0.8461538461538461,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'death from any because': {'Outcomes'}, 'tennessee': {'Participants'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'death from any because': {'Outcomes-general'}, 'tennessee': {'Location'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}}}",cardio,A3QFXP9WDS19PR,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9
24-39,"we studied a tennessee medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. During 5 days of therapy, patients taking azithromycin , as compared with those who took no antibiotics , had an increased risk of cardio vascular death. Patients who took amoxicillin had no increase in the risk of death during the period. the risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxavin. During 5 days of azithromycin therapy , there was a small absolute increase in cardiovascular deaths which was most pronounced among patients with a high baseline risk of cardiovascular disease. azithromycin (347795 prescriptions), antibiotics (1391180 control periods), amoxicillin (1348672 prescriptions), ciprofloxacin (264626 prescriptions), levofloxacin (193906 prescriptions)",College,male,0.46153846153846156,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'tennessee': {'Participants'}, 'noncardiovascular illness': {'Participants'}, 'no antibiotic': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'tennessee': {'Location'}, 'noncardiovascular illness': {'Condition'}, 'no antibiotic': {'Control'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A3F6TS7I3CSUM8,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9
24-39,"At this kind of modern world there are lot of sudden cardiac death,azithromycin is thought to have minimal cardio toxicity .Tennessee medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication.The cohort included patients who took azithromycin(347,795 prescription),propensity-score. during 5 days of therapy,patients taking azithromycin. patients who took amoxicillin had no increase in the risk of death during this period.relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death with an estimated 47 additional cardiovascular deaths per 1 million courses. the risk of cardiovascular death was significantly greater.there was small absolute increase in cardiovascular deaths. which was most pronounced among patients with a high baseline risk of cardiovascular disease .this is funded by National heart ,lung,and blood institute and the agency for healthcare quality.",College,female,0.46153846153846156,NEJMoa1003833,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'tennessee': {'Participants'}, '347,795': {'Participants'}, 'amoxicillin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'tennessee': {'Location'}, '347,795': {'Sample-size'}, 'amoxicillin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A1RVRSK2GTUVGK,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3
24-39,"Effect of Rosiglitazone on myocardial infarction and death from cardiovascular causes risk. We did searches of published literature from the Food and Drug administration as well as a clinical-trails registry maintained by the drug manufacturer GlaxoSmithKline. Only studies of more than 24 weeks, using a randomized control group not taking rosiglitazone, and has outcome date for myocardia infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. All occurences of myocardial infarction and death from cardiovascular causes were counted and sorted. In these trials the mean age of the subjects were approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. Rosignlitazone was associated with a large increase in risk of myocardial infarction as well as an increased risk of death from cardiovascular causes.",College,male,1.0,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, '56 year': {'Participants'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, '56 year': {'Age'}, '24 week': {'Duration'}, 'control group': {'Control'}, '42 trial': {'Sample-size'}}}",cardio,A2ELH7YDLFNJUZ,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF
24-39,"hiazolidinedione drugs are widely used to lower blood glucose levels in patients wit the type of 2 diabetes mellitus introglitazone , which was removed from the market because of hepatoxicity  , and two currently available agents, rosiglitazone and pioglitazone the thiazolidinediones are agonists for peroxisome-profiiferator-activated nuclear receptor are ligand-activated nuclear transcription factors the modulate gen expression,lowering blood glucose primarily by increasing insulin sensitivity in peripheral tissues rosiglitazone was introduced in 1999 and is widely used used as monotherapy or fixed dose combinations with either mertformin the original approval of rosiglitazone was based on the ability  of the drug to reduce blood glucose and glycated hemoglobin levels intial studies were not adequately powered to do determine the effects of the agent on micro vascular complications diabetes, including cardiovascular morbidity and morality however, the effect of any anti diabetic therapy on cardiovascular outcomes is particularly important because more than 65% of deaths in patients",College,male,0.46153846153846156,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,AIV02RLU34H13,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,1,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI
40-60,"Rosiglitzone is widely used to treat patients with type II DM, but its effect on cardiovascular morbidity and mortality has not been determined. A study was conducted of searches of published literature, the website of the FDA and a clinical trial registry maintained by GiaxoSmithKline. Criteria for inclusion in the meta-analysis included a study duration of more than 24 weeks, the use of randomized control group not receiving rosiglitazone, and the availability of outcome data for MI and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. The study was limited by lack of access to original source data, which would have enabled time-to-event analysis. Despite limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for Type 2 diabetes.",Some College,female,0.8461538461538461,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '24 week': {'Duration'}, 'control group': {'Control'}, '42 trial': {'Sample-size'}}}",cardio,A98E8M4QLI9RS,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X
24-39,"116 people were chosen as being potentially relevant for the study but only 42 met the inclusion critera which was a study of more then 24 weeks, the use of a randomized control group not receiving rosiglitazone and the availability of outcome data for myocardial infarction and death from cardiovascular causes.All occurrences of myocardial and infarction and death from cardiovascular causes were tabulated. In the 42 trials the mean age was approximately 56 years old and the baseline glycated hemoglobin level was 8.2%. The rosiglitazone grup as compared to the control group the odds ratio for mycardio infarction was 1.43 and the odds ratio for death from cardiovascular causes was 1.64. Rosiglilazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Despite limitations the serious adverse effects of treatment with rosiglitazone for type 2 diabetes should be considered. ",High School,female,0.7692307692307693,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '56 year': {'Participants'}, '1.43': {'Outcomes'}, '1.64': {'Outcomes'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '56 year': {'Age'}, '1.43': {'Effect-strength'}, '1.64': {'Effect-strength'}, '24 week': {'Duration'}, 'control group': {'Control'}, '42 trial': {'Sample-size'}}}",cardio,A2YUCJ28XANFOX,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG
24-39,"There is a medication called Rosiglitazone that is used to treat people who have type two diabetes mellitus. The effect it has on death or possible death by cardiovascular reasons is not defined. We made an attempt to find material from several sources to find out if there were any associated risk. The sources were various published literature, web site of the food and drug administration, and a registry of clinical trials by the manufacturer named GlaxoSmithKline. We established certain criteria the found material had to meet. The criteria included overall time of the study and use of a control group. Out of the 116 relevant studies only 42 met the standard set. The mean of all the data was used to establish the information to be used. The average age of those in the studies was 56 years old.The drug Rosiglitazone had a close link with a large increase in myocardial infarction and risk of death by cardiovascular reasons.",Some College,male,0.9230769230769231,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '56 year': {'Participants'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '56 year': {'Age'}, 'control group': {'Control'}}}",cardio,A39GH5GG2B7KA1,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q
15-24,"Rosiglitazone is a popular Type 2 Diabetes medication, but has not been tested for cardiovascular side effects. A meta-analysis was conducted on this subject. 116 studies were examined, and 42 met the criteria for the study: study duration of 24 or more weeks, use of a randomized control group that did not recieve the medication, and availability of myocardial infarction and cardiovascular death data. The average age of the patients in the studies was 56 years old, and the average baseline glycated hemoglobin level was 8.2%. The risk of both myocardial infarction and death from cardiovascular disease in the rosiglitazone group was higher than that of the control group. The studies showed that rosiglitazone was associated with significantly higher rates of myocaridal infarction. It was also associated with cardiovascular death, but this association was only borderline significant. The study could have been improved with better access to original source data, but still suggests that cardiovascular effects should be considered in patients taking rosiglitazone.",College,female,0.8461538461538461,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '56 year': {'Participants'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '56 year': {'Age'}, 'control group': {'Control'}}}",cardio,A3QFXP9WDS19PR,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW
24-39,"We conducted searches of the published literature, the web site of the food and drug administration, and a clinical-trails registry maintained by the drug manufacturer. criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks , the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infraction and death from cardiovascular causes.we tabulated all occurrences of myocardial infraction and death from cardiovascular causes. data were combined by means of a fixed-effects model. In the 42 trials the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infraction was 1.43, and the odds ratio for death from cardiovascular causes was 1.64.",College,male,0.46153846153846156,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}, '56 year': {'Participants'}, '1.43': {'Outcomes'}, '1.64': {'Outcomes'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}, '56 year': {'Age'}, '1.43': {'Effect-strength'}, '1.64': {'Effect-strength'}, '24 week': {'Duration'}, 'control group': {'Control'}, '42 trial': {'Sample-size'}}}",cardio,A3F6TS7I3CSUM8,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,1,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G
24-39,"The wide research about to treat patients with the type 2 diabetes. there is a lot of symptoms and chances when someone have diabetes to occur cardio attack.this study shows some randomized control not receiving rosiglitazone. and the availability included a study duration of more than 24 weeks,the use of the outcome data is very precious.and 116 potentially studies and 42 trails men the inclusion criteria. we tabulated all occurrences of myocardial infraction.data were combined by means of a fixed effects model. in the rosiglitazone group as compared with the control group.rosiglitazone was associated with a significance.our studywas limited by a lack of access to original source data and which has some kinds of despite these limitation,patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosilitazone for type 2 diabetes.            ",College,female,0.46153846153846156,NEJMoa072761,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'diabete': {'Participants'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'diabete': {'Condition'}, '24 week': {'Duration'}, 'control group': {'Control'}}}",cardio,A1RVRSK2GTUVGK,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,1,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB
40-60,"A study enrolled 10744 overweight or obese 55 yr olds w/ preexisting cardiovascular disease, Type II DM or both to assess cardiovascular consequences of weight mgmt w/ & without sibutramine in subjects at high risk of cardiovascular events. All received sibutramine in addition to participating in a weight mgmt program during a 6 week single blind lead-in period after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906) or placebo (4898). The primary end point was the time from randomization to the 1st occurrence of a primary outcome event (nonfatal MI, nonfatal stroke, resuscitation after cardiac arrest or cardiovascular death). The mean duration of treatment was 3.4 yrs. The mean weight loss during the lead-in period was 2.6kg. The blood pressure decreased in both groups, greater reductions in placebo group. Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. ",Some College,female,0.8461538461538461,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, 'preexist cardiovascular disease': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, 'placebo': {'Control'}}}",cardio,A98E8M4QLI9RS,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN
24-39,"Long term effects of sibutramine have not been established as of yet. A study enrolled 10,744 overweight or obese subjects that were all 55 years old or older and had preexisting cardiovascular disease and/or type 2 diabetes mellitus. Subjects received sibutramine and participation in weight-management programs for the 6-week, single-blind, lead-in period. After 9804 subjects had random assignment in a double-blind fashion to sibutramine. The mean duration of the treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg, after randomization the subjects in the sibutramine group maintained further weight reduction. Mean blood pressure decresed in both groups, more so in the placebo group. Rates of nonfatal myocardial infarction and nonfatal strokes were higher in the sibutramine group. Cardiovascular death rates did not increase. Subjects with preexisting cardiovascular conditions receiving siburatmine treatment had an increased risk of nonfatal myocardial infarction and nonfatal strokes but no increase risk to cardiovascular death or death from any cause.",College,male,1.0,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, '55 year': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'type 2 diabete': {'Participants'}, 'cardiovascular death': {'Outcomes'}, 'overweight or obese subject': {'Participants'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, '55 year': {'Age'}, 'preexist cardiovascular disease': {'Condition'}, 'type 2 diabete': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, 'overweight or obese subject': {'Condition'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A2ELH7YDLFNJUZ,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1
60+,"The study consisted of of 10,744 overweight or obese individuals who were over the age of 55 and had either preexisting cardiovascular disease, type 2 diabetes mellitus or both. All subjects in the study received sibutramine and participated in a weight management program for six weeks after which a random amount received sibutramine or a placebo. The groups end point was from randomization to the first occurrence of an event such as nonfatal stroke. The duration of treatment was for 3.4 years. Weight loss at the six week point was 2.6 kg and after randomization the sibutramine group achieved further weight reduction. Both groups had decreased blood pressure, the greater in the placebo group. Primary outcome events were more substantial in the sibutramine group than the placebo along with the same outcome for myocardia infarction and nonfatal stroke. In essence, subjects who recevied long term sibutramine treatment had an increase in infarction and nonfatal stroke.                                                                                                 ",College,female,0.6923076923076923,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'type 2 diabete': {'Participants'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, 'preexist cardiovascular disease': {'Condition'}, 'type 2 diabete': {'Condition'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A2VXMRI706CDGI,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86
24-39,"10,744 overweight or obese subjects ages 55 and older were enrolled in this study who had preexisting cardiovascular disease, type 2 diabetes or both to asses weight management with cardiovascular consequences. The duration of treatment was 3.4 years and the mean weight loss during the lead-in period was 2.6 kg. The mean blood pressure was decreased in both groups with greater reduction in the placebo group. Mean difference being 1.2 vs 1.4 hg. The risk of a  primary outcome event was 11.5% in the sibutramine group as compared with 10.0% in the placebo group. The nonfatal myocardial infarction and nonfatal stroke rates were 4.1% for the sibutramine group and 2.6% in the placebo group. The rates of cardiovascular death and death from any cause were not increased. Subjects with preexisting cardiovascular conditions that were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and non fatal stroke but not of cardiovascular death or death from any cause. ",High School,female,0.7692307692307693,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'type 2 diabete': {'Participants'}, 'cardiovascular death': {'Outcomes'}, 'overweight or obese subject': {'Participants'}, '3.4 year': {'Intervention'}, '10.0 %': {'Outcomes'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, 'preexist cardiovascular disease': {'Condition'}, 'type 2 diabete': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, 'overweight or obese subject': {'Condition'}, '3.4 year': {'Duration'}, '10.0 %': {'Effect-strength'}, 'placebo': {'Control'}}}",cardio,A2YUCJ28XANFOX,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5
60+,"There was a study done on the long-term effects of sibutramine treatment on cardiovascular events and death.  The study enrolled 10,744 overweight and obese people, 55 years and older, with preexisting cardiovascular, diabetes or both.  All people received situtramine and participated in a 6 week, weight management program.  An equal number were given sibutramine and placebo.   The study went on for 3.4 years.  The medium Weight loss was 2.6 kg.  Subjects in the sibutramine group achieved and maintained further weight reduction.  The blood pressure decreased in both groups, with great reduction in the placebo group.  In both groups, the rates of cardiovascular death and feather from any other cause were not increased.  Subjects were preexisting cardiovascular conditions, who received long term sibutramine treatment had an increased risk of non fatal heart infarctions and nonfatal stroke but not of cardiovascular death.  Study funded by Abbott ClinicalTrials. ",Some College,female,0.9230769230769231,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, '55 year': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, '55 year': {'Age'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,AAN06KVDS2XRY,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II
24-39,"The article is about the effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects.  They use 10,477 over weight of obese subjects, in 55 years of age or older. They were also preexisting cardiovascular disease.  All the subjects received sibutramine in in addition to participating in a weight management program during a 6-week, Single-blind, lead-in period, after which 9804 subjects.The overall duration of treatment was 3.4 years. The average weight loss during the period was 2.6 kilogram.  The risk of primary outcome was 11.4%.  The rates of nonfatal myocardial infarction, 1.28.  Hazard ratio for nonfatal stroke was 1.36. The rates of cardiovascular death and death from any cause were not increased.  Subjects with preexsting cardiovascular conditions who were receiving long-term sibutramine treatment had and increased risk of nonfatal myocardial infarction and non fatal stroke.",College,male,0.38461538461538464,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'obese': {'Participants'}, '55 year': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, '11.4 %': {'Outcomes'}, '3.4 year': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'obese': {'Condition'}, '55 year': {'Age'}, 'preexist cardiovascular disease': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, '11.4 %': {'Effect-strength'}, '3.4 year': {'Duration'}}}",cardio,A1DOY340I9VN92,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN
24-39,"cardiovascular outcomes in overweight and obese subjects.this study enrolled 10744 overweight persons and had a research on those who are affected by cardio problems.all the patient  are participating in a weight management programs. the mean duration of treatment was 3.4 years..the mean weight loss during the lead in period was 2.6kg. due to increase of weight the blood pressure level will automatically increases.the primaryend point was the time from randomization to the first occurrence of a primary outcome event. the risk of a primary outcome event was 11.4%in the sibutramine group as compared with 10.0% in the placebo group.the rate of cardiovascular death and death from any cause were not increased. who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infraction and nonfatal stroke but not of cardiovascular death.this treament is fully funded by abbott,clinicaltrails ",College,female,0.46153846153846156,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'cardiovascular outcome': {'Outcomes'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, 'cardiovascular death': {'Outcomes'}, '3.4 year': {'Intervention'}, '10.0 %': {'Outcomes'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'cardiovascular outcome': {'Outcomes-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, '3.4 year': {'Duration'}, '10.0 %': {'Effect-strength'}, 'placebo': {'Control'}}}",cardio,A1RVRSK2GTUVGK,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K
24-39,"we enrolled in our study 10744 overweight or obese subjects , 55 years of age or older , with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight management program during a 6 week, single blind, lead in period , after which 9804 subjects underwent random assignment in a double blind fashion to sibutramine or placebo . The primary end point was the time from randomization to the first occurrence of a primary outcome event. Subjects with preexisting cardiovascular conditions who were receiving long term sibutramine treatment had an increased risk of nonfatal myocardial infraction and nonfatal stroke  but not of cardiovascular death or death from any cause.",College,male,0.46153846153846156,NEJMoa1003114,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '55 year': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'type 2 diabete': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, 'overweight or obese subject': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '55 year': {'Age'}, 'preexist cardiovascular disease': {'Condition'}, 'type 2 diabete': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, 'overweight or obese subject': {'Condition'}, 'placebo': {'Control'}}}",cardio,A3F6TS7I3CSUM8,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP
40-60,High blood pressure is caused by too high of sodium intake and it will increase your likelihood of developing cardiovascular disease. Most people throughout the world get about 3.95g of sodium in their diet each day. There were 1.65 million deaths from cardiovascular disease in 2010. Research discovered that many of these deaths were in people who had a much greater intake of sodium than the 3.95 per day. Many of these deaths were in low and middle income countries and were premature - meaning the person died before they should have. The country that was the most affected by this was Georgia but Kenya was least affected. This is why researchers are now saying that we should do our best to keep our sodium intake to around 2g per day. Doing so is healthier for us and will help prevent us from suffering from a premature death. Research was conducted by organizations like the Bill and Melinda Gates Foundation.,College,female,0.9230769230769231,NEJMoa1304127,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A25AJ66CYVUTBR,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB
24-39,"Data was collected from people in 66 countries to understand sodium levels in diets around the world, and how high sodium might contribute to cardiovascular disease and related deaths. High sodium intake is responsible increasing blood pressure, and increased blood pressure can cause death from cardiovascular causes. 1.65 million annual deaths occur from cardiovascular causes that are attributed to high sodium intake. Men are at especially high risk to develop cardiovascular disease from high sodium intake, with 61.9% of the deaths that were studied occurring in men, and 38.1 deaths occurring in women. These deaths that were attributed to high sodium made up 9.5% of all deaths from cardiovascular causes. Deaths associated with high sodium intake occurred most often in the country of Georgia, and least in the country of Kenya. High sodium is considered to be intakes above the reference level of 2.0 g per day.",College,female,0.8461538461538461,NEJMoa1304127,"{'Coarse': {'death from cardiovascular cause': {'Outcomes'}, '66 country': {'Participants'}, '1.65 million': {'Outcomes'}, '9.5 %': {'Outcomes'}}, 'Fine': {'death from cardiovascular cause': {'Outcomes-general'}, '66 country': {'Location'}, '1.65 million': {'Effect-strength'}, '9.5 %': {'Effect-strength'}}}",cardio,A83OOIGU4606R,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK
40-60,"Data was collected from surveys on sodium intake as determined by urinary excretion and diet in people from 66 countries and was used to quantify the global consumption of sodium according to age, sex and country. The effects of sodium on blood pressure, according to age, race and the presence or absence of hypertension were calculated in a new meta-analysis of 107 random interventions. Cause specific mortality was derived from the Global Burden of Disease Study 2010. The estimated mean level of global sodium consumption was 3.95g/day and regional mean levels ranged from 2.18 to 5.51g/day. Globally 1.65 million annual deaths from cardiovascular causes were attributed to sodium intake above the 2.0 g/day reference level; 61.9% were men and 38.1 were women. These deaths accounted for 1 of every 10 deaths from cardiovascular causes. 4 of every 5 deaths occurred in low and middle income countries and 2 out of 5 were premature before age 70. The highest death rates from cardiovascular causes associated with high sodium intake was in the country of Georgia and lowest in Kenya.",Some College,female,0.8461538461538461,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '66 country': {'Participants'}, '1.65 million': {'Outcomes'}, '1 of every 10': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '66 country': {'Location'}, '1.65 million': {'Effect-strength'}, '1 of every 10': {'Effect-strength'}}}",cardio,A98E8M4QLI9RS,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q
24-39,"The risk of death from high sodium consumption is higher in low and middle-income countries such as Georgia and Kenya. The cardiovascular effects from the high sodium consumption are an increase in blood pressure which also is a risk factor for cardiovascular disease. The global study that was done in 2010 proved that the people who lived in ""poor"" countries and ""undereducated"" countries were at a higher risk for death from cardiovascular causes because they had a higher sodium intake. If these people had access to education about the consumption of foods and drinks high in sodium their total risk of death from cardiovascular causes would decrease. If they lower their sodium intake to even the reference intake of 2.0 g per day then their risk would decrease. In 2010 the mean level of global sodium consumption was 3.95 g per day. That is 1.95 g over the reference intake and greatly increases a persons risk of cardiovascular disease.",Some College,female,0.7692307692307693,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}}}",cardio,A329WHNJKAKTW7,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,1,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530
24-39,"While high sodium increases blood pressure and is a risk factor for cardiovascular disease the effects on sodium intake on global cardiovascular mortality are unknown. Data was collected from urine and diet from people in 66 countries which accounts for 74.1% of adults throughout the world. The effects of sodium on blood pressure according to age, race and presence of hypertension were calculated from data in a new meta analysis of 107 randomized interventions and the effects of blood pressure on cardiovascular mortality according to age were calculated from a meta-analysis of cohorts. Using comparative risk assessment, the cardiovascular effects of current sodium intake were calculated compared with a reference intake of 2.0 g of sodium per day according to age, sex and country. In 2010 the estimated mean level of global sodium consumption was 3.95 g a day. Globally, 1.65 million deaths were attributed to high sodium intake. 61.9% of these deaths occurred in men and 38.1% in women. 2 out of ever 5 deaths were before the age of 70. ",High School,female,0.7692307692307693,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, '66 country': {'Participants'}, '74.1 %': {'Participants'}, '1.65 million': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, '66 country': {'Location'}, '74.1 %': {'Sample-size'}, '1.65 million': {'Effect-strength'}}}",cardio,A2YUCJ28XANFOX,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'A'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ
40-60,"High blood pressure is a risk factor for cardiovascular diseases and eating high sodium foods increases blood pressure, but its effect on global cardiovascular mortality is uncertain.A data collected from 66 countries on sodium intake was used to quantify global consumption of sodium by age, sex and country. Globally 1.65 million annual deaths from cardiovascular causes were attributed to high sodium intake. The gender difference was 61.9% men and 38.1% women and they were 9.5% of deaths from cardiovascular diseases. 4 of every 5 deaths occurred in low and middle income countries, and 2 of every 5 deaths were premature (before the age 70). The rate of death caused by cardiovascular causes resulted from high sodium intake was highest in country of Georgia and lowest in Kenya.According to this modeling study, in 2010, a total of 1.65 million deaths were attributed to high sodium consumption (above reference level 2.0g per day).",College,female,0.9230769230769231,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '66 country': {'Participants'}, '1.65 million': {'Outcomes'}, '9.5 %': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '66 country': {'Location'}, '1.65 million': {'Effect-strength'}, '9.5 %': {'Effect-strength'}}}",cardio,AISNLDPD2DFEG,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O
60+,"A global study was done on whether high sodium intake, which increases blood pressure is a risk factor for cardiovascular disease and deaths associated with that.  They collected data accounting for 74.1% of adults throughout the world.  They then randomly selected 107 people and then broke it down by age, sex and country.  The study indicated that average global consumption was 3.95 grams per day but these levels ranged from 2.18 to 5.51 per day, by various regions.  What the study found was that 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption was above the 2.0 grams per day.  This study was founded by the bill and Melinda Gates Foundation.  It was interesting to note that the highest levels of death from sodium intake was highest in the country of Georgia and lowest in Kenya.  So as you can see, sodium intake varied greatly by regions.  ",Some College,female,0.9230769230769231,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '74.1 %': {'Participants'}, '1.65 million': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '74.1 %': {'Sample-size'}, '1.65 million': {'Effect-strength'}}}",cardio,AAN06KVDS2XRY,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'A'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0
15-24,"High sodium intake increases blood pressure but the effects of sodium on cardiovascular mortality are uncertain. The effects of sodium on blood pressure, according to demographics and the presence or absence of hypertension were calculated from a new meta-analysis and the effects of blood pressure on cardiovascular mortality were calculated. We estimated the cardiovascular effects of current sodium intake according to demographics. In 2010, the mean level of global sodium consumption was 3.95 g per day and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths were attributed to high sodium intake; 61.9% of these deaths occurred in men and 38.1% in women. These deaths accounted for nearly 1 of 10 deaths from cardiovascular causes. 4 of 5 deaths occurred in low and middle-income countries, and 2 of 5 deaths were premature. The rate of death associated with sodium intake above the reference level was highest in Georgia and lowest in Kenya. In this study, 1.65 million deaths from were attributed to sodium consumption above a reference level.",Some College,female,0.8461538461538461,NEJMoa1304127,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '1.65 million': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '1.65 million': {'Effect-strength'}}}",cardio,A1CUPUT2GVV8CU,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX
40-60,"A study on the association of drinking coffee with the risk of death remains unclear.There was an examination of the association of drinking coffee with total and cause specific mortality among 229,119 men and 173,141 women in the NIH-AARP Diet and Health Study who were 50-71 years of age at baseline.  Participants with cancer, heart disease, and stroke were excluded.  Consumption was assessed once at baseline.During follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died.  In age-adjusted models, the risk of death was increased among coffee drinkers.  However, coffee drinkers were more likely to smoke.  After adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality.  Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality.",High School,female,0.7777777777777778,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A1B78YH6IB8K3Z,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO
40-60,"One of the worlds most widely consumed beverages is coffee, but it is unclear if it can be associated the cause of any deaths. In the National Institutes of Heath --AARP Diet and Health Study of men and women between the ages of   50 to 71 cause-specific morality and subsequent total they examined the association of coffee drinking. Consumption was assessed excluding those with diseases like heart attract , stroke, and cancer, heart disease.The study followed people from 1995 to 2008 , nearly 6 million people were followed.between 18,000 and 34,000 people died. Death risk increased with coffee drinkers in age adjusted models. But adjustment had to be made for people who smoked tobacco and drank coffee and other con-founders that were potential, inverse association was significant between morality and coffee consumption. In the over all perspective coffee consumption inversely was association with the cause of death. Therefore leaving the data inclusive in showing whether it was a casual associational finding.",High School,male,0.6666666666666666,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'man': {'Participants'}, 'woman': {'Participants'}, '50 to 71': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'man': {'Sex'}, 'woman': {'Sex'}, '50 to 71': {'Age'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A3ZWMVK6GNTJ8,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'D'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM
15-24,"Even though coffee is one of the most popular beverages in the world, it's risks remain unknown. A study was done to examine the effects of coffee drinking on total and cause-specific mortality among men and women from fifty to seventy one years old. The study involved over 5,000,000 people, and over the course of the research over 30,000 men and over 18,000 women died. Coffee drinking did increase the risk of death, but coffee drinkers were also more likely to participate in smoking, which has a significant impact on lifespan. For men drinking less than one cup of coffee per day, the hazard ratio was 0.99. Those drinking six or more cups of coffee a day experienced a hazard ratio of 0.90. Women's risks differed a bit - women drinking less than one cup had a hazard ratio of 1.01, and those drinking six or more cups were at a ratio of 0.85. While this study shows that coffee consumption is inversely associated with both total and cause-specific mortality, it does not promote a causal or associational finding. ",Some College,female,0.9444444444444444,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, 'man': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, 'man': {'Sex'}, 'woman': {'Sex'}}}",diet,A2ZQVXEOBZBOEF,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'C', 'D'], 'Intervention': ['A', 'C'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O
40-60,"A trial was conducted to see if there was an association between coffee consumption and the risk of death. 229,119 men and 173,141 women participated, ranging in age from 50-71. Those with cancer, heart disease, and stroke were excluded. During the follow-up between 1995 and 2008, 33,731 men and 18,784 women died. While the risk of death was increased in coffee drinkers, they were also more likely to be smokers. After adjusting for tobacco-smoking status, a significant inverse association was found.Hazard ratios for men were .99 for drinking less than 1 cup of coffee per day, .94 for 1 cup/day, .90 for 2-3 cups/day, .88 for 4-5 cups/day, and .90 for 6 or more cups/day. The hazard ratios for women were 1.01 for less than 1 cup/day, .95 for 1 cup/day, .87 for 2-3 cups/day, .84 for 4-5 cups/day, and .85 for 6 or more cups/day. Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for cancer. Whether this was causal or associational could not be determined from the data.",College,female,0.7222222222222222,NEJMoa1112010,"{'Coarse': {'coffee': {'Intervention'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A122XBTHLAFX51,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4
40-60,"Coffee is one of the most widely consumed beverages, and it's effects on mortality are somewhat unclear. A study was done involving 229,119 men and 173,141 women who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. The study examined the association of coffee drinking with subsequent total and cause-specific mortality. Initially, it was found that the risk increased among coffee drinkers. However, coffee drinkers were also more likely to smoke; therefore, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Specifically, men who drank less than 1 cup a day had a .99 risk compared to  .88 for men who drank 4 or 5 cups a day. The respective hazard ratios for women were 1.01 for those who drank less than 1 cup a day, decreasing to .84 for those who drank 4 or 5 cups a day. Overall, coffee consumption was inversely associated with a lower risk for total and cause-specific death.     ",College,female,0.7222222222222222,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, '50 to 71': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, '50 to 71': {'Age'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG
24-39,"It still remains unclear whether coffee has any association with increased risk of death. 229,119 men and 173,141 women in the National Institutes of Health, AARP Diet and Health Study, ages 50-71, were studied based on coffee consumbion. None of the participants had cancer, heart disease, or stroke. Between 1995 and 2008, 33,731 men and 18,784 women died.  In an age adjusted model, coffee drinkers had an increased risk of death, however this link disappeared after adjusting for tobacco smoking and other confounders, turning into an inverse association. Inverse associations were observed in deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for cancer-related deaths. Results were similar in subgroups including non-smokers and those with excellent health.In this large study, coffee consumption was inversely associated with both total and cause-specific mortality, but the data can not show whether it was causal or correlational.",College,male,0.7777777777777778,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A3CFULTNTVCYE2,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M
24-39,"The goal of the this study is examine the link between consuming coffee and death.229,119 men and 173,141 women between 50 to 71 years old took place in the study between 1995 and 2008.  Prospective participants with cancer, heart disease, and stroke were screened out.Throughout the aforementioned timeline, 33,731 men and 18,784 women passed away.  Coffee drinkers were more likely to smoke, with that given an increase between coffee and death was shown, even with just one daily cup.  Participants succumbed to mortality due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections.  Similar findings occurred with those who never smoked and were in great physical shape.The end of the study showed an inverse association between natural mortality and cause-specific.  The conclusion could be causal or associational, but is unknown what the reasoning is.",College,female,0.7222222222222222,NEJMoa1112010,"{'Coarse': {'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, '50 to 71': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, '50 to 71': {'Age'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A1E66M679AFI3S,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H
40-60,"We examined the association of coffee drinking w/ subsequent total & cause-specific morality among 229,119 men & 173,141 women in National Institutes of health.  People ranging from 50-71 yrs old & w/exclusion of cancer, heart disease, & strokes.  Between 1995-2008 33,731 men & 18,784 women died.  The risk of death was increased among coffee drinkers, but they were more likey to smoke.  After adjustment of smoking & other potentiial confounders, there was a significant inverse association.  .99 (95% confidence interval(CI) .95-1.04) for drinking less then 1 cup a day, .94(95% CI .90-.099) @ 1 cup, .90(95% CI .86-93 @ 2-3 cups, .88 (95% CI .84-93@ 4-5 cups. .90(95% CI .85-.96)@ 6 plus cups per day.  Invers associations were observed for deaths due to heart & respitory disease, stroke, diabetes, and other infections, injuries & accidents.  In this prospective study, coffee drinking was inversely associated w/total & cause specific morality.  Associational facts aren't determined from our data.",Some High School,female,0.7777777777777778,NEJMoa1112010,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,AU3EIPG4ZRRMZ,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ
40-60,"The possible advantage for weight loss of a diet that emphasizes proteinm, fat, or carbs hasn't been established & are few studies extended beyond 1 yr.  We assigned 811 overweight adults to 1 of 4 diets, the targeted % of energy derived from fat, protein, and carbs in the 4 diets were 15, 20, & 65%, 20, 25, & 55%, 15, 40, & 45% 25, 35, & 40%.  They had similar foods & met guidelines for cardiovascular health & were offered individual classes for 2 yrs.  At 6 months each lost about 6kg that repre4sented 7% of initial weight the begain to regain it after 12 months.  By 2yrs it remained similar in thosw who were assigned to a diet with 15% protein & them assigned with a 25% protein.  In them assigned to 20% fat & those assigned to a diet w40% fat and in them 65% finished the trial, average weight loss was 4kg.  14-15% had reduced up to 10% of initial body weight.  Satiety, hunger, satisfaction w/diet & group sessions were similar.  Reduced calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasized.",Some High School,female,0.7777777777777778,NEJMoa0804748,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,AU3EIPG4ZRRMZ,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM
40-60,"The advantage for weight loss on a diet that emphasizes protein, fat or carbohydrates has not been established.  There are few studies that extend beyond 1 year.In a study, 811 overweight adults were assigned to one of four diets;  the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%, 20, 25, and 55%, 40, 15 and 45% and 40, 25, and 35%.  The diets consisted of similar foods and met guidelines for cardiovascular health.  Participants were offered group and individual instructional sessions for 2 years.At 6 months, participants of each diet had lost an average of 6 kg, and began to regain after 12 months.  By 2 years, weight loss remained similar in those assigned 15% & 25% protein; 20% & 40% fat; 65% & 35% carbohydrates.  Satisfaction with the diet, and attendance at sessions were similar for all diets.  Attendance at sessions was strongly associated with weight loss.  Lipid related risk factors and fasting insulin levels improved.Regardless of micronutrient emphasis, diets result in meaningful weight loss.",High School,female,0.7777777777777778,NEJMoa0804748,"{'Coarse': {'lipid relate risk factor': {'Outcomes'}, 'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,A1B78YH6IB8K3Z,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX
24-39,"We compared the result of weight loss with four different diets. For this study we looked for adult participants who were overweight. The four diets were distributed randomly to the 811 subjects. Each diet emphasized weight loss possibilities, by distributing proteins, fats, or carbohydrates into different energy consumptions. Each one of the groups were offered group and individual instructional sessions for 2 years. All groups compared similarity in satiety, hunger, satisfaction with their diets, and group attendance. After 6 months all 4 groups seemed to share an average weight loss of 6kg, however, they began regaining the weight after 12 months. At year 2 all averaged a 3% kg weight loss. All diets showed to have improved lipid related risk factors and fasting insulin levels. End conclusion, is that all reduced calorie diets will result in meaningful weight loss, in spite of what macronutrient was emphasized.",Some College,female,0.6666666666666666,NEJMoa0804748,"{'Coarse': {'lipid relate risk factor': {'Outcomes'}, 'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}}}",diet,A31ZHT1TVCFADY,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH
40-60,"A trial was conducted to see whether weight loss was better or worse depending on the percentage of fat, protein and carbohydrates consumed. Four diets were used, with the following percentages: 20% fat, 15% protein, 65% carbohydrates; 20, 25, 55; 40, 15, 45; and 40, 25, 35 respectively. Change in body weight was to be observed comparing low fat versus high fat, average protein versus high protein, and low carbohydrate versus high carbohydrate.After 6 months, participants in each diet lost an average of 6 kg, or 7% of their initial weight. After one year they began to gain weight back. After 2 years, the amount of weight lost was similar between the average protein and the high protein: 3.0 and 3.6 kg respectively. Also similar was the low fat versus the high fat: 3.3 kg. As well as the high carbohydrates versus low carbohydrates: 2.9 and 3.4 kg respectively. Therefore, reduced calorie diets resulted in weight loss no matter which nutrient they emphasized, fat, protein, or carbohydrates.",College,female,0.7222222222222222,NEJMoa0804748,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '3.0': {'Outcomes'}, '3.6': {'Outcomes'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '3.3': {'Outcomes'}, '3.4': {'Outcomes'}, '2.9': {'Outcomes'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '3.0': {'Effect-strength'}, '3.6': {'Effect-strength'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '3.3': {'Effect-strength'}, '3.4': {'Effect-strength'}, '2.9': {'Effect-strength'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,A122XBTHLAFX51,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D
15-24,"A research study examined the effect of weight loss diets with different compositions of three macronutrients - fat, protein, and carbohydrates. Over eight hundred overweight adults were put on a selected diet, chosen from four different compositions of these macronutrients. While all four diets had different compositions, they contained similar foods. Each participant had lost about six kilograms after six months of group or individual instructional sessions helping them maintain either a diet low in fat, protein, or carbohydrates. Each diet had a similar effect on the participant's weight, showing that a reduced calorie diet will be helpful in weight loss regardless of macronutrient composition. Participants also reported similar satisfaction and hunger levels and improved their lipid-related risk factors and fasting insulin levels. From this study we can conclude that a reduction in calories is the most important factor in weight loss. ",Some College,female,0.9444444444444444,NEJMoa0804748,"{'Coarse': {'lipid relate risk factor': {'Outcomes'}, 'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '6 month': {'Duration'}}}",diet,A2ZQVXEOBZBOEF,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ
40-60,"811 overweight adults were assigned to one of four diets; the diets consisted of similar foods and met guidelines for cardiovascular health. The percentages of energy from fat, protein and carbohydrates varied in the four diets as 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and lastly 40, 25 and 35%. The participants were offered group and individual instructional sessions for 2 years. After 6 months of dieting, all of the participants had lost an average of 6 kg which represented 7% of their initial weight. After 2 years, weight loss remained similar for those who were assigned to a diet of 15% protein versus those who were assigned to a diet of 25% protein (3.0 and 3.6 kg, respectively). In those assigned to a diet with 20% fat compared to those assigned to a diet with 40% fat both experienced 3.3 kg of weight loss. In those assigned to a diet of 65% carbohydrates and those with 35% carbohydrates experienced weight loss of 2.9 and 3.4 kg respectively. Overall, 80% of those who completed the trial lost an average of 4 kg irrespective of the macro nutrient diet they were on. ",College,female,0.7222222222222222,NEJMoa0804748,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '3.6': {'Outcomes'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '3.3': {'Outcomes'}, '3.4': {'Outcomes'}, '2.9': {'Outcomes'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '3.6': {'Effect-strength'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '3.3': {'Effect-strength'}, '3.4': {'Effect-strength'}, '2.9': {'Effect-strength'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,A3D8ZG1VV5FO35,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH
24-39,"Reduced-calorie diets result in weight loss regardless of which macro-nutrients they emphasize. Few studies extend beyond one year, and there is no clear link showing the advantage of either a protein, fat or carbohydrate based diet. The four diets used had the following macro compositions of fat, protein, and carbohydrates. (20%,15%,65%; 20%,25%,55%;40%,15%,45%;40%,25%,35%)In our study, 811 overweight adults were assigned similar diets with different macronutrient compositions. At 6 months, the average participant showed 6kg or 7% of weight loss, regardless of which macro-nutrients the diet emphasized. At 2 years, the average weight loss remained similar at 4kg among 80% of the participants. Only 14 to 15% of the participants lost at least 10% of their intiial body weight. Satiety, hunger, satisfaction, and attendance at group sessions were similar for all diets, and attendance was strongly associated with weight loss. All dieets improved lipid-related risk factors and fasting insulin levels.",College,male,0.7777777777777778,NEJMoa0804748,"{'Coarse': {'lipid relate risk factor': {'Outcomes'}, 'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '20': {'Intervention'}, '15': {'Intervention'}, '65': {'Intervention'}, '25': {'Intervention'}, '55': {'Intervention'}, '40': {'Intervention'}, '45': {'Intervention'}, '35': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '20': {'Intensity'}, '15': {'Intensity'}, '65': {'Intensity'}, '25': {'Intensity'}, '55': {'Intensity'}, '40': {'Intensity'}, '45': {'Intensity'}, '35': {'Intensity'}}}",diet,A3CFULTNTVCYE2,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS
40-60,"A two year study on weight loss was done. It measured three factors, Protein, fat and Carbohydrates. These measured factors were adjusted per group in 811 over weight adults to see which dieting group lost the most amount of weight. Although the participants were asked to specifically follow a percentage, little consistent weight loss was seen. Initially those who stuck to the diet lost an average of four kg despite differences in percentage of protein, fat or carbohydrates that were assigned. These individuals were also offered group sessions in order to lose the weight. Attendance to these meetings strongly influenced the weight loss outcome. All the people who participated in the study saw improved lipid related factors and fasting insulin rates. Both were less then before. One thing to note is that a reduced calorie diet resulted in weight loss no matter the macro nutrients they were given. Satiety and hunger while dieting were also influenced by group attendance no matter what diet the participants were on.",Some College,female,0.6666666666666666,NEJMoa0804748,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '2 year': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '2 year': {'Duration'}}}",diet,A2LTOS0AZ3B28A,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD
15-24,"Losing weight is not always as simple as eating less and exercising more. It can be affected by diet and lifestyle choices. A recent study that took place over the course of twenty years has shown this. The study started out with a large sample size of participants who were free of chronic diseases and not obese and followed up with them every four years. On average, participants gained a little over 3 pounds in each four year time period. Weight increase correlated the most with eating potato chips, potatoes, sugary beverages, unprocessed red meat and processed meat. On the other hand, eating vegetables, whole grains, fruits, nuts and yogurt were all correlated with weight loss. Lifestyle factors also had an impact on the participants' weights. Physical activity was correlated with weight loss while alcohol use, smoking, not getting enough sleep and watching tv were all correlated with weight gain. ",College,female,0.7777777777777778,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}, 'free of chronic disease': {'Participants'}, 'not obese': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}, 'free of chronic disease': {'Condition'}, 'not obese': {'Condition'}}}",diet,APGX2WZ59OWDN,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2
15-24,"While many have heard the advice ""eat less and exercise more"" when it comes to advice for losing weight, a research study has shown that long-term weight gain can be hard to control. Over 100,000 men and women in the United States free of obesity and chronic disease were investigated in terms of their eating habits and lifestyle changes over time. Over the four year period in which the investigation took place, participants gained around 3.35 pounds. This weight gain can be attributed to a higher intake of potato and potato products such as chips, sugar sweetened beverages, and both unprocessed and processed meat. A higher consumption of healthier foods such as vegetables, fruits, and whole grains could be attributed to weight loss. Lifestyle changes were investigated as well, and reduction in physical activity, smoking, alcohol use, sleeping habits, and watching television could all be attributed to weight gain as well as the participants dietary habits. ",Some College,female,0.9444444444444444,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'long term': {'Outcomes'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}}}",diet,A2ZQVXEOBZBOEF,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH
24-39,"Dietary and other lifestyle behaviors may affect the success of ""eat less; exercise more"" weight management strategies.Investigations were performed in 3 groups of 120,000 U.S. non-obese men and women free of chronic diseases with follow-ups from 1986 to 2006, 1991 to 2003, and 1986 to 2006, evaluating changes in lifestyle factors and weight change at 4 year intervals. Adjustments were made for age, baseline BMI for each period, and all lifestyle factors. Results were similar among each group and sex.Participants gained an average of 3.35 lb over each 4 year period. Weight increase was most associated with increased consumption of potato chips, potatoes, sweetened drinks, unprocessed red meats, and processed meats. It was inversely associated with consumption of vegetables, whole grains, fruits, nuts,  and yogurt. Physical activity, alcohol use, smoking, sleep, and television use were also linked with weight change..",College,male,0.7777777777777778,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'u.s.': {'Participants'}, 'free of chronic disease': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'u.s.': {'Location'}, 'free of chronic disease': {'Condition'}}}",diet,A3CFULTNTVCYE2,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN
40-60,"Long term weight gain was seen in men and women across the board wen a twenty year study was done. The study looked at 120,877 men and women who were not over weight nor had chronic health conditions at the beginning. Every 4 years individuals were evaluated and adjustments were made for age, baseline body mass index and lifestyle factors. An interesting component to the diet study was the increase of processed foods to the diets of the participants. This significantly increased weight gain for those people who weighed in every four years. Processed foods considered were potato chips, potatoes, soda pop and unprocessed red meats. an average of 3.5 pounds over the 4 year period were gained. Or one pound a year on average. If these individuals ate a significant amount of vegetables, whole grains, fruits, nuts and yogurt one could help alleviate that gain. The study also concluded that for people who smoked or were former smokers they also gained a bit weight. The study ended by saying if several of these factors were watched, obesity could be avoided. ",Some College,female,0.6666666666666666,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}}}",diet,A2LTOS0AZ3B28A,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR
24-39,"Lifestyle changes, including what a person eats, may prevent weight gain over a long period of time.Three separate investigations of 120,877 people took place between 1986 and 2006.  Each person wasn't obese and did not suffer from a chronic illness.  Changes in lifestyles and weight change occurred every four years.  Every four years the average weight gain was 3.35 pounds.  Increased weight gain occurred most frequently with the intake of starchy foods, sugar-sweetened foods, unprocessed red meat, and processed meat.  Decreased weight gain was observed most frequently with eating vegetables, while grains, fruits, nuts, and yogurt.  Participants who took part in physical activities lost weight.  Those who drank alcohol, smoked, slept more than 6 hours, or watched television also gained weight.The study as a whole proved that specific dietary and lifestyle factors do affect long-term weigh gain.",College,female,0.7222222222222222,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}, 'not obese': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}, 'not obese': {'Condition'}}}",diet,A1E66M679AFI3S,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'A', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD
40-60,"We performed prospective investigations involving 2 seperate cohorts that included 120,877 U.S. genders who were free of chronic diseases & not obese @ baseline.  W/follow up times of 1986-2006, 1991-2003, 1986-2006. The relationships of changed lifestyle factors & weight were evaluated @ 4 yr intervals w/multivariable adjustments mad for age, baseline body mass index for each period & all lifestyle factors simultaneiously cohort & sex specific results were similar.  Within each 4yr period they gained an average of 3.35 lbs on the basis of increased daily servings of individual dietary components.  4 yr change was most strongly associated with intake of potatoe chips, potatoes, sugar sweetened beverages, processed and unprocessed red meats & inversely associated w/intake of vegetables, whole grains, fruits, nuts, and yogurt.  Aggregate dietary changes were associated w/substantial different physical activity, alcohol, tobacco use.  Former smokers, sleep(more weight gain with 6-8 hours of sleep) and television watching.",Some High School,female,0.7777777777777778,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, '120,877': {'Participants'}, 'u.s.': {'Participants'}, 'free of chronic disease': {'Participants'}, 'not obese': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, '120,877': {'Sample-size'}, 'u.s.': {'Location'}, 'free of chronic disease': {'Condition'}, 'not obese': {'Condition'}}}",diet,AU3EIPG4ZRRMZ,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5
24-39,"This text focuses on how changing diet and lifestyle impacts long term weight gain in both men and women.  It specifically discusses how  the ""eat less and exercise more"" mantra isn't a hard and fast rule, because it depends on a lot of other factors.The investigators monitored 3 groups totaling 120,877 American men and women (without chronic disease or obesity), and checked in on them in the following time periods:  1986 to 2006, 1991 to 2003, and 1986 to 2006.  There were evaluations at 4 year intervals with adjustments made for differences between participants.The study found that, within each 4 year period, the selected people in the study gained (on average) 3.35 pounds each time!  The biggest factors in weight gain: eating a lot of unhealthy food.  Other things that impacted weight gain: exercise, drinking, smoking, sleep and watching TV (unhealthy habits resulted in more weight gain).The overall message:  just eating less and exercising more aren't the only things that impact your overall health.",College,female,0.7777777777777778,NEJMoa1014296,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}}}",diet,A5R0NQCWSPEJ9,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0
24-39,"The relationship between weight gain, lifestyle changes, caloric intake (amount of food eaten) and exercise is actually a lot more complicated that one might have previously thought. A study investigating more than 100,000 people over a period of 4 years in three different segments saw a correlation between aging and specific types of food eaten. On average, participants gained an average of 3.35 pounds. What appeared to have a substantial effect was the increased intake of chips, potatoes, added sugar, unprocessed and processed meat. All of these showed a marked increase in weight gain on average. Increased consumption of vegetable, whole grains, fruit, nuts, and yogurt actually had the opposite effect and showed an decrease in weight across those 4 years on average. Other lifestyle change such as alcohol use, smoking, sleep, and watching television also appeared to have an effect that varied across participants.",Some College,male,0.6666666666666666,NEJMoa1014296,"{'Coarse': {'lifestyle': {'Intervention'}}, 'Fine': {'lifestyle': {'Intervention-general'}}}",diet,AZYUCL6B0YROY,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX
40-60,"Observational cohort studies & a seconday prevention trial has shown an inverse association between adherence to the Mediterranean and cardiovascular diet and risk.  We randomly assigned people that were high cardiovascular risk with no cardiovascular disease at enrollment to 1 of 3 diets.  Mediterranean spplement w/extra virgin olive oil, next  a supplement w/mixed nuts ora control diet.  They got quarterly and individual group education classes & depending on assignment, free provision of extra virgin olive oil, mixed nuts, or small nonfood gifts.  7447 people had enrolled ranging from 55-80yrs old.  2 groups had good adherence to the intervention, primary end point event occurred in 288 people.  Multivariable adjusted hazard ratios were .70% confidence interval.  .54-.92 & .72 (95 ci, .54-.96 for teh group assigned w/extra virgin oil.  96 events.  The nuts group had 83 events respectively versus the control group 109 events. Those with high cardiovascular risk reduced the incidence of major events.  Funded by Spanish gvt Inst. de Salud Carlos III & others.",Some High School,female,0.7777777777777778,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'high cardiovascular risk': {'Participants'}, 'no cardiovascular disease': {'Participants'}, '7447': {'Participants'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'control': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'high cardiovascular risk': {'Condition'}, 'no cardiovascular disease': {'Condition'}, '7447': {'Sample-size'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'control': {'Control'}, '109': {'Effect-strength'}}}",diet,AU3EIPG4ZRRMZ,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'A', 'A', 'C', 'A'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C
15-24,"Studies show an inverse association between adherence to the Mediterranean diet and cardiovascular risk. In a randomized trail done in Spain people who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, were given on of three diets: A Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fats). The participants received quarterly individual and group educational services as well as group assignments that sometimes gave a free provision of extra-virgin olive oil, mixed nuts or small nonfood gifts. The primary end point was the rate of any major cardiovascular events, such as stroke or death. After the interim analysis the trail was stopped after a follow up of 4.8 years. 7,447 people were enrolled (ages 55 to 80 years) and 57% were women. Among people with high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oul or nuts reduced the chance of major events compared to those who followed the control diet.",High School,female,0.5555555555555556,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'high cardiovascular risk': {'Participants'}, 'no cardiovascular disease': {'Participants'}, '55 to 80 year': {'Participants'}, '57 %': {'Participants'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'control': {'Intervention'}, 'fat': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'high cardiovascular risk': {'Condition'}, 'no cardiovascular disease': {'Condition'}, '55 to 80 year': {'Age'}, '57 %': {'Sex'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'control': {'Control'}, 'fat': {'Control'}}}",diet,AI6U09NVOZ62B,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A', 'A'], 'Intervention': ['B', 'A', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84
24-39,"Mediterranean diets have been observed to reduce the risk of cardiovascular disease .  The multi-center trial  took place in Spain, where a total of 7,447 people took part in three separate groups.  Depending on the group, assistance ranged from education to free food (nuts or extra-virgin olive oil).  The group that participated in the Mediterranean diet supplemented with mixed nuts had the fewest cardiovascular events at 83 events.  The second group, Mediterranean diet with extra-virgin olive oil, had 96 cardiovascular events.  Lastly, participants who were only advised to reduce fat intake had 109 cardiovascular events.  The data was taken over a span of 4.8 years (on average per subject).  Participants ranged from 55-80 years and were all at high-risk for cardiovascular disease.  None of the people reported adverse effects from any of the diet changes. Overall, both Mediterranean groups showed less incidence of heart attack, stroke, or death from cardiovascular issues.",College,female,0.7222222222222222,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'adverse effect': {'Outcomes'}, 'fat': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'adverse effect': {'Adverse-effects'}, 'fat': {'Control'}, '109': {'Effect-strength'}}}",diet,A1E66M679AFI3S,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'B', 'A', 'A'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH
24-39,"A study was performed on 7447 participants who were at high risk of cardiovascular risk, but had no current disease at time of enrollment. The purpose of the study was to analyze the association of cardiovascular risk's, to adhering to a Mediterranean diet and it's effects on the participants. All subjects for the study ranged in age of 55 to 80 years old. About half were women, and the other half men. They were grouped into three groups. One group was assigned a Mediterranean diet with supplemented extra virgin olive oil. The other group was assigned a Mediterranean diet supplemented with nuts. And lastly one group, a controlled diet. The trial lasted 4.8 years. Each group was administered with free provisions of their appointed diet, and educational sessions. The end result concluded that those who supplemented their Mediterranean diet with extra virgin olive oil or nuts, reduced the incidence of major cardiovascular events. ",Some College,female,0.6666666666666666,NEJMoa1200303,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '7447': {'Participants'}, '55 to 80 year': {'Participants'}, '4.8 year': {'Intervention'}, 'control': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '7447': {'Sample-size'}, '55 to 80 year': {'Age'}, '4.8 year': {'Duration'}, 'control': {'Control'}}}",diet,A31ZHT1TVCFADY,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'A', 'A', 'C', 'A'], 'Intervention': ['B', 'B', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['B'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF
24-39,"The results to a study conducted in Spain have shown that people who are at a high risk for heart-related health issues were able to decrease their likelihood of suffering a major heart attack or similar by following a diet consisting of Mediterranean foods.  Only people who are at risk but had not already been diagnosed with heart disease were asked to participate in the study.  Over seven thousand people were put into three, randomly assigned groups and given diets to follow-two separate types of Mediterranean diets (one including extra-virgin olive oil and the other including mixed nuts), and one low fat diet.  They were also given periodic educational information and free food based on the group they were assigned to. At the end of the study, the two groups who were given Mediterranean based diets had the best overall results for reduced risk of heart related issues with the diet including mixed nuts being the most successful.     ",High School,female,0.8333333333333334,NEJMoa1200303,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'spain': {'Participants'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'spain': {'Location'}, 'fat': {'Control'}}}",diet,AZBZBTTME3HAI,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654
40-60,"According to a 4.8 year trial funded by the Spanish government's Instituto de Salud Carlos III and others, in addition to observational cohort studies, it was determined that a Mediterranean diet supplemented with either extra-virgin olive oil or mixed nuts, resulted in a better outcome with regard to cardiovascular disease than a control diet which recommended a reduction in dietary fats. This trial, which enrolled a total of 7447 persons from the ages of 55 to 80, of whom 57% were women, was well adhered to by the participants, who received quarterly group and individual educational sessions. These participants started with no cardiovascular disease at enrollment, but were considered high-risk. 288 participants suffered primary end-point events. The control group suffered the most events (109), followed by the Mediterranean diet with extra-virgin olive oil (96 events), and lastly, the Mediterranean diet supplemented with mixed nuts (83). There were no adverse effects related to the diet.",College,female,0.4444444444444444,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'no cardiovascular disease': {'Participants'}, '7447': {'Participants'}, '57 %': {'Participants'}, '96': {'Outcomes'}, '83': {'Outcomes'}, '4.8 year': {'Intervention'}, 'adverse effect': {'Outcomes'}, 'control': {'Intervention'}, 'fat': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'no cardiovascular disease': {'Condition'}, '7447': {'Sample-size'}, '57 %': {'Sex'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, '4.8 year': {'Duration'}, 'adverse effect': {'Adverse-effects'}, 'control': {'Control'}, 'fat': {'Control'}, '109': {'Effect-strength'}}}",diet,A1MS7QDYURPAH6,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A', 'A'], 'Intervention': ['B', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE
40-60,"A observational cohort study and secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk.In a trial in Spain,  randomly assigned participants who were at high cardiovascular risk, but with no disease at enrollment, were assigned to a Mediterranean diet supplemented with either extra virgin olive oil, a Mediterranean diet supplemented with mixed nuts or a control diet (advice to reduce dietary fat).  Participants received quarterly individual and group educational sessions.  On the basis of results, trial was stopped after a median follow up of 4.8 years.7447 persons participated (age 55 - 80 years); 57% were women.  The Mediterranean diet groups self reported good adherence to the intervention.  No diet adverse effects were reported.Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra virgin olive oil or nuts reduced the incidence of major cardiovascular events.",High School,female,0.7777777777777778,NEJMoa1200303,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'high cardiovascular risk': {'Participants'}, '7447': {'Participants'}, '57 %': {'Participants'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'adverse effect': {'Outcomes'}, 'control': {'Intervention'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'high cardiovascular risk': {'Condition'}, '7447': {'Sample-size'}, '57 %': {'Sex'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'adverse effect': {'Adverse-effects'}, 'control': {'Control'}, 'fat': {'Control'}}}",diet,A1B78YH6IB8K3Z,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89
40-60,"A trial was conducted in Spain to see whether a Mediterranean Diet was correlated to cardiovascular disease, and whether it could help with prevention of this disease. 7447 people were enrolled in the test, ranging in age from 55-80 years old. 57% of them were women. Three diets were set up: a Mediterranean diet that added in extra-virgin olive oil, a Mediterranean diet that added in mixed nuts, or a control diet that consisted of advice to reduce dietary fat. The participants were given individual and group education along with free extra-virgin olive oil, mixed nuts, or small nonfood gifts, depending on which of the 3 groups they were placed in. The end goal was to evaluate the rate of major cardiovascular events. The trial was stopped after 4.8 years. The end result was a cardiovascular event occurring in 288 participants. 96 of them in the olive oil group, 83 in the mixed nuts group, and 109 in the control group. The conclusion was a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the occurrence of major cardiovascular events in those at high risk.",College,female,0.7222222222222222,NEJMoa1200303,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '7447': {'Participants'}, '57 %': {'Participants'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'control': {'Intervention'}, 'fat': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '7447': {'Sample-size'}, '57 %': {'Sex'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'control': {'Control'}, 'fat': {'Control'}, '109': {'Effect-strength'}}}",diet,A122XBTHLAFX51,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150
24-39,"A 2009 influenza A (H1N1) virus is the cause for the first influenza pandemic since 41 years. Adults between 18 and 64 years old are receiving two doses of an inactivated, split-virus 2009 H1N1 vaccine for a group trail in Australia. There is a total of 240 people equally divided by age, each person receiving 2 vaccines 21 days apart. People randomly chosen either got a 15 ug or 30 ug dose. Antibody titers were measured using hemagglutination-inhibition and microneutralization assays before and 21 days after vaccination was received. The end points for coprimary immunogenicity were those who had antibody titers of 1:40 or more on hemagglutination-inhibition assay.21 days after the first does, 114 of 120 people that received 15-ug had titers 1:40 or more (95%). Out of 119 people who received 30-ug dosage only 106 had titers of 1:40 or more. (89.1%). After the second dose the result was similar. No one seemed to have been affected by the vaccine.  Discomfort at the injection site was reported by 56.3% of the people. 53.8% reported symptoms like headaches. ",Some College,female,0.875,NEJMoa0907413,"{'Coarse': {'immunogenicity': {'Outcomes'}, '240': {'Participants'}, 'adult': {'Participants'}, '18 and 64': {'Participants'}, '21': {'Intervention'}, '114 of 120': {'Outcomes'}, '89.1 %': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '240': {'Sample-size'}, 'adult': {'Age'}, '18 and 64': {'Age'}, '21': {'Duration'}, '114 of 120': {'Effect-strength'}, '89.1 %': {'Effect-strength'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A3RZLDKSVK9W3N,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['D']}}",,1,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U
15-24,"A new influenza A virus is the reason for a recent influenza pandemic. In order to create an appropriate vaccine, a group trial in healthy adults will be conducted in Australia. The study was split into two groups: one that received more of the injection than the other. Different measurements were then taken after three weeks. This was done to evaluate the immunogenicity and safety of the vaccine after the doses. Three weeks after the first vaccine was administered, it was found that 95% of the recipients who had received the lower dosage had appropriate levels. Of those who received the higher dose, 89.1% had appropriate levels. Similar findings were reported after the second vaccine administration. No serious adverse symptoms were reported, however, 56.3% of recipients reported local discomfort and 53.8% of recipients reported systemic symptoms.This concludes that a single dose of the lesser amount is immunogenic in adults. ",Some College,female,0.875,NEJMoa0907413,"{'Coarse': {'immunogenicity': {'Outcomes'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}}}",immunization,A3P3ST7ED4JQCK,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'B', 'A', 'C'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY
15-24,"A study is currently being conducted in Australia on an inactivated H1N1 (2009) split virus vaccine and the effects on adults that are considered healthy from ages 18 to 64. 240 participants were separated into groups based on age, one being 50 years and greater with the other being less then 50 years old. Participants in each group were then randomly chosen for a dose of 15-ug or a dose of 30-ug given via intramuscular injection of the hemagglutinin antigen. After 21 days of vaccination, 114 out of 120 or approximately 95% of participants given 15-ug dose showed antibody titers of 1:40. 106 out of 119 or approximately 89.1% of participants given the dose of 30-ug of the vaccine showed 1:40 antibody titers. A second trial dose of the vaccine was ran and the results were congruent with the initial results. The inactivated 2009 H1N1 virus vaccine proves to be immunogenic in healthy adults when given in a single dose of 15-ug. Only mild adverse effects were observed in around half of the participants in the study. ",Some College,female,0.75,NEJMoa0907413,"{'Coarse': {'240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '21': {'Intervention'}, '89.1 %': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '21': {'Duration'}, '89.1 %': {'Effect-strength'}, 'australia': {'Location'}}}",immunization,ADGH08WUP68ZF,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99
40-60,"A randomized, observer-blind, parallel-group trial evaluating 2 doses of inactivated split virus 2009 H1N1 vaccine in healthy adults age 18 to 64 is ongoing at a site in Australia. The immunogenicity and safety of a vaccine was evaluated after each of 2 scheduled doses given 21 days apart. 240 subjects, equally divided into 2 age groups groups were enrolled and randomly received either 15 ug or 30 ug hemagglutinin antigen by IM injection. Antibody titers were measured at baseline and 21 days after vaccination. The coprimary immongenicity end points were the proportion of subjects w/ antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer & the factor increase in the geometric mean titer. By day 21 after the 1st dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects who received the 15ug does and in 106 of 119 subjects who received the 30ug dose. A single 15-us dose of 2009 H1N1 vaccine was immunogenic in adults with mild to moderate associated reactions.",Some College,female,0.75,NEJMoa0907413,"{'Coarse': {'immunogenicity': {'Outcomes'}, '240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '21': {'Intervention'}, '114 of 120': {'Outcomes'}, '106 of 119': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '21': {'Duration'}, '114 of 120': {'Effect-strength'}, '106 of 119': {'Effect-strength'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A98E8M4QLI9RS,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3
40-60,"A new influenza A virus (H1N1) has caused the first influenza pandemic in 41 years, therefore a safe and effective vaccine is needed. A randomized group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults is ongoing at a single site in Australia. The immunogenicity and safety of the vaccine was evaluated after each of two scheduled doses, administered 21 days apart to a total of 240 subjects, equally divided into two age groups (under 50 and over 50). The subjects randomly received either a lower dosage or a higher dosage of the vaccine. By day 21 after the first dose, antibody titers of 1:40 or more were observed in 95 percent of the subjects who received the lower dosage, and 89.1 percent of the subjects who received the higher dosage. A similar result was observed after the second dose of vaccine. Only local discomfort and milt to moderate systemic symptoms were reported. Conclustion: single lower dose of 2009 H1N1 was immunogenic in adults, with mild-to-moderate vaccine related reactions.",College,female,0.875,NEJMoa0907413,"{'Coarse': {'immunogenicity': {'Outcomes'}, '240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '21': {'Intervention'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '21': {'Duration'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,AAB13RUHSABEV,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5
24-39,"This describes a study in which they are attempted to test a novel vaccine against the 2009 influenza H1N1. The study evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses. Subjects were at a single site in Australia, and were divided into two age groups (less than or over 50 years old) and randomly received ether 15ug or 30ug of hemagglutinin antigen intramuscularly. By 21 days after the first dose, antibody titers of 1:40 or more were found in 95.0% of subjects receiving the 15ug dose and 89.1% of subjects receiving the 30ug dose. A similar result was seen after the second dose of vaccine. No deaths, serious adverse events, or adverse events of interest were reported. About half of subjects described local discomfort at the site of injection, and about half reported mild to moderate systemic symptoms (headaches, etc). Thus, a single 15ug dose of 2009 H1N1 vaccine was immunogenic in adults with mild-to-moderate vaccine-associated reactions.",College,male,0.875,NEJMoa0907413,"{'Coarse': {'immunogenicity': {'Outcomes'}, 'adult': {'Participants'}, '21': {'Intervention'}, '95.0 %': {'Outcomes'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, 'adult': {'Age'}, '21': {'Duration'}, '95.0 %': {'Effect-strength'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A3LW4YHAM1JH1X,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'A', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH
40-60,"A study was done in Australia to evaluate the immunogenicity and safety of the 2009 Influenza A (H1N1) vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 healthy adults between the ages of 18 and 64 years old were divided equally into two age groups (< 50 years and > or = 50 years), and underwent randomization to receive either 15 ug or 30 ug of hemagglutinin antigen by intramuscular injection. By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0 %) who received the 15 ug dose and in 106 of 119 subjects (89.1 %) who received the 30 ug dose. A similar result was observed after the second dose of the vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort such as injection-site tenderness or pain was reported by 56.3 % of the subjects. Overall, a single 15 ug dose of 2009 HnN1 vaccine was immunogenic in adults.",College,female,0.875,NEJMoa0907413,"{'Coarse': {'hemagglutinin antigen by intramuscular injection': {'Intervention'}, 'immunogenicity': {'Outcomes'}, '240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '18 and 64': {'Participants'}, '21': {'Intervention'}, '114 of 120': {'Outcomes'}, '95.0 %': {'Outcomes'}, '106 of 119': {'Outcomes'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '18 and 64': {'Age'}, '21': {'Duration'}, '114 of 120': {'Effect-strength'}, '95.0 %': {'Effect-strength'}, '106 of 119': {'Effect-strength'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'australia': {'Location'}}}",immunization,A3D8ZG1VV5FO35,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW
24-39,There was a widespread influenza A epidemic in 2009.  Researchers had to come up with a vaccine for influenza A.  More than 200 healthy adults between 18 and 64 years of age were recruited to be a part of a group study.  They were split into two groups and one group received 15 micrograms of hemagglutinin antigen while the other group received 30 micrograms.  After 21 days researchers measured antibodies and hemagglutination-inhibition in the members of the focus groups.   In the group that received the 15 microgram dosage antibodies were measured at 95.0% while the group that received 30 micrograms was at 89.1%.  Researchers repeated the same test and received almost the same results.  No serious reactions were reported among the memebers of the focus group.   An estimated 56% of the group members reported pain at the injection site after receiving the immunization.  Another 53% reported having headaches after receiving the injection.  The results of the study concluded that adults who received the 15 microgram dosage were immune to influenza A.,College,female,0.75,NEJMoa0907413,"{'Coarse': {'healthy': {'Participants'}, 'adult': {'Participants'}, '18 and 64': {'Participants'}, '21': {'Intervention'}, '95.0 %': {'Outcomes'}, '89.1 %': {'Outcomes'}}, 'Fine': {'healthy': {'Condition'}, 'adult': {'Age'}, '18 and 64': {'Age'}, '21': {'Duration'}, '95.0 %': {'Effect-strength'}, '89.1 %': {'Effect-strength'}}}",immunization,A2XS5QI4YX493N,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['B', 'A', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8
15-24,"In seven African countries an ongoing phase 3 study of malaria a vaccine RTS SVAS01 is in progress. The purpose of the study is to evaluate the safety, immunogenicity, and effectiveness of the RTS SVAS01 vaccine.  Two age groups of a total of 15,460 children were selected to participate in the study from March 2009 to January 2011, one group being ages 6 to 12 weeks, and the other being ages 5 to 17 months. Three doses of the vaccine were administered and data collection began 12 months after vaccination. Initial incidence in episodes of clinical Malaria was 0.32 episodes per person year in the vaccine group and the control group showed 0.55 episodes per person per year. The efficacy of the group who received the vaccines was 55.8% while the control group had an efficacy of 50.4%. The efficacy against severe malaria of the RTS SVAS01 vaccine was also analyzed to be 47.3%, compared with the efficacy of the control (non-malaria vaccine) group at 45.1%. Both groups presented the same quantity of serious adverse events. ",Some College,female,0.75,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, 'serious adverse event': {'Outcomes'}, 'three dos': {'Intervention'}, '12 month': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, 'serious adverse event': {'Adverse-effects'}, 'three dos': {'Intensity'}, '12 month': {'Duration'}}}",immunization,ADGH08WUP68ZF,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD
40-60,"The first results of the Phase 3 trial of RTS,S/AS01 Malaria vaccine in African children showed that the vaccine provided protection against both clinical and severe malaria in the children.  The study involved over 15,000 children in two age categories: 6 to 12 weeks and 5 to 17 months of age. These children were vaccinated with either the RTS,S/AS01 vaccine, or a non malaria comparator vaccine.   The end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination of the first 6000 children who were aged 5 to 17 months and received all 3 doses of the vaccine according to protocol.  We then evaluated vaccine efficacy against severe malaria in both age categories after 250 children had an episode of severe malaria. For clinical malaria, the vaccine efficacy was 55.8 % in the per protocol population versus 50.4 % in the intention to treat population. Efficacy in severe malaria was 47.3 % in the per protocol population versus 45.1% in the intent to treat population.",College,female,0.5,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 's / as01': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, 'non malaria comparator vaccine': {'Intervention'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 's / as01': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, 'non malaria comparator vaccine': {'Control'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '12 month': {'Duration'}}}",immunization,AON59V5VZU2AK,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['B', 'A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH
40-60,"An ongoing study of the efficacy, safety and immunogenicity of a malaria vaccine RTS, SVAS01 is being conducted in seven African countries. From March 2009 through January 2011, 15460 children were in enrolled in two age categories -- 6 to 12 weeks of age and 5 to 17 months of age -- for vaccination with either RTS, SVAS01 or a non-malaria comparator vaccine. In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, SVAS01 group and 0.55 episodes per person-year in the control group. Vaccine efficacy against severe malaria was 45.1 % in the intention-to-treat population and 47.3 % in the per-protocol population. Overall, rigorous clinical testing in the seven African countries has shown its potential to boost malaria prevention and save lives. Specifically, the RTS, SVAS01 vaccine provided protection against both clinical and severe malaria in African children.",College,female,0.875,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'march 2009 through january 2011': {'Intervention'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'non malaria comparator vaccine': {'Intervention'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'march 2009 through january 2011': {'Duration'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'non malaria comparator vaccine': {'Control'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}}}",immunization,A3D8ZG1VV5FO35,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W
40-60,"This is a summary of the first results of Phase 3 trial of RTS,S/AS01  manufactured by GlaxoSmithKline's Malaria Vaccine in african children. This study was conducted  in seven african countries. During March 2009 thru January 2011 15,460 children in two age categories -6 to 12 weeks of age and 5 to 17 months of age. After the first 14 months and there first dose of the vaccine the incidence of first episodes of clinical malaryia in the first group of children was .32 episodes per person and the RTS,SVAS01 was 0.55 episodes per person. The vaccinne required three doses to be given and was shown efficiacy against severe malaryia inn both age categories. There was a follow up after 11 months and serious adverse events occured with a similar frequency in the two study groups.In conclusion the RTS,SVAS01 vaccine provided  protection against both clinical and severe malaryia in african children.",College,female,0.875,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 's / as01': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'serious adverse event': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 's / as01': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'serious adverse event': {'Adverse-effects'}, 'three dos': {'Intensity'}}}",immunization,A1AZV2XOQK7RSW,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A', 'C'], 'Outcomes': ['A', 'B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO
40-60,"An ongoing phase 3 study of the efficacy, safety, and immungenicity of candidate malaria vaccine RTS SVAS01 is being conducted in 7 African countries. From March 2009 to Jan 2011, 15460 children were enrolled in 2 age categories-6 to 12 weeks and 5 to 17 months-for vaccination w/ either RTS, SVAS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria for 12 months after vaccination in the 1st 6000 children 5 to 17 months who received all 3 doses of vaccine according to protocol After 250 children had an episode of malaria, the vaccine efficacy was evaluated against sever malaria in both age categories. Vaccine efficacy against severe malaria was 45.1% in the intention to treat population and 47.3% in the per-protocol population. Vaccine efficacy against severe malaria in combined age categories was 34.8% in per protocol population during average f/u of 11 months. The RTS, SVAS01 vaccine provided protection against both clinical and severe malaria in African children. ",Some College,female,0.75,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, 'non malaria comparator vaccine': {'Intervention'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '34.8 %': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, 'non malaria comparator vaccine': {'Control'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '34.8 %': {'Effect-strength'}, '12 month': {'Duration'}}}",immunization,A98E8M4QLI9RS,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5
24-39,"In March 2009 to January 2001, there was a trial study of the malaria vaccine. For nearly two years, the phase 3 trial of the malaria vaccine was conducted with African children. There were 15,460 children that were enrolled and they were grouped into two categories. These categories included infants from 6 to 12 weeks of age and infant to toddlers from 5 to 17 months of age. The children were given either the RTS,SVAS01 or a non-malaria vaccine. To determine the success rate, 6,000 children in the 5 to 17 months age group received three doses of the vaccine. Fourteen months after the initial dose, the incidence of malaria in the 6,000 children was 0.23 less when the RTS, SVAS01 was used versus the control group. Thus, the success of the incidence of malaria in this group was 55.8%. Additionally, the vaccine success rate against severe malaria was 47.3% in this group. That is a 2.2% difference than the control group. Thus, the results prove that the RTS, SVAS01 vaccine helped provide immunity against malaria.",College,female,0.625,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, '55.8 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, '55.8 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, 'three dos': {'Intensity'}}}",immunization,A1IIF95II8FISQ,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['B', 'A', 'A', 'A'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF
40-60,"This is a summary of the first results of an ongoing malaria vaccine study carried out with 15,460 children (ages 6-12 weeks and 5-17 months) from seven African countries from March 2009 to January 2011. It is testing the immunogenicity, saftey, and efficacy of the RTS, SVAS01 vaccine as compared to a control of a non-malaria vaccine. Fourteen months after administration, there had been .32 episodes of malaria per person-year in the older vaccinated group, and .55 episodes per person-year in the control group. The overall efficacy rate is 50.4% in the intention-to-treat group, and 55.8% in the per-protocol group. The efficacy against severe malaria is 45.1% in the intention-to-treat group and 47.3% in the per-control group. Combining age categories, efficacy against severe malaria is 34.8% in the per-protocol group at 11 months. Safety is deemed equal for all groups. Incidence of convulsive seizures after vaccination was 1.04 per 1000. The RTS, SVAS01 vaccine is considered safe and effective against clinical and severe malaria in African children.",College,female,0.875,NEJMoa1102287,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '34.8 %': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '34.8 %': {'Effect-strength'}}}",immunization,A2M18DZEPD1XGA,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C', 'A'], 'Outcomes': ['B', 'A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P
24-39,"Researchers conducted a study in Africa on more than 15,000 children between March 2009 and January 2011.  These children were placed into two groups of age 6 weeks - 12 weeks and 5 to 17 months.  The study was conducted to test the effects of a malaria vaccine vs. a non-malaria vaccine.  Children aged 5 to 17 months were given the vaccine 3 times over a course of 12 months.  250 out of 6000 of these children had an episode of severe malaria which led the researchers to test the vaccine in both age groups. A small portion of children reported having convulsive seizures after receiving the vaccine.  The effect of the vaccine was 45.1% in the population that was intended to be treated and 47.3% in the per-protocol population.  Only 0.32 episodes of malaria were found in the first 6000 children in the age group of 5 to 17 months and 0.55 episoded in the control group of children.  The results concluded that the SVAS01 vaccine was effective in protecting against malaria.",College,female,0.75,NEJMoa1102287,"{'Coarse': {'child': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'child': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '12 month': {'Duration'}}}",immunization,A2XS5QI4YX493N,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'C', 'A', 'B'], 'Outcomes': ['B', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,1,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B
24-39,"In order to assess the idea that the MMR vaccine causes autism, a study of Danish children born in the 1990s was conducted.  Researchers accessed children's vaccine records as well as their autism status via Danish government records.  Over 500,000 children were included in the study.  Of these, 82% had received the MMR vaccine.  Of these, approximately 750 were diagnosed with an autistic disorder or another autistic-spectrum disorder.  The researchers than adjusted the figures for potential confounders and determined that the relative risk for autism in the vaccinated group was 0.83; that same statistic was 0.92 fo the unvaccinated group.  This proved that there was no correlation between the MMR vaccine and autism, including no association between the child's age at the time of vaccine, the time since the child was vaccinated or the date of vaccination and the child developing an autistic disorder.",College,female,0.5,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}, 'unvaccinated': {'Control'}}}",immunization,A3BDVHNMJECSKG,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I
40-60,"Many people believe that children's vaccine are a cause of autism. Specifically, the vaccination against measles, mumps, and rubella - referred to as the MMR vaccine - has been singled out as a cause. To determine if cause and effect can be determined, researchers obtained information from several Danish governmental record keepers on children born in Denmark over seven years, from 1991 to 1998. Of the almost 540,000 children studied, 440, 000 (or about 82%) had received the MMR vaccine. Of that total group, about 740 children had been diagnosed with some form of autism-spectrum disorder. Results comparing the rate of autism diagnosis in vaccinated versus non-vaccinated children showed no statistically significant connection between the vaccine and an autism diagnosis, even when controlled for factors like a child's age when he or she was vaccinated or the interval between vaccination and diagnosis of the disorder. The results of the study show that there is no evidence of a link between MMR vaccinations and development of autism. ",College,female,0.875,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A1SXNLUT6WM90L,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X
15-24,"In recent years a hypotheses has emerged that the vaccine against Rubella, Measles, and Mumps (MMR Vaccine) can cause Autism. A retrospective study was conducted to challenge the hypothesis in Denmark between January of 1991 and December 1998. Information was obtained from the Danish National Board of Health on the status of MMR vaccination on the subjects selected and information was obtained from the Danish Psychiatric Central Register on the same selected subjects regarding autism status. 440,655 children out of 537,303 children selected for the study had received the MMR vaccine. A diagnosis of autistic disorder was discovered in 316 children, and a diagnosis of other autistic spectrum disorders was found in 422 children. The results break down to a relative risk of 0.92 for autistic disorder and a relative risk of 0.83 for another autistic spectrum disorder. No parallels were drawn between time since vaccination, vaccination age, or vaccination date and diagnosis of autism. This study supports the hypothesis that MMR vaccine causes Autism is inaccurate and unfounded. ",Some College,female,0.75,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, '537,303': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, '537,303': {'Sample-size'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}}}",immunization,ADGH08WUP68ZF,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37
40-60,"537,303 Danish children born between January 1991 and December 1998 were studied to determine whether the MMR vaccine may cause autism. The Danish Civil Registration System provided birth data and unique identification numbers for the study. The criteria for autism was determined by the Danish Psychiatric Central Register, an organization which stores diagnostic data. 316 of the children were diagnosed with autistic disorder and 422 with other autistic-spectrum disorders. 82% (440,655) of the total number of children had received the MMR vaccine. Researchers calculated that the relative risk of autistic disorder is 0.92, and the relative risk of autistic-spectrum disorders is 0.83. They found no link between vaccination age, length of time since vaccination, or date of vaccination and the diagnoses. The researchers concluded that there is no evidence that autistic disorders are caused by the MMR vaccine.",College,female,0.875,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, '537,303': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, '537,303': {'Sample-size'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}}}",immunization,A2M18DZEPD1XGA,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY
40-60,"A retrospective cohort study of all children born in Denmark from January 1991 thru Dec 1998. The cohort was selected on the basis of data from Danish Civil Registration System that assigns an ID # to every born infant and new resident in Denmark. Information on the children's autism status was obtained from the Danish Psychiatric Central Register. Of the 537303 children in the cohort (representing 2129864 person-years), 440655 (82%) had received the MMR vaccine. We identified 316 children with a dx of autistic disorder and 422 with a dx of other autistic-spectrum disorders. The relative risk of autistic disorder in the group of vaccinated children compared to the unvaccinated group was .92 (95% confidence interval, .68 to 1.24) and the relative risk of another autistic-spectrum disorder was .83 (95% confidence interval, .65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination or the date of vaccination and the development of autistic disorder. The study provides strong evidence against the hypothesis that MMR vaccine causes autism",Some College,female,0.75,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, 'unvaccinated': {'Control'}}}",immunization,A98E8M4QLI9RS,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK
40-60,"Although some people believe there is a causal connection between a child taking the MMR (Measles, Mumps and Rubella) vaccine and development of autism, this study found no link between the vaccine and development of autism in children. The study looked at children born in Denmark between 1991 and 1998. A total of 537,303 children were included in the study. Information came from the Danish National Board of Health (vaccine) and the Danish Psychiatric Civil Registry (autism). Additional information was obtained from the Danish Civil Registration System, the Danish Medical Birth Registry, the National Hospital Registry and Statistics Denmark.No association was found to indicate any correlation between a child developing autism from taking the vaccine. There was no association even after considering the age of the child when vaccinated, the time since vaccination or the time between the vaccination and a diagnosis of autism. ",College,female,0.625,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, '537,303': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, '537,303': {'Sample-size'}}}",immunization,A8QOTDLW0QMPH,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09
24-39,"The article is about the civil survey of the vaccination against the measles, mumps, and rubella which they are causes for autism. Every ones know about the sever effects of autism. They collect autism status from the various non profitable organizations like the danish board of health, Statistics Denmark. From their investigation 537,303 children in the cohort, 440,655 had received the MMR vaccine.  They identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After completing their adjustment for potential con founders.  After the vaccination process the risk will be reduced in good ratio. the risk factor reduced to 0.92. Another autistic spectrum disorder risk factor reduced to 0.83.  There was no association between the age at the time of vaccination and the development of the autistic disorder.This study strongly prove against the hypothesis the MMR vaccination causes autism. ",College,male,0.625,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, '537,303': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, '537,303': {'Sample-size'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}}}",immunization,A1DOY340I9VN92,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z
60+,"A Danish study investigated whether the measles/mumps/rubella (MMR) vaccine causes autism in children.  An uncontrolled, retrospective study of all children born in Denmark between 1991 and 1998 was performed.  Information about births, MMR-vaccination status and autism status for each child was obtained from official records maintained by the government of Denmark.  Records from 537,303 children were examined.  440,665 (82 percent) of the children had received the MMR vaccine.  316 children had received a diagnosis of autistic disorder, and 422 children had received a diagnosis of other autistic-spectrum disorders.  The relative risk of autistic disorder in the group of vaccinated children was compared to the unvaccinated group.  The risk of being diagnosed with autism or autistic disorder was similar in each group.  There was also no association with the age of vaccination, time of vaccination, or date of vaccination with the development of autistic disorder.",College,male,0.875,NEJMoa021134,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, '537,303': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, '537,303': {'Sample-size'}, 'unvaccinated': {'Control'}}}",immunization,A11DLGQTOOSIWR,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY
24-39,"A study that looked at the risk of pertussis in children found that protection against pertussis decreased in the five years following the fifth dose of the DTap vaccine, which is the typical dosage.  The study, done in California on members of Kaiser Permanente Nothern California, included a group of children who were vaccinated approximately between ages 4 and 7; children who were vaccinated as infants or those who had received more than five doses were excluded.  A group of children that had pertussis was compared against two control groups.  The polymerase-charin-reaction (PRC) status of the children was also taken into account.  The risk of pertussis as it related to time that had elapsed since the fifth DTaP dose was then examined.  Those calculations showed that after the fifth dose of DTap, it became increasingly likely to acquire pertussis: the risk went up by 42% per year, on average.  ",College,female,0.5,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3BDVHNMJECSKG,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV
40-60,"In a studied funded by Kaiser Permanente, children in California were assessed for risk of pertussis relative to the time since the 5th dose of DTaP from 2006 to 2011. There was a lg. outbreak in 2010. A controlled study was done involving members of Kaiser in N. California who were vaccinate with DTaP at 47 to 84 months. They were compared with 2 sets of controls: those who were PCR-neg. for pertussis and matched controls from gen. population of plan members. Children who received whole-cell pertussis vaccine during infancy or who received pertussis containing vaccine after their 5th dose of DTaP were excluded. 277 children were compared ages 4 to 12 who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. After the 5th dose of DTaP, the odds of acquiring pertussis increased by and average of 42% per year. Protection against pertussis waned during the 5 years after the 5th dose of DTap. ",Some College,female,0.75,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, '2006 to 2011': {'Intervention'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, '277': {'Participants'}, '4 to 12': {'Participants'}, '3318': {'Participants'}, '6086': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, '2006 to 2011': {'Duration'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, '277': {'Sample-size'}, '4 to 12': {'Age'}, '3318': {'Sample-size'}, '6086': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A98E8M4QLI9RS,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ
24-39,"By the age of 7, children receive five doses of the diphtheria, tetanus, and a cellular pertussis or DTaP.  In California they assessed the risk of pertussis in children who had five doses of DTaP from 2006-2011, which included a large outbreak in 2010.  There was a control study with members of Kaiser Permanente Northern California vaccinated with DTaP between 47 to 84 months.  Children with positive polymerase chain reaction of pertussis were compared with two control groups. The two control groups were those PCR negative and closely matched controls from general population of health plan members.  They studied the risk of pertussis since the fifth DTaP dose. Those who had the whole cell vaccine in infancy or any additional pertussis vaccine after the fifth dose were not studied.277 children from 4-12 years old were positive PCR for pertussis with 3318 PCR negative controls and 6086 matched controls.  Those who received the fifth dose earlier were more likely to be PCR positive. The odds of acquiring pertussis after the fifth dose increased an average of 42% per year.",Some College,female,0.875,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, 'health plan member': {'Intervention'}, '277': {'Participants'}, '3318': {'Participants'}, '6086': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, 'health plan member': {'Control'}, '277': {'Sample-size'}, '3318': {'Sample-size'}, '6086': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A3P46WP16JCU2V,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3
40-60,"By the time they reach age seven, American children have received five doses of three vaccines: diphtheria, tetanus, and accellular pertussis (also called DTaP). The DTaP vaccine is unusual, as the length of protection from the virus is unknown. Research was done recently with children in California who are members of a Kaiser Permanente insurance coverage group, to attempt to determine how long DTaP protection lasts. The study included 227 children, who received the vaccine at 47 to 84 months of age. The study looked at pertussis sufferers and examined how long it had been between their last DTaP vaccine and the contraction of pertussis, and used non-pertussis infected children and members of the general Kaiser Permanente insurance group as controls. (Kaiser Permanente funded the study.) Results showed that after the fifth (and final) dose of DTaP, the odds of a child contracting petrussis went up by 42% each year. ",College,female,0.875,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1SXNLUT6WM90L,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'A', 'B'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C
40-60,"In the United States the average child receives five doses of diptheria, tetanus , and DTaP vaccine before they are 7 years of age. In 2010 there was a large outbreak of Pertussis in children in California. A Kaiser Permanete general population of health club memberss did a study that study shown logistic regression to examine the risk of pertussis in relation to the timesince the fifth DTaP dose. Children who received whole cell pertussis vaccine during infancy or who received any pertussis containing vaccine after their fifth dose were excluded. 277 children were compared ranging from 4 to 12 years of age who had been PCR Positive for Pertussis. In the study the PCR Positive children were more likely to have received the 5th DTaP dose earlier than PCR negative controls were. The duration of protection after the five doses of DTaP is still unknown. The odds of acquiring pertussis had actually increased.",College,female,0.875,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, '277': {'Participants'}, '4 to 12': {'Participants'}, 'united states': {'Participants'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, '277': {'Sample-size'}, '4 to 12': {'Age'}, 'united states': {'Location'}}}",immunization,A1AZV2XOQK7RSW,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q
40-60,"Children in the United States receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) before they turn 7 years old. This is the age by which most children begin school, thus being exposed to other children and also more likely to come in contact with infections. Following a case-controlled study of 277 children aged 4-12, who had pertussis as evidenced by a positive PCR assay, in California from 2006 to 2011, researchers found that the protection of the acellular pertussis vaccine, after five doses in children ages 4 to 12 years, waned during the 5 years following the fifth dose of the vaccine. This showed that these children are 42% more likely to acquire pertussis than children who received the fifth DTaP vaccine later than children with a negative PCR assay. The study had a 95% confidence interval. Therefore it can be concluded a study should be conducted with children receiving either more than 5 doses or with a longer interval between each of the first five doses.",College,female,0.875,NEJMoa1200850,"{'Coarse': {'acellular pertussis vaccine': {'Intervention'}, 'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, '2006 to 2011': {'Intervention'}, 'pertussis': {'Outcomes'}, '277': {'Participants'}, '4 to 12': {'Participants'}, '42 %': {'Outcomes'}, 'united states': {'Participants'}}, 'Fine': {'acellular pertussis vaccine': {'Intervention-general'}, 'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, '2006 to 2011': {'Duration'}, 'pertussis': {'Outcomes-general'}, '277': {'Sample-size'}, '4 to 12': {'Age'}, '42 %': {'Effect-strength'}, 'united states': {'Location'}}}",immunization,A141OEKVSKTOP9,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM
24-39,"In united states ,all the children receive five doses of diphteria,tetnus,and cellular pertussis(DTaP) vaccine before 7 years of age.pertusis is very dangerous,so we have to prevent it.children are basically have less anti power.so we have to protect children from attacking  this kinds of disease.in California the research institution has conducted one research, comparison of positive positive polymerase chain reaction assay with two sets of controls.people affected by PCR negative for pertussis in relation to the duration of time since fifth DTap dose.the research institution compared 277 children with the age of 4 to 12 of age.PCR with 3318 and 6086 mostly liked to receive fifth DTaP earlier than PCR negative .this research shows of PCR(0.001) matched controls of (0.005).if the fifth dose of  DTaP indicates the ratio of 1.42. the odds of acquiring pertussis increased by an average of 42% per yearprotection against pertussis wanted during the 5years after the fifth dose of DTaPwe have to thank to kaiser permanente,funded by him",College,female,0.625,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr negative': {'Intervention'}, '277': {'Participants'}, '4 to 12': {'Participants'}, '3318': {'Participants'}, '6086': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, 'pcr negative': {'Control'}, '277': {'Sample-size'}, '4 to 12': {'Age'}, '3318': {'Sample-size'}, '6086': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A1RVRSK2GTUVGK,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU
40-60,"Children in the United States receive 5 doses of diphtheria, tetanus and acellular pertussis (DTaP) vaccine before the age of 7. It is unknown how long the DTaP vaccine is effective after the 5 doses. A case control study, from 2006 - 2011, was conducted to determine the risk of pertussis in children in California (Kaiser Permanente Northern California members vaccinated with DTaP between 47 to 84 months) after the 5th dose of DTaP. Children (ages 4 - 12) with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay were compared to pertussis PCR negative children and closely matched controls from the general population of health plan members. Statistical analysis was used to determine the risk of pertussis relative to the duration of time since the 5th DTaP dose. The study found PCR positive children were more likely to have received the 5th DTaP dose earlier that PCR negative controls or matched controls . After the 5th dose of DTaP the odds of getting pertussis increased by an average of 42% per year with odds ratio of 1.42 (95% Confidence interval 1.21 to 1.66)",College,female,0.875,NEJMoa1200850,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, 'health plan member': {'Intervention'}, '42 %': {'Outcomes'}, 'united states': {'Participants'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, 'health plan member': {'Control'}, '42 %': {'Effect-strength'}, 'united states': {'Location'}}}",immunization,A3A5AKXXPFA08I,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,1,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O
24-39,"about breast cancer , they have randomized by taking 4560 women and spliting them into two groups, on of the group receive exemestane and another recieve placebo.women had median age 62.5 score of 2.3% risk score first check is 35 months. 11 cases in exemestane 32 cases in placeb and event occured in 88% of exemestane and 85% of the placebo these event should be bone fractures heart attacks other cancers or treatment related death.3 years follow up showed exemestane and serious toxic effects.",College,male,0.7692307692307693,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '88 %': {'Outcomes'}, '85 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '88 %': {'Adverse-effects'}, '85 %': {'Adverse-effects'}}}",breast,A3LR3OFECDICRK,NEJMoa1103507,"{'Coarse': {'Participants': ['B', 'A', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT
40-60,"Breast cancer must be found at earlier stages for treatment to be most effective. A 1976 to 2008 mammography study found that while mammography is effective at detecting early stage breast cancer, there were troubling findings. In 2018, 31% of breast cancer cases were over diagnosed due primarily to hormone-replacement therapy.  Over the past 30 years, around 1.3 million cases were over diagnosed. Researchers concluded that screening mammography has not impacted cases that advance to further stages and has little effect on the mortality rate.",College,female,0.9230769230769231,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8,"{'Coarse': {'screen mammography': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}}}",breast,A13ZQSOMIZAN4Y,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['C', 'A'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,2,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME
40-60,"A trial that lasted five years has shown that Adjuvant therapy with an aromatase inhibitor improves outcome when compared to Tamokifen. These trials lasted 5 years and studied a total of approximately 4,700 patients. After a follow up at the 68 month mark the survival rate was found to be higher in the aromatase inhibitor group over the Tamokifen group and with a 95% confidence rate. Also the adverse events reported at a higher rate in the aromatase inhibitor group.",College,female,0.7692307692307693,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ,"{'Coarse': {'5 year': {'Intervention'}, 'survival': {'Outcomes'}, 'adverse event': {'Outcomes'}}, 'Fine': {'5 year': {'Duration'}, 'survival': {'Outcomes-general'}, 'adverse event': {'Adverse-effects'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['C', 'A', 'B'], 'Outcomes': ['B', 'B', 'D'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H
40-60,"Aromatase inhibitors are better than tamoxifen or raloxifene in treating breast cancer. Exemestane was very effective in reducing breast cancer in a study of post-menopausal women that had an increased risk of developing it. Compared to those given a placebo, there was a 65% reduction. Plus, there were only very slightly more adverse effects with exemestane than with the placebo. This shows that exemestane effected the quality of life as much as those who received no treatment. A 3 year follow-up showed there were no serious side effects.",College,female,0.7692307692307693,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A122XBTHLAFX51,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG
40-60,Ever since mammograms were introduced the number of early stage cancer cases has shown a substantial decrease. Even though variables such as hormone replacement therapy and other adjusted trends were found it shown that breast cancer had possibly been overdiagnosed in almost 1.3 million women in the US in the past 30 years. Thus this study found that while screening is important it only has a small minimal effect on the death rate from the disease.,College,female,0.7692307692307693,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY
24-39,Research done between 1976 and 2008 suggests that breast cancer detection in women has doubled since the United States started conducting mammograms.  These studies were conducted in women over 40.  Conducting breast cancer screens in women has also lead to an 8% decrease in the diagnosis of late stage breast cancer.   These studies do not include data from hormone-replacement therapy and women under the age of 40.  Cancer screens should be conducted in all women in order to detect breast cancer in the early stage.,College,female,0.6923076923076923,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, 'united states': {'Participants'}, '8 %': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, 'united states': {'Location'}, '8 %': {'Effect-strength'}, 'double': {'Effect-strength'}}}",breast,A2XS5QI4YX493N,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,2,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL
24-39,"A study that compared rates of breast cancer deaths between women were screened regularly and those who were not found that the death rate was lower in those who had been screened.  The researchers arrived at this conclusions by comparing not only contemporary groups of women but also historical groups.  In all, data from over 40,000 women with breast cancer was taken into account.  Additionally, the researchers concluded that not only does the screening itself reduce breast-cancer deaths, but so does the availability of mammograms.  ",College,female,0.7692307692307693,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE,"{'Coarse': {'woman': {'Participants'}, 'historical': {'Intervention'}}, 'Fine': {'woman': {'Sex'}, 'historical': {'Control'}}}",breast,A3BDVHNMJECSKG,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX
40-60,"Treatment with an aromatase inhibitor is better than treatment with tamoxifen in premenopausal breast cancer, especially early, hormone receptor positive kind. Two separate trials, by Pfizer, of 4690 women showed that the 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. They also had only slightly more adverse side effects than those given tamoxifen. The research found that women treated with adjuvant treatment with exemstane plus ovarian suppression medication were also more likely to stay in remission.",College,female,0.7692307692307693,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,A122XBTHLAFX51,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW
24-39,"In these trials,2 groups of women were studied. The first group was given exemestane w/ovarian suppression. The other group was given taxifen w/ovarian suppression for 5 years. At the end of the trial the survival rate was 91.1% for the exemenstane group and 87.3% in the tamoxifen group.  There was 194 deaths overall. 30.6% of patients in the exemestane group reported adverse side effects and 29.4% in the tamoxifen group. Exemestane plus ovarian suppression significantly reduced reoccurrence. ",High School,female,0.7692307692307693,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM,"{'Coarse': {'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'woman': {'Participants'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}, '30.6 %': {'Outcomes'}, '29.4 %': {'Outcomes'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'woman': {'Sex'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}, '30.6 %': {'Adverse-effects'}, '29.4 %': {'Adverse-effects'}}}",breast,A2YUCJ28XANFOX,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'B', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X
40-60,"A study conducted between 1976 and 2008 has shown that breast cancer is massively over-diagnosed.  Specifically, as many as one-third of all breast cancer cases - roughly those of 1.3 million US women over the duration of the study - were over-diagnosed. The definition of ""over-diagnosed"" included finding tumors during breast cancer screening that would never have been symptomatic. Over 70,000 US women met this characteristic in 2008. Most likely, this over-diagnosis has been caused by the increase in US patients having exploratory mammograms ",College,female,0.7692307692307693,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A1SXNLUT6WM90L,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3
24-39,"A study has been conducted on more than 40,000 women in Norway ages 50-69.  The study tested the death rate of women who had and had not had a mammogram.  Half of the women received mammograms every two years and the other half did not.  The group that was screened saw the death rate drop by 10% and in the group of women who were not screened the rate was an average of 5 deaths per 100,000 women.  The results show that regular breast cancer screening accounted for almost 1/3rd of the total reduction in breast cancer deaths.",College,female,0.6923076923076923,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '10 %': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '10 %': {'Effect-strength'}}}",breast,A2XS5QI4YX493N,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'B', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y
24-39,"Testing has shown that an aromatase inhibitor (exemestane) improves the outcome in post-menopausal women with breast cancer. 4690 patients were tested over the 5 year time frame. All women in the test did go through ovarian suppression via different methods. The survival rate, after 5 1/2 years, was higher for those also taking exemestane as opposed to tamoxifen. The rate of women who were free of cancer after 5 years was also higher for those taking exemestane. The treatment was found to also aid pre-menopausal women.",Some College,male,0.5384615384615384,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A2WP9EC483LJY4,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'D', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,2,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH
40-60,"A Norwegian study of breast cancer screening, begun in 1996 and finishing in 2005, has shown that breast cancer screening does impact the mortality rate of breast cancer. The study of 40,075 women, divided into four groups for comparison and screened for breast cancer every two years, plus two groups that had been formed ten years earlier. The study discovered that breast cancer screening reduced breast cancer mortality rates by 2.4 women for every 100,00. That is a reduction in mortality of about a third annually. ",College,female,0.7692307692307693,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29,"{'Coarse': {'breast cancer mortality': {'Outcomes'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '40,075': {'Participants'}, '2.4': {'Outcomes'}, 'a third': {'Outcomes'}}, 'Fine': {'breast cancer mortality': {'Outcomes-general'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '40,075': {'Sample-size'}, '2.4': {'Effect-strength'}, 'a third': {'Effect-strength'}}}",breast,A1SXNLUT6WM90L,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'A', 'A'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'A'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,2,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI
40-60,"Effective cancer screening increases early detection and decreases instances of cancer advanced to late stage diagnosis. The introduction of mammogram screenings in the US has been linked with doubling the number of cases of early stage breast cancer, and decreasing the rate of late stage cancer diagnosis. It is estimated that breast cancer has been grossly over diagnosed, and despite increases in the number of early stage breast cancer found, mammograms have only marginally reduced the rate of advanced stage breast cancer found.",College,female,0.7692307692307693,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'late stage': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'double': {'Effect-strength'}}}",breast,AAB13RUHSABEV,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3
40-60,"There was a study done in Norway to determine if making mammograms more readily available would lessen the the amount of deaths that occur in women between the ages of 50-90. It was found that in the area where the tests were made available every two years the death rate dropped by 7.2 compared to the area where additional testing wasn't made available.  Overall the difference between the two groups was less, only 2.4 less deaths reported a year. Results show that additional testing does make a slight improvement and shouldn't be discounted.",Some College,female,0.7692307692307693,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}, '2.4': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}, '2.4': {'Effect-strength'}}}",breast,A1D35QE18L3J5Z,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'D', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['D'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,2,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q
40-60,Studies have shown that patient outcomes are better in postmenopausal women that receive adjuvant therapy with an aromatase inhibitor instead of tamoxifen. Controlled trials demonstrated that adjuvant therapy showed a higher rate of survival at 5 years. However the overall survival and grade 3 or 4 adverse effects were not significantly different between the two groups. The results support previous published studies examining the effects of the two treatments. ,Some College,female,0.9230769230769231,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX,"{'Coarse': {'5 year': {'Intervention'}, 'woman': {'Participants'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'5 year': {'Duration'}, 'woman': {'Sex'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,A5PUKKK7BIV3,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['C', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6
40-60,"After thirty years studies have found that breast cancer screening programs do not reduce breast cancer rates for advanced cancer. In fact the incidence of over-diagnosis where non-symptomatic tumors are found is high with 1.3 million over-diagnoses in the last 30 years and at a rate of 31% in 2008. So while screening rates have doubled the amount of early stage cancer detected, mammography screening is having only a limited effect on the rate of fatal breast cancers.",Some College,female,0.9230769230769231,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'double': {'Effect-strength'}}}",breast,A5PUKKK7BIV3,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV
40-60,A study done shows promising results for the drug Exesestane for breast cancer prevention in post-menopausal women. Aromatase inhibitors like Exemestane are shown to prevent more types of beast cancer and have fewer side effects than Tamoxifen and Raloxifene in patients with early-stage breast cancer. 4560 women median age 62.5 w/ various risk factors were assigned to a group given Exemestane or a placebo & results showed Exemestane sig. reduced invasive breast ca in post-menopausal women who were in the moderate risk grp for developing the ca.,Some College,female,1.0,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, 'placebo': {'Control'}}}",breast,A98E8M4QLI9RS,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'B', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31
40-60,A study of 4560 women aged 62.5 w/ a median Gail risk score of 2.3% were given the drug exemestane or a placebo to see which helped more. After 35 moths a follow up was done. 11 breast cancers were found in women who used Exemestane and 32  in the placebo group. The study showed giving women who prev had breast cancer the drug Exemestane had a 65% reduction in invasive breast cancer. A f/u was done 3 years later and found that Exemestane also had no serious toxic side effects and helped maintain their quality of life after breast cancer. ,Some College,female,1.0,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '65 %': {'Effect-strength'}}}",breast,A98E8M4QLI9RS,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'D', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['D'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC
24-39,"They did a study on a drug called Exemestane on postmenopausal women. The women were given either the drug or a placebo at random. Some of the women who received the drug had very aggressive breast cancer. Some who were given the placebo also had aggressive breast cancer. The rate of aggressive breast cancer was around 35%. A lot of the women who received the drug had adverse effects. Fractures, heart problems and even death occurred as a result. It was shown that the drug did decrease breast cancer.",Some College,female,0.6923076923076923,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, 'placebo': {'Control'}}}",breast,AHYXP6QIMYJLD,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'D', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R
40-60,A 32 year study was done comparing the early and late stages of breast cancer in women over 40.  It concluded that since the inception of mammography screening began in the US there were a large number of diagnoses.  It also discovered a great portion of diagnoses would never develop in to advance stage cancer.  In 2008 it was estimated that 31% of all breast cancer diagnoses were over diagnosed in this manner.  This shows mammography screening has a very slight impact on the total death rate attributed to breast cancer.,College,female,0.8461538461538461,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF,"{'Coarse': {'breast cancer': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}}}",breast,A90NKJUJ7HTEQ,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3
40-60,A recent study has revealed that a new drug is showing great promise in reducing breast cancer among high-risk post-menopausal women over 35 years old.  The random trial of 4560 women revealed Exemestane significantly lowered the incidence of the invasive disease among those considered to be moderate risk. A follow-up study three years alter also revealed no serious toxic effects from the drug and only small changes in health-related quality of life.,College,female,0.7692307692307693,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '35 year': {'Participants'}, '4560': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '35 year': {'Age'}, '4560': {'Sample-size'}}}",breast,A2KROBPV0YPE4A,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8
40-60,"Cancer screening programs are vital for early detection and reducing lives lost to breast cancer. They have been studying for the past 40 yrs to help eradicate it. Mammograms have increased early detection rates & the rate which women present w/ late stage breast cancer has decreased quite a bit. There is still no cure but women are being treated earlier and becoming cancer free at higher rates. It is commonly misdiagnosed because of benign tumors, some caused by hormone replacement therapy, making statistic about diagnoses not always accurate.",Some College,female,1.0,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB,"{'Coarse': {'breast cancer': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}}}",breast,A98E8M4QLI9RS,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'D'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,2,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q
24-39,"A screening mammography study was performed over two years in Norway, and focused on women between the ages 50 and 69. The women were split into 4 different groups: lived in countries with screening between 1996 and 2005, and those that lived in countries that didn't have screen. Using the screening methods, the study found there were only 7.2 deaths per 100,000 women presenting with breast cancer. In Norway, the study found that the screening presented a reduction of 1/3 in the total death count.",Some College,male,0.5384615384615384,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP,"{'Coarse': {'screen mammography': {'Intervention'}, 'norway': {'Participants'}, '50 and 69': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'norway': {'Location'}, '50 and 69': {'Age'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}}}",breast,A2WP9EC483LJY4,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'C'], 'Intervention': ['A', 'D', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ
24-39,For postmenopausal women with breast cancer the adjuvant therapy worked better than tamofoxifen. The researchers used analysis from 4690 patients who were in the trials. In pre-menopausal women with this specific type of breast cancer had a significant reduction in recurrence when taking tamoflexin with ovarian suppression and the treatment that is the topic of this trial. After a follow up 68 moths later the survival rate was about 91% and the survival rate at five years cancer free was about 92%. Postmenopausal women had similar outcomes. ,College,female,0.5384615384615384,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}}}",breast,A2X0O6DN8NQWCJ,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['D', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['D'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319
40-60,"The Cancer Registry of Norway and the research council of Norway funded this study about the effects on screening mammography on breast cancer in Norway. 40,000 female subjects between the ages of 50-69 were offered a mammography screening every two years. The final result concluded that the rate of death dropped by 7.2 per 100,000 people. It is important to note that the historical use of control subjects does not take into account chronologic trends associated with advances in breast cancer.",College,female,0.7692307692307693,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15,"{'Coarse': {'screen mammography': {'Intervention'}, 'norway': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}, 'historical': {'Intervention'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'norway': {'Location'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}, 'historical': {'Control'}}}",breast,AAB13RUHSABEV,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2
40-60,"A drug, Exemestane, is being studied for the prevention of Breast Cancer prevention in Postmenopausal women.  Of the over 4000 women who were at an increased risk the average age was 62.5 years.  The study divided the women into two groups, with one getting the drug and the other a placebo.  After nearly three years the number of cancer cases in the group taking the drug was about one third of the group which was just given the placebo.  No significant increase in side affects were seen with the group taking the drug.",Some College,male,0.8461538461538461,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}, 'placebo': {'Control'}}}",breast,A2IXFVW8GE5NYE,NEJMoa1103507,"{'Coarse': {'Participants': ['B', 'B', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'D', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['D'], 'Conclusion-general': ['B']}}",,2,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2
24-39,"A program in Norway started a study in 1996 to determine if screening women between the ages of 50-69 every two years would reduce the rate of mortality due to breast cancer. Previous studies were not helpful because they did not include current advances in breast cancer treatment or awareness. They compared the results of similar groups of woman who had and did not have screenings. They analyzed data from over 40,000 women and it concluded that the screenings reduced the rate of mortality by 10%. ",College,female,0.8461538461538461,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '10 %': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '10 %': {'Effect-strength'}}}",breast,A1GBNOE5A5PD06,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23
24-39,"They performed a study comparing the treatments of exemestane in premenopausal breast cancer compared to patients using tamoxifen (both with ovarian suppression). The study combined data from 4690 patients in two phase 3 trials, randomly assigning the women into either the exemestane or the tamoxifen group. The study found at follow-up 5 years later that a higher percentage of women in the exemestane group (92.8%) were free of breast cancer compared to the tamoxifen group (87.3%). There was no difference in deaths between groups however.",College,male,0.8461538461538461,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, '92.8 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, '92.8 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A3LW4YHAM1JH1X,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL
40-60,"In Norway, 40,075 breast cancer patients were screened over two decades (1986-1995 and 1996-2005). Each group of patients were divided by screening event (group number one received a mammography and group number two did not).  The results showed that between the two groups who received the screening, the death rate decreased by 7.2 deaths and those which were not screened, by 4.8 deaths (respectively) per 100,000 persons -years.  This data does not take into account any changes in technology which may have occurred over the 20 year span. ",College,female,0.6923076923076923,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3,"{'Coarse': {'norway': {'Participants'}, '40,075': {'Participants'}, '7.2': {'Outcomes'}, '4.8': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, '40,075': {'Sample-size'}, '7.2': {'Effect-strength'}, '4.8': {'Effect-strength'}}}",breast,A2UC2SLI4NPS53,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'A', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ
40-60,"Many drugs are used to prevent breast cancer, including raloxifene and tamoxifen. Patients prefer aromatase inhibitors because of low side effects. Academic study showed extemestane is very effective (65% reduction of invasive breast cancer). 4560 participants (menopausal women 35 or higher showing risk factors). Studied quality of life (impacted by treatment). Participants given placebo or extemestane. Follow up 3 years later. No significant difference in quality of life. Exemestane reduces incidences of breast cancer in menopausal women.  ",College,female,0.7692307692307693,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,AOHQSD0GH8HTE,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC
24-39,"For pre-menopausal women with hormone-receptor positive (HRP) breast cancer, there is another promising treatment available. This treatment is called Adjuvant Exemestane with an aromatase inhibitor. It is also called hormone receptor. A five-year follow up study has shown that, compared to the Tamoxifen treatment, Exemsestane had a higher disease-free survival rate and a higher rate of freedom from cancer. This is great news for women looking for an alternative treatment to suppress the likelihood of HRP breast cancer returning. ",College,female,0.6153846153846154,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK,"{'Coarse': {'5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,AJXWXKU4SX70U,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS
40-60,"An attempt has been made to see if Rosiglitazone; a drug used to treat people who have type two diabetes mellitus, has can cause cardiovascular death or the possibility of death.  Various sources like the food and drug administration and the clinical trials by GlaxoSmithKline (the manufacturer) were used use to find out the associated risks.  The average age of the people in the studies was 56 and 42 out of 116 met the standard.  It was concluded that Rosiglitazone increased the chance of myocardial infarction of death. ",College,male,0.8461538461538461,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,A2XK1V2CEUVC6G,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S
40-60,There was recently research conducted on the effect of Rosiglitazone on myocardial infection and death from cardiovascular risks. The study was based on research conducted by the FDA and the drug manufacturer GlaxoSmithKline. It lasted 24 weeks and counted 42 trials of 116 potentially relevant studies. Most participants were around 56-years-old. The study found that there was an increased risk of death from cardiovascular disease because of the major increase in risk of myocardial infarction.,College,female,0.9230769230769231,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, '24 week': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, '24 week': {'Duration'}, '42 trial': {'Sample-size'}}}",cardio,A25AJ66CYVUTBR,NEJMoa072761,"{'Coarse': {'Participants': ['B', 'C', 'A'], 'Intervention': ['D', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF
40-60,"Forty-two (42) studies regarding ROSIGLITAZONE, a Type 2 Diabetes drug, were examined for cardiovascular side effect data. The studies has these points in common : 24 or more weeks in length, use of a ROSIGLITAZONE-free control group, and myocardial and cardiovascular death data. The average age of patients was 56, hemoglobin level of 8.2%. There were significantly higher myocardial infarction deaths among ROSIGLITAZONE users and some increase in cardiovascular death.",Some College,male,0.9230769230769231,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, 'control group': {'Control'}}}",cardio,A1WNHGZ8S46T3C,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF
24-39,"Studies have shown that taking more sodium than 3.95g per day increases risk of high blood pressure which will likely increase one's chance of getting cardiovascular disease.  Specifically there were 1.65 million deaths from the disease and research shows they were getting over the threshold of 3.95g.  More specifically those affected were from low and middle income countries.  Due to this data from such organizations as the Bill and Melinda Gates foundation, researchers suggest reducing sodium intake to 2g per day,",College,male,0.7692307692307693,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,AXY0D2AMLKE2A,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM
60+,"There is a drug containing an ingredient called hiazolidinedione, which are included in many medications used to lower blood sugar levels in people with type II diabetes.  It was removed from the market because of concerns of hepatoxicity.  Studies determined if these kinds of drugs add complications to people with cardiovascular disease or diabetes.  It was determined that the effect could not determined.  The study showed that 65% of death in patients occur because of diabetes and heart issues and that medication is extremely important.",Some College,female,0.9230769230769231,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI,"{'Coarse': {'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,AAN06KVDS2XRY,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['D', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['D'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,2,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7
40-60,"A study was done to see if there was an increased risk of cardiovascular death for patients taking Azithromycin. The study compared patients who took Azithromycin to patients taking amoxicillin, ciprofloxacin or levofloxacin, and to people taking no antibiotics at all. Over five days of therapy the highest risk was for patients taking Azithromycin or levofloxacin. The next level of risk was for patients taking ciprofloxacin. Patients taking amoxicillin had no increased risk when compared to people not on antibiotics.",College,female,0.6923076923076923,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'no antibiotic': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'no antibiotic': {'Control'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A8QOTDLW0QMPH,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'B'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0
24-39,Information was gathered from people residing in 66 countries. It was about sodium levels and their effect on diseases of the heart and related death. People who have a diet high in sodium are at risk of heart disease and high blood pressure. Men are more subsebtable to the effects with 61.9% of death compared to 38.1% with women dying from cardiovascular diseases. Only 9.5% of the deaths were connected to a high sodium diet. The country Georgia had the most deaths compared to Kenya. 2000 mg per day Is considered high sodium.,Some College,male,0.9230769230769231,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK,"{'Coarse': {'66 country': {'Participants'}, '9.5 %': {'Outcomes'}}, 'Fine': {'66 country': {'Location'}, '9.5 %': {'Effect-strength'}}}",cardio,A39GH5GG2B7KA1,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ
40-60,"There are some antibiotics that increase your risk of cardiovascular death. Medications that were studied and discovered to contribute to this type of a death include Azithromycin, Ciprofloxacin, and Levoloxacin. A 5-day treatment with these is dangerous, which is why Amoxicillin should be used instead. There's no increased risk of cardiac related death with it. This is something that people who already have an increased risk of dying from a cardiac related incident should pay special attention to.",College,female,0.9230769230769231,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A25AJ66CYVUTBR,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF
24-39,"A study on the link between sudden cardiac death and use of antibiotic medication was done using a Tennessee Medicaid group. The short term effects of azithromycin, ciprofloxacin and levfloxacin on the heart were monitored as patients took the medicine over the course of five days. Those who were treated with azithromycin were at the highest risk of cardiac events compared to those who took one of the other medications. Patients with higher baseline risk of cardiovascular disease were more likely to die due to antibiotic use.",College,female,0.9230769230769231,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, 'ciprofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, 'ciprofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A6CVN7CSC1K26,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M
24-39,"From a large and diverse enough sample size to account for 74.1% of humans, researchers collected data to compare race, age, and the presence of hypertension to the level of sodium intake and its effect on blood pressure and cardiovascular mortality.  The metrics of sodium were defined by a comparison to the global average intake to postulate a connection between demographic and the 1.65 million deaths related to sodium intake.  61.9% of these deaths are men and 40% of these deaths occurred before the individual was 70 years old.",College,male,0.9230769230769231,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ,"{'Coarse': {'74.1 %': {'Participants'}, '1.65 million': {'Outcomes'}}, 'Fine': {'74.1 %': {'Sample-size'}, '1.65 million': {'Effect-strength'}}}",cardio,AY4QOQCWAJ0RN,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'A'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC
24-39,"A study about the cardiovascular outcomes of overweight and obese patients looked at 10744 subjects affected by cardio problems. The test subjects were enrolled in a weight management program and the average treatment duration was 3.4 years. Patients taking sibutramine were compared against a placebo group and the primary end point was the time from randomization to the first occurrence of a primary outcome event. The risk of nonfatal cardiac events was 11.4% in the sibutramine group and 10% in the placebo group, but death rates were similar.",College,female,0.9230769230769231,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K,"{'Coarse': {'sibutramine': {'Intervention'}, 'cardiovascular outcome': {'Outcomes'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '11.4 %': {'Outcomes'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'cardiovascular outcome': {'Outcomes-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '11.4 %': {'Effect-strength'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A6CVN7CSC1K26,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M
40-60,"In a Tennessee Medicaid cohort study designed to detect an increased risk of death related to short term cardic effects of medication, the following medications were considered: azithromycin, amoxicillan, ciprofloxacin ,and levofloxacin. In 5 days of therapy, patients had an increased risk of cardiovascular death taking azithromycin compared to no meds, while patients who took amoxicillian had no increased risk of death at all.  The risk with azithromycin was much greater than with ciprofloxican.",College,female,0.8461538461538461,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'tennessee': {'Participants'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'tennessee': {'Location'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,AON59V5VZU2AK,NEJMoa1003833,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R
40-60,"A study funded by the Bill and Melinda Gates Foundation studied Sodium Chloride (salt) consumption in the world, accounting for 74.1% of adults, the lowest consumption being in the nation of Kenya and the highest in the nation of Georgia. One hundred and seven (107) people of differing age, gender, and nationality were randomly chosen to study the supposed risk of 1.65 million deaths per year from salt consumption above 2 grams per day. The global average was 3.95 grams of salt per day per person, but ranged from 2.18 to 5.51 grams.",Some College,male,0.9230769230769231,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0,"{'Coarse': {'74.1 %': {'Participants'}, '1.65 million': {'Outcomes'}}, 'Fine': {'74.1 %': {'Sample-size'}, '1.65 million': {'Effect-strength'}}}",cardio,A1WNHGZ8S46T3C,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'A'], 'Intervention': ['A'], 'Outcomes': ['B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J
40-60,"This study involved a Tennessee Medicaid cohort to assess whether there was an increased risk of death from short term cardiac effects from taking one of 4 different types of antibiotics over a 5 day period. Results showed that there was no incraesed risk with the amoxicillin, but a small absolute increase in the CV deaths among patients with a high baseline risk of cardiovascular disease.  The risk was significantly greater with azithromycin than with ciprofloxaciin, but not much different than levofloxacin.",College,female,0.8461538461538461,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, 'amoxicillin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, 'amoxicillin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,AON59V5VZU2AK,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H
24-39,"Analysis of approximately one third of all studies on Rosiglitazone, a drug used to treat type two diabetes, show that it significantly increases the risk of myocardial infarction. It also revealed an increased risk of death from cardiovascular causes. These results are not entirely inclusive because researchers had only limited access to the studies' original source data. The results, however, should not be ignored by either patients or providers when discussing the possibility of starting Rosiglitazone.",Some College,female,0.6923076923076923,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,AUPHYAKC58LPA,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC
15-24,"Out of all the macrolides used in medicinal practices, azithromycin is one of the least harmful. A study was done to determine risk of cardiac-related death due to these medications. One group in the study took macrolides while the other did not. Those taking azithromycin had a higher risk of heart-related death than the amoxicillin group. They also had a much higher risk of cardiovascular-related death than the ciprofloxacin group. Overall, treatment with azithromycin led to a small increase in the risk of cardiovascular death. ",College,female,0.6153846153846154,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}}}",cardio,A34RU3V8G203GN,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS
24-39,Treatment with rosiglitazone for type 2 diabetes should be carefully considered due to its serious effects. A group of 42 people were studied over 24 weeks. Some were given rosiglitazone. They checked the outcome data for myocardial infarction and death from cardiovascular causes. In the group given rosiglitazone the ratio for mycoardio infarction was 1.43 and the odds of death from cardiovascular causes was 1.64. This shows that rosigliglitazone is associated with a high risk of myocardial infarction or death from cardiovascular causes.,College,female,1.0,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}, '1.43': {'Outcomes'}, '1.64': {'Outcomes'}, '24 week': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}, '1.43': {'Effect-strength'}, '1.64': {'Effect-strength'}, '24 week': {'Duration'}}}",cardio,A2Y9ZNZ0F24GHB,NEJMoa072761,"{'Coarse': {'Participants': ['D', 'A', 'C'], 'Intervention': ['D', 'B', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL
15-24,"10,744 overweight individuals over the age of 55 that have had cardiovascular disease, type 2 diabetes, or both were investigated under the effects of sibutramine or a placebo and a weight management program for 6 weeks. The duration of treatment was 3.4 years and the result included: an average of 2.6 kg of weight loss at 6 weeks in the drug group, both groups decreased in blood pressure, and sibutramine seems to have a more substantial effect than placebo. Those under long term sibutramine had increase risk of infarction and nonfatal stroke.",College,male,0.8461538461538461,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, '10,744': {'Participants'}, 'type 2 diabete': {'Participants'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, '10,744': {'Sample-size'}, 'type 2 diabete': {'Condition'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A3723CQM6I92CU,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI
40-60,"Because the drug AZITHROMYCIN produced reports of heart arrhythmias and cardiovascular death, a cohort (observational study) was devised to test this danger. Patients with serious non-cardiovascular illness were excluded, and the time frame was during and after hospitalization. In a five day test, patients receiving AZITHROMYCIN had an increased death rate, while patients who took AMOXICILLEN had no increase. There was an additional 47 deaths by cardiovascular failure per 1 million patients, similar to LEVOFLOXACIN.",Some College,male,0.9230769230769231,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'levofloxacin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'levofloxacin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A1WNHGZ8S46T3C,NEJMoa1003833,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ
15-24,"According to demographics and calculated meta-analysis, having a high amount of sodium in the diet increases blood pressure. Studies have not yet shown the effects that sodium has on cardiovascular death, though. In 2010, it was shown that 1.65 million deaths were directly associated with high amounts of sodium consumption above the normal reference levels. This data also showed that the most deaths occurred in low and middle-income countries, with Georgia having the highest reference level and Kenya with the lowest.",College,female,0.6153846153846154,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX,"{'Coarse': {'sodium consumption': {'Intervention'}, '1.65 million': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, '1.65 million': {'Effect-strength'}}}",cardio,A34RU3V8G203GN,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X
15-24,A study was done to assess cardiovascular consequences of weight management with and without sibutramine in those at high risk of cardiovascular events. Overweight or obese subjects that were at least 55 years old and that had preexisting medical conditions participated in the study. The subjects received both sibutramine and a weight management program for 6 weeks. The end results concluded that those receiving the sibutramine on a long-term basis had an increased risk of infraction and stroke (nonfatal) but not of cardiovascular death.,College,female,0.6153846153846154,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '55 year': {'Participants'}, 'cardiovascular event': {'Outcomes'}, 'cardiovascular death': {'Outcomes'}, 'overweight or obese subject': {'Participants'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '55 year': {'Age'}, 'cardiovascular event': {'Outcomes-general'}, 'cardiovascular death': {'Outcomes-general'}, 'overweight or obese subject': {'Condition'}}}",cardio,A34RU3V8G203GN,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB
60+,"In a study of sodium intake and its impact on cause specific mortality related to cardiovascular causes, results showed that globally, 1.65 million (or one out of 10) annual deaths from cardiovascular causes were attributable to sodium intake above 2.0 g/day reference level. Also considered in the study were aspects such as age, country, blood pressure, race and absence or presence of hypertension. The highest cardiovascular caused death counts related to high sodium consumption were in the country of Georgia and the lowest were in Kenya.",College,female,0.8461538461538461,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q,"{'Coarse': {'sodium consumption': {'Intervention'}, 'death from cardiovascular cause': {'Outcomes'}, '1.65 million': {'Outcomes'}}, 'Fine': {'sodium consumption': {'Intervention-general'}, 'death from cardiovascular cause': {'Outcomes-general'}, '1.65 million': {'Effect-strength'}}}",cardio,A37CE37LHUN8M6,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL
24-39,Employing a fixed effects model researchers measured the efficacy of rosiglitazone as a treatment in patients diagnosed with Type 2 Diabetes and findings showed a potential risk for serious adverse cardiovascular effects in men. The study spanning 24 weeks examined the symptoms and chances of a diabetes patients risk of cardio attack. This study paid particular attention to all the occurrences of myocardial infraction data collected from 116 studies and the 42 traits of the men included. ,College,female,0.7692307692307693,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'diabete': {'Participants'}, '24 week': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'diabete': {'Condition'}, '24 week': {'Duration'}}}",cardio,A35F1LYW2ZXWLT,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4
15-24,"Research was conducted in published literature, the FDA website, and clinical-trial registries. Search parameters included studies lasting longer than 24 weeks, randomized control groups without the use of rosiglitazone, and available results for myocardial infraction and cardiovascular related deaths. In the 42 available trials, the average subject age was 56 years and the average baseline glycated hemoglobin level was 8.2%. The ratio of myocardial infarction of the drug to control group was 1.43 and 1.64 for cardiovascular death.",College,male,0.8461538461538461,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, '56 year': {'Participants'}, '1.43': {'Outcomes'}, '1.64': {'Outcomes'}, '24 week': {'Intervention'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, '56 year': {'Age'}, '1.43': {'Effect-strength'}, '1.64': {'Effect-strength'}, '24 week': {'Duration'}, 'control group': {'Control'}}}",cardio,A3723CQM6I92CU,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS
40-60,"Sibutramine treatment effects cardiovascular health. One study looked at 10,477 overweight people age 55+ who had preexisting cardiovascular disease. When they participated in a 6-week weight management program, 11.4% of them were able to lose 2.6kg. There was no increase in cardiovascular death. However, when they received long-term sibutramine treatment their risk of nonfatal myocarial infarcation and suffering a non fatal stroke did seem to rise.",College,female,0.9230769230769231,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'preexist cardiovascular disease': {'Participants'}, 'cardiovascular death': {'Outcomes'}, '11.4 %': {'Outcomes'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'preexist cardiovascular disease': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, '11.4 %': {'Effect-strength'}}}",cardio,A25AJ66CYVUTBR,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6
40-60,In 2010 a global study showed that the average sodium consumption for a person worldwide was almost twice the recommended limit of 2.0g/day. Increased sodium intake increases the risk of cardiovascular disease. This risk is evidenced most in low/middle income countries where people are not as educated about the connection between elevated high blood pressure and the  increased cardiovascular risk associated with a high sodium intake. Education on limiting intake of high sodium food and drink would decrease deaths from cardiovascular disease.,College,female,0.6923076923076923,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530,"{'Coarse': {'sodium consumption': {'Intervention'}}, 'Fine': {'sodium consumption': {'Intervention-general'}}}",cardio,A8QOTDLW0QMPH,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D
24-39,"A comprehensive 3.4 year study of 10,744 overweight or obese participants showed that subjects with preexisting cardiovascular conditions who received siburatmine had an increased risk of adverse side effects but no increase risk in cardiovascular death.  Of the 10,744 subjects 9804 were further enrolled in a double blind test, where weight loss was achieved and mean blood pressure levels decreased more pronouncedly in the placebo group. Both groups did not show an increase in cardiovascular death rates.  ",College,female,0.7692307692307693,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1,"{'Coarse': {'overweight': {'Participants'}, 'obese': {'Participants'}, '10,744': {'Participants'}, 'cardiovascular death': {'Outcomes'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'overweight': {'Condition'}, 'obese': {'Condition'}, '10,744': {'Sample-size'}, 'cardiovascular death': {'Outcomes-general'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A35F1LYW2ZXWLT,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67
24-39,Data collection from 66 countries on sodium intake was taken. Globally 1.65 million deaths occur each year due to cardiovascular causes attributed to high sodium intake. 61.9% of men and 38.1% of women is the gender difference and account for 9.5% of deaths from cardiovascular disease. 4 out of 5 deaths happened in low to middle income countries. 2 out of 5 deaths were premature (before the age of 70). The highest rate of death was in the country Georgia and lowest in Kenya.,College,male,1.0,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O,"{'Coarse': {'66 country': {'Participants'}, '1.65 million': {'Outcomes'}, '9.5 %': {'Outcomes'}}, 'Fine': {'66 country': {'Location'}, '1.65 million': {'Effect-strength'}, '9.5 %': {'Effect-strength'}}}",cardio,A2ELH7YDLFNJUZ,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY
60+,"Almost 11,000 subjects aged 55+ who had been diagnosed with either heart disease, Type 2 diabetes, or both were studied for 3.3 years. The placebo group fared better on almost all metrics, including blood pressure as well as nonfatal mycocardial infarctions and stroke rates. Cardiovascular death rates were no affected. Subjects with previously diagnosed cardiovascular conditions had an greater risk of nonfatal mycocardial infarction and non-fatal stroke; however, neither cardiovascular nor death by all all causes were unaffected. ",College,male,0.8461538461538461,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5,"{'Coarse': {'type 2 diabete': {'Participants'}, 'cardiovascular death': {'Outcomes'}, 'placebo': {'Intervention'}}, 'Fine': {'type 2 diabete': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, 'placebo': {'Control'}}}",cardio,A2H1QUGX0SOUMH,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['C', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S
15-24,"A study was done looking at the effects of sibutramine on cardiovascular events in overweight people, over the age of 55 with cardiovascular and/or diabetes. Both the control and test group were given a weight management program, but the control group were given a placebo rather than sibutramine. The study lasted 3.4 years and both groups lost weight and had reduced blood pressure. Subjects who received the sibutramine had increased risks of non fatal heart infractions and non fatal stroke.",Some College,male,0.6923076923076923,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'cardiovascular event': {'Outcomes'}, '3.4 year': {'Intervention'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, '3.4 year': {'Duration'}, 'placebo': {'Control'}}}",cardio,A1L8MS88CH35ZP,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0
40-60,A Tennessee Medicaid cohort was designed to detect an increased risk of death from short term cardiac effects of azithromycin and amoxicillin during 5 days of therapy.  Subjects who took amoxicillin had no increased risk of death. Those who took azithromycin had an associated risk of cardiovascular death which was greater among patients with a high baseline risk of cardiovascular disease. There was an estimated 47 additional cardiovascular deaths per 1 million courses with the azithromycin..,College,female,0.8461538461538461,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'tennessee': {'Participants'}, 'amoxicillin': {'Intervention'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'tennessee': {'Location'}, 'amoxicillin': {'Control'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,AON59V5VZU2AK,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK
24-39,"A study was conducted, of over 10,000 overweight or obese people in their 50s; who also had preexisting cardiac problems or type 2 diabetes. it tested the cardiac issues of weight management with and without Sibutramine in people who were at high risk of a cardiac event. They all took Sibutramine, after a double blind study that used the drug as well as a placebo. They measured the time of treatment, until the occurrence of a bad health event. Blood pressure levels went down. There were no deaths.",Some College,female,0.6923076923076923,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, 'type 2 diabete': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, 'type 2 diabete': {'Condition'}, 'placebo': {'Control'}}}",cardio,AHYXP6QIMYJLD,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,2,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB
40-60,"In a clinical research trial study determining which nutrients are advantageous in weight loss ( carbohydrates, proteins, fats), 811 overweight adults we were assigned 1 out of 4 random diets, which consisted of similar foods containing carbs, fats and protein.  At 6 months, the weight loss was 6 kg.  However, weight gain occurred after 12 months. In 2 years, weight remained the same in those whose diet contained 15%-25% protein. Those assigned 20%-40%, fat in their diet, lost an average of 4 kg. All three nutrient diets produced weight loss.",College,female,0.8888888888888888,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '20': {'Intervention'}, '15': {'Intervention'}, '25': {'Intervention'}, '40': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '20': {'Intensity'}, '15': {'Intensity'}, '25': {'Intensity'}, '40': {'Intensity'}}}",diet,A1CYGMPC6W59KK,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW
40-60,"According to a study of 120,877 people, lifestyle changes may prevent weight gain.  Between 1986 and 2006, healthy people were examined every four years.  The average weight gain during the four years was 3.35 pounds.  Increased weight correlated with intake of starchy food, meat, alcohol, smoking, people who sleep more than 6 hours, and tv watchers.  Decreased weight was seen with a vegetarian diet.  Overall, the study shows that specific dietary and lifestyle factors affect long-term weight gain.",College,male,0.8333333333333334,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}}}",diet,A2C4VDQC5HQ1YP,NEJMoa1014296,"{'Coarse': {'Participants': ['B', 'C', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['B'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU
40-60,"In an effort to determine if coffee, one of the worlds most-consumed beverages, is a contributing factor to death, a National Institutes of Health study followed nearly 6 million people between the ages of 50 and 71 between 1995 and 2008. Coffee consumption was examined in those people not suffering from diseases like heart disease, stroke and cancer.  Of the people who died, death risk did increase with coffee consumption, but once adjustments were made for con-founders (like smoking), an inverse association with cause of death was shown. ",College,male,0.8333333333333334,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM,"{'Coarse': {'coffee': {'Intervention'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A2C4VDQC5HQ1YP,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'A', 'D'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB
40-60,"A 4.8 year trial was done by the Spanish government's Instituto de Salud Carlos III on the Mediterranean diet. To divide the 7447 people aged 55 -80 they supplemented the diet into either extra virgin olive oil users or Mixed nut users. The study wanted to see if there was a difference between the two groups. Neither group showed any signs of heart disease at the beginning of the study, but were considered at risk for some kind of cardiovascular event. 288 individuals had a problem according to the studies conclusion. ",Some College,female,0.6666666666666666,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '7447': {'Participants'}, '4.8 year': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '7447': {'Sample-size'}, '4.8 year': {'Duration'}}}",diet,A2LTOS0AZ3B28A,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'A', 'A', 'A'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,2,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22
40-60,"Weight loss trials are being conducted. Four diets were used with different percentages to observe changes in body weight. After 6 months the results were in.  It was found that participants in general average lost was 7 percent of their initial weight. After a year most had started to gain their weight back. It was deduced that between the protein, fat and carbohydrates that reduced calorie diets resulted in weight loss no matter which of the three nutrients was emphasized.",College,female,0.7222222222222222,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '3.0': {'Outcomes'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '3.0': {'Effect-strength'}, '6 month': {'Duration'}}}",diet,A1AZV2XOQK7RSW,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01
40-60,"In a clinical research trial determining dietary and other lifestyle behaviors in weight management, investigations were done among 120,000 non-obese men and women that were free of chronic disease and from the US. Evaluations of changes in lifestyles and weight changes were performed every 4 years between the years 1986-2006, 1991-2003, and 1986-2006. Participants gained 3.35 lbs every 4 years. Weight increase was more prevalent in those that did not eat as healthy. Stress, alcohol use, physical activity and smoking influenced weight change.",College,female,0.8888888888888888,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'free of chronic disease': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'free of chronic disease': {'Condition'}}}",diet,A1CYGMPC6W59KK,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29
40-60,"In a cardiovascular study and prevention trial conducted in Spain, a Mediterranean diet supplemented with extra virgin olive oil, mixed nuts, or the general reduction of dietary fat, resulted in fewer cardiovascular events among persons at high cardiovascular risk. The study involved 7447 persons between the ages of 55-80, and 57% were women. Participants had no cardiovascular disease at enrollment.  Participants received quarterly individual and group educational sessions throughout the study. Study lasted 4.8 yrs and results recorded.",College,female,0.6666666666666666,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'high cardiovascular risk': {'Participants'}, 'no cardiovascular disease': {'Participants'}, '7447': {'Participants'}, '57 %': {'Participants'}, 'spain': {'Participants'}, 'fat': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'high cardiovascular risk': {'Condition'}, 'no cardiovascular disease': {'Condition'}, '7447': {'Sample-size'}, '57 %': {'Sex'}, 'spain': {'Location'}, 'fat': {'Control'}}}",diet,AGHKGWDYPVDFE,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A', 'A'], 'Intervention': ['B', 'B', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB
40-60,"Investigations of 120,877 healthy people were conducted in 2 cohorts. Lifestyle factors and weight were taken at 4 year intervals with adjustments for age and baseline BMI. All lifestyle factors, cohort, and sex specific results were similar.  3.35 pounds was gained on average each interval, with increased amounts of potatoes, chips, sugary beverages, and red meats, and inversely associated with increased vegetables, whole grains, fruits, nuts, and yogurt. This change included physical activity, alcohol and tobacco use, sleep, and TV watching.",College,male,0.7777777777777778,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5,"{'Coarse': {'lifestyle': {'Intervention'}, '120,877': {'Participants'}}, 'Fine': {'lifestyle': {'Intervention-general'}, '120,877': {'Sample-size'}}}",diet,A21DI93ONQ4P6J,NEJMoa1014296,"{'Coarse': {'Participants': ['B', 'C', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8
40-60,A study was conducted to examine the link between consuming coffe and death. This study was conducted over twelve years and included smokers and non-smokers. Coffee drinkers were found to be more likely to smoke thus given that increase in many illnesses. Similar findings were found with those who had never smoked yet drank coffee and shown increased mortality as well.  The study ended up showing an direct association between natural death or cause specific. Study found it is unknown the reasoning.,College,female,0.7222222222222222,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H,"{'Coarse': {'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, 'man': {'Participants'}}, 'Fine': {'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, 'man': {'Sex'}}}",diet,A1AZV2XOQK7RSW,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,2,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O
40-60,"A study of 7447 participants who were high risk cardiovascular risk, but no disease at time were used to analyze the association of disease risk's by using the Mediterranean diet.  Ages were 55 to 80 years old, half were women and half men and divided into three groups each given the diet.  One group was given extra virgin olive oil, one nuts, and the last a controlled diet.  The Trial was 4.8 years.  The result showed that extra virgin olive oil or nuts reduced the incidence of major cardiovascular events.",College,female,0.6111111111111112,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '7447': {'Participants'}, '55 to 80 year': {'Participants'}, '4.8 year': {'Intervention'}, 'control': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '7447': {'Sample-size'}, '55 to 80 year': {'Age'}, '4.8 year': {'Duration'}, 'control': {'Control'}}}",diet,A90NKJUJ7HTEQ,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'B', 'A', 'C', 'A'], 'Intervention': ['B', 'B', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['B'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV
15-24,"Reduced-calorie diets result in weight loss regardless of whether they are protein, fat, or carbohydrate based. In our study, 811 overweight adults were assigned similar diets with a focus on these three different nutrient makeups. After 6 months, the average participant showed 6kg of weight loss, regardless of which nutrient the diet emphasized. After 2 years, the average weight loss was similar, at 4kg. Only 14 - 15% of the participants lost at least 10% of their starting body weight. ",Some College,female,0.7777777777777778,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '3.0': {'Outcomes'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}, '15': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '3.0': {'Effect-strength'}, '6 month': {'Duration'}, '2 year': {'Duration'}, '15': {'Intensity'}}}",diet,A3SGR153YCJ1XN,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I
40-60,The results of a study conducted in Spain showed that people who are at a high risk for heart-related health issues were able to decrease their likelihood of suffering a major heart attack or similar by following a Mediterranean diet. Seven thousand participants were assigned to either of the two Mediterranean diets including extra-virgin olive oil or mixed nuts or to a third group who were assigned to a low fat diet. The two groups on the Mediterranean based diets had the best results overall for reduced risk of heart related issues.  ,College,female,0.7222222222222222,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'spain': {'Participants'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'spain': {'Location'}, 'fat': {'Control'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'B', 'A', 'A'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG
40-60,"A two year weight loss study measured protein, fat, and carbohydrates. The factors were adjusted per group for 811 overweight adults. Objective was to see which group lost the most weight. Participants were asked to follow a percentage, with little consistent weight loss seen. Those who stuck with it, lost an average of 4 kg. They were offered group sessions, attendance influenced outcome. All participants lipids and fasting insulin rates improved. Reduced calorie diet also resulted in weight loss. Satiety and hunger were also influenced.",College,female,0.8333333333333334,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '2 year': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '2 year': {'Duration'}}}",diet,AOHQSD0GH8HTE,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK
40-60,"20 year study on long term weight gain looked at 120,877 men and women not overweight or with chronic health conditions. Evaluations and adjustments every 4 years  for baseline BMI and lifestyle factors. An increase in processed foods (chips, potatoes etc.) in their diets increased weight gain. Average of 3.5 lbs over 4 years. If these people ate better and included vegetables, whole grain, fruit and nuts they could help alleviate the gain. Smokers and former smokers gained weight. If factors are watched, obesity can be avoided.  ",College,female,0.8333333333333334,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, 'long term': {'Outcomes'}, '120,877': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}, '120,877': {'Sample-size'}}}",diet,AOHQSD0GH8HTE,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465
40-60,"After a study of both men and woman, ranging in time from 1995 to 2008 the National Institute of heath noted a potential increased risk of death by people ages 50-71 who consumed coffee. When these numbers were adjusted for other risk factors such as smoking tobacco and compared to groups that included non-smokers the data still found significant risk. In the end the study couldn't determine whether the risk stemmed from coffee drinking or that it was merely correlative. ",College,male,0.7777777777777778,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M,"{'Coarse': {'coffee': {'Intervention'}, 'man': {'Participants'}, 'woman': {'Participants'}, '1995': {'Intervention'}, '2008': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}, 'man': {'Sex'}, 'woman': {'Sex'}, '1995': {'Duration'}, '2008': {'Duration'}}}",diet,A2O4QKZW68XFQA,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,2,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6
24-39,"Studies show an inverse association between the Mediterranean diet and cardiovascular risk. People at high risk with no cardiovascular disease were randomly assigned to 1 of 3 diets: Mediterranean supplement with extra virgin olive oil, a supplement with mixed nuts, and a control diet. The study consisted of 7447 people ranging 55-80 years old.  96 events occured in the group with olive oil, compared with 83 in the nuts group, and 109 in the control group. ",College,male,0.7777777777777778,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'no cardiovascular disease': {'Participants'}, '7447': {'Participants'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'control': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'no cardiovascular disease': {'Condition'}, '7447': {'Sample-size'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'control': {'Control'}, '109': {'Effect-strength'}}}",diet,A3CFULTNTVCYE2,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'A', 'C', 'A'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4
15-24,"Mediterranean diets can reduce the risk of cardiovascular disease. 7,447 people separated into 3 groups took part in a trial in Spain; the two groups assigned a Mediterranean diet supplemented with nuts or olive oil had 83 and 96 cardiovascular events, respectively. The last group only advised to reduce fat intake had 109 events. Data was taken over 4.8 years. Participants ranged from 55-80 years old and were all at high risk for cardiovascular disease. ",Some College,female,0.7777777777777778,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '96': {'Outcomes'}, '83': {'Outcomes'}, 'spain': {'Participants'}, '4.8 year': {'Intervention'}, 'fat': {'Intervention'}, '109': {'Outcomes'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '96': {'Effect-strength'}, '83': {'Effect-strength'}, 'spain': {'Location'}, '4.8 year': {'Duration'}, 'fat': {'Control'}, '109': {'Effect-strength'}}}",diet,A3SGR153YCJ1XN,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'B', 'B', 'A', 'A'], 'Intervention': ['B', 'B', 'B'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z
40-60,"Over 800 adults participated in a study examining weather differing ratios of fat, protein, and carbs effect weight loss differently.  Each adult was put on a selected diet, but all contained similar foods.  After 6 months of diet and group or individual instructional sessions, each participant lost about 6 kg, regardless of the specific diet.  The study showed that reduction in calories is the most important factor in weight loss, that hunger levels are unaffected by type of diet, and that diet improves fasting insulin levels.",College,male,0.8333333333333334,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ,"{'Coarse': {'fast insulin level': {'Outcomes'}, 'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, 'adult': {'Participants'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, 'adult': {'Age'}, '6 month': {'Duration'}}}",diet,A2C4VDQC5HQ1YP,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB
15-24,"Long-term weight gain can be hard to control. Over 100,000 people in the USA free of obesity and chronic disease were investigated for their eating habits and lifestyle changes over a 4 year period. They gained about 3.35 pounds, which can be attributed to a higher intake of potato products, sugary drinks, and meat, as well as reduction in physical activity, smoking, drinking, and watching television. Eating more vegetables, fruits, and whole grains can be attributed to weight loss. ",Some College,female,0.7777777777777778,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH,"{'Coarse': {'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}, 'long term': {'Outcomes'}}, 'Fine': {'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}, 'long term': {'Outcomes-general'}}}",diet,A3SGR153YCJ1XN,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'A', 'A', 'B'], 'Intervention': ['B', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI
60+,The text is putting forth some figures about coffee drinkers and the risk of death from drinking coffee. The figures did show an increase of a risk of death from drinking coffee. But when they took other factors into consideration the figures changed a bit. They had to take into account the risk factor from smoking in relation to the cause of death. After they took into account the effects of smoking they found that there was a significant inverse  association among the coffee drinkers.,Some College,male,0.7222222222222222,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A1X8YRYS8MBDWX,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ
24-39,"The benefits of a diet that focuses on protein, fat, or carbohydrates haven't been explored.  811 overweight adults were placed in one of four diets, including a control group.  All four diets has similar meals and met cardiovascular guidelines.  The study lasted for years, where participants were given the option to have group or individual sessions.  Six months in to the study participants lost, on average, 6 kg.  After 1 year, participants began to gain the weight back.  Participants who had regular attendance achieved greater weight loss.",College,female,0.7222222222222222,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}}}",diet,A1E66M679AFI3S,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q
24-39,"There was a study that examined the association of drinking coffee and total and cause specific mortality. 229,119 men and 173,131 women participated and during the follow up a total of  33,731 men and 18,784 women died. It was accessed that the risks of death increased with coffee drinkers. However, a correlation was discovered that coffee drinkers tend to smoke. Once the number was adjusted for those who did not, the effects of coffee on total and cause specific mortality was inversely associated.",Some College,male,0.6666666666666666,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO,"{'Coarse': {'total': {'Outcomes'}, 'cause specific': {'Outcomes'}, 'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'total': {'Outcomes-general'}, 'cause specific': {'Outcomes-general'}, 'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, 'woman': {'Sex'}}}",diet,AZYUCL6B0YROY,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U
40-60,"A recent 20-yr study confirmed weight loss is affected by diet and lifestyle. A large sample of persons free of chronic diseases and obesity enrolled with a follow-up every four years. Those who ate sugary and starchy foods, chips, unprocessed red meat and processed meat, and had poor lifestyle choices such as alcohol use, smoking, and lack of sleep, lost the least amount of weight. Those who ate veggies, whole grains, fruits, nuts, and yogurt, and exercised, lost the most. On avg, participants gained slightly more than 3lbs every four years. ",College,female,0.6666666666666666,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}, 'free of chronic disease': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}, 'free of chronic disease': {'Condition'}}}",diet,AGHKGWDYPVDFE,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE
40-60,"Four diet solutions were tested in a weight-loss study, with overweight adults as participants. These diets, distributed at random, emphasized weight loss possibilities, distributing proteins, fat, or carbohydrates into different energy consumptions. The groups, offered two years of individual and group sessions of instruction, were measured using metrics like satiety, hunger, diet satisfaction, and group attendance. After two years, all groups averaged a 3% kg weight loss, proving weight loss regardless of the emphasized macronutrient.",College,male,0.6111111111111112,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '2 year': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '2 year': {'Duration'}}}",diet,A2L95L7STG9LFP,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['A', 'D'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX
40-60,"In a clinical research trial studying the effects of coffee consumption on mortality, 229,119 men and 173,141 women, without heart disease, stroke, or cancer, between the ages of 50-71 years, were evaluated.  Initial findings showed that coffee consumption increased the risk of mortality in cases where there were smokers. After adjustments were made to the study to factor in the smokers, the results showed that coffee consumption was associated with a lower risk of mortality and those that drink a cup or less per day.",College,female,0.8888888888888888,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'heart disease': {'Participants'}, 'cancer': {'Participants'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'heart disease': {'Condition'}, 'cancer': {'Condition'}}}",diet,A1CYGMPC6W59KK,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA
40-60,"A trial was conducted to find the connection between coffee consumption and the risk of death. It included 229,119 men and 173,141 women who were healthy and 50-71 years old. After 13 years, 33,731 men and 18,784 women died. Coffee drinkers had increased deaths, but so did smokers. After smoking was adjusted for, an inverse association was found. Hazard ratios for both genders generally decreased with more coffee consumption for deaths from disease and stroke, but not from cancer. The validity of this study couldn't be determined from the data.",College,male,0.7777777777777778,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4,"{'Coarse': {'coffee': {'Intervention'}, '229,119': {'Participants'}, 'man': {'Participants'}, '173,141': {'Participants'}, 'woman': {'Participants'}, 'stroke': {'Participants'}, 'cancer': {'Participants'}}, 'Fine': {'coffee': {'Intervention-general'}, '229,119': {'Sample-size'}, 'man': {'Sex'}, '173,141': {'Sample-size'}, 'woman': {'Sex'}, 'stroke': {'Condition'}, 'cancer': {'Condition'}}}",diet,A21DI93ONQ4P6J,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN
40-60,"A study involving 100,000 people over a 4 year period, saw a correlation between aging and specific types of food eaten. Specifically, participants gained an average of 3.35 pounds. The increased intake of chips, potatoes, added sugar, unprocessed and processed meat appeared to increase weight gain. Conversely, increased consumption of vegetable, whole grains, fruit, nuts, and yogurt actually showed a decrease in weight across the 4 year period. Lifestyle factors such as alcohol use and smoking appeared to have a varied affect on participants.",College,female,0.7222222222222222,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX,"{'Coarse': {'lifestyle': {'Intervention'}}, 'Fine': {'lifestyle': {'Intervention-general'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,2,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM
24-39,"A lifestyle impact study carried out between 1986 to 2006 involving 3 groups of 120,877 American men and women without chronic disease or obesity. Every 4years, adjustments were made for differences in participants. Selected people in the study were shown to have gained on average 3.35 pounds each 4 year period with eating unhealthy food being the biggest factor in weight gain while exercise, drinking, smoking, sleep and watching tv also impacting it. It also showed that just eating less and exercising more isn't just a fixed rule.",College,male,0.8888888888888888,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0,"{'Coarse': {'lifestyle': {'Intervention'}, 'woman': {'Participants'}, 'man': {'Participants'}, '120,877': {'Participants'}}, 'Fine': {'lifestyle': {'Intervention-general'}, 'woman': {'Sex'}, 'man': {'Sex'}, '120,877': {'Sample-size'}}}",diet,A14XU2MC4NWN28,NEJMoa1014296,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX
24-39,"811 overweight adults were assigned to one of four diets where the percentages of energy from fat, protein, and carbs varied. The participants were offered instructional sessions for 2 years, either as a group or individually. After 6 months, all participants had experienced an average loss of 6kg, or 7% of their initial weight. At the end of the two years, about 80% of the participants had further lost an average of 4kg no matter which version of the diet they had.",Some College,male,0.8333333333333334,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH,"{'Coarse': {'diet': {'Intervention'}, '811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}, '811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}}}",diet,A2WP9EC483LJY4,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10
24-39,"A study was done to test out a Mediterranean Diet and it's effectiveness against cardiovascular disease. With over 7,000 participants and 3 groups studied (Diet with nuts added, diet with extra virgin olive oil added, control diet), the study was conducted over 4.8 years. After the study, 288 participants had a cardiovascular event happen to them. Of these 288 people, there was a slight increase in events in the control group. The study concludes that extra-virgin olive oil or nuts with a Mediterranean Diet can help reduce disease. ",College,male,0.8333333333333334,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, '4.8 year': {'Intervention'}, 'control': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, '4.8 year': {'Duration'}, 'control': {'Control'}}}",diet,A1M5BJTQIXCM33,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'A'], 'Intervention': ['B', 'A', 'A'], 'Outcomes': ['C', 'C', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D
40-60,"In a study of cardiovascular high risk, 7,447 people between the ages of 55 and 80 years old were enrolled in order to show any association between a Mediterranean diet and cardiovascular risk. Of all those people in the randomized trial done in Spain, 57% were women. There were three Mediterranean diets introduced: a diet supplemented with extra-virgin olive oil, another supplemented with mixed nuts, and another was to control the diet by reducing dietary fats. The study focused on the rate of heart attack,  stroke, or death.",College,female,0.8888888888888888,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84,"{'Coarse': {'mediterranean diet': {'Intervention'}, '57 %': {'Participants'}, 'spain': {'Participants'}, 'control': {'Intervention'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, '57 %': {'Sex'}, 'spain': {'Location'}, 'control': {'Control'}, 'fat': {'Control'}}}",diet,A1CYGMPC6W59KK,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,2,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7
40-60,"A study was done to examine the effects of coffee among men and women ages fifty to seventy one years old. Quite a bit about how coffee effects people is unknown. A research study of 5,000,000 showed that 30,000 men and 18,000 women died during the course. The study found that coffee drinkers are more likely to be smokers too which accounts for the high mortality rate during the study. The researchers also showed that the difference of how much coffee a man or woman consumed during the day also had an affect on mortality.",Some College,female,0.6666666666666666,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}, 'man': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}, 'man': {'Sex'}, 'woman': {'Sex'}}}",diet,A2LTOS0AZ3B28A,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'C', 'D'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,2,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR
24-39,"Over 500,000 Danish children born in the 90s were studied in an attempt to ascertain whether there is a connection between the MMR vaccine and autism.  Using Danish Civil Registration as well as Danish Psychiatric Central Register data, the researchers were able to determine that of this group, over 440,000 children had received the MMR vaccine and 316 children has been diagnosed with an autistic disorder and 422 with autism-spectrum disorders.  From this they concluded that there is no connection between autism and the MMR vaccine. ",College,female,0.5,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY,"{'Coarse': {'autism': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A3BDVHNMJECSKG,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY
24-39,"A study was conducted to determine if the MMR vaccine can cause austim. 440,655 children out of the 537,303 selected for the study received the vaccination. A diagnosis of autism was discovered in 316 children and diagnosis of other autistic spectrum disorders were found in 422 children. The results show the relative risk is 0.92 for autistic disorder and a relative risk of 0.83 for another autistic disorder. The study concludes MMR causing Autism is inaccurat and unfounded.",High School,female,0.625,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, '537,303': {'Participants'}, '0.92': {'Outcomes'}, '0.83': {'Outcomes'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, '537,303': {'Sample-size'}, '0.92': {'Effect-strength'}, '0.83': {'Effect-strength'}}}",immunization,A2YUCJ28XANFOX,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM
60+,"A study of Danish children born in the 1990s was conducted to assess whether the MMR vaccine causes autism.  Of over 500,000 children studies 82% had received the vaccine and 750 were diagnosed with autistic disorder or autistic-spectrum disorder.  The relative risk for autism in the vaccinated group was .83 versus .92 in the unvaccinated group proving there was no correlation between the MMR vaccine and autism, including no association with child's age at time of vaccination, time since vaccination and onset or time since vaccination.",College,female,0.875,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'unvaccinated': {'Control'}}}",immunization,A2YTQDLACTLIBA,NEJMoa021134,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'B', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5
24-39,"A study was done in Denmark, from January 1991 through December, 1998, to identify any increased risk of autism in association with the MMR vaccine. 537303 children were studied in total, with 316 children having a diagnosis of autism, and 422 being diagnosed as on the autistic spectrum. The risk of children being diagnosed with autism was approximately the same between groups of vaccinated and unvaccinated children. The researchers found this to be strong evidence against the idea that the MMR vaccine causes autism.",College,female,0.875,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, 'unvaccinated': {'Control'}}}",immunization,A83OOIGU4606R,NEJMoa021134,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO
24-39,"There was a survey done, which studied the measles, mumps and rubella (MMR) vaccine; trying to link them to autism. Autism has some severe effects. They collected autism statistics from various public agencies. Out of 537,303 kids vaccinated, 440,655 received the MMR vaccine. 316 of those had true autism and 422 were diagnosed with other autism spectrum disorders. There was no link found between age at vaccination and development of autism. This study shows that MMR vaccine, doesn't neccessarily cause autism",Some College,female,0.875,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z,"{'Coarse': {'autism': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, '537,303': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, '537,303': {'Sample-size'}}}",immunization,AHYXP6QIMYJLD,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO
60+,"Despite many people's belief that the measles, mumps and rubella (MMR) vaccine causes autism a 7 year study of children in Denmark disproves this.  Of the 540,000 children studied via records kept by the Danish government there was no statistically significant connection between the vaccine and an autism diagnosis even when controlled for factors like the child's age at vaccination and/or the interval between vaccination and diagnosis of autism disorder.  ",College,female,0.875,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A2YTQDLACTLIBA,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP
24-39,"Although some people believe there is a causal connection between a child taking the MMR ( measles, mumps and rubella) vaccine and development of autism . The study looked at children born in Denmark between 1991 and 1998. A total of 537,303 children were included in the study. Additional information was obtained from the Danish Civil Registration System, the Danish Medical Birth Registry, the National Hospital Registry and Statistics Denmark. the time since vaccination or the time between the vaccination and a diagnosis a astism/.",College,male,0.625,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, '537,303': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, '537,303': {'Sample-size'}}}",immunization,A3F6TS7I3CSUM8,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,2,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB
24-39,"A Danish study looked into 537,303 children's records to find out if there was a link between the MMR vaccine and autism.  Out of the total amount of children, 440,665 were vaccinated between 1991 and 1998.  316 were diagnosed with autism and 422 children were on the spectrum.  Children who were not vaccinated had the same chances of being on the spectrum or being diagnosed with autism.  Concluding that there's no link to being vaccinated and being diagnosed with an autistic disorder.",College,female,0.75,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY,"{'Coarse': {'autism': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, '537,303': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, '537,303': {'Sample-size'}}}",immunization,A1E66M679AFI3S,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['A', 'D', 'A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E
40-60,"A random observer-blind parallel grp trial evaluating 2 doses of inactive split virus 2009 H1N1 vaccine in healthy adults age 18 to 64 is going in Australia. 240 subjects, equal divided into 2 age grps were enrolled & randomly given 15ug or 30ug hemagglutinin antigen. Antibody titers were measured at baseline & 21 days after vaccination. By day 21 after 1st dose, antibody titers of 1:40 or more were seen in 114/120 subjects who received 15us and 106/119 who received 30ug. A single 15ug dose was immunogenic in adults w/ mild-moderate reactions.",Some College,female,0.75,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3,"{'Coarse': {'240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '21': {'Intervention'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '21': {'Duration'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A98E8M4QLI9RS,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'A', 'A', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55
40-60,"Two hundred and forty Australians aged 18 to 64 were divided into two age groups (over 50 and under 50), and were given a vaccine against the deadly 2009 INFLUENZA A (H1N1) virus, given in two doses 21 days apart of either 15 micro grams (ug) or 30 ug. There were antibodies still detectable at 1:40 blood serum dilution (""titer test"") 21 days after the first shot in 114 of 120 (95%) of the 15 ug subjects, 106 of 119 (89.1%) of the 30 ug group, meaning a positive immune response. A single 15 ug dose was effective, with no severe side effects.",Some College,male,0.75,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW,"{'Coarse': {'240': {'Participants'}, '21': {'Intervention'}, '114 of 120': {'Outcomes'}, '106 of 119': {'Outcomes'}, '89.1 %': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, '21': {'Duration'}, '114 of 120': {'Effect-strength'}, '106 of 119': {'Effect-strength'}, '89.1 %': {'Effect-strength'}, 'australia': {'Location'}}}",immunization,A1WNHGZ8S46T3C,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'B', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH
40-60,"A study is currently being conducted in Australia on an inactivate H1N1 (2009) split virus vaccine and the effects on adults that are healthy ages 18 to 64. 240 participants in 2 groups, 50 yrs or older and less than 50 years. Each grp was randomly chosen for 15ug dose or 30ug. After 21 days, 114 out of 120 who were given 15ug show antibody titers of 1:40. 106 out of 119 give 30ug showed 1:40 titers. This vaccine proves to be immunogenic in healthy adults when given a single dose of 15-ug. Only mild adverse effects observed in 1/2 participants.",Some College,female,0.75,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99,"{'Coarse': {'240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, '21': {'Intervention'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, '21': {'Duration'}, 'australia': {'Location'}}}",immunization,A98E8M4QLI9RS,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3
24-39,A group trial with two doses of a 2009 H1N1 vaccine was conducted at a single site in Australia. The subjects randomly received a high or low dosage. By 21 days after the first dose antibody titers of 1:40 were observed in 95% of the subjects who received the lower dose and 89.1% in the group with the higher dose. Side effects reported were local discomfort and mild to moderate systemic symptoms. The study concluded a single lower dose was immunogenic in adults with mild to moderate reactions. ,High School,female,0.625,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5,"{'Coarse': {'adult': {'Participants'}, '21': {'Intervention'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'adult': {'Age'}, '21': {'Duration'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A2YUCJ28XANFOX,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'A', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['A', 'A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E
24-39,"In 2009 H1N1 caused the first flu pandemic in 41 years. There was a study conducted in Australia with adults 18-64 years old. They had two doses of an inactivated H1N1 virus vaccine. There were 240 people divided equally and they received 2 vaccines. There were 15 ug doses and 30 ug doses that were given randomly. The study measured peoples antibody titers after being given the vaccine and 120 people that got 15 ug had 95% while those that received 30 ug had 89.1%. The second dose was given, the result was similar and vaccine wasn't effective.",College,female,0.875,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U,"{'Coarse': {'240': {'Participants'}, 'adult': {'Participants'}, '89.1 %': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, 'adult': {'Age'}, '89.1 %': {'Effect-strength'}, 'australia': {'Location'}}}",immunization,A3NUUMIAEIAN5,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'C', 'B', 'A'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,2,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC
24-39,"In 2009 the H1N1 vaccine was tested on individuals in Australia.  The goal of the study was to discover the immunogenicity and safety of the vaccine.  Participants were separated in to two groups, those younger than 50 years old and those older than 50.  Participants were randomly selected to receive 15ug or 30ug of hemagglutinin antigen intramuscularly.  21 days after the first of two doses, the researchers concluded that one dose of 15ug was the most beneficial.  There were no serious impacts on health, including no deaths.",College,female,0.75,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH,"{'Coarse': {'immunogenicity': {'Outcomes'}, '21': {'Intervention'}, 'australia': {'Participants'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, '21': {'Duration'}, 'australia': {'Location'}}}",immunization,A1E66M679AFI3S,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'B', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H
24-39,"To create a vaccine for the new influenza a trial will be conducted in Australia. Two groups will participate, one will receive more then the other. Three weeks after the first vaccine 95% of recipients who got the lower dose had appropriate levels and the other group had 89.1%. Similar findings were found after the second administration. No serious side effects reports other then local discomfort and 53.8% reported systemic symptoms. The study concludes a single dose of the less amount in adults is immunogenic. ",High School,female,0.625,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY,"{'Coarse': {'adult': {'Participants'}, '89.1 %': {'Outcomes'}, 'local discomfort': {'Outcomes'}, 'systemic symptom': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'adult': {'Age'}, '89.1 %': {'Effect-strength'}, 'local discomfort': {'Adverse-effects'}, 'systemic symptom': {'Adverse-effects'}, 'australia': {'Location'}}}",immunization,A2YUCJ28XANFOX,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'B', 'C'], 'Intervention': ['B', 'B', 'A'], 'Outcomes': ['A', 'A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF
24-39,"After the 2009 influenza A epidemic, researchers worked to develop a vaccine.  In a study of over 200 healthy adults split into two groups (group one received 15 micrograms of hemagglutinin antigen; group two received 30 microgram), researchers found, but looking at rate of anitbodies and hemagglutination-inhibition in the two groups, that the 15 mg dosage led to immunity.  A repeat test confirmed these results.  No serious reactions were reported; minor side effects included pain at the injection site and headache.  ",College,female,0.5,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8,"{'Coarse': {'healthy': {'Participants'}, 'adult': {'Participants'}}, 'Fine': {'healthy': {'Condition'}, 'adult': {'Age'}}}",immunization,A3BDVHNMJECSKG,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'A', 'C', 'A'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ
24-39,"More than 15,000 African children participated in a study on the effects of the malaria vaccine.  The study was conducted between March 2009 and January 2011.  The children were separated by age, 6 to 12 week and 5 to 17 months.  The latter being vaccinated three times over a span of 12 months.  250 out of the 6,000 children in this group contracted severe malaria, at which time the vaccine was tested in the younger group.  Less than 1% of those vaccinated contracted malaria, concluding SVAS01 vaccine is effective against malaria.",College,female,0.75,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, '12 month': {'Duration'}}}",immunization,A1E66M679AFI3S,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['B', 'A', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H
24-39,From March 09 to Jan 11 there were two groups of children (6-12 weeks and 5-17 months) that were included in a study  of a malaria vaccine. The results of the analysis showed that the malaria vaccine was able to protect the African children that were in the study from clinical and severe malaria. In the study the vaccine was effective against the severe form of malaria 45.1% of the time for the kids that were in the intention to treat population. In the per protocol population the vaccine was effective 47.3% of the time.,College,female,0.875,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}}}",immunization,A3NUUMIAEIAN5,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'B', 'C', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14
40-60,"In phase 3 of the RTS,SVAS01 the malaria vaccine was given to 15,460 African children from March 2009 through January 2011. Age categories were 6-12 weeks and 5-17 months. Three doses were given. After 11 months adverse events were similar in all groups. After 14 months, there had been 0.32 episodes of malaria per person and the RTS,SVAS01 was 0.55 episodes per person. The RTS,SVAS01 vaccine has been determined to protect against clinical and severe malaria in African children.",College,female,0.875,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'march 2009 through january 2011': {'Intervention'}, '15,460': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'march 2009 through january 2011': {'Duration'}, '15,460': {'Sample-size'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'three dos': {'Intensity'}}}",immunization,A2M18DZEPD1XGA,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A', 'C'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB
40-60,"The first results of an ongoing malria vaccine study was carried out between 2009 and 2011 and involved more than 15,000 children from seven different African countries who were enrolled as participants.  The first group of 6,000 children were injected with either the vaccine under study (RTS) or an alternate vaccine that did not affect malaria.  After the first 250 children in the group contracted malaria researchers compared the groups and found that RTS had a positive impact on preventing malaria.",College,male,0.75,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A1LKDOJ1P1JFH4,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['B', 'B', 'C', 'A'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W
24-39,"Over 15,000 children enrolled in this study in two age categories. 6-12 weeks and 5-17 months to be vaccinated with either the RTS,SVAS01 or a non-malaria comparator vaccine. 14 month after the first dose the first episodes of malaria were reported in the first 6000 children in the older age group. 0.32 episodes per person per year in the RTS and 0.55 per person per year in the control group. Efficacy is 45.1% and 47.3%. The study concludes that the RTS provided protection against both clinical and severe malaria. ",High School,female,0.625,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'non malaria comparator vaccine': {'Intervention'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'non malaria comparator vaccine': {'Control'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}}}",immunization,A2YUCJ28XANFOX,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'A', 'C', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,2,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ
40-60,"Over 15000 African children received the RTS,S/AS01 vaccine against Malaria. Six thousand children of 5 to 17 months were given the usual protocol of three doses of vaccine and compared to children 6 to 12 weeks old not yet fully dosed. The vaccine was 55.8% effective in treating Malaria among the per-protocol group,  50.4% effective  in the 6 to 12 week group. Among children of both age groups, 250 developed severe Malaria (meaning a delay in care). The vaccine was effective in 47.3% of the protocol group and 45.1% in the non-protocol group.",Some College,male,0.75,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH,"{'Coarse': {'rts': {'Intervention'}, 's / as01': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '6 to 12 week': {'Participants'}, '5 to 17 month': {'Participants'}, 'malaria': {'Outcomes'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 's / as01': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '6 to 12 week': {'Age'}, '5 to 17 month': {'Age'}, 'malaria': {'Outcomes-general'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, 'three dos': {'Intensity'}}}",immunization,A1WNHGZ8S46T3C,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'C', 'A', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW
24-39,"15,460 children from seven African countries were used in a study of malaria vaccine RTS SVAS01. The study tests the safety, effectiveness and immunogenicity of the vaccine in two age groups: 6-12 weeks and 5-17 months. The children received 3 doses of the vaccine and were evaluated 12 months later. The efficacy of the vaccinated groups was higher than in the control groups (55.8% and 47.3% compared to 50.4% and 45.1%). Both groups had similar levels of adverse reactions to the vaccine.",College,female,0.75,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, 'malaria': {'Outcomes'}, '50.4 %': {'Outcomes'}, '55.8 %': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, 'malaria': {'Outcomes-general'}, '50.4 %': {'Effect-strength'}, '55.8 %': {'Effect-strength'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, '12 month': {'Duration'}}}",immunization,A6CVN7CSC1K26,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['C', 'A', 'A', 'B'], 'Outcomes': ['B', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4
24-39,"A study on the phase 3 trial of the RTS,SVAS01 malaria vaccine enrolled at over 15000 infants (6-12 weeks) and toddlers (5-17 months) in Africa.  The participants were given either the malaria vaccine or a non-malaria vaccine.  Toddlers were given three doses.  Fourteen months later the incidence of malaria was recorded: the RTS,SVAS01 vaccine group had an over 2% decrease in malaria incidence compared to the control, suggesting that vaccine provides immunity.",College,female,0.5,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF,"{'Coarse': {'rts': {'Intervention'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'three dos': {'Intensity'}}}",immunization,A3BDVHNMJECSKG,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'A', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID
24-39,"DTaP is a combination vaccination: diphtheria, tetanus, and accellular pertussis.  Children in America receive five doses of DTaP by age seven.  A study was done on 227 children to find out how long the DTaP immunity lasts.  The children were vaccinated between 47 to 84 months.  Specifically, the study looked at children who were had pertussis at the time.  Those who were not infected were part of the controlled group.  The study concluded that the chance of a child contracting pertussis went up 42% annually after the last dose.",College,female,0.75,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1E66M679AFI3S,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'B', 'B'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['B'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4
40-60,"To study the effectiveness of diphtheria, tetanus and acellular pertussis (DTaP) vaccine after the 5th dose, children vaccinated with DTaP were tested for presence of pertussis using polymerase-chain-reaction (PCR) assay. PCR positive children (ages 4 - 12) compared to PCR negative children matched the controls from the general population. It was also found that children with 5th DTaP dose were more likely to be PCR positive and that the increased odds of getting pertussis among these children were 42% per year. ",College,male,0.875,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, 'pcr negative': {'Intervention'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, 'pcr negative': {'Control'}, '42 %': {'Effect-strength'}}}",immunization,AO33H4GL9KZX9,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['A', 'A'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['B']}}",,2,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI
60+,"Pertussis is a very dangerous disease and we need to protect our children.  In the United States all children receive 5 doses of diphtheria, tetnus and cellular pertussis (DTaP).  Kaiser Permanente conducted a study of the duration of time since the 5th dose and development of pertussis.  The study found the odds of acquiring pertussis increased by an average of 42% per year after the 5th dose waned and the earlier age at which a child received the 5th dose increased the odds of development of pertussis.",College,female,0.875,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}, 'united states': {'Participants'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}, 'united states': {'Location'}}}",immunization,A2YTQDLACTLIBA,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO
24-39,"A Kaiser-Permanente-funded study looked at California children and their risk of pertussis relative to the elapsed time since their fifth dose of the DTaP vaccine.  Children vaccinated between approximately age 4 and 7 were compared against two sets of controls.  Children who were vaccinated as infants or those who received more than five doses of the vaccine were excluded.  The study found that following the fifth DTaP dose, the chances of getting pertussis increase by an average of 42% per year.",College,female,0.5,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3BDVHNMJECSKG,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H
24-39,"A study of 277 children aged 4-12 in California were evaluated from 2006 to 2011 to see the effectiveness of a 5-dose pertussis (DTaP) vaccine. Included children had a positive PCR assay. Experts found the pertussis vaccine for this group waned following the fifth dose, and that these children are 42% more likely to acquire pertussis than those who had the fifth DTap later than children with a negative PCR assay (95% confidence interval). Thus, a new study should examine children receiving more than 5 doses or longer intervals between doses.",College,female,0.625,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, '2006 to 2011': {'Intervention'}, 'pertussis': {'Outcomes'}, '277': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, '2006 to 2011': {'Duration'}, 'pertussis': {'Outcomes-general'}, '277': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A2VHG0ZDQMZ2T0,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'A', 'B'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3
24-39,A study was done in California that studied the fact that the pertussis or DTap vaccine decreased in effectiveness after five years of receiving the fifth dose. The study included children who were part of Kaiser Permanente Northern California and were given the vaccine between 4 and 7. There was a group that had been given the vaccine that was compared to two groups that were not. The risk of pertussis as related to the last dose of the vaccine was taken into account. On average the risk increased to 42% almost every year after the last shot.,College,female,0.875,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3NUUMIAEIAN5,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH
24-39,"Children in the U.S receive five doses of three different vaccines before the age of seven. There was a study done of the decrease of pertussis in relation to that fifth dose. Children that got whole cell vaccine in infancy or after the fifth dose, they were excluded. The study included 277 kids between the ages of four and twelve who were PCR positive for pertussis. Those positive kids, were found to be more likely to have received the fifth dose earlier. Duration of protection is unknown. There was an increase in contracting pertussis. ",Some College,female,0.875,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, '277': {'Participants'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, '277': {'Sample-size'}}}",immunization,AHYXP6QIMYJLD,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,2,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA
24-39,The study assessed the risk of pertussis in children who had 5 doses of DTaP from 2006-2011. They watched the risk of pertussis after the fifth DTaP dose. Those that had the whole cell vaccine in infancy or any additional pertussis vaccines after the 5th one were not studied.  277 children ages 4-12 were positive PCR for pertussis. The study found that those who received the 5th dose early were more likely to be PCR Positive. The odds of acquiring pertussis after the 5th dose increased 42% on average per year.,High School,female,0.625,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, '277': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, '277': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A2YUCJ28XANFOX,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,2,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW
24-39,"For women, getting mammogram can detect early stage breast cancer but it also yields a lot of false positives. For early detection, it is an effective tool, but only marginally successful in reducing advanced stage breast cancer. ",College,female,0.8461538461538461,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2WNTEVRT68JXT,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3_3NL0RFNU0G8O56WLYPNJICWFMHS4KR
40-60,"During a study on breast cancer, 4,560 women were randomly split into two groups.  One of the groups received exemastane and the other group recieved a placebo. After 3 years, follow up showed exemestane and serious toxic events.",High School,female,0.6923076923076923,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, 'placebo': {'Control'}}}",breast,A24WVG86YLB7QK,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT_324G5B4FB4TJB370WUB8241GZLF074
24-39,"There was a trial that lasted five years that showed Adjuvant therapy as well as aromatase inhibitor improves the outcome, when you compare it to Tamokifen. They studied roughly 4,700 patients. Survival rate was found to be higher in the inhibitor group than the Tamokifen.",College,female,0.6923076923076923,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H,"{'Coarse': {'5 year': {'Intervention'}, 'survival': {'Outcomes'}}, 'Fine': {'5 year': {'Duration'}, 'survival': {'Outcomes-general'}}}",breast,A1E88GHZQWP0QT,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['C', 'A', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ
24-39,"A study done between 1976 and 2008 shows breast cancer is massively over-diagnosed. 1.3 million US women during the study were over-diagnosed which was one-third of all breast cancer cases. Over 70,000 US women in 2008 had tumors that would never have been symptomatic.",College,male,1.0,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2ELH7YDLFNJUZ,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['C', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3_3WRFBPLXRB94VGYKVOAG0ZLD2C73NG
24-39,"A study that compared rates of breast cancer between women that were screened often and those who hadn't, the death rate was lower in those who were screened. They compared women of different groups. Study contained 40,000 women.",College,female,0.6923076923076923,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A1E88GHZQWP0QT,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX_3PMBY0YE28O7JEQ9N72CB1UN3039CL
40-60,Mammograms between 1976 and 2008 on women above 40 suggests that cancer detection doubled in women in the US. Hormone replacement therapy & women under 40 were not included. Mammograms should be conducted in all women to detect early stages of cancer.,High School,female,0.6923076923076923,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL,"{'Coarse': {'early stage': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}, 'double': {'Outcomes'}}, 'Fine': {'early stage': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}, 'double': {'Effect-strength'}}}",breast,A24WVG86YLB7QK,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B', 'B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,3,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL_3I33IC7ZWGN8QF8CIKR6VJWLXRAA2U
24-39,A study compared the treatments of exemestane and tamoxifen in premenopausal breast cancer. The study found 5 years later that a higher percentage of women taking exemestane were free of breast cancer compared to those taking tamoxifen. There was no difference in deaths.,College,male,1.0,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL,"{'Coarse': {'5 year': {'Intervention'}, 'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'5 year': {'Duration'}, 'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A2ELH7YDLFNJUZ,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK
24-39,"A Norwegian study from 1996 to 2005 on breast cancer screenings have shown breast cancer screening does impact the mortality rate of breast cancer victims by 2.4 women for every 10,000. A reduction in mortality of about a third annually.",College,male,1.0,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI,"{'Coarse': {'woman': {'Participants'}, '2.4': {'Outcomes'}, 'a third': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '2.4': {'Effect-strength'}, 'a third': {'Effect-strength'}}}",breast,A2ELH7YDLFNJUZ,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['B'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,3,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI_3Q8GYXHFEQNOIROXKHPVZLPLH4NC50
40-60,"A study of 4560 women with a median age of 62.5 showed Exesestane significantly reduced invasive breast cancer in women at moderate risk. For post menopausal women, Exemestrane has fewer side effects than Tamoxifen and Raloxifene in patients with early stage breast cancer.",College,female,0.9230769230769231,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}}}",breast,A13ZQSOMIZAN4Y,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'B', 'A'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31_30IQTZXKALRDQIDRE7F6W3E41E1X03
24-39,"40,075 cancer patients were screened over two decades. The results showed those who received the screening the death rate decreased by 7.2 and those who were not screened by 4.8 deaths per 100,000 persons. The data does not take into account technology changes.",High School,female,0.7692307692307693,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ,"{'Coarse': {'40,075': {'Participants'}, '7.2': {'Outcomes'}, '4.8': {'Outcomes'}}, 'Fine': {'40,075': {'Sample-size'}, '7.2': {'Effect-strength'}, '4.8': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'A'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ_3UWN2HHPUZQ8FXJZL3BH87TPUSFSN6
24-39,The study found that in the area where tests are made available every 2 years the death rate dropped by 7.2 compared to where additional testing is not available. Overall the difference between the two groups was less at only 2.4 deaths reported a year. ,High School,female,0.7692307692307693,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q,"{'Coarse': {'2 year': {'Intervention'}, '7.2': {'Outcomes'}, '2.4': {'Outcomes'}}, 'Fine': {'2 year': {'Duration'}, '7.2': {'Effect-strength'}, '2.4': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['C', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q_31HQ4X3T3TVIRXGE9QV2VFP0PXFSL4
24-39,Extemestane is very effective at 65% reduction in breast cancer. Participants were given placebo or extemestane and followed in 3 years. No significant difference in quality of life. The study concludes exemestane reduces incidences of breast cancer in menopausal women. ,High School,female,0.7692307692307693,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC_3QEMNNSB2YKDAN8U86Z3HBLZTA17DH
40-60,A 32 year study in women over 40 found a large number of mammography diagnoses that would never develop to advance stage cancer. Over 31% of all breast cancers were over diagnosed showing that mammography screening has very slight impact on the breast cancer death rate. ,College,female,0.9230769230769231,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '40': {'Age'}}}",breast,A13ZQSOMIZAN4Y,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3_3VELCLL3GL4WXL7OAWDK41X721E1FM
24-39,A study testing 4690 women over 5 years showed that an aromatase inhibtor improves the outcome of post-menopausal women with breast cancer. The survival rate and those cancer-free after 5 years were higher for those taking exemestane for both pre- and post-menopausal women.,College,male,0.8461538461538461,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH,"{'Coarse': {'4690': {'Participants'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}}}",breast,A9BVDYQU2VTIJ,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'D', 'A'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO
24-39,"A study on Exemestane taken by postmenopausal women found many women had adverse effects. Around 35% of those in the study had aggressive breast cancer. Fractures, heart issues and death occurred as a result. However the drug was shown to decrease breast cancer.",College,male,1.0,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}}}",breast,A2ELH7YDLFNJUZ,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'D', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R_3ZAK8W07I5ZL9EJW924JCWF07WJU07
24-39,Two separate trials by Pfizer showed the 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. There was slightly more adverse side effects then with tamoxifen. Research found adjuvant w/ovarian suppression were more likely to stay in remission. ,High School,female,0.7692307692307693,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW,"{'Coarse': {'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,A2YUCJ28XANFOX,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2
24-39,"This study looks at the effects on mammography screenings on breast cancer in Norway. 40,000 subjects between 50-69 were offered a screening every 2 years. The study concluded that the death rate dropped by 7.2 per 100,000 people. ",High School,female,0.7692307692307693,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2,"{'Coarse': {'norway': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2_3GGAI1SQEWJMQY93CG6HGN073ZKCMX
40-60,"A study in Norway of 40,000 women aged 50-69 showed regular breast cancer screening accounted for 1/3 of reduction in breast cancer deaths. Half the women got mammograms every two years, with the death rate dropping 10%, and half had no screening with 5 deaths per 100,000.",College,female,0.7692307692307693,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '10 %': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '10 %': {'Effect-strength'}}}",breast,A122XBTHLAFX51,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'B', 'B'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,3,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y_36H9ULYP63F3S2NS0LJQ81TTWI7FJX
24-39,"While screening rates have doubled the amount of early stage cancer detected, screenings have limited effected on the rate of fatal breast cancers due to the incidence of over diagnosing non symptomatic tumors which is high at 1.3 million. ",High School,female,0.7692307692307693,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'double': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'double': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV_3VNXK88KKD33INW9EOXH1TICO7T9VU
24-39,"A group of researchers in Norway studied women, aged 50 to 69, and found that women who were screened for breast cancer regularly had a reduced rate of mortality by 10% versus he women who were not screened regularly. The study included 40000 women.",College,female,0.8461538461538461,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23,"{'Coarse': {'norway': {'Participants'}, 'woman': {'Participants'}, '10 %': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, 'woman': {'Sex'}, '10 %': {'Effect-strength'}}}",breast,A2WNTEVRT68JXT,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'A'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'A'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23_3JNQLM5FT57PMYZGFBGW4XCWR342LZ
24-39,Analysis from 4690 patients in this trial with premenopasual symptoms had a reduction in recurrence when taking tamoflexin w/ovarian suppression. After a 68 months the survival rate was 91% of and  at 5 years cancer free was 92%. Postmenopusal women had similar outcomes. ,High School,female,0.7692307692307693,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319,"{'Coarse': {'4690': {'Participants'}, 'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'survival': {'Outcomes'}}, 'Fine': {'4690': {'Sample-size'}, 'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'survival': {'Outcomes-general'}}}",breast,A2YUCJ28XANFOX,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['C', 'A', 'A'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6
24-39,Early stage cancer cases decreased after mammograms were introduced. Variables like hormone replacement surgery and other trends over diagnosed 1.3 million women in the US in the last 30 years. So the study shows that the screening's effects on the death rate are minimal.,College,male,0.8461538461538461,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY,"{'Coarse': {'early stage': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'early stage': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A9BVDYQU2VTIJ,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,3,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY_3H0W84IWBLNSKC69DF8TSAUKUYMER6
40-60,"Mammograms have increased early detection rates & the rate which women present w/ late state breast cancer has decreased a lot. It is commonly misdiagnosed because of benign tumors, making statistics about diagnoses not always accurate. ",Some College,female,1.0,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A98E8M4QLI9RS,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,3,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q_3OJSZ2ATDTHI6AT1T0HKJZX7GTZ573
24-39,Exemestane shows at being effective in reducing breast cancer compared to those given a placebo there was a 65% reduction with only slightly more adverse side effects. A 3 year follow up showed there were no serious side effects. ,High School,female,0.7692307692307693,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A2YUCJ28XANFOX,NEJMoa1103507,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG_3DH6GAKTYZAZS89RNXE0LGOZLRTZYI
24-39,A recent study of 4560 patients revealed Exemestane significantly lowered chances of breast cancer in post-menopausal women over 35. A follow-up showed no serious toxic effects from the drug and only small changes in quality of life health-wise.,College,male,0.8461538461538461,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}}}",breast,A9BVDYQU2VTIJ,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'A', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8_3STRJBFXOXC8MRBBDQORQK872GEKT8
24-39,"A screening mammography study in Norway focused on women between 50 and 69 who lived in countries with screening 1996 and 2005 for two years. The study found there were only 7.2 deaths per 100,000 women with breast cancer. It also found screenings reduced deaths by 1/3.",College,male,0.8461538461538461,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ,"{'Coarse': {'screen mammography': {'Intervention'}, 'norway': {'Participants'}, '50 and 69': {'Participants'}, 'woman': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}}, 'Fine': {'screen mammography': {'Intervention-general'}, 'norway': {'Location'}, '50 and 69': {'Age'}, 'woman': {'Sex'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}}}",breast,A9BVDYQU2VTIJ,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'A', 'C'], 'Intervention': ['C', 'A', 'D'], 'Outcomes': ['D', 'A'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,3,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ_3PEIJLRY6UE6Y8EC7E8R3YN82JAXWZ
40-60,"Mammography study from 1976-2008 found that while the test is effective at detecting early stage breast cancer, there's an over diagnosis of cases, and little effect on mortality rate. In 2018, 31% were over diagnosed, and 1.3 million in the last 30 years.",College,female,0.7692307692307693,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}}}",breast,A122XBTHLAFX51,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME_3V26SBZTBEZZXYJWJJGJZNX1RLCZZO
40-60,Adjuvant Exemestane with an aromatase inhibitor has a higher disease-free survival rate and freedom from cancer rate than Tamoxifen in pre-menopausal women with hormone-receptor positive breast cancer. This was shown in a 5 year follow up study.,College,female,0.7692307692307693,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS,"{'Coarse': {'5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A122XBTHLAFX51,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['C', 'B', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15
24-39,"Exemestane, a drug, was introduced for the prevention of breast cancer among older women. Researchers gave the drug to 2,000 women and found that they their rate of getting breast cancer was a third from the average woman in the same age group. ",College,female,0.8461538461538461,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2WNTEVRT68JXT,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'D'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2_3EWIJTFFVPS4KIMAJ2PE8ETXL8HE02
40-60,"35 month study of 4560 women aged 62.5, who previously had breast cancer, with Gail risk score of 2.3% shows Exemestane reduced breast cancer by 65%. 11 cancers were found in the Exemestane group compared to 32 in placebo group. After 3 years no serious side effects found.",College,female,0.7692307692307693,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '11': {'Outcomes'}, 'placebo': {'Intervention'}, '32': {'Outcomes'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '11': {'Effect-strength'}, 'placebo': {'Control'}, '32': {'Effect-strength'}, '65 %': {'Effect-strength'}}}",breast,A122XBTHLAFX51,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'D', 'D', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['A', 'A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['D'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC_3K4J6M3CXFEY59GJHZCVXNQM7A8AG6
24-39,"In women who take adjuvant therapy with an aromatase inhibitor for breast cancer, five year survival rates are higher than if that women had just taken tamosifen. However, long term survival rates were the same for both groups.",College,female,0.8461538461538461,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6,"{'Coarse': {'5 year': {'Intervention'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}}, 'Fine': {'5 year': {'Duration'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}}}",breast,A2WNTEVRT68JXT,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'B', 'B'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45
40-60,"Exemestane plus ovarian surpression significantly reduces reoccurrence of cancer. The result of a 5 year study with two groups: one given extemestane and the other tamoxifen, both had ovarian suppression. Survival rate for exemenstane was 91.1% versus 87.3% for tamoxifen.",College,female,0.9230769230769231,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X,"{'Coarse': {'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, '91.1 %': {'Outcomes'}, '87.3 %': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, '91.1 %': {'Effect-strength'}, '87.3 %': {'Effect-strength'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,AVBRJBJONL47I,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J
40-60,A Tennessee Medicaid study was made to compare cardiac effects during five days use of AZITHROMYCIN or AMOXICILLEN. Patients with a high risk of cardiovascular disease had an increase in death of about 47 per 1 million using AZITHROMYCIN. AMOXICILLEN users had no increase.,Some College,male,0.9230769230769231,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}, '5': {'Duration'}}}",cardio,A1WNHGZ8S46T3C,NEJMoa1003833,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'D'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK_3BWI6RSP7HUI2TMU41ANNT3KTNR7E1
24-39,"Worldwide, the average sodium intake is almost twice the recommended limit, which is shown to increase the risk of cardiovascular disease. This is most evident in low/middle income countries where there is less health education. More education would reduce these deaths.",College,female,1.0,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D,"{'Coarse': {}, 'Fine': {}}",cardio,A1S6MEOVLLSVX2,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D_3LEIZ60CDKKKR71JFLMKMZV8CJQZ9D
40-60,"Researchers studied the effect of sodium intake on blood pressure and cardiovascular deaths across race, age, and hypertension status. They found that, out of related 1.65 millions deaths, men accounted for 61.9% with 40% of the deaths occurring before the age of 70. ",College,male,0.8461538461538461,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,AO33H4GL9KZX9,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC_3YT88D1N09J3NADHYBI087498IL3KW
24-39,"A study at Tennessee Medicaid determined that the short term effects of cardiac medication, over a five day period, increased the risk of death when using Azithromycin, no increased risk with Amoxicillan, and a mild increased risk with ciprofloxacin.",College,female,0.8461538461538461,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R,"{'Coarse': {'azithromycin': {'Intervention'}, 'tennessee': {'Participants'}, 'ciprofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'tennessee': {'Location'}, 'ciprofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,AS1RGVFH2M3ET,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R_39ASUFLU6YSCH8SLMEELHSG8VFIEXD
24-39,Recent research on Rosiglitazone which was based on 42 trials of 116 potentially relevant studies over 24 weeks indicate there is a a higher risk of death from cardiovascular disease with it because of an increased risk of myocardial infection.,College,female,0.6923076923076923,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}, '24 week': {'Intervention'}, '42 trial': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}, '24 week': {'Duration'}, '42 trial': {'Sample-size'}}}",cardio,A3DAJROQC1BLNI,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF_3L0KT67Y8F12RWNDS5KSPNRWYI9YS4
24-39,"The drug Azithromycin produced reports of heart arrhythmia and cardiovascular death, and as a result a study was set up to test the danger. This confirmed the link between this drug and increased death rate of nearly 47 per 1 million people.",College,male,0.6153846153846154,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, '1 million': {'Outcomes'}, '47': {'Outcomes'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, '1 million': {'Effect-strength'}, '47': {'Effect-strength'}}}",cardio,AD70PPBAJSCPV,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ_3KB8R4ZV1FS3OJLBNDCRSYASPYSGBI
40-60,There is the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes. It is associated with a significant increase in the risk of myocardial infarction and an increase in the risk of death from cardiovascular causes.,College,female,1.0,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,A3D8ZG1VV5FO35,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL_33F859I567YHOFGM7JU9DYMT4WZHB8
24-39,"A study was conducted on people who resided in 66 countries on the on how much sodium levels influenced cardiac disease.  61.9% of men and 38.1% of women die from cardiovascular disease.  9.5% of those deaths had high (2,000 mg) sodium diets.",College,female,0.8461538461538461,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ,"{'Coarse': {'66 country': {'Participants'}, '9.5 %': {'Outcomes'}}, 'Fine': {'66 country': {'Location'}, '9.5 %': {'Effect-strength'}}}",cardio,A1E66M679AFI3S,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ_3MB8LZR5BGEK3E364HM04TYQ84NKL2
40-60,"11000 people over the age of 55 who were dx w/ heart disease, type II diabetes or both were studied for 3.3 years. The placebo group was better off on almost all metrics including blood pressure as well as nonfatal MI or strokes. Cardiovascular rates were not affected.",Some College,female,0.8461538461538461,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S,"{'Coarse': {'placebo': {'Intervention'}}, 'Fine': {'placebo': {'Control'}}}",cardio,A98E8M4QLI9RS,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'A'], 'Intervention': ['C', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S_3XC1O3LBOT7J6XTTYQ0S5KLMR30LT3
24-39,"Sodium information was taken from people globally. High sodium causes cardiovascular issues which lead to 1.65 million deaths globally, with the highest death rate in Georgia. Men were more affected than woman and 80 percent happened in lower and middle income areas. ",College,male,0.46153846153846156,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A17MUXOICSH29I,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,3,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY_3X66WABAJX3YLOHY8KXLAFCG10GG3G
24-39,"Azithromycin, Ciprofloxacin, and Levoloxacin have all been found to contribute to deaths due to a cardiovascular event after a 5-day treatment.  Amoxicillin was found to not increase cardiac-related deaths after a 5-day treatment.",College,female,0.8461538461538461,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A1E66M679AFI3S,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF_3HPZF4IVNNEMKFYHVJUSAINECAKYCX
24-39,A group was studied for 5 days using antibiotics. It was determined azithromycin is the highest risk of a cardiac event compared to those who took other medications. Those with higher risk of cardiovascular disease were more likely to die due to antibiotic use. ,High School,female,0.7692307692307693,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M,"{'Coarse': {'azithromycin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, '5': {'Duration'}}}",cardio,A2YUCJ28XANFOX,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M_32XVDSJFP0I9SGH1FNHB4ARLRV02MH
24-39,This study about cardiovascular outcomes of overweight and obese patients looked at over 10000 subjects impacted by cardio problems. The subjects were put in a weight management program for over 3 years. Patients taking sibutramine showed no difference from placebo patients.,College,male,0.6153846153846154,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M,"{'Coarse': {'sibutramine': {'Intervention'}, 'cardiovascular outcome': {'Outcomes'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, 'placebo': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'cardiovascular outcome': {'Outcomes-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, 'placebo': {'Control'}}}",cardio,AD70PPBAJSCPV,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,3,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M_37TRT2X24RCDFLBCVJXUPB28HQ9JBP
24-39,"people aged 55+ with preexisting cardiovascular disease participated in this study. After a 6 week weight management program, 11.4% lost 2.6kg. No increase in cardiovascular death. With long-term sibutramine there was a rise of myocardial infarction and non fatal stroke. ",High School,female,0.7692307692307693,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6,"{'Coarse': {'sibutramine': {'Intervention'}, 'preexist cardiovascular disease': {'Participants'}, 'cardiovascular death': {'Outcomes'}, '11.4 %': {'Outcomes'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'preexist cardiovascular disease': {'Condition'}, 'cardiovascular death': {'Outcomes-general'}, '11.4 %': {'Effect-strength'}}}",cardio,A2YUCJ28XANFOX,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['D', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['A']}}",,3,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6_37KGEN7NJ4BB5QFK91KFHRT97A2PPM
24-39,"A study compared Azithromycin, amoxicillin, ciprofloxacin and levofloxacin to see if there was an increased risk of cardiovascular death. Over 5 days the highest risk patients were taking Azithromycin and levofloxacin, then ciprofloxacin. Amoxicillin had no increased risk.",College,male,0.7692307692307693,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, 'levofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, 'levofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A9BVDYQU2VTIJ,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'B'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0_39U1BHVTDMC2QT34SKWS9YR5RUQT34
24-39,"42 studies regarding ROSIGLITAZONE were exmined for cardiovascular side effect data, where participnats shared common values and average age of 56. Outsomes identified that there was a higher rate of myocardial infarction dealths and some increase in cardiovascular dealth.",College,female,0.7692307692307693,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}}}",cardio,A35F1LYW2ZXWLT,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF_3EFVCAY5L4UUDND5S7DKY9C79F7J8Z
24-39,A recent comprehensive study of over 10000 overweight and obese participants found that subjects with preexisting cardiovascular conditions who received siburatmine had increased side effects. A second study enrolled most of them into a weight loss program.,College,male,0.6153846153846154,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67,"{'Coarse': {'overweight': {'Participants'}, 'obese': {'Participants'}}, 'Fine': {'overweight': {'Condition'}, 'obese': {'Condition'}}}",cardio,AD70PPBAJSCPV,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67_3WQQ9FUS6BFOV4FT4F030LTU1FFB8X
24-39,Many prescriptions that aim to lower blood sugar levels also contain hiazolidinedione as an ingredient.  Hiazolidinedione was removed due to a concern of hepatoxicity.  No link was found between the ingredient and complications.  Concluding that medication is important.,College,female,0.8461538461538461,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7,"{'Coarse': {}, 'Fine': {}}",cardio,A1E66M679AFI3S,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'C', 'C'], 'Outcomes': ['D', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['D'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['D'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7_3PS7W85Z80NO5VSK9TX20BURRMUT9F
24-39,A study lasted for 3.4 years that looked at the effects of sibutamine on cardiovascular events in overweight people who had existing cardiovascular problems and/or diabetes. Both groups lost weight and saw a reduction in blood pressure.,Some College,female,0.7692307692307693,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0,"{'Coarse': {'overweight': {'Participants'}, 'cardiovascular event': {'Outcomes'}, '3.4 year': {'Intervention'}}, 'Fine': {'overweight': {'Condition'}, 'cardiovascular event': {'Outcomes-general'}, '3.4 year': {'Duration'}}}",cardio,A329WHNJKAKTW7,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0_3ITXP059PX4CW7SE65JPF0C8L81JSK
24-39,"A study of 10,744 overweight individuals aged 55 with cardiovascular disease and type 2 diabetes compared sibutramine or a placebeo with a weight management program for 6 weeks for 3.4 years. Results showed siburtamine was more effective was an increased risk of stroke. ",College,female,0.7692307692307693,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, '10,744': {'Participants'}, 'type 2 diabete': {'Participants'}, '3.4 year': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, '10,744': {'Sample-size'}, 'type 2 diabete': {'Condition'}, '3.4 year': {'Duration'}}}",cardio,A35F1LYW2ZXWLT,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'B', 'A'], 'Intervention': ['A', 'A', 'A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI_3X4JMASXCNU6DFAQ9BNO76NCICI0B4
24-39,"In a recent study or sodium intake as it relates to cardiac issues results showed that 1 out of 10 deaths from cardiovascular causes were related to high sodium intake. This study took into account age, country and blood pressure.",College,male,0.6153846153846154,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL,"{'Coarse': {'death from cardiovascular cause': {'Outcomes'}}, 'Fine': {'death from cardiovascular cause': {'Outcomes-general'}}}",cardio,AD70PPBAJSCPV,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL_358UUM7WR0O7BXRZQ7UNM0238GA7RF
24-39,According to a recent study designed through strict parameters using rosiglitazone reduced myrocardial infarctions and baseline glycated hemoglobin. This made a significant difference relative to the control group in the study.,College,male,0.6153846153846154,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'control group': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'control group': {'Control'}}}",cardio,AD70PPBAJSCPV,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,3,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS_31IBVUNM9TKCJXNMHAX9BP4NR6MFVS
24-39,"Over 10,000 overweight or obese people in their 50's who had either cardiac issues or type 2 diabetes were studied.  The goal of the study was to find out if Sibutramine was beneficial for cardiac health.  No deaths occurred and blood pressure levels decreased.",College,female,0.8461538461538461,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, 'type 2 diabete': {'Participants'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, 'type 2 diabete': {'Condition'}}}",cardio,A1E66M679AFI3S,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB_3XIQGXAUMDTR8TDBZ60FBIOR9SNX7J
40-60,Study shows that taking more than 3.95g of sodium per day increases risk of high blood pressure which may increase one's chance of getting cardiovascular disease causing 1.65 million deaths according to research. Researchers suggest reducing sodium intake to 2g per day.,Some College,female,0.8461538461538461,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A2VNK2H6USLQTK,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM_3GFK2QRXXA2XWPU218PWBFWO9K95W6
40-60,"Based on a study by Medicaid cohort, patients having a high baseline risk of cardiovascular disease saw small increased risk of death when taking amoxicillin. No difference noted with levoflaxacin but increased risk of death with ciproflaxaciin and more so with azithromycin.",College,female,0.8461538461538461,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}}}",cardio,A2H57LNGH6LPMF,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H_3SNLUL3WO58Y6A8IYVQ2AG7OAZSULO
40-60,"A fixed effects research study was completed to see if rosiglitazone can be used to treat Type 2 Diabetes. Their 24 week study found a potential adverse side effect for men, in particular where myocardial infractions may occur and cause a cardio attack. ",Some College,female,0.9230769230769231,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'diabete': {'Participants'}, '24 week': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'diabete': {'Condition'}, '24 week': {'Duration'}}}",cardio,A2LZ5AVXVIJUXJ,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['D', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4_3X0H8UUIT29Y2RSDD4244Q6GN47WSP
40-60,"The highest consumption of salt in the world is the nation of Georgia, the lowest Kenya. A study with 107 randomly chosen people was taken to study a supposed risk of 1.65 millions in deaths per year from salt consumption above 2 grams per day. The global average is 3.95.",College,female,0.9230769230769231,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A12I4JOVZ1HZW8,NEJMoa1304127,"{'Coarse': {'Participants': ['D', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J_37FMASSAYDCHKAR6D1CUDAN845RIB7
24-39,"Demographics and calculated meta-analysis, especially from low and middle-income countries like Georgia and Kenya show that a high sodium diet increases blood pressure. In 2010 1.65 millions deaths were directly associated with high sodium.",College,male,0.7692307692307693,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A9BVDYQU2VTIJ,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X_3PXX5PX6LYJ2ES881DKHWCZPRXIBAS
24-39,"The study showed that Rosiglitazone, a drug to treat people with type two diabetes, increased the chance of myocardial infarction of death. The average age of people involved in the study was 56. Clinical trials by GlaxoSmithKline were used to help find out associated risks.",Some College,female,0.7692307692307693,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,A329WHNJKAKTW7,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S_3Y9N9SS8LZWV94776UWD4U9JO843DX
24-39,One third of studies on the drug Rosiglitazone show that it increases the risk of myocardial infarction and death from cardiovascular causes. The results are not inclusive because of researchers' listed access to original source data but it shouldn't be ignored either.,College,male,0.7692307692307693,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}}}",cardio,A9BVDYQU2VTIJ,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC_3KYQYYSHYWSKVT0TPSG5SX7UJZWOD9
40-60,A study with overweight and obese people at least 55 years old with preexisting medical conditions was conducted to asses cardiovascular issues with and without sibutramine.  Long term use of sibutramine increased the risk of infraction and stroke but not cardio death.,High School,female,0.9230769230769231,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, 'obese': {'Participants'}, '55 year': {'Participants'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, 'obese': {'Condition'}, '55 year': {'Age'}}}",cardio,A24WVG86YLB7QK,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB_3WRFBPLXRB94VGYKVOAG0ZLD2CD3NM
40-60,"Azithromycin showed a higher risk of heart-related death than  amoxicillin, and much higher risk of cardiovascular death than ciprofloxaicin, in a study done with a group taking macrolids and another group not. Overall azithromycin lead to a increase of cardiovascular death.",College,female,0.9230769230769231,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}}}",cardio,A12I4JOVZ1HZW8,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS_336YQZE83WZ1RD0OX6J92HUXBIM5M6
60+,"A study was conducted to see if coffee consumption increased the risk of death. Initial results suggested that it did, but then it was determined that coffee drinkers tend to also smoke. After adjustment for the non-smokers, the opposite effect was found to be the case.",Some College,male,0.8888888888888888,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U_3A4NIXBJ77KFT239PTZGJ6QUSXSLMP
60+,"In a weight loss study, obese adults were tested with four different diet complexes, with each providing proteins, fat, and carbohydrates into different ratios. The participants were given instruction sessions as well. A weight loss of 3% was found among all of the groups.",Some College,male,0.8888888888888888,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, 'adult': {'Participants'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, 'adult': {'Age'}}}",diet,A18V6K2TMWMSWD,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX_3O7L7BFSHFAFRD3QNSEKEITT2R9EIH
24-39,"In a study to measure the effect of coffee on the risk of death, researchers observed men and women ages 50-71 for 13 years. They found that there was a correlation, but that there was also correlation between coffee consumption and smoking. ",College,female,0.8333333333333334,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN,"{'Coarse': {'coffee': {'Intervention'}, 'man': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'coffee': {'Intervention-general'}, 'man': {'Sex'}, 'woman': {'Sex'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1112010,"{'Coarse': {'Participants': ['A', 'A', 'C', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN_3137ONMDKHQ1VMXVX4EHT6GDNEHEGP
60+,"Weight loss is affected by diet/lifestyle as confirmed by a recent study. Diets including sugary and starchy foods (and certain meats) along with poor lifestyle lost the least amount of weight. Healthy foods (veggies, etc.) and exercise contributed to greater weight loss.",Some College,male,0.8888888888888888,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'weight loss': {'Outcomes'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE_3EFE17QCRDQG51XOI5G43NWT35XSHX
24-39,"In a study to test different ratios of protein, fat and carbohydrates in weight loss diets, researchers found that there was no difference in weight loss among the three different ratios. Instead they found the most important factor to be reduction in calories. ",College,female,0.8333333333333334,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '3.0': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '3.0': {'Effect-strength'}}}",diet,A1Y22RY2G8RBAG,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK_3R2PKQ87NXTD31V34Q23RQY2BT0IMA
60+,"Scientific testing studied the effects of coffee consumption and its' relation to death rate. Study results indicated that coffee drinkers that were also smokers had an increased risk of death, while non-smokers had a reduced risk of death.",Some College,male,0.8888888888888888,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA_3N2BF7Y2VRFD76KJY8KIREXNBGEMHE
40-60,"A study was conducted with the purpose of examining the association of how the aging process is affected by specific foods eaten among 100,000 people over a four-year period. Aging and weight gain were seen among those who ate unhealthy foods, were smokers and drank alcohol.",College,female,0.8888888888888888,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM,"{'Coarse': {}, 'Fine': {}}",diet,A1CYGMPC6W59KK,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM_3LEIZ60CDKKKR71JFLMKMZV877S9ZW
24-39,"In a study focusing on coffee drinkers and the risk of death, an initial correlation was shown. However, other factors such as smoking were taken into consideration, since it was found that many coffee drinkers also smoke, and there was no strong correlation afterward. ",College,female,0.8333333333333334,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ,"{'Coarse': {'coffee': {'Intervention'}, 'man': {'Participants'}}, 'Fine': {'coffee': {'Intervention-general'}, 'man': {'Sex'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ_33TIN5LC05VKMHREJZK18SM61DRY9X
24-39,"NIH did a study to see if there was a correlation between drinking coffee and death. They did find that some of the coffee drinkers had an increased risk of death but after adjusting to other lifestyle factors, there was no strong correlation found. ",College,female,0.8333333333333334,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB_3UWN2HHPUZQ8FXJZL3BH87TPPHCNS7
24-39,"In a study of over 120,000 adults, it was found that in four years, an average of 3.35 pounds was gained. Factors that may lead to this included consumption of chips, sugary beverages and meats, and it was found that increasing exercise and healthy diet may counteract that. ",College,female,0.8333333333333334,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8,"{'Coarse': {'diet': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'A'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8_3WLEIWSYHP2N02GQOQ1YC5JP5B4H2P
60+,"A study was performed on 811 overweight adults each given various amounts of fats, proteins and carbs. After six months all had lost about 7 percent of their starting weigh. At the end of two years , 80 percent had lost some additional weight.",College,female,0.7777777777777778,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10,"{'Coarse': {'811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}}, 'Fine': {'811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}}}",diet,A1WML1ZP2ISAR7,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['C', 'A', 'A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10_3X87C8JFV7WTIUWR1V3YC1OUUSZSQZ
24-39,"It is more important to reduce calories in a diet rather than focusing on a certain macronutrient split. In a study, four different ratios were given to groups and all four lost the same average amount of weight. Diets containing 15-25% protein kept the weight off longest. ",College,female,0.8333333333333334,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW,"{'Coarse': {'diet': {'Intervention'}, '15': {'Intervention'}, '25': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}, '15': {'Intensity'}, '25': {'Intensity'}}}",diet,A1Y22RY2G8RBAG,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,3,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW_3GS6S824SRI1ME0858LI5WWAVU8NWM
24-39,"In a study to measure diet and lifestyle behaviors for weight management, researchers found that weight increased more by those who watch television, eat starchy foods and drink sugary drinks. There was a decrease in weight for those who exercise and eat vegetables. ",College,female,0.8333333333333334,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}, 'man': {'Participants'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}, 'man': {'Sex'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29_3ZOTGHDK5JWQXIJBMIBUNWTUFRHSOR
24-39,"In a study to test the efficacy of the Mediterranean Diet, researchers found that in 3 groups of people with increased cardiovascular risk, the two groups who were given nuts or extra virgin olive oil had fewer cardiovascular events than those following a low fat diet. ",College,female,0.8333333333333334,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'fat': {'Control'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D_3NOKK93PR2T3B814R9OTT3V1AY2EE8
24-39,"A Spanish study looked at the link between cardiovascular risk and a Mediterranean diet, specifically the rates of heart attack, stroke, or death.  8,000 people between 55 and 80 were randomized into three diets: 1) adding olive oil 2) adding mixed nuts, 3) reducing fats.",College,female,0.7777777777777778,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'fat': {'Control'}}}",diet,A3BDVHNMJECSKG,NEJMoa1200303,"{'Coarse': {'Participants': ['D', 'A', 'C', 'A', 'B'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['D'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7_3TVSS0C0E2LZHR5S247UEV22KCWWTY
60+,"In a weight loss trial that lasted six months it was found that no matter what the intake of proteins, fats and carbohydrates you consume so long as the calories are reduced you will lose about seven percent of the weight you began with. ",College,female,0.7777777777777778,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01,"{'Coarse': {'weight loss': {'Outcomes'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, '6 month': {'Duration'}}}",diet,A1WML1ZP2ISAR7,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'B', 'C'], 'Outcomes': ['C', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['D'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01_3RANCT1ZVG2MT1M67I18WDBJTPJBUM
24-39,"In a study of over 800 adults, it was found that the most important factor in maintaining was not the differing ratios of carbohydrates, fat and protein. The study found that a reduction in calories and group/individual sessions were more important.  ",College,female,0.8333333333333334,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB,"{'Coarse': {'adult': {'Participants'}}, 'Fine': {'adult': {'Age'}}}",diet,A1Y22RY2G8RBAG,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB_3Y4W8Q93L05FLD9QQ42JNP12AH4VD2
24-39,"A 20 year study on weight gain found increased intake of processed food led to more weight gain.  This weight gain could be avoided by eating more vegetables, whole grains, fruit and nuts.  Regarding smokers, both current and former smokers gained weight in the study.",College,female,0.7777777777777778,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465,"{'Coarse': {}, 'Fine': {}}",diet,A3BDVHNMJECSKG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465_3HSYG7LRBKJ9J8LOJHAZPTLBESQKKE
24-39,"In a study on people who had increased cardiovascular risk, researchers found that those who followed a Mediterranean diet supplemented with nuts or extra virgin olive oil had a slight reduction in cardiovascular events compared to those following a low fat diet. ",College,female,0.8333333333333334,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'fat': {'Control'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB_3FE7TXL1LJ80DVFT7GOSLJBQWY0Q2U
60+,"A study of individuals at high risk of cardiovascular disease, looked into the association of disease risk and its' association with the Mediterranean diet. Results of the study indicated that extra virgin oil or nuts in one's diet reduced major cardiovascular disease.",Some College,male,0.8888888888888888,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV_3QY5DC2MXS5C6IYMCKN4F3248N7UFJ
24-39,"There are many factors that go into successful weight loss, but a study that analyzed macronutrient composition showed that is not one of them. Regardless of macro split, all participants lost a similar amount of weight and found more success in regular meeting attendance. ",College,female,0.8333333333333334,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A1Y22RY2G8RBAG,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q_3R6P78PK7LW3K5FSNZ3CSSGEQO0TGQ
24-39,A study showed that the most important dietary factor in weight loss was not the percentage of macros that make up a diet and that any reduction in calories will lead to a weight loss. The average weight lost was 6 kg. among all participants in six months. ,College,female,0.8333333333333334,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, '6 month': {'Duration'}}}",diet,A1Y22RY2G8RBAG,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I_33PPO7FECW0AZ7PQRX3080B82F4IDO
24-39,"A Spanish trial of nearly 8,000 people 55-80 years old showed that Mediterranean diets reduce risk of cardiovascular disease.  Those who added nuts or olive oil to their diet had fewer cardiovascular events than those who were instructed to simply reduce their fat intake.",College,female,0.7777777777777778,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'fat': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'fat': {'Control'}}}",diet,A3BDVHNMJECSKG,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'C', 'A', 'A'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z_3RANCT1ZVG2MT1M67I18WDBJTPEUB0
24-39,"A study of over 100,000 Americans showed that over a four year period, the average weight gained was 3.35 pounds. The main factor in weight gain was consumption of unhealthy foods such as sugary drinks and potato products. Increased physical activity can help reduce weight. ",College,female,0.8333333333333334,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX,"{'Coarse': {}, 'Fine': {}}",diet,A1Y22RY2G8RBAG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'B', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX_3X1FV8S5JYCIXXJHSU3RTA4ZN9GGVT
24-39,"There are many factors that can cause long-term weight gain, including eating starchy foods and sugary drinks, smoking and watching television. Factors that can promote weight loss include increased physical activity and eating vegetables, fruits and whole grains. ",College,female,0.8333333333333334,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI,"{'Coarse': {'weight loss': {'Outcomes'}, 'man': {'Participants'}, 'long term': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'man': {'Sex'}, 'long term': {'Outcomes-general'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['B']}}",,3,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI_3I33IC7ZWGN8QF8CIKR6VJWLSG9A22
24-39,"A study to measure the effect of coffee on older individuals (50-71) showed that although there was a higher mortality rate among coffee drinkers than non-coffee drinkers, there was also correlation between coffee drinkers and smokers, so the effect of coffee is unknown. ",College,female,0.8333333333333334,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A1Y22RY2G8RBAG,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR_3E1QT0TDFQUYICTZAPSKM8X7RO68I7
40-60,A study was conducted over twelve years to examine the link between consuming coffee and death. Participants included both smokers and non-smokers. It was found in both smokers and non-smokers who drank coffee that there was an increased rate of mortality. ,College,female,0.7222222222222222,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O_3CFVK00FWM6D4ZIH2DSZUAT82X9L6B
40-60,"A study noted a potential increased risk of death by people age 50-71 who drank coffee. When considering smokers and groups that included non-smokers significant risk was still found.  In the end, the study couldn't determine if the risk was from drinking coffee or not.",College,female,0.6666666666666666,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,AF56P9JE4N741,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,3,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6_3XLBSAQ9Z5XGDODQ0OO08342CH0Z76
24-39,"A study running from 1986 to 2006 found that lifestyle correlates with long-term weight gain.  More starchy food and meat, more alcohol, smoking, more sleep, and more TV watching were all associated with more weight gain.  Vegetarianism correlated with lower weight.",College,female,0.7777777777777778,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU,"{'Coarse': {'lifestyle': {'Intervention'}, 'long term': {'Outcomes'}}, 'Fine': {'lifestyle': {'Intervention-general'}, 'long term': {'Outcomes-general'}}}",diet,A3BDVHNMJECSKG,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['A'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['A']}}",,3,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU_3OB0CAO74IAD1N9XHB8TL9KUKQTYHH
40-60,"In a study of 7447 people ages 55-80 years old the Mediterranean diet was studied. There were three different types of items added to the diet to see how it affected people in general.  Olive Oil, a supplement and mixed nuts were all added in. ",Some College,female,0.6666666666666666,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4,"{'Coarse': {'mediterranean diet': {'Intervention'}, '7447': {'Participants'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, '7447': {'Sample-size'}}}",diet,A2LTOS0AZ3B28A,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4_3V5Q80FXIYC86U9R95CW8BIFM6E32W
40-60,A study of 7000 participants in Spain showed that people at high risk for heart related health issues decreased their likelihood of suffering a major heart attach by following a Mediterranean diet which included extra virgin olive oil or mixed nuts.,High School,female,0.7777777777777778,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'spain': {'Participants'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'spain': {'Location'}}}",diet,A1B78YH6IB8K3Z,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'B', 'A', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG_39OWYR0EPLCTNRIRMLKTIO8H4BEFYY
24-39,"In a 4.8 year Spanish study on the Mediterranean diet, the effects of supplementing one's diet with olive oil or mixed nuts.  Participants were at-risk but showed no signs of heart disease at the start of the study; at the end, 288 or 7447 had problems.",College,female,0.7777777777777778,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22,"{'Coarse': {'mediterranean diet': {'Intervention'}, '7447': {'Participants'}, '4.8 year': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, '7447': {'Sample-size'}, '4.8 year': {'Duration'}}}",diet,A3BDVHNMJECSKG,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'A', 'A', 'A'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22_32UTUBMZ7HHM6GB6C8BDSZD27WMBV5
24-39,An Australian study in 2009 of H1N1 vaccine was tested in 2 groups those 50 years old and younger and those older than 50 years. The goal of the study was to see the immunogenicity and safety of the vaccine.  Results showed one dose 15ug was the most beneficial and low risk.,College,female,0.875,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H,"{'Coarse': {'immunogenicity': {'Outcomes'}, 'australia': {'Participants'}}, 'Fine': {'immunogenicity': {'Outcomes-general'}, 'australia': {'Location'}}}",immunization,A2P791EA88YGSV,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H_3MB8LZR5BGEK3E364HM04TYQ8H7LKD
40-60,"Denmark had studied over 500,000 Danish children in the 90s to ascertain whether MMR vaccine causes autism. Danish Civil Registration and Danish Psychiatric register data revealed that there is no connection between autism and the MMR vaccine.",Some College,female,0.875,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A2VNK2H6USLQTK,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY_39K0FND3AI0YXJC5S2AQASAJ381MAV
24-39,A study funded by Kaiser-Permanente discerned that children vaccinated between the ages of 4-7 (excluding infants who received more than 5 doses) against pertussis found that the chances of getting pertussis increased by an average of 42%/year following the 5th dose.,College,male,0.75,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}}}",immunization,A35F1LYW2ZXWLT,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H_3EJJQNKU9SQ44MXB3GGZDDRXMSHRHU
24-39,"A Danish study asked if there was a link between the MMR vaccine and autism using 440,665 children records who were vaccinated between 1991 and 1998. The chances of being on the spectrum or being diagnosed with autism were the same for vaccinated vs. non-vaccinated children.",College,female,0.625,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A2VHG0ZDQMZ2T0,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'B', 'B'], 'Intervention': ['A', 'A', 'D'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E_3P59JYT76M5D5B7LOKINQOMDLTYT2R
24-39,The risk of pertussis in children who had 5 doses of DTaP from 2006-2011. 277 children ages 4-12 were positive PCR for pertussis.  It found that who received the 5th dose early were more likely to be PCR Positive. After the 5th dose increased 42% on average per year.,College,male,0.625,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}, '277': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}, '277': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,A1DOY340I9VN92,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'A'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW_3JMSRU9HQJFKDJNQMZD3T7JNGJWVE8
40-60,A new Influenza study was done to see if a lower dose vaccine was as effective as the standard dose given. 3 weeks later the group given the lower does was tested to see if it was effective. 95% of the people who had received it had good levels in their systems.,Some College,female,0.75,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF,"{'Coarse': {}, 'Fine': {}}",immunization,A2LTOS0AZ3B28A,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF_3C6FJU71TREI69FHHAFS4O9KKQQYU3
24-39,"240 Australians, between the ages of 18 and 64 were broken up into 2 groups (above and below 50) for a study using the vaccine against the deadly influenza A virus (H1N1). The vaccine was given in 2 doses 21 days apart and it was found that a single 15 ug dose was effective.",Some College,female,0.875,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH,"{'Coarse': {'240': {'Participants'}, '18 and 64': {'Participants'}, '21': {'Intervention'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, '18 and 64': {'Age'}, '21': {'Duration'}, 'australia': {'Location'}}}",immunization,A324VBRLXHG5IB,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'B', 'C', 'A'], 'Intervention': ['B', 'A', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH_3K3R2QNK8CO358799YNC57GTBFD9UT
24-39,DTaP is a combination vaccination. Children born in America receive five doses of DTaP by age seven. A study to find how long it lasts. The study concluded that the chance of a child contracting pertussis went up 42% annually after the last dose.,Some College,male,0.75,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3P57IUDHUKNCE,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4_3018Q3ZVOJBPUZPXXA67WR4TAZURAR
24-39,"The malaria vaccine was given to 15,460 African children.  Age categories were 6-12 weeks and 5-17 months. Three doses were given. After 14 months there had been 0.32 episodes of malaria per person. The RTS, SVAS01 vaccine has been determined to  protect against malaria. ",College,male,0.625,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}, 'three dos': {'Intensity'}}}",immunization,A1DOY340I9VN92,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB_3RYC5T2D74EWH3VZMTO4MMTO9KMRPX
40-60,"All children are supposed to receive five ""DTaP"" vaccinations (Diphtheria; Tetanus or ""lock jaw""; and Pertussis ""Whooping Cough""). Kaiser Permanente did a study and found that after the shots waned, a child had a 42% increase in the chance of getting Pertussis each year.",Some College,male,0.75,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1WNHGZ8S46T3C,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO_3UNH76FOCTQZT1A888O6DESQ61JMYO
24-39,"15,000 African children were given the RTS,S/AS01 vaccine that works against malaria. The vaccine was found to be 47.3 percent effective in the group of children that had received the three full doses of the vaccine, while it was 45.1 percent effective in the other group.",College,male,0.875,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW,"{'Coarse': {'rts': {'Intervention'}, 's / as01': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 's / as01': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,AJITIN95JSBAR,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'C', 'A', 'C'], 'Outcomes': ['C', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW_3IJXV6UZ1Y440H8V9YYKDPSCN8RIRG
40-60,"Experts found, during a study of 277 children aged 4-12, that the pertussis vaccine for this group waned following the fifth dose, and that these children are 42% more likely to acquire pertussis than those who had the fifth dose at a later interval. ",College,female,0.875,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, '277': {'Participants'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, '277': {'Sample-size'}, '42 %': {'Effect-strength'}}}",immunization,AAB13RUHSABEV,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3_3VFJCI1K40KQ4Q20JAYHSDFW7SMGR2
40-60,"The study examined 537,303 Danish children born between 1991 and 1998 in order to examine if there was a causal connection between the MMR vaccine and development of autism. The study also looked at the timing of vaccinations and diagnosis of autism. ",College,female,0.75,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, '537,303': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, '537,303': {'Sample-size'}}}",immunization,A2OGCXGLS44ZAO,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB_3AWETUDC93DD28UMJFSXZSUBWN6IZ1
40-60,"Between 2009 and 2011 more then 15,000 African children were given a malaria vaccine. Some children were injected with the vaccine RTS and some were injected with an alternative. After it was found that 250 children contracted malaria RTS was more effective.",Some College,female,0.75,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['B', 'B', 'C', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W_33UKMF931A57PA1Y7Z2JRBV3MA1TTI
24-39,Researchers have conducted a study on the DTaP vaccine.  Children are testing positive for pertussis using PCR after 5 doses of the vaccine.  The results concluded that the odds of children being diagnosed with pertussis were 42% per yer.,College,female,0.75,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A2XS5QI4YX493N,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['C']}}",,3,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI_39K0FND3AI0YXJC5S2AQASAJ3APAMB
24-39,A malaria vaccine was able to protect African children from clinical and severe malaria.  Two groups of children 6-12 weeks and 5-17 months old were studied from March 09 to January 11.  The study showed a 47.3 effectiveness.,College,male,0.75,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,AXY0D2AMLKE2A,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'B', 'C', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14_3C5W7UE9CGBATWKY3C24U0LH4TZXMZ
40-60,"15,460 African children from 7 different countries was given the malaria vaccine. The test was to see how effective and safe the malaria shot was. It was given to 2 age groups. 6-12 weeks and 5-17 months. The Vaccine was found to be very effective.",Some College,female,0.75,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, 'malaria': {'Outcomes-general'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4_35USIKEBNS13SZL2EQ8E72XXDK56NK
40-60,"A malaria vaccine was trialed on 15,000 african children between March 2009 and January 2011. The children were vaccinated 3 times over 12 months. 250 children out of 6,000 contracted Malaria. Once the trial was done on the younger set less then 1% did.",Some College,female,0.75,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}, '12 month': {'Duration'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['A', 'B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H_3N2BF7Y2VRFD76KJY8KIREXNH8AMH0
24-39,A study was done in California to research whether or not the pertussis (DTap) vaccine decreased in effectiveness five years after receiving the fifth dose. The risk of pertussis increased to 42% almost every year after the last shot. ,College,female,0.75,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH,"{'Coarse': {'dtap': {'Intervention'}, 'california': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'dtap': {'Intervention-general'}, 'california': {'Location'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1LMDMSKQ96PHP,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,3,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH_3IKZ72A5B51ZBSEDFJBI18AA5EGFNT
24-39,A u.s. based study was done on vaccines given in 5 doses before age 7. the study was related to the decrease of pertussis in relation to when the child received the 5th dose of the vaccine. children who were pcr positive for pertussis got the 5th dose earlier in life. ,College,female,0.5,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, 'pcr positive': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, 'pcr positive': {'Outcomes-general'}}}",immunization,A2L53B1MI02U0W,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'B', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA_3BF51CHDTWVG4SDC93XKTHQAD130HO
15-24,"The Danish government has proven that the measles, mumps, and rubella vaccine does not cause vaccine by conducting a 7 year study of 540,000 children in Denmark. They concluded that there was no statistically significant connection between the vaccine and autism diagnosis.",College,female,0.75,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP,"{'Coarse': {'autism': {'Outcomes'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A8L1M76RJIDVG,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP_3JC6VJ2SAC40PCRZ03T4TQZXIGB5AV
40-60,An Australian study was performed on adults 18- 64 years old. @ doses of inactivated H1N1 was given to them. They divided the groups into 2 different sets of 240 people each. Their their titers were measured to see if the vaccine helped. It did not.,Some College,female,0.75,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC,"{'Coarse': {'240': {'Participants'}, 'adult': {'Participants'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, 'adult': {'Age'}, 'australia': {'Location'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'C', 'B', 'A'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,3,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC_3LS2AMNW5GBEK24YUEMPSWET3VLQOF
24-39,The study is about two doses of 2009 H1N1 vaccine was conducted at a single site in Australia. By 21 days after the first dosage 95% of the subjects who received the lower dose and 89.1% in the group with higher dosage. It concluded the lower dosage to moderate reaction.,College,male,0.625,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E,"{'Coarse': {'21': {'Intervention'}, '89.1 %': {'Outcomes'}, 'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'21': {'Duration'}, '89.1 %': {'Effect-strength'}, 'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A1DOY340I9VN92,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'A', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,3,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E_39JEC7537VM5GL3CQ8783JJKV7IVCE
24-39,"Over 15,000 children enrolled in this study in two age categories. About a year after the first dose the first episodes of malaria were still in the 6000 children in the older age group. In conclusion RTS provided protection against both clinical and severe malaria.   ",Some College,male,0.75,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A3P57IUDHUKNCE,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'A'], 'Intervention': ['A', 'C', 'C', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ_3Z9WI9EOZ09IHIKGDW72C15JS2RHK0
40-60,"A study of Danish children born in the 1990s concluded that there was no correlation between the MMR vaccine and autism, including no association with the child's age at the time of vaccination, time since vaccination and onset or time since vaccination.",College,female,0.875,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,AAB13RUHSABEV,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5_3U4J9857OFWKVQAAUA8XMLXZQ3W7B9
24-39,"A study recorded for over fourteen months on a phase 3 trial of the RTS,SVAS01 malaria vaccine enrolled at over 15000 infants and toddlers showed a 2% decrease in incidents of malaria over the control, suggesting it may provide immunity.",College,male,0.875,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID,"{'Coarse': {'rts': {'Intervention'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}}}",immunization,A9BVDYQU2VTIJ,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'A'], 'Intervention': ['A', 'B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,3,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID_39KFRKBFIOGNT4VKLO3J5IHV11NYO4
24-39,"An Australian study on an inactive H1N1 split virus vaccine found that when healthy adults ages 18-64 were given a single dose of 15-ug, the vaccine proves to be immunogenic with only mild adverse effects in 1/2 participants. ",College,female,0.75,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3,"{'Coarse': {'healthy': {'Participants'}, 'adult': {'Participants'}, 'australia': {'Participants'}}, 'Fine': {'healthy': {'Condition'}, 'adult': {'Age'}, 'australia': {'Location'}}}",immunization,A2WETCIWJT79CQ,NEJMoa0907413,"{'Coarse': {'Participants': ['A', 'A', 'B', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3_3GFK2QRXXA2XWPU218PWBFWO9Y05WP
24-39,"Researchers have discovered that autism is not caused by MMR vaccinations.  More than 400,000 children received the vaccine and only 316 of them were diagnosed with autism.  Another 422 of these children were diagnosed with autistic spectrum disorder.",College,female,0.75,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM,"{'Coarse': {'autism': {'Outcomes'}, 'autistic spectrum': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'autistic spectrum': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A2XS5QI4YX493N,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'B'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM_3I02618YA1ROXVNGQNJ9RXG8FG3PU5
40-60,"240 healthy adults in Australia age 18-24 were enrolled in a group trial to evaluate 2 doses of inactive H1N1 vaccine (one lower, one higher). It was concluded that a single lower dosage was immunogenic in adults with mild-moderate reactions.",College,female,0.875,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55,"{'Coarse': {'240': {'Participants'}, 'healthy': {'Participants'}, 'adult': {'Participants'}, 'australia': {'Participants'}}, 'Fine': {'240': {'Sample-size'}, 'healthy': {'Condition'}, 'adult': {'Age'}, 'australia': {'Location'}}}",immunization,AAB13RUHSABEV,NEJMoa0907413,"{'Coarse': {'Participants': ['D', 'A', 'B', 'A'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['D'], 'Condition': ['A'], 'Location': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,3,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55_3U088ZLJVLEY1I8142JKUK0XSQ3W09
15-24,A study was performed in Denmark in the 90's to see if there is a link between in MMR vaccine and autism.  Researchers found that there was not sufficient evidence to say that the MMR vaccine is linked with autism as vaccinated and unvaccinated children had the same risk. ,College,female,0.875,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}, 'unvaccinated': {'Control'}}}",immunization,A1L0ICCUXH42R0,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'B', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO_3P4MQ7TPPYX7X2D07RKDRNJV9R8BBG
24-39,"A survey was done to study the measles, mumps and rubella (MMR) vaccine and its potential link to autism. Statistics were collected from a number of public agencies. No link was found between age at vaccination and the development of autism. ",College,female,0.75,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A1LMDMSKQ96PHP,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO_37TD41K0AIUPOTM8WD23SWZDV0TSC4
24-39,"After the 2009 influenza A epidemic, researchers led a study of over 200 adults to develop a vaccine. They found that injecting 15 micrograms of hemagglutinin antigen into healthy adults led to immunity, whereas injecting 30 micrograms did not. ",College,female,0.75,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ,"{'Coarse': {'healthy': {'Participants'}, 'adult': {'Participants'}}, 'Fine': {'healthy': {'Condition'}, 'adult': {'Age'}}}",immunization,A1LMDMSKQ96PHP,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'A', 'C', 'A'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Condition': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,3,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ_3PW9OPU9PR5CWRVCM1YDKI3IT9221K
40-60,A number of mammography diagnoses never develop to advanced stage cancer.  The screening has slight impact on breast cancer death rate.,College,male,0.8461538461538461,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3_3VELCLL3GL4WXL7OAWDK41X721E1FM,"{'Coarse': {'breast cancer': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}}}",breast,A1S1K7134S2VUC,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3_3VELCLL3GL4WXL7OAWDK41X721E1FM_3PH3VY7DJMIV33ER8WWC0J3JEA5WZE
40-60,"This study looks at mammography in Norway. 40,000 subjects screened every 2 years. Death rate dropped by 7.2 per 100,000 people.",College,male,0.8461538461538461,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2_3GGAI1SQEWJMQY93CG6HGN073ZKCMX,"{'Coarse': {'norway': {'Participants'}, '2 year': {'Intervention'}, '7.2': {'Outcomes'}}, 'Fine': {'norway': {'Location'}, '2 year': {'Duration'}, '7.2': {'Effect-strength'}}}",breast,A1S1K7134S2VUC,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2_3GGAI1SQEWJMQY93CG6HGN073ZKCMX_3L4D84MIL0DN6YEYVB7QBM56GOIHJH
40-60,A Norwegian study from 1996 to 2005 shows breast cancer screening does impact the mortality rate by 2.4 women for every 10000 anually.,Some College,female,1.0,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI_3Q8GYXHFEQNOIROXKHPVZLPLH4NC50,"{'Coarse': {'woman': {'Participants'}, '2.4': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '2.4': {'Effect-strength'}}}",breast,A98E8M4QLI9RS,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI_3Q8GYXHFEQNOIROXKHPVZLPLH4NC50_39GAF6DQWSLLTITEABIOMN0TUL8V1U
40-60,Trials by Pfizer showed 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. Side effects rates differ.,College,male,0.8461538461538461,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2,"{'Coarse': {'5 year': {'Intervention'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'5 year': {'Duration'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,A1S1K7134S2VUC,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'B', 'B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['C']}}",,4,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO
40-60,A five-year study showed higher cancer survival rates using Adjuvant therapy with an aromatase inhibitor compared to just Tomokifen.,College,female,0.7692307692307693,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ,"{'Coarse': {'5 year': {'Intervention'}, 'survival': {'Outcomes'}}, 'Fine': {'5 year': {'Duration'}, 'survival': {'Outcomes-general'}}}",breast,A2KROBPV0YPE4A,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22
40-60,A study done over 40 years has shown that breast cancer has been being over-diagnosed.  This was about a third of all cases.,Some College,male,0.8461538461538461,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3_3WRFBPLXRB94VGYKVOAG0ZLD2C73NG,"{'Coarse': {'breast cancer': {'Outcomes'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, '40': {'Age'}}}",breast,A2IXFVW8GE5NYE,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'D'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['C'], 'Duration': ['D'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3_3WRFBPLXRB94VGYKVOAG0ZLD2C73NG_3XCC1ODXDMWHHFWEM63TMRJYHSBRQI
40-60,"A study consisting of 40,000 women, show that the death rate was lower in women who were screened for breast cancer on a regular basis.",Some College,male,0.8461538461538461,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX_3PMBY0YE28O7JEQ9N72CB1UN3039CL,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A2IXFVW8GE5NYE,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX_3PMBY0YE28O7JEQ9N72CB1UN3039CL_3JAOYWH7VJP0MIKF0KVBEKKA10I9LO
40-60,"Women taking tamoflexin w/ovarian suppression had a survival rate of 91% after 68 months and after five years, 92% were cancer free.",Some College,male,0.8461538461538461,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6,"{'Coarse': {'ovarian suppression': {'Intervention'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'survival': {'Outcomes'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'survival': {'Outcomes-general'}}}",breast,A2IXFVW8GE5NYE,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7
24-39,A recent study found that when treating premenopausal breast cancer a higher percent of women taking exemestane were free of cancer.,College,male,0.7692307692307693,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK,"{'Coarse': {'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'exemestane': {'Intervention'}}, 'Fine': {'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}}}",breast,AD70PPBAJSCPV,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6
40-60,"Exemestane showed a 65% reduction in breast cancer, with only slightly more adverse side effects, compared to those given a placebo. ",College,female,0.8461538461538461,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG_3DH6GAKTYZAZS89RNXE0LGOZLRTZYI,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,A3D8ZG1VV5FO35,NEJMoa1103507,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG_3DH6GAKTYZAZS89RNXE0LGOZLRTZYI_3YJ6NA41JC1FJFCMEOFVKV7X2FQJPM
24-39,Mammograms between 1976 and 2008 on women over 40 showed that cancer detection doubled in the US. Mammograms should be given annually.,College,male,0.7692307692307693,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL_3I33IC7ZWGN8QF8CIKR6VJWLXRAA2U,"{'Coarse': {'woman': {'Participants'}, '40': {'Participants'}, 'double': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '40': {'Age'}, 'double': {'Effect-strength'}}}",breast,AD70PPBAJSCPV,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,4,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL_3I33IC7ZWGN8QF8CIKR6VJWLXRAA2U_3PPTZCWALR5QJ6I5WNX68ULXQ9SQZ8
24-39,A study showed Exesestane reduced breast cancer in women at moderate risk and had fewer side effects in post menopausal women. ,College,female,0.6923076923076923,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31_30IQTZXKALRDQIDRE7F6W3E41E1X03,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2WETCIWJT79CQ,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['D', 'A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['D'], 'Conclusion-general': ['A']}}",,4,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31_30IQTZXKALRDQIDRE7F6W3E41E1X03_3DL65MZB8E0OEAHQVIIY3FVYYNLCEK
24-39,"2,000 women who used the drug Exemestane found their rate of getting breast cancer was one third the average in the same age group.",College,male,0.6923076923076923,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2_3EWIJTFFVPS4KIMAJ2PE8ETXL8HE02,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A1KR3HNLXSLC10,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2_3EWIJTFFVPS4KIMAJ2PE8ETXL8HE02_308Q0PEVB9YYWHC9FHYYM4SIKXPI9M
40-60,A 20-year study showed a significant decrease in the death rate from breast cancer among those screened and not screened for the disease.,College,female,0.7692307692307693,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ_3UWN2HHPUZQ8FXJZL3BH87TPUSFSN6,"{'Coarse': {}, 'Fine': {}}",breast,A2KROBPV0YPE4A,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['C', 'C', 'B'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ_3UWN2HHPUZQ8FXJZL3BH87TPUSFSN6_3WOKGM4L721QW9ZZDGSADQNBT1RO06
24-39,Exemestane plus ovarian surpression reduces reoccurrence of cancer and had a higher survival rate versus tamoxifen.,College,female,0.6923076923076923,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J,"{'Coarse': {'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A2WETCIWJT79CQ,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM
40-60,Studies show Extemestane is effective in a 65% reduction in breast cancer. It has been shown to reduce incidences in menopausal women.,Some College,male,0.8461538461538461,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC_3QEMNNSB2YKDAN8U86Z3HBLZTA17DH,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '65 %': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '65 %': {'Effect-strength'}}}",breast,A2IXFVW8GE5NYE,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC_3QEMNNSB2YKDAN8U86Z3HBLZTA17DH_3Z9WI9EOZ09IHIKGDW72C15JVDJKHK
40-60,A mammography study found that screenings reduced deaths by 1/3.  This study focused on women between the ages of 50 and 69.,College,male,0.6153846153846154,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ_3PEIJLRY6UE6Y8EC7E8R3YN82JAXWZ,"{'Coarse': {'50 and 69': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'50 and 69': {'Age'}, 'woman': {'Sex'}}}",breast,A2JTV44ZIGMS5D,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'C', 'C'], 'Intervention': ['A', 'D', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ_3PEIJLRY6UE6Y8EC7E8R3YN82JAXWZ_3OONKJ5DKD4RGW29BWPZX7JUK4DOBF
24-39,A 35 month study of 4560 women age 62.5 who had breast cancer previously showed Exemestrane reduced cancer by 65%.,College,male,0.7692307692307693,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC_3K4J6M3CXFEY59GJHZCVXNQM7A8AG6,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}, '4560': {'Participants'}, '35 month': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}, '4560': {'Sample-size'}, '35 month': {'Duration'}, '65 %': {'Effect-strength'}}}",breast,AD70PPBAJSCPV,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'D', 'D', 'A'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['D'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC_3K4J6M3CXFEY59GJHZCVXNQM7A8AG6_30BXRYBRP5I9CIEX2AQ50CZEIKSHWD
40-60,"Cancer cases decreased with the use of mammograms. However, over diagnosis occurred as well in 1.3 million women in the US.",College,female,0.8461538461538461,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY_3H0W84IWBLNSKC69DF8TSAUKUYMER6,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A3D8ZG1VV5FO35,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY_3H0W84IWBLNSKC69DF8TSAUKUYMER6_3TVRFO09GL0QNE2D301PUN6S821LX9
40-60,Exemestane lowers breast cancer chances in post-menopausal woman. No toxic effects or quality of life changes occurred from the drug.,College,female,0.7692307692307693,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8_3STRJBFXOXC8MRBBDQORQK872GEKT8,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2KROBPV0YPE4A,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8_3STRJBFXOXC8MRBBDQORQK872GEKT8_30IQTZXKALRDQIDRE7F6W3E455T0XK
40-60,"A recent breast cancer study of a drug, exemestane, given to 4460 women over a 3 year period showed serious toxic events.",College,male,0.6153846153846154,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT_324G5B4FB4TJB370WUB8241GZLF074,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2JTV44ZIGMS5D,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT_324G5B4FB4TJB370WUB8241GZLF074_3EJJQNKU9SQ44MXB3GGZDDRXQ40RH5
40-60,Pre-menopausal women with hormone-receptor positive breast cancer using exemestane had a higher survival rate than those on tamoxifen. ,College,female,0.8461538461538461,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15,"{'Coarse': {'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,A3D8ZG1VV5FO35,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6
40-60,"Breast cancer screenings have increased early stage detection, but aren't effective in limiting fatal cancers because of over diagnosis.",College,female,0.7692307692307693,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV_3VNXK88KKD33INW9EOXH1TICO7T9VU,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}}}",breast,A2KROBPV0YPE4A,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV_3VNXK88KKD33INW9EOXH1TICO7T9VU_34Q075JO1YY50HSY7EUZ1UA30P810L
40-60,A study from 1976-2008 shows mammograms are effective at detecting early stage breast ca but it has little effect on mortality rate. ,Some College,female,1.0,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME_3V26SBZTBEZZXYJWJJGJZNX1RLCZZO,"{'Coarse': {'early stage': {'Outcomes'}}, 'Fine': {'early stage': {'Outcomes-general'}}}",breast,A98E8M4QLI9RS,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME_3V26SBZTBEZZXYJWJJGJZNX1RLCZZO_39GHHAVOMGCTUMQ3G4N7HXW2BIEJ4D
40-60,Women have better breast cancer success rates taking adjuvant therapy with an aromatase inhibitor than taking tamosifen.,College,male,0.6153846153846154,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45,"{'Coarse': {'woman': {'Participants'}, 'breast cancer': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}}}",breast,A2JTV44ZIGMS5D,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['C', 'C', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X
40-60,"it is important for women to get a mammogram to detect early stage breast cancer, but can yield false positives on occasion.",College,male,0.6153846153846154,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3_3NL0RFNU0G8O56WLYPNJICWFMHS4KR,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2JTV44ZIGMS5D,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3_3NL0RFNU0G8O56WLYPNJICWFMHS4KR_33L7PJKHCHJORQ9A41RO0FZGB688TL
40-60,A study of 4690 women shows the survival and cancer-free rate after 5 years was higher when taking exemestane  pre & post menopausal women,Some College,female,1.0,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO,"{'Coarse': {'4690': {'Participants'}, '5 year': {'Intervention'}, 'woman': {'Participants'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}}, 'Fine': {'4690': {'Sample-size'}, '5 year': {'Duration'}, 'woman': {'Sex'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}}}",breast,A98E8M4QLI9RS,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'D', 'A'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['D'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD
40-60,Adverse effects were noted in a study done on postmenopausal women taking Exemestane. The drug was shown to decrease breast cancer. ,Some College,female,1.0,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R_3ZAK8W07I5ZL9EJW924JCWF07WJU07,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'postmenopausal': {'Participants'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'postmenopausal': {'Condition'}, 'woman': {'Sex'}}}",breast,A98E8M4QLI9RS,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R_3ZAK8W07I5ZL9EJW924JCWF07WJU07_3IXEICO79341NCQMBMUQG13P5B1T63
24-39,In the area where tests are given every two years the death rate dropped by 7.2%. This equates to 2.4 deaths per year.,College,male,0.7692307692307693,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q_31HQ4X3T3TVIRXGE9QV2VFP0PXFSL4,"{'Coarse': {'2 year': {'Intervention'}, '7.2': {'Outcomes'}, '2.4': {'Outcomes'}}, 'Fine': {'2 year': {'Duration'}, '7.2': {'Effect-strength'}, '2.4': {'Effect-strength'}}}",breast,AD70PPBAJSCPV,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['C', 'B', 'C'], 'Outcomes': ['D', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q_31HQ4X3T3TVIRXGE9QV2VFP0PXFSL4_3GD6L00D3TI23VZ5WJHXZRHG3S81MV
24-39,Mammograms have increased early detection rates and decreased rate of women presenting with late stage breast cancer.,College,female,0.6923076923076923,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q_3OJSZ2ATDTHI6AT1T0HKJZX7GTZ573,"{'Coarse': {'breast cancer': {'Outcomes'}, 'late stage': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2WETCIWJT79CQ,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q_3OJSZ2ATDTHI6AT1T0HKJZX7GTZ573_34S6N1K2ZW4T1O2YYWJ3R1IYKCTLHR
24-39,A Norway study showed regular breast cancer screening reduced breast cancer deaths by 1/3. Mammograms decreased the death rate.,College,female,0.6923076923076923,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y_36H9ULYP63F3S2NS0LJQ81TTWI7FJX,"{'Coarse': {'norway': {'Participants'}}, 'Fine': {'norway': {'Location'}}}",breast,A2WETCIWJT79CQ,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y_36H9ULYP63F3S2NS0LJQ81TTWI7FJX_3WQ3B2KGE916K4V85UROLB6MRTL1BN
40-60,Study of 4000 women ages 50 to 69 found women screened for breast cancer regularly had 10% reduced rate or mortality vs women who weren't.,College,female,0.7692307692307693,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23_3JNQLM5FT57PMYZGFBGW4XCWR342LZ,"{'Coarse': {'woman': {'Participants'}, '10 %': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '10 %': {'Effect-strength'}}}",breast,AOHQSD0GH8HTE,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'D', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'A'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,4,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23_3JNQLM5FT57PMYZGFBGW4XCWR342LZ_3X31TUMD7Y7IXDHKW7GIZE2R3NVL1Q
40-60,"High (2,000 mg) sodium diets cause 9.5% of cardiac/cardiovascular disease deaths out of 100 men and women from 66 countries. ",Some College,female,0.7692307692307693,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ_3MB8LZR5BGEK3E364HM04TYQ84NKL2,"{'Coarse': {'66 country': {'Participants'}, '9.5 %': {'Outcomes'}}, 'Fine': {'66 country': {'Location'}, '9.5 %': {'Effect-strength'}}}",cardio,AW1SWNQFPIUKF,NEJMoa1304127,"{'Coarse': {'Participants': ['A', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,4,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ_3MB8LZR5BGEK3E364HM04TYQ84NKL2_3X4JMASXCNU6DFAQ9BNO76NCIJ20B2
40-60,"The antibiotic, azithromycin, was tested in a five day study and found to provide a risk of cardiac events.",College,female,1.0,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M_32XVDSJFP0I9SGH1FNHB4ARLRV02MH,"{'Coarse': {'azithromycin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, '5': {'Duration'}}}",cardio,A1OBU9NMV1C3S5,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M_32XVDSJFP0I9SGH1FNHB4ARLRV02MH_3G0WWMR1UW5W2H4MTZMCD7EOCCAQNB
24-39,The research is about the perception ofther aim to lower blood sugar levels contain hiazolidnedione as an ingredient. ,College,male,0.38461538461538464,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7_3PS7W85Z80NO5VSK9TX20BURRMUT9F,"{'Coarse': {}, 'Fine': {}}",cardio,A1DOY340I9VN92,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'C', 'C'], 'Outcomes': ['D', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['D'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['D'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7_3PS7W85Z80NO5VSK9TX20BURRMUT9F_374TNBHA8CGQEG8001VNUNCVGYPYQO
24-39,Rosiglitazone were examined for cardiovascular side effect data from 42 studies. Participants are average age of 56. ,College,male,0.38461538461538464,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF_3EFVCAY5L4UUDND5S7DKY9C79F7J8Z,"{'Coarse': {'rosiglitazone': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}}}",cardio,A1DOY340I9VN92,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF_3EFVCAY5L4UUDND5S7DKY9C79F7J8Z_3TOK3KHVJU34EKZJYFDJS5XYXYW7OM
40-60,Some studies show that Rosiglitazone increases occurrences of myocardial infarction and death related to cardiovascular causes.,College,male,0.8461538461538461,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC_3KYQYYSHYWSKVT0TPSG5SX7UJZWOD9,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'myocardial infarction': {'Outcomes'}, 'death': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'myocardial infarction': {'Outcomes-general'}, 'death': {'Outcomes-general'}}}",cardio,A1SNL49AU2I5BV,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC_3KYQYYSHYWSKVT0TPSG5SX7UJZWOD9_3JC6VJ2SAC40PCRZ03T4TQZXHAVA57
24-39,Azithromycin and levofloxacin poses greater risk than ciproflaxcin of cardiovascular death. Amoxicillin shows no increase. ,Some College,female,0.7692307692307693,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0_39U1BHVTDMC2QT34SKWS9YR5RUQT34,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}, 'levofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}, 'levofloxacin': {'Control'}}}",cardio,A2Q3FS9G8ITCN7,NEJMoa1003833,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'A', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0_39U1BHVTDMC2QT34SKWS9YR5RUQT34_3LUY3GC630LMZKBKDFQYH52O71NP7C
40-60,A recent study noted that high sodium intake contributed to 10% of deaths from all cardiovascular-related causes.,College,male,0.8461538461538461,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL_358UUM7WR0O7BXRZQ7UNM0238GA7RF,"{'Coarse': {}, 'Fine': {}}",cardio,A1SNL49AU2I5BV,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL_358UUM7WR0O7BXRZQ7UNM0238GA7RF_3R9WASFE201TSHSWI7MCWVHJFPGZFG
24-39,"Effects of Sibutramine on cardiac health were studied in over 10,000 people. Research shows no deaths occurred and blood pressure lowered.",College,female,1.0,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB_3XIQGXAUMDTR8TDBZ60FBIOR9SNX7J,"{'Coarse': {'sibutramine': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}}}",cardio,A2Y9ZNZ0F24GHB,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB_3XIQGXAUMDTR8TDBZ60FBIOR9SNX7J_3KV0LJBBH36QW0YMUDWC5IZT39TRM6
24-39,Georgia has the highest death rate related to sodium. Sodium related deaths are more prevalent in men and low and middle income areas. ,Some College,female,0.7692307692307693,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY_3X66WABAJX3YLOHY8KXLAFCG10GG3G,"{'Coarse': {}, 'Fine': {}}",cardio,A2Q3FS9G8ITCN7,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY_3X66WABAJX3YLOHY8KXLAFCG10GG3G_3IO1LGZLKAIIPSYY8OJVP572NH968I
60+,"Test found sibutramine, caused weight loss with no increase in cardiovascular death in 6 week trial, but long term, increased occurrence.",College,female,0.8461538461538461,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6_37KGEN7NJ4BB5QFK91KFHRT97A2PPM,"{'Coarse': {'sibutramine': {'Intervention'}, 'cardiovascular death': {'Outcomes'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}}}",cardio,A37CE37LHUN8M6,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'D', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6_37KGEN7NJ4BB5QFK91KFHRT97A2PPM_37ZHEEHM6X7FSV6XFHTR42ZN25R73E
24-39,a 24 week study found that rosiglitazone has a potentially adverse side effect in men. this can lead to heart attacks. ,College,female,0.6923076923076923,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4_3X0H8UUIT29Y2RSDD4244Q6GN47WSP,"{'Coarse': {'rosiglitazone': {'Intervention'}, '24 week': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, '24 week': {'Duration'}}}",cardio,A2L53B1MI02U0W,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4_3X0H8UUIT29Y2RSDD4244Q6GN47WSP_3H0W84IWBLNSKC69DF8TSAUKU72ER4
40-60,"For patients at risk for cardiovascular disease, levoflaxin is safer than amoxicillin, ciproflaxacin, and azithromycin.",College,male,0.8461538461538461,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H_3SNLUL3WO58Y6A8IYVQ2AG7OAZSULO,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}}}",cardio,A1SNL49AU2I5BV,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H_3SNLUL3WO58Y6A8IYVQ2AG7OAZSULO_3LOZAJ85YEYKMSG5TUJKFR7JYLB2X0
24-39,Sodium intake is roughly two times what is recommended. More education on sodium's effects would reduce deaths from cardiovascular issues.,College,female,1.0,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D_3LEIZ60CDKKKR71JFLMKMZV8CJQZ9D,"{'Coarse': {}, 'Fine': {}}",cardio,A2Y9ZNZ0F24GHB,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['B'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D_3LEIZ60CDKKKR71JFLMKMZV8CJQZ9D_3HHRAGRYX9Q8S3NCDCB361O4SN3O9W
24-39,a study was conducted on to assess salt consumption and the risk of death. 1.65 million deaths a year occur from high salt consumption. ,College,female,0.6923076923076923,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J_37FMASSAYDCHKAR6D1CUDAN845RIB7,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,A2L53B1MI02U0W,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['B', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J_37FMASSAYDCHKAR6D1CUDAN845RIB7_3UJ1CZ6IZIA4P8DTH3FVEQT33GLS54
40-60,Rosiglitazone is used to treat Type 2 Diabetes. A major side effect to this medication is an increase risk of myocardial infaction. ,Some College,female,0.7692307692307693,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL_33F859I567YHOFGM7JU9DYMT4WZHB8,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'diabete': {'Participants'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'diabete': {'Condition'}}}",cardio,A14L7ICRNLCAQY,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL_33F859I567YHOFGM7JU9DYMT4WZHB8_3C44YUNSI2A2GTCU4STKHXCKTDADPF
40-60,Overweight persons with preexisting cardiovascular conditions could suffer side effects when receiving suburatmine. ,College,male,0.8461538461538461,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67_3WQQ9FUS6BFOV4FT4F030LTU1FFB8X,"{'Coarse': {'overweight': {'Participants'}}, 'Fine': {'overweight': {'Condition'}}}",cardio,A1SNL49AU2I5BV,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67_3WQQ9FUS6BFOV4FT4F030LTU1FFB8X_3LBXNTKX0SGVMC14E3YZPEFX4RPX9R
24-39,"This study determined that the short term effects of cardiac medication, increasing the risk of death when using Azithromycin.",College,male,0.38461538461538464,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R_39ASUFLU6YSCH8SLMEELHSG8VFIEXD,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,A1DOY340I9VN92,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R_39ASUFLU6YSCH8SLMEELHSG8VFIEXD_3RYC5T2D74EWH3VZMTO4MMTO8FJPRH
24-39,"In this research states sodium intake on blood pressure and cardiovascular deaths across race, age and hypertension status.  ",College,male,0.38461538461538464,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC_3YT88D1N09J3NADHYBI087498IL3KW,"{'Coarse': {}, 'Fine': {}}",cardio,A1DOY340I9VN92,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC_3YT88D1N09J3NADHYBI087498IL3KW_3STRJBFXOXC8MRBBDQORQK872PQTKB
24-39,a study done to assess the effects of azithromycin on the heart. the study confirmed that there is a link to death from azithromycin. ,College,female,0.6923076923076923,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ_3KB8R4ZV1FS3OJLBNDCRSYASPYSGBI,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,A2L53B1MI02U0W,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ_3KB8R4ZV1FS3OJLBNDCRSYASPYSGBI_3BXQMRHWK0JICSQ3Y7RHATMDA8VMU3
24-39,Patients with a high risk cardiovascular disease has an increased rate of death when treated with AZITHROMYCIN compared to AMOXICILLEN.,College,female,0.6923076923076923,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK_3BWI6RSP7HUI2TMU41ANNT3KTNR7E1,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,A3RH84U74MARF5,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK_3BWI6RSP7HUI2TMU41ANNT3KTNR7E1_3GLB5JMZFYGW3GJV193XNOYSSMJGDA
24-39,Results of a study on people using siburtamine to manage their weight had a greater risk of death than those taking a placebo.,College,female,0.9230769230769231,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI_3X4JMASXCNU6DFAQ9BNO76NCICI0B4,"{'Coarse': {'placebo': {'Intervention'}}, 'Fine': {'placebo': {'Control'}}}",cardio,A2XS5QI4YX493N,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI_3X4JMASXCNU6DFAQ9BNO76NCICI0B4_3WRFBPLXRB94VGYKVOAG0ZLD2LSN33
24-39,a study of overweight people 55 years and up was conducted. long term use of this sibutramine increases the risk of a heart attack. ,College,female,0.6923076923076923,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB_3WRFBPLXRB94VGYKVOAG0ZLD2CD3NM,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}, '55 year': {'Participants'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}, '55 year': {'Age'}}}",cardio,A2L53B1MI02U0W,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB_3WRFBPLXRB94VGYKVOAG0ZLD2CD3NM_30LSNF239VGNWXRAU8JJCHK4A8R2IK
24-39,Sodium intake of more than 3.95g per day increases one's chance of cardiovascular disease and should be limited to 2g per day.,College,female,0.6923076923076923,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM_3GFK2QRXXA2XWPU218PWBFWO9K95W6,"{'Coarse': {}, 'Fine': {}}",cardio,A3RH84U74MARF5,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM_3GFK2QRXXA2XWPU218PWBFWO9K95W6_3JC6VJ2SAC40PCRZ03T4TQZXHA8A5K
24-39,Studies on Rosiglitazone indicate a higher risk of death from cardiovascular disease due to and increased risk of myocardial infection.,College,female,0.6923076923076923,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF_3L0KT67Y8F12RWNDS5KSPNRWYI9YS4,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}}}",cardio,A3RH84U74MARF5,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF_3L0KT67Y8F12RWNDS5KSPNRWYI9YS4_3180JW2OT5XBQ5U3U96HMP2G7X1J58
60+,"Azithromycin, Ciprofloxacin, Levoloxacin, but not Amoxicillin, are related to fatal cardiovascular events after 5-day treatments. ",College,male,0.8461538461538461,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF_3HPZF4IVNNEMKFYHVJUSAINECAKYCX,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}, '5': {'Duration'}}}",cardio,A2H1QUGX0SOUMH,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF_3HPZF4IVNNEMKFYHVJUSAINECAKYCX_3SNVL38CI5DR0A90R4T11A83E3BKC4
24-39,Following research is about cardiovascular of obese peoples looked sample over 10000 subjects. They were put in a 3 year program.,College,male,0.38461538461538464,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M_37TRT2X24RCDFLBCVJXUPB28HQ9JBP,"{'Coarse': {'obese': {'Participants'}}, 'Fine': {'obese': {'Condition'}}}",cardio,A1DOY340I9VN92,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'A'], 'Intervention': ['C', 'A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M_37TRT2X24RCDFLBCVJXUPB28HQ9JBP_3RGU30DZTBT9YCF9M8N33RD2TSTMJ3
60+,Meta-analysis from low & middle-income counties (Georgia and Kenya) indicate that high-sodium intake increases blood pressure.,College,male,0.8461538461538461,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X_3PXX5PX6LYJ2ES881DKHWCZPRXIBAS,"{'Coarse': {}, 'Fine': {}}",cardio,A2H1QUGX0SOUMH,NEJMoa1304127,"{'Coarse': {'Participants': ['D', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['D'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X_3PXX5PX6LYJ2ES881DKHWCZPRXIBAS_3E1QT0TDFQUYICTZAPSKM8X7W808IA
60+,A 3.4-year study indicated overweight subjects with cardiovascular and/or diabetic issues lost weight while using sibutamine.,College,male,0.8461538461538461,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0_3ITXP059PX4CW7SE65JPF0C8L81JSK,"{'Coarse': {'overweight': {'Participants'}}, 'Fine': {'overweight': {'Condition'}}}",cardio,A2H1QUGX0SOUMH,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'A', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0_3ITXP059PX4CW7SE65JPF0C8L81JSK_3D3VGR7TA10PAEQCOVRX9JQN3HNR3Z
40-60,Those who are the average age of 56 and take Rosiglitazon to treat type two diabetes have an increased chance of myocardial infarction.,College,female,1.0,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S_3Y9N9SS8LZWV94776UWD4U9JO843DX,"{'Coarse': {'myocardial infarction': {'Outcomes'}, 'diabete': {'Participants'}}, 'Fine': {'myocardial infarction': {'Outcomes-general'}, 'diabete': {'Condition'}}}",cardio,A1OBU9NMV1C3S5,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S_3Y9N9SS8LZWV94776UWD4U9JO843DX_3OS4RQUCRA0XAJPGCT69ADAGOMTBFL
24-39,"In a study of people over the age off 55 with heart disease and/or type II diabetes, the placebo group had better metrics.",College,female,0.6923076923076923,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S_3XC1O3LBOT7J6XTTYQ0S5KLMR30LT3,"{'Coarse': {'placebo': {'Intervention'}}, 'Fine': {'placebo': {'Control'}}}",cardio,A3RH84U74MARF5,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['C', 'C', 'A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S_3XC1O3LBOT7J6XTTYQ0S5KLMR30LT3_3Y5140Z9DY1JO4SGW6UV8USXLICPIN
60+,A rigorous double-blind study indicates rosiglitazone reduces mycrocardial infractions and baseline glycated hemoglobin. ,College,male,0.8461538461538461,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS_31IBVUNM9TKCJXNMHAX9BP4NR6MFVS,"{'Coarse': {'rosiglitazone': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}}}",cardio,A2H1QUGX0SOUMH,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS_31IBVUNM9TKCJXNMHAX9BP4NR6MFVS_3R2UR8A0IB1YTZ5AGSHHM4AMZP2OXL
24-39,Risks for cardiovascular deaths increased in azithromycin compared to amoxicillin and ciprofloxacin in patients taking macrolids.,Some College,female,1.0,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS_336YQZE83WZ1RD0OX6J92HUXBIM5M6,"{'Coarse': {'azithromycin': {'Intervention'}, 'cardiovascular death': {'Outcomes'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'cardiovascular death': {'Outcomes-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}}}",cardio,A2XSGALF8O9ISQ,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'B'], 'Intervention': ['A', 'C', 'B'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS_336YQZE83WZ1RD0OX6J92HUXBIM5M6_3X1FV8S5JYCIXXJHSU3RTA4ZSS3GVN
60+,A study of coffee drinking and mortality initially was positive. Results were reversed when it was found that smoking was also a factor.,Some College,male,0.8888888888888888,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U_3A4NIXBJ77KFT239PTZGJ6QUSXSLMP,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,4,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U_3A4NIXBJ77KFT239PTZGJ6QUSXSLMP_3KAKFY4PGVNCHFNTY8XOVRPWB7OI39
60+,"In a study of the link of coffee drinking and mortality, outcome was positive. Smoking of coffee drinkers reversed study results.",Some College,male,0.8888888888888888,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ_33TIN5LC05VKMHREJZK18SM61DRY9X,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['A']}}",,4,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ_33TIN5LC05VKMHREJZK18SM61DRY9X_3ZPPDN2SLWHMGCANJY871PUQJ6S9E9
24-39,"It doesn't matter if you smoke or not, it turns out Coffee increases mortality.  This was a study done over twelve years.",College,female,0.7777777777777778,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O_3CFVK00FWM6D4ZIH2DSZUAT82X9L6B,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A1VC6F0FYG1L5I,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'B'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,4,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O_3CFVK00FWM6D4ZIH2DSZUAT82X9L6B_3X3OR7WPZ0L08D15VSPXEOPZ8X78L2
60+,"A weight gain of 3.35 pounds was observed in a four year study. The gain was attributed to eating unhealthy foods (sugary drinks, potato).",Some College,male,0.8888888888888888,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX_3X1FV8S5JYCIXXJHSU3RTA4ZN9GGVT,"{'Coarse': {}, 'Fine': {}}",diet,A18V6K2TMWMSWD,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX_3X1FV8S5JYCIXXJHSU3RTA4ZN9GGVT_3VELCLL3GL4WXL7OAWDK41X7XVKF1P
60+,A link between lifestyle and weight gain was found in a study. Diet was one of the factors. Less weight was found with a vegetarian diet.,Some College,male,0.8888888888888888,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU_3OB0CAO74IAD1N9XHB8TL9KUKQTYHH,"{'Coarse': {'diet': {'Intervention'}, 'lifestyle': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}, 'lifestyle': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU_3OB0CAO74IAD1N9XHB8TL9KUKQTYHH_3LBXNTKX0SGVMC14E3YZPEFXZC59XK
60+,"In a study, attendance at meetings was found to have a greater effect on weight loss than the consumption of macronutrients.",Some College,male,0.8888888888888888,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q_3R6P78PK7LW3K5FSNZ3CSSGEQO0TGQ,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q_3R6P78PK7LW3K5FSNZ3CSSGEQO0TGQ_3P1L2B7AD2A3T5OL29ETBAFZN2KOLU
60+,A study of the Mediterranean diet and its possible effect on reduction of cardiovascular disease found a positive correlation.,Some College,male,0.8888888888888888,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV_3QY5DC2MXS5C6IYMCKN4F3248N7UFJ,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV_3QY5DC2MXS5C6IYMCKN4F3248N7UFJ_3IOEN3P9S840ESED93AGAVKU4WL61H
24-39,"When researchers observed older people for 13 years, they found a correlation between death and both coffee consumption and smoking.",College,female,0.7777777777777778,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN_3137ONMDKHQ1VMXVX4EHT6GDNEHEGP,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A5R0NQCWSPEJ9,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'B', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,4,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN_3137ONMDKHQ1VMXVX4EHT6GDNEHEGP_3Y9N9SS8LZWV94776UWD4U9JJ2ND39
60+,"A study of adults found that weight gain was related to eating chips, sugary drinks and meat. Exercise and diet may change that outcome.",Some College,male,0.8888888888888888,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8_3WLEIWSYHP2N02GQOQ1YC5JP5B4H2P,"{'Coarse': {'diet': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8_3WLEIWSYHP2N02GQOQ1YC5JP5B4H2P_3YMTUJH0DT1N8PM8SY1BJ3JB0O6T4S
60+,A study on weight loss found that the reduction of calories was more effective than manipulation of intake of macronutrients.,Some College,male,0.8888888888888888,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01_3RANCT1ZVG2MT1M67I18WDBJTPJBUM,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01_3RANCT1ZVG2MT1M67I18WDBJTPJBUM_3GDTJDAPVVWKEVJQV4QCE14O826M8R
24-39,A study found that reducing any calories (not just macros) was the most important factor in weight loss-an average of 6 kg in 6 months.,College,female,0.7777777777777778,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I_33PPO7FECW0AZ7PQRX3080B82F4IDO,"{'Coarse': {'weight loss': {'Outcomes'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, '6 month': {'Duration'}}}",diet,A5R0NQCWSPEJ9,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'B', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I_33PPO7FECW0AZ7PQRX3080B82F4IDO_3HUTX6F6VV8XSJ2DS3WOWEGQH2UO26
24-39,Researchers found that reducing calories was more important in reducing weight in adults than adjusting the ratios of food.,College,female,0.7777777777777778,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB_3Y4W8Q93L05FLD9QQ42JNP12AH4VD2,"{'Coarse': {'adult': {'Participants'}}, 'Fine': {'adult': {'Age'}}}",diet,A5R0NQCWSPEJ9,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB_3Y4W8Q93L05FLD9QQ42JNP12AH4VD2_3A7Y0R2P2P9KSOED0FPCE8T0VHLXJ7
24-39,A study about the Mediterranean diet added other items that were not staples to see how it affected older people.,College,female,0.7777777777777778,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4_3V5Q80FXIYC86U9R95CW8BIFM6E32W,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A5R0NQCWSPEJ9,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4_3V5Q80FXIYC86U9R95CW8BIFM6E32W_39GXDJN2OUZ34IDZ9WR31XN1ZVK8VW
24-39,Researchers found that people who eat poorly and are sedentary gained weight over time; healthier people lost weight.,College,female,0.7777777777777778,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29_3ZOTGHDK5JWQXIJBMIBUNWTUFRHSOR,"{'Coarse': {}, 'Fine': {}}",diet,A5R0NQCWSPEJ9,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29_3ZOTGHDK5JWQXIJBMIBUNWTUFRHSOR_3NKQQ8O39ZQF8YKQLESER3ZJWF8DUI
24-39,"Eating poorly and an unhealthy lifestyle can cause long term weight gain.  To lose weight, increase exercise and eat healthy foods.",College,female,0.7777777777777778,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI_3I33IC7ZWGN8QF8CIKR6VJWLSG9A22,"{'Coarse': {'lifestyle': {'Intervention'}, 'long term': {'Outcomes'}}, 'Fine': {'lifestyle': {'Intervention-general'}, 'long term': {'Outcomes-general'}}}",diet,A5R0NQCWSPEJ9,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI_3I33IC7ZWGN8QF8CIKR6VJWLSG9A22_3GU1KF0O4JM91WEAQW2EM7OKLD4BPD
24-39,A Spanish study of older people examined the link between heart disease and the Mediterranean diet by modifying it between groups.,College,female,0.7777777777777778,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7_3TVSS0C0E2LZHR5S247UEV22KCWWTY,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A5R0NQCWSPEJ9,NEJMoa1200303,"{'Coarse': {'Participants': ['A', 'C', 'C', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7_3TVSS0C0E2LZHR5S247UEV22KCWWTY_3TS1AR6UQRZA87MQZCUT5BOK0HQF7S
60+,Researchers that caloric intake reduction was more a factor in weight loss as compared to changing macronutrient intake. ,Some College,male,0.8888888888888888,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK_3R2PKQ87NXTD31V34Q23RQY2BT0IMA,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A18V6K2TMWMSWD,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK_3R2PKQ87NXTD31V34Q23RQY2BT0IMA_3JRJSWSMQI601AL72P7XACR4JES3EW
60+,A study on weight gain found a correlation with the quantity of processed food intake. Eating more healthy food reversed this effect.,Some College,male,0.8888888888888888,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465_3HSYG7LRBKJ9J8LOJHAZPTLBESQKKE,"{'Coarse': {}, 'Fine': {}}",diet,A18V6K2TMWMSWD,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465_3HSYG7LRBKJ9J8LOJHAZPTLBESQKKE_33CID57105EE7GVZJBU1N7HOSBSL30
40-60,A recent study showed diets rich in sugary/starchy foods led to less weight loss than healthy foods and exercise. ,College,male,0.6666666666666666,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE_3EFE17QCRDQG51XOI5G43NWT35XSHX,"{'Coarse': {'diet': {'Intervention'}, 'weight loss': {'Outcomes'}}, 'Fine': {'diet': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}}}",diet,A1L82EA5PNL5RO,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE_3EFE17QCRDQG51XOI5G43NWT35XSHX_34HJIJKLP6H2LHQXXT1QKL7WX9IV46
24-39,A study proves that a Mediterranean diet with mixed nuts and olive oil has raised ones chances of heart disease and related problems. ,Some College,male,0.7777777777777778,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22_32UTUBMZ7HHM6GB6C8BDSZD27WMBV5,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A16KMPWYUZO0M6,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22_32UTUBMZ7HHM6GB6C8BDSZD27WMBV5_3QY5DC2MXS5C6IYMCKN4F3248SRUFD
24-39,A study shows that the Mediterranean diet reduces heart issues in people 55-80 especially those who added nits or olive oil.,College,female,0.7777777777777778,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z_3RANCT1ZVG2MT1M67I18WDBJTPEUB0,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A1VC6F0FYG1L5I,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z_3RANCT1ZVG2MT1M67I18WDBJTPEUB0_378XPAWRUDYC10ME7NCYIZ32HHDIA2
40-60,There is a potential increased risk of death for people age 50-71 who drink coffee including both smokers and non-smokers.,College,female,0.7222222222222222,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6_3XLBSAQ9Z5XGDODQ0OO08342CH0Z76,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,4,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6_3XLBSAQ9Z5XGDODQ0OO08342CH0Z76_3M68NM076ISO7XDU7XPVGM278U96R7
40-60,"When studying the Mediterranean diet, high risk patients given nits or extra olive oil had less cardiovascular events.",College,male,0.6666666666666666,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D_3NOKK93PR2T3B814R9OTT3V1AY2EE8,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}}}",diet,A1L82EA5PNL5RO,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D_3NOKK93PR2T3B814R9OTT3V1AY2EE8_3GDTJDAPVVWKEVJQV4QCE14O822M8N
24-39,Studies show that coffee drinkers who also smoked had a more likely chance of death.  Non-smokers who drink coffee are less likely to die.,College,female,0.7777777777777778,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA_3N2BF7Y2VRFD76KJY8KIREXNBGEMHE,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A1VC6F0FYG1L5I,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA_3N2BF7Y2VRFD76KJY8KIREXNBGEMHE_3CFJTT4SXUBUIYOG0K0E881CG97I7B
24-39,"According to a study, if you drink alcohol, smoke and eat unhealthy foods you will be more likely to gain weight and age faster.",Some College,male,0.7777777777777778,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM_3LEIZ60CDKKKR71JFLMKMZV877S9ZW,"{'Coarse': {}, 'Fine': {}}",diet,A16KMPWYUZO0M6,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM_3LEIZ60CDKKKR71JFLMKMZV877S9ZW_37Z929RLGAT6AAOJIZXTH6ZHE4ETS4
40-60,Obese adults tested with 4 unique diets each including macronutrients in different ratios experienced a 3% weight loss. ,College,male,0.6666666666666666,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX_3O7L7BFSHFAFRD3QNSEKEITT2R9EIH,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}, 'adult': {'Participants'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}, 'adult': {'Age'}}}",diet,A1L82EA5PNL5RO,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX_3O7L7BFSHFAFRD3QNSEKEITT2R9EIH_3U84XHCDIDYJU1V7YQQT5RKSLKMZ48
40-60,"Study shows coffee drinkers age 50-71 have a higher death rate than no coffee, but because some coffee drinkers smoke, effects unknown.",Some College,female,0.8888888888888888,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR_3E1QT0TDFQUYICTZAPSKM8X7RO68I7,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A98E8M4QLI9RS,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,4,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR_3E1QT0TDFQUYICTZAPSKM8X7RO68I7_37W3JXSD67TVYD4MCAUTMCUHZJGWYZ
40-60,People experienced a slight reduction in cardiovascular events while following a Mediterranean diet compared to a low fat diet.,College,female,0.7222222222222222,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB_3FE7TXL1LJ80DVFT7GOSLJBQWY0Q2U,"{'Coarse': {'mediterranean diet': {'Intervention'}, 'cardiovascular event': {'Outcomes'}, 'fat': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}, 'cardiovascular event': {'Outcomes-general'}, 'fat': {'Control'}}}",diet,A3D8ZG1VV5FO35,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'A'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB_3FE7TXL1LJ80DVFT7GOSLJBQWY0Q2U_37M28K1J0RY8WB6KP5XYU0I2UW3AJ7
40-60,"In a 6 month study of  811 overweight adults,  all lost about 7% of the their body weight. In 2 years 80% lost additional body weight.. ",College,male,0.7777777777777778,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10_3X87C8JFV7WTIUWR1V3YC1OUUSZSQZ,"{'Coarse': {'811': {'Participants'}, 'overweight': {'Participants'}, 'adult': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}}, 'Fine': {'811': {'Sample-size'}, 'overweight': {'Condition'}, 'adult': {'Age'}, '6 month': {'Duration'}, '2 year': {'Duration'}}}",diet,A1L0T8IFHPA77E,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['C', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10_3X87C8JFV7WTIUWR1V3YC1OUUSZSQZ_38JBBYETQPVLJ64B23CGKHJAXEB4E5
40-60,"Calorie reduction leads to weight loss regardless of the macronutrient split. However, diets with protein kept the weight off longest.",College,female,0.7222222222222222,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW_3GS6S824SRI1ME0858LI5WWAVU8NWM,"{'Coarse': {'weight loss': {'Outcomes'}, 'diet': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'diet': {'Intervention-general'}}}",diet,A3D8ZG1VV5FO35,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW_3GS6S824SRI1ME0858LI5WWAVU8NWM_3KJYX6QCMAWSOZ9I00OUQNWFF63JVG
40-60,A large study of people showed those with high risk heart issues lessened the chance of a heart attack by following a Mediterranean diet.,College,male,0.6666666666666666,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG_39OWYR0EPLCTNRIRMLKTIO8H4BEFYY,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A1L82EA5PNL5RO,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG_39OWYR0EPLCTNRIRMLKTIO8H4BEFYY_3QUO65DNQV96CVBFBN6U2XBI0T6UON
40-60,There has been no correlation found between drinking coffee and death as reported by the NIH. Other factors were considered but ruled out.,Some College,female,0.6666666666666666,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB_3UWN2HHPUZQ8FXJZL3BH87TPPHCNS7,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A2LTOS0AZ3B28A,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB_3UWN2HHPUZQ8FXJZL3BH87TPPHCNS7_37Z929RLGAT6AAOJIZXTH6ZHE40TSQ
40-60,Pertussis vaccine was studied to see how effective it is long term. After 5 years it was still 42% effective against Dtap.,Some College,female,0.75,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH_3IKZ72A5B51ZBSEDFJBI18AA5EGFNT,"{'Coarse': {'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH_3IKZ72A5B51ZBSEDFJBI18AA5EGFNT_3I33IC7ZWGN8QF8CIKR6VJWLY922AF
24-39,Denmark studied children in the 90's.  Danish Civil Registration and Danish Psychiatric revealed no link between autism and MMR vaccine.,College,male,0.625,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY_39K0FND3AI0YXJC5S2AQASAJ381MAV,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A3EQVD21IG27DG,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY_39K0FND3AI0YXJC5S2AQASAJ381MAV_3NS0A6KXC5TZ6HORTRSUEGHVHD7ZGP
60+,After the 2009 Flue epidemic researchers injected subjects and found that injecting small doses of the flu innoculated their subjects.,College,female,0.625,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ_3PW9OPU9PR5CWRVCM1YDKI3IT9221K,"{'Coarse': {}, 'Fine': {}}",immunization,AR4UI9K92BUT3,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ_3PW9OPU9PR5CWRVCM1YDKI3IT9221K_351SEKWQS12WVQFHCC1S0TIPPHGDMJ
15-24,"MMR vaccine does not cause autism. Of 400,000 children examined, 316 were diagnosed with autism, another 422 children were on the spectrum",College,male,0.625,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM_3I02618YA1ROXVNGQNJ9RXG8FG3PU5,"{'Coarse': {'autism': {'Outcomes'}, '422': {'Outcomes'}, '316': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, '422': {'Effect-strength'}, '316': {'Effect-strength'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A3723CQM6I92CU,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'D'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM_3I02618YA1ROXVNGQNJ9RXG8FG3PU5_3HRMW88U17B2W6EN00DXLMY6VS60MC
40-60,"According to one study, there is no link between the MMR vaccine and Autism. 40,665 children who were vaccinated were at no increased risk",Some College,male,0.875,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E_3P59JYT76M5D5B7LOKINQOMDLTYT2R,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A2LGTYVFPKU2TD,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'D', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['D'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E_3P59JYT76M5D5B7LOKINQOMDLTYT2R_3EICBYG645HWPQ3I9JTP0V8Q0NNJCZ
24-39,An Australian study examined dosages levels of the 2009 H1N1 vaccine and found that outcomes were slightly better in the low dose group.,College,female,0.5,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E_39JEC7537VM5GL3CQ8783JJKV7IVCE,"{'Coarse': {'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A3BDVHNMJECSKG,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E_39JEC7537VM5GL3CQ8783JJKV7IVCE_3RRCEFRB7NXNC3SRSCAQJ9DP06FB4D
24-39,"A study that looked at 15000 infants and toddlers found that the RTS,SVAS01 malaria vaccine decreased the incidence of malaria.",College,female,0.5,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID_39KFRKBFIOGNT4VKLO3J5IHV11NYO4,"{'Coarse': {'rts': {'Intervention'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'malaria': {'Outcomes-general'}}}",immunization,A3BDVHNMJECSKG,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'A'], 'Intervention': ['A', 'C', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID_39KFRKBFIOGNT4VKLO3J5IHV11NYO4_3BGYGHDBBY5JLCD855YRP1DNMM3223
60+,"In a 14 month trial with 15,460 African children age 6 weeks to 17 months. malaria vaccine was found to protect against malaria.",College,female,0.875,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB_3RYC5T2D74EWH3VZMTO4MMTO9KMRPX,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, '15,460': {'Participants'}, '14 month': {'Intervention'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, '15,460': {'Sample-size'}, '14 month': {'Duration'}, 'malaria': {'Outcomes-general'}}}",immunization,A37CE37LHUN8M6,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['B', 'B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB_3RYC5T2D74EWH3VZMTO4MMTO9KMRPX_3OF2M9AATH9483KAJID9C89OOX9KZ4
24-39,Children test positive for pertussis using PCR after 5 doses of the vaccine. 42% of children per year will be diagnosed with pertussis.,Some College,female,0.875,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI_39K0FND3AI0YXJC5S2AQASAJ3APAMB,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3RZLDKSVK9W3N,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['C']}}",,4,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI_39K0FND3AI0YXJC5S2AQASAJ3APAMB_374TNBHA8CGQEG8001VNUNCVH8HQYT
24-39,"In a large study of children in two different age groups, it was concluded that RTS provides immunity to both clinical and severe malaria.",Some College,female,0.875,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ_3Z9WI9EOZ09IHIKGDW72C15JS2RHK0,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A14M2EERU7E8KD,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ_3Z9WI9EOZ09IHIKGDW72C15JS2RHK0_3WRFBPLXRB94VGYKVOAG0ZLD3WKN3I
40-60,"The RTS,S?AS01 vaccine works against malaria. If three doses are given to children it is 47.3% effective compared to 45.1%.",Some College,female,0.75,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW_3IJXV6UZ1Y440H8V9YYKDPSCN8RIRG,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}, '45.1 %': {'Outcomes'}, '47.3 %': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}, '45.1 %': {'Effect-strength'}, '47.3 %': {'Effect-strength'}, 'three dos': {'Intensity'}}}",immunization,A2NGY0LAM66P0N,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'A', 'C', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW_3IJXV6UZ1Y440H8V9YYKDPSCN8RIRG_3KRVW3HTZO62XFYZ92WHVS4PQL2MS0
24-39,Children in Africa were given the RTS vaccination and an alternative. Results show that the RTS vaccine was more effective.,College,male,0.75,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W_33UKMF931A57PA1Y7Z2JRBV3MA1TTI,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A3U7EIF0P9GQKI,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W_33UKMF931A57PA1Y7Z2JRBV3MA1TTI_3180JW2OT5XBQ5U3U96HMP2G86E5JQ
40-60,If a child gets 5 DTap doses or more they are more likely to get Pertussis. The risk increased 42% a year after the 5th dose.,Some College,female,0.75,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW_3JMSRU9HQJFKDJNQMZD3T7JNGJWVE8,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A2NGY0LAM66P0N,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['A']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['A'], 'Conclusion-general': ['A']}}",,4,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW_3JMSRU9HQJFKDJNQMZD3T7JNGJWVE8_3QAVNHZ3ENPER1UKSQ9BAFVU4AZLAV
24-39,A study in the US shows that pertussis vaccines given before age 7 often correlate with whether or not that child will get the illness.,Some College,female,0.875,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA_3BF51CHDTWVG4SDC93XKTHQAD130HO,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}}}",immunization,A14M2EERU7E8KD,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA_3BF51CHDTWVG4SDC93XKTHQAD130HO_3MX2NQ3YCAFCLPZSBDLIDYAVJ4QX53
24-39,African children in 7 countries were given the malaria vaccine. it was tested to see how safe and effective it was & yielded great results,College,female,0.5,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4_35USIKEBNS13SZL2EQ8E72XXDK56NK,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A2L53B1MI02U0W,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4_35USIKEBNS13SZL2EQ8E72XXDK56NK_3T3IWE1XG78UXU96QV8OM6KG246QT7
40-60,"A fifth dose of Pertussis vaccine cause 42% less cases of pertussis, according to a study on ages 4-12 years old.",Some College,female,0.75,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3_3VFJCI1K40KQ4Q20JAYHSDFW7SMGR2,"{'Coarse': {'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1GCIKCWCY4FSI,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3_3VFJCI1K40KQ4Q20JAYHSDFW7SMGR2_3E337GFOLAT5PSA8Q3H0JTAM7ZRGNH
24-39,An H1N1 study was performed on adults who were given inactive doses of H1N1. Their titer level revealed the vaccine does not help. ,College,male,0.75,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC_3LS2AMNW5GBEK24YUEMPSWET3VLQOF,"{'Coarse': {'adult': {'Participants'}}, 'Fine': {'adult': {'Age'}}}",immunization,A3U7EIF0P9GQKI,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,4,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC_3LS2AMNW5GBEK24YUEMPSWET3VLQOF_3L4D84MIL0DN6YEYVB7QBM56DF0JHG
24-39,A Denmark study found that there was not sufficient evidence linking the MMR vaccine and autism in both vaccinated and unvaccinated kids ,College,male,0.75,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO_3P4MQ7TPPYX7X2D07RKDRNJV9R8BBG,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'denmark': {'Participants'}, 'unvaccinated': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'denmark': {'Location'}, 'unvaccinated': {'Control'}}}",immunization,A3U7EIF0P9GQKI,NEJMoa021134,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO_3P4MQ7TPPYX7X2D07RKDRNJV9R8BBG_3LYA37P8IR88Q5HUD4X6QQ2LXRSKBX
24-39,in Australia a study was done on the h1n1 vaccine. the vaccine was given in 2 doses  and it found that a single 15ug dose was effective. ,College,female,0.5,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH_3K3R2QNK8CO358799YNC57GTBFD9UT,"{'Coarse': {'australia': {'Participants'}}, 'Fine': {'australia': {'Location'}}}",immunization,A2L53B1MI02U0W,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH_3K3R2QNK8CO358799YNC57GTBFD9UT_34J10VATJGJ4OGTVWJ9K8ZI7RMKQII
40-60,The H1N1 vaccine was tested to see how safe it was.The conclusion by the Australian study was one dose of 15ug was safe and effective.,Some College,female,0.75,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H_3MB8LZR5BGEK3E364HM04TYQ8H7LKD,"{'Coarse': {'australia': {'Participants'}}, 'Fine': {'australia': {'Location'}}}",immunization,A2NGY0LAM66P0N,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H_3MB8LZR5BGEK3E364HM04TYQ8H7LKD_3Z9WI9EOZ09IHIKGDW72C15JS4OKH4
40-60,"There was a vaccine trial for 15,000 African children. After 3 shots each over 12 months, 250 children contracted Malaria.",Some College,female,0.75,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H_3N2BF7Y2VRFD76KJY8KIREXNH8AMH0,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}, '12 month': {'Intervention'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}, '12 month': {'Duration'}}}",immunization,A1GCIKCWCY4FSI,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['B', 'B', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H_3N2BF7Y2VRFD76KJY8KIREXNH8AMH0_3A1PQ49WVI2GBHYU5M1K7M9KJYW1HQ
24-39,A group trial to evaluate 2 doses of inactive H1N1 vaccine concluded that a lower dose was immunogenic with mild-moderate reactions.,College,female,0.875,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55_3U088ZLJVLEY1I8142JKUK0XSQ3W09,"{'Coarse': {}, 'Fine': {}}",immunization,A3RH84U74MARF5,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,4,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55_3U088ZLJVLEY1I8142JKUK0XSQ3W09_33JKGHPFYDF5H26U16FVWYUJ3L0NMT
24-39,"A 7 years study of 540,000 children in Denmark showed no statistically significant connection between MMR vaccine and autism.",College,female,0.875,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP_3JC6VJ2SAC40PCRZ03T4TQZXIGB5AV,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}, 'denmark': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}, 'denmark': {'Location'}}}",immunization,A3RH84U74MARF5,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP_3JC6VJ2SAC40PCRZ03T4TQZXIGB5AV_34FNN24DCNU1LUP2G97KWCH4LAD5YA
24-39,I new study of the influenza vaccine found a smaller dose was approximately 95% as effective as the standard dose.,Some College,female,0.75,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF_3C6FJU71TREI69FHHAFS4O9KKQQYU3,"{'Coarse': {}, 'Fine': {}}",immunization,A1G5UBN2E7G5KP,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF_3C6FJU71TREI69FHHAFS4O9KKQQYU3_3YDGXNSEO0F4A5UKP0QGS7NOSZA84P
24-39,A pertussis vaccination study found that children who received pertussis vaccination increased their chances by 42% of getting pertussis.,College,male,0.75,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H_3EJJQNKU9SQ44MXB3GGZDDRXMSHRHU,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3U7EIF0P9GQKI,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['D', 'B'], 'Conclusion': ['D']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,4,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H_3EJJQNKU9SQ44MXB3GGZDDRXMSHRHU_30MVJZJNHNYURSWFXZJYY57IU2K9J8
24-39,a study done on danish children born between 1991 & 1998 examined the correlation with the timing of MMR shot and am autism diagnosis. ,College,female,0.5,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB_3AWETUDC93DD28UMJFSXZSUBWN6IZ1,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A2L53B1MI02U0W,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,4,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB_3AWETUDC93DD28UMJFSXZSUBWN6IZ1_3C2NJ6JBKB2FAY21ROWBHPGLXG32N1
24-39,There was a study  done in Australia that found the H1N1 vaccine has side effects only about 50% of the time in healthy adults.,Some College,female,0.875,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3_3GFK2QRXXA2XWPU218PWBFWO9Y05WP,"{'Coarse': {'healthy': {'Participants'}, 'adult': {'Participants'}, 'australia': {'Participants'}}, 'Fine': {'healthy': {'Condition'}, 'adult': {'Age'}, 'australia': {'Location'}}}",immunization,A14M2EERU7E8KD,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'C', 'B'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['C']}}",,4,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3_3GFK2QRXXA2XWPU218PWBFWO9Y05WP_3LBXNTKX0SGVMC14E3YZPEFX50SX9D
15-24,DTaP combination vaccine was found to lose efficacy after one year of the last vaccine. A child can develop pertussis after one year?,College,male,0.625,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4_3018Q3ZVOJBPUZPXXA67WR4TAZURAR,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}}}",immunization,A3723CQM6I92CU,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4_3018Q3ZVOJBPUZPXXA67WR4TAZURAR_3EQHHY4HQTD1Z342M3LEPCA0GED5G2
24-39,"A study found that after DTaP shots waned, children had a 42% increased chance of Pertussis. This is why 5 vaccinations are recommended.",College,female,0.875,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO_3UNH76FOCTQZT1A888O6DESQ61JMYO,"{'Coarse': {'child': {'Participants'}, 'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A3RH84U74MARF5,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'B'], 'Conclusion': ['D']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,4,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO_3UNH76FOCTQZT1A888O6DESQ61JMYO_3FE7TXL1LJ80DVFT7GOSLJBQ2R32Q1
24-39,A malaria vaccine was shown to be 47.3 percent effective in African children ages 6-12 weeks and 5-17 months old.,College,female,0.875,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14_3C5W7UE9CGBATWKY3C24U0LH4TZXMZ,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A3RH84U74MARF5,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,4,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14_3C5W7UE9CGBATWKY3C24U0LH4TZXMZ_3EJPLAJKEN1X9OZLHEJ82P46NZNZ66
24-39,"Studies have shown that there is no link to autism for the measles, mumps, and rubella (MMR) any time after you get the vaccination.",College,male,0.75,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO_37TD41K0AIUPOTM8WD23SWZDV0TSC4,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A195R8LWDEDB6K,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO_37TD41K0AIUPOTM8WD23SWZDV0TSC4_3PMBY0YE28O7JEQ9N72CB1UN4IY9CH
40-60,Danish children were studied in the 1990's to see if the MMR vaccine caused autism. It was concluded that it did not.,Some College,female,0.75,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5_3U4J9857OFWKVQAAUA8XMLXZQ3W7B9,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A2LTOS0AZ3B28A,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,4,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5_3U4J9857OFWKVQAAUA8XMLXZQ3W7B9_3NPFYT4IZDPA1MOCS949HV1K9DNXG4
24-39,Adjuvant therapy with an aromatose inhibitor is better than tamosifen,College,male,0.6923076923076923,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X,"{'Coarse': {}, 'Fine': {}}",breast,A1KR3HNLXSLC10,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X_3Q5C1WP23NM4VOEZ4K0BIP6UH1H51G
40-60,A study showed that Exemestrane reduced cancer by 65% in certain women.,College,female,0.7692307692307693,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC_3K4J6M3CXFEY59GJHZCVXNQM7A8AG6_30BXRYBRP5I9CIEX2AQ50CZEIKSHWD,"{'Coarse': {'woman': {'Participants'}, '65 %': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '65 %': {'Effect-strength'}}}",breast,AAB13RUHSABEV,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_3ZWFC4W1UVSKQQ658QSZASFK5GMFR7_32EYX73OY1U9983V3FNYWSGNFDBRUC_3K4J6M3CXFEY59GJHZCVXNQM7A8AG6_30BXRYBRP5I9CIEX2AQ50CZEIKSHWD_3137ONMDKHQ1VMXVX4EHT6GDWK4GEZ
24-39,Regular breast cancer screens result in 10% reduced mortality for women.,College,male,0.6923076923076923,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23_3JNQLM5FT57PMYZGFBGW4XCWR342LZ_3X31TUMD7Y7IXDHKW7GIZE2R3NVL1Q,"{'Coarse': {'woman': {'Participants'}, '10 %': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '10 %': {'Effect-strength'}}}",breast,A1KR3HNLXSLC10,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1000727_33L7PJKHCHJORQ9A41RO0FZG6YGT8T_3E4GGUZ1T9CE2SHYUB4VPXZH1T9K23_3JNQLM5FT57PMYZGFBGW4XCWR342LZ_3X31TUMD7Y7IXDHKW7GIZE2R3NVL1Q_3E47SOBEYRH0UFJCR18POUTQQKECIN
24-39,"When tests are done every two years, the death rate drops to below 3. ",College,female,0.7692307692307693,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q_31HQ4X3T3TVIRXGE9QV2VFP0PXFSL4_3GD6L00D3TI23VZ5WJHXZRHG3S81MV,"{'Coarse': {'2 year': {'Intervention'}}, 'Fine': {'2 year': {'Duration'}}}",breast,A2B115J2WDWGNM,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['C', 'B', 'C'], 'Outcomes': ['D', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['D'], 'Conclusion-general': ['C']}}",,5,NEJMoa1000727_3WMOAN2SRCIO7P03FYGMJUDWSF6VNC_37ZHEEHM6X7FSV6XFHTR42ZN1N837Q_31HQ4X3T3TVIRXGE9QV2VFP0PXFSL4_3GD6L00D3TI23VZ5WJHXZRHG3S81MV_3I2PTA7R3UFVUBJJWMUWLFXKM36QKJ
40-60,A study of women aged 50-69 shown mammography screenings reduce death.,College,female,0.7692307692307693,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ_3PEIJLRY6UE6Y8EC7E8R3YN82JAXWZ_3OONKJ5DKD4RGW29BWPZX7JUK4DOBF,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1000727_3KWTYT0871OHLVI3XUIU24F8AUK5LP_3E7TUJ2EGD7HO6WNN3XNV7C5NXR9DQ_3PEIJLRY6UE6Y8EC7E8R3YN82JAXWZ_3OONKJ5DKD4RGW29BWPZX7JUK4DOBF_3OWEPKL08AXMWZZ7X0D6DGXTBDCN7Q
40-60,A Norway study showed that mammograms decrease breast cancer deaths by 1/3.,College,female,0.7692307692307693,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y_36H9ULYP63F3S2NS0LJQ81TTWI7FJX_3WQ3B2KGE916K4V85UROLB6MRTL1BN,"{'Coarse': {'norway': {'Participants'}}, 'Fine': {'norway': {'Location'}}}",breast,AAB13RUHSABEV,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'D'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,5,NEJMoa1000727_3IO1LGZLKAIIPSYY8OJVP572LGE86L_3TPZPLC3M1X4Y1AXB3N84OQ81HTP3Y_36H9ULYP63F3S2NS0LJQ81TTWI7FJX_3WQ3B2KGE916K4V85UROLB6MRTL1BN_3TOK3KHVJU34EKZJYFDJS5XY1K07O2
40-60,Women who took exemestane showed higher survival rate.,College,female,0.7692307692307693,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD,"{'Coarse': {'woman': {'Participants'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}}, 'Fine': {'woman': {'Sex'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD_33M4IA01QHM1QCXQ8KYLGZFRE3HRXE
24-39,in Norway mammography 40000 subjects screened every 2 years ,College,female,0.5384615384615384,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2_3GGAI1SQEWJMQY93CG6HGN073ZKCMX_3L4D84MIL0DN6YEYVB7QBM56GOIHJH,"{'Coarse': {'norway': {'Participants'}, '2 year': {'Intervention'}}, 'Fine': {'norway': {'Location'}, '2 year': {'Duration'}}}",breast,A1RVRSK2GTUVGK,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'A', 'A'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1000727_3RXPCZQMQQW2BL3JLGJ2MMXJ2VQG15_3TMSXRD2X7LY87TJ0LNK8PJ7WV51W2_3GGAI1SQEWJMQY93CG6HGN073ZKCMX_3L4D84MIL0DN6YEYVB7QBM56GOIHJH_3TMFV4NEP9ZGJ7D4Z6WZNZ6FFC0W8X
24-39,40000 women shows the death rate was lower screened for breast cancer ,College,female,0.5384615384615384,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX_3PMBY0YE28O7JEQ9N72CB1UN3039CL_3JAOYWH7VJP0MIKF0KVBEKKA10I9LO,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A1RVRSK2GTUVGK,NEJMoa1000727,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1000727_340UGXU9DZM12FKCCZS8XP5Q09DVUE_326O153BMJJYJ2N4VED9NLDGEOBEDX_3PMBY0YE28O7JEQ9N72CB1UN3039CL_3JAOYWH7VJP0MIKF0KVBEKKA10I9LO_3Y5140Z9DY1JO4SGW6UV8USXPB2IPW
24-39,now a days women suffered from cancer and after 5 years 92% reduced.,College,female,0.5384615384615384,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7,"{'Coarse': {'5 year': {'Intervention'}, 'woman': {'Participants'}}, 'Fine': {'5 year': {'Duration'}, 'woman': {'Sex'}}}",breast,A1RVRSK2GTUVGK,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['C', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7_3QAVNHZ3ENPER1UKSQ9BAFVU7TWLAX
24-39,Screening for mammography diagnoses has slight impact on death rate.,College,male,0.6923076923076923,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3_3VELCLL3GL4WXL7OAWDK41X721E1FM_3PH3VY7DJMIV33ER8WWC0J3JEA5WZE,"{'Coarse': {}, 'Fine': {}}",breast,A1KR3HNLXSLC10,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1206809_3EF8EXOTT2GC2NTKTM45JZPZUSI1JF_3ZGVPD4G6U23BMAXDRR1DZWK5GATZ3_3VELCLL3GL4WXL7OAWDK41X721E1FM_3PH3VY7DJMIV33ER8WWC0J3JEA5WZE_3H7XDTSHKDCVCMJMI48NFCND3OFWG1
40-60,Trials show a higher survival rate with aromatase inhibitor than tamoxifen.,College,female,0.7692307692307693,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO,"{'Coarse': {'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,AAB13RUHSABEV,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO_3ZPBJO59KQMA3CE6LFLF8OATBB4HD0
40-60,Significant death rate decrease in breast cancer  in a 20 year study.,College,female,0.5384615384615384,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ_3UWN2HHPUZQ8FXJZL3BH87TPUSFSN6_3WOKGM4L721QW9ZZDGSADQNBT1RO06,"{'Coarse': {}, 'Fine': {}}",breast,A3MV3MK1DR9MNZ,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1000727_3KMS4QQVK3BY3MTAI6J29GT6ANJFK3_38JBBYETQPVLJ64B23CGKHJA1A04EQ_3UWN2HHPUZQ8FXJZL3BH87TPUSFSN6_3WOKGM4L721QW9ZZDGSADQNBT1RO06_31T4R4OBOT135V2G8A4SX53HC967C0
15-24,Breast cancer patients show higher survival on exemestane then tamoxifen. ,Some College,female,0.9230769230769231,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6,"{'Coarse': {'breast cancer': {'Outcomes'}, 'survival': {'Outcomes'}, 'exemestane': {'Intervention'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'survival': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}, 'tamoxifen': {'Control'}}}",breast,ADGH08WUP68ZF,NEJMoa1404037,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'B'], 'Outcomes': ['A', 'D', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['A'], 'Effect-strength': ['D'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6_352YTHGROWYX3GVDS4KM5KGNYXYH48
24-39,Survival is better with Adjuvant than just Tomokifen.,College,female,0.7692307692307693,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22,"{'Coarse': {'survival': {'Outcomes'}}, 'Fine': {'survival': {'Outcomes-general'}}}",breast,A2B115J2WDWGNM,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22_37W3JXSD67TVYD4MCAUTMCUH8JXWYP
15-24,Mammograms over diagnosed 1.3 million US women but lowered cancer cases. ,Some College,female,0.9230769230769231,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY_3H0W84IWBLNSKC69DF8TSAUKUYMER6_3TVRFO09GL0QNE2D301PUN6S821LX9,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,ADGH08WUP68ZF,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Location': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1206809_3CP1TO84PUMBK9WVNO0PN8GZ3KG25Z_3L2IS5HSFB3OUAB3A86HN8BDEEXUNY_3H0W84IWBLNSKC69DF8TSAUKUYMER6_3TVRFO09GL0QNE2D301PUN6S821LX9_386PBUZZXGIPSUXOMWMO3EYDXBXJL8
15-24,Tamoxifen had lower survival rate then Extemestane w/ovarian suppression.,Some College,female,0.9230769230769231,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM,"{'Coarse': {'ovarian suppression': {'Intervention'}, 'survival': {'Outcomes'}, 'tamoxifen': {'Intervention'}}, 'Fine': {'ovarian suppression': {'Intervention-general'}, 'survival': {'Outcomes-general'}, 'tamoxifen': {'Control'}}}",breast,ADGH08WUP68ZF,NEJMoa1404037,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'A'], 'Outcomes': ['B', 'D', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM_3MAOD8E57RVGBE5YFDH47FAHD4CNX2
15-24,Toxic events ensued in an exemestane study of 4460 women on breast cancer. ,Some College,female,0.9230769230769231,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT_324G5B4FB4TJB370WUB8241GZLF074_3EJJQNKU9SQ44MXB3GGZDDRXQ40RH5,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,ADGH08WUP68ZF,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'A'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1103507_3ATPCQ38J9VYR01JB5Y14NXQACBAYR_3AAPLD8UCD2HK1A375LUDSSF9ODTHT_324G5B4FB4TJB370WUB8241GZLF074_3EJJQNKU9SQ44MXB3GGZDDRXQ40RH5_379J5II41P1HHEBW8VBX6YLLS31LEP
15-24, Breast cancer risk is lower in post-menopausal women taking Exemestane.  ,Some College,female,0.9230769230769231,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8_3STRJBFXOXC8MRBBDQORQK872GEKT8_30IQTZXKALRDQIDRE7F6W3E455T0XK,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,ADGH08WUP68ZF,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_3RJSC4XJ11F4OZTH81WB4KNK7W450B_3LYA37P8IR88Q5HUD4X6QQ2LVY0BK8_3STRJBFXOXC8MRBBDQORQK872GEKT8_30IQTZXKALRDQIDRE7F6W3E455T0XK_3EF8EXOTT2GC2NTKTM45JZPZZ5SJ12
24-39,Exemestane led to more premenopausal women being free of breast cancer.,College,female,0.7692307692307693,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6,"{'Coarse': {'premenopausal': {'Participants'}, 'woman': {'Participants'}, 'breast cancer': {'Outcomes'}, 'exemestane': {'Intervention'}}, 'Fine': {'premenopausal': {'Condition'}, 'woman': {'Sex'}, 'breast cancer': {'Outcomes-general'}, 'exemestane': {'Intervention-general'}}}",breast,A3BDVHNMJECSKG,NEJMoa1404037,"{'Coarse': {'Participants': ['A', 'B', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6_3KOPY89HM9N8CQ7ZGQIO7S4WXO2J3O
15-24,"Compared with a placebo, Exemestane had a breast cancer reduction of 65%. ",Some College,female,0.9230769230769231,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG_3DH6GAKTYZAZS89RNXE0LGOZLRTZYI_3YJ6NA41JC1FJFCMEOFVKV7X2FQJPM,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'placebo': {'Intervention'}, '65 %': {'Outcomes'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'placebo': {'Control'}, '65 %': {'Effect-strength'}}}",breast,ADGH08WUP68ZF,NEJMoa1103507,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['A', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_3TXWC2NHN0BNQVF5KTSCQ6Y5ON3S9F_35L9RVQFCP3WKEPS7AB4IOEHS2SHUG_3DH6GAKTYZAZS89RNXE0LGOZLRTZYI_3YJ6NA41JC1FJFCMEOFVKV7X2FQJPM_3BF51CHDTWVG4SDC93XKTHQAHLI0HB
24-39,A recent Norwegian study showed breast cancer screenings impact mortality.,College,female,0.7692307692307693,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI_3Q8GYXHFEQNOIROXKHPVZLPLH4NC50_39GAF6DQWSLLTITEABIOMN0TUL8V1U,"{'Coarse': {}, 'Fine': {}}",breast,A3BDVHNMJECSKG,NEJMoa1000727,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1000727_3I33IC7ZWGN8QF8CIKR6VJWLWBMA29_3QUO65DNQV96CVBFBN6U2XBI4R1UOI_3Q8GYXHFEQNOIROXKHPVZLPLH4NC50_39GAF6DQWSLLTITEABIOMN0TUL8V1U_3WI0P0II62DNS6S9HKX9MSCZYIMDR9
40-60,Exesestane has fewer side effects in women and reduce breast cancer.,Some College,female,0.6923076923076923,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31_30IQTZXKALRDQIDRE7F6W3E41E1X03_3DL65MZB8E0OEAHQVIIY3FVYYNLCEK,"{'Coarse': {'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A2VNK2H6USLQTK,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'D', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['D'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_33F859I567YHOFGM7JU9DYMT2TTHBU_3FPRZHYEPZSH3L7TXFW7AGFQN64V31_30IQTZXKALRDQIDRE7F6W3E41E1X03_3DL65MZB8E0OEAHQVIIY3FVYYNLCEK_31LM9EDVOMDFGU09Y923G62223KJNR
40-60,One third of women who took exemestrane reduced their cancer risk.,College,female,0.7692307692307693,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2_3EWIJTFFVPS4KIMAJ2PE8ETXL8HE02_308Q0PEVB9YYWHC9FHYYM4SIKXPI9M,"{'Coarse': {'woman': {'Participants'}}, 'Fine': {'woman': {'Sex'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1103507_358010RM5FETJJE7H43VHW4UTOKXVR_3FK0YFF9P011FU9CHP2DTB79EO5VV2_3EWIJTFFVPS4KIMAJ2PE8ETXL8HE02_308Q0PEVB9YYWHC9FHYYM4SIKXPI9M_3NL0RFNU0G8O56WLYPNJICWFQGLK42
40-60,Women over 40 doubled their cancer detection over the last 20 years.,College,female,0.7692307692307693,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL_3I33IC7ZWGN8QF8CIKR6VJWLXRAA2U_3PPTZCWALR5QJ6I5WNX68ULXQ9SQZ8,"{'Coarse': {'woman': {'Participants'}, '40': {'Participants'}, 'double': {'Outcomes'}}, 'Fine': {'woman': {'Sex'}, '40': {'Age'}, 'double': {'Effect-strength'}}}",breast,A1AZV2XOQK7RSW,NEJMoa1206809,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['C', 'D'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['A'], 'Age': ['A'], 'Location': ['C'], 'Intervention-general': ['C'], 'Duration': ['D'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1206809_32VNZTT0A8PASA9GO9WGJOITGWYR4S_3K4J6M3CXFEY59GJHZCVXNQM6Z4GAL_3I33IC7ZWGN8QF8CIKR6VJWLXRAA2U_3PPTZCWALR5QJ6I5WNX68ULXQ9SQZ8_317HQ483I8DJLJG3GRH345N2PTPNIN
15-24,Breast cancer over-diagnosis occurs in 1/3 of all cases in a 40 year study.,Some College,female,0.9230769230769231,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3_3WRFBPLXRB94VGYKVOAG0ZLD2C73NG_3XCC1ODXDMWHHFWEM63TMRJYHSBRQI,"{'Coarse': {'breast cancer': {'Outcomes'}, '40': {'Participants'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, '40': {'Age'}}}",breast,ADGH08WUP68ZF,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['C'], 'Duration': ['D'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1206809_39LNWE0K4VHWG90CDSTPI0FWSD0IUZ_37U1UTWH9W7BBBWI0CMT00YYIN78R3_3WRFBPLXRB94VGYKVOAG0ZLD2C73NG_3XCC1ODXDMWHHFWEM63TMRJYHSBRQI_3OJSZ2ATDTHI6AT1T0HKJZX7KQX57Z
24-39,Extremestane reduces breast cancer after menopause.,College,female,0.7692307692307693,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC_3QEMNNSB2YKDAN8U86Z3HBLZTA17DH_3Z9WI9EOZ09IHIKGDW72C15JVDJKHK,"{'Coarse': {'breast cancer': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}}}",breast,A2B115J2WDWGNM,NEJMoa1103507,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_33OOO72IVI6Q3TZNLD7T21VZWTOTCU_3E1QT0TDFQUYICTZAPSKM8X7VO78IC_3QEMNNSB2YKDAN8U86Z3HBLZTA17DH_3Z9WI9EOZ09IHIKGDW72C15JVDJKHK_36W0OB37HXZD6DJ2DXACZGTWZPMZHH
15-24,"Mammograms are important to diagnose cancer, but may give false positives. ",Some College,female,0.9230769230769231,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3_3NL0RFNU0G8O56WLYPNJICWFMHS4KR_33L7PJKHCHJORQ9A41RO0FZGB688TL,"{'Coarse': {}, 'Fine': {}}",breast,ADGH08WUP68ZF,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1206809_373ERPL3YPTU9VO63AXORWULWPWRTT_3Y4W8Q93L05FLD9QQ42JNP12EMRVD3_3NL0RFNU0G8O56WLYPNJICWFMHS4KR_33L7PJKHCHJORQ9A41RO0FZGB688TL_3ATPCQ38J9VYR01JB5Y14NXQG36YAY
24-39,Mammograms led to more early detection and less late stage breast cancer.,College,female,0.7692307692307693,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q_3OJSZ2ATDTHI6AT1T0HKJZX7GTZ573_34S6N1K2ZW4T1O2YYWJ3R1IYKCTLHR,"{'Coarse': {'breast cancer': {'Outcomes'}, 'late stage': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'late stage': {'Outcomes-general'}}}",breast,A3BDVHNMJECSKG,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C', 'A'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1206809_3SLE99ER0OY3F0GGD50GD5QYZ6WBZB_3TXD01ZLD522821XS3RLOZ5DNYNU4Q_3OJSZ2ATDTHI6AT1T0HKJZX7GTZ573_34S6N1K2ZW4T1O2YYWJ3R1IYKCTLHR_3NLZY2D53QA6EH11HM6X0FAZB5JLQT
24-39,Exemestane decreased breast cancer in women but had adverse effects.,College,female,0.7692307692307693,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R_3ZAK8W07I5ZL9EJW924JCWF07WJU07_3IXEICO79341NCQMBMUQG13P5B1T63,"{'Coarse': {'exemestane': {'Intervention'}, 'breast cancer': {'Outcomes'}, 'woman': {'Participants'}}, 'Fine': {'exemestane': {'Intervention-general'}, 'breast cancer': {'Outcomes-general'}, 'woman': {'Sex'}}}",breast,A3BDVHNMJECSKG,NEJMoa1103507,"{'Coarse': {'Participants': ['A', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['A'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1103507_3PB5A5BD0WRGM7ILAW0BNWOW5K17GA_3BQU611VFQ55LGJ6BNSL9BTFW5899R_3ZAK8W07I5ZL9EJW924JCWF07WJU07_3IXEICO79341NCQMBMUQG13P5B1T63_3M81GAB8A14U18FPQ9H3MCEUZB4QBA
40-60,Mammograms detect early stage breast cancer but have no effect on mortality,College,female,0.7692307692307693,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME_3V26SBZTBEZZXYJWJJGJZNX1RLCZZO_39GHHAVOMGCTUMQ3G4N7HXW2BIEJ4D,"{'Coarse': {'breast cancer': {'Outcomes'}, 'early stage': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}, 'early stage': {'Outcomes-general'}}}",breast,AAB13RUHSABEV,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1206809_3P4RDNWND6RN2TPI1TPBBY6LBUDIJ8_38BQUHLA9XLNZN662LF8BNUOR2YOME_3V26SBZTBEZZXYJWJJGJZNX1RLCZZO_39GHHAVOMGCTUMQ3G4N7HXW2BIEJ4D_33FOTY3KEN6PU9NEJUNJWVC49KBC17
24-39,Screenings help detect breast cancer early but don't reduce fatal cancer. ,College,female,0.7692307692307693,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV_3VNXK88KKD33INW9EOXH1TICO7T9VU_34Q075JO1YY50HSY7EUZ1UA30P810L,"{'Coarse': {'breast cancer': {'Outcomes'}}, 'Fine': {'breast cancer': {'Outcomes-general'}}}",breast,A2B115J2WDWGNM,NEJMoa1206809,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Location': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1206809_3MTMREQS4W3U2V6JW4GDJQCA0KVAW9_3TR2532VIQF799UHZSGMEVGG29Z6JV_3VNXK88KKD33INW9EOXH1TICO7T9VU_34Q075JO1YY50HSY7EUZ1UA30P810L_3W8CV64QJ3KY0M1P9ZGDMSR3KMY9HC
24-39,Azithromycin increases risk of cardiac events according to 5 day study.,College,male,0.7692307692307693,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M_32XVDSJFP0I9SGH1FNHB4ARLRV02MH_3G0WWMR1UW5W2H4MTZMCD7EOCCAQNB,"{'Coarse': {'azithromycin': {'Intervention'}, '5': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, '5': {'Duration'}}}",cardio,AXY0D2AMLKE2A,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'A', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['A'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003833_3PJ71Z61R5NNWBGB7ADSU5BWYHI19K_3F0BG9B9MQ8G8Y3L42MHUWV0BEHY7M_32XVDSJFP0I9SGH1FNHB4ARLRV02MH_3G0WWMR1UW5W2H4MTZMCD7EOCCAQNB_3OS46CRSLGKG04UBGHU5HJRAYHX6VE
24-39,research on cardiovascular problems in obese people,Some College,male,0.5384615384615384,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M_37TRT2X24RCDFLBCVJXUPB28HQ9JBP_3RGU30DZTBT9YCF9M8N33RD2TSTMJ3,"{'Coarse': {'obese': {'Participants'}}, 'Fine': {'obese': {'Condition'}}}",cardio,A2W70GF8D5D14K,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'B', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003114_34MAJL3QP58I98OEDJVK1QFDBAH34K_3WYP994K18CX4YPGLSHPOIV4G3WY6M_37TRT2X24RCDFLBCVJXUPB28HQ9JBP_3RGU30DZTBT9YCF9M8N33RD2TSTMJ3_3R0T90IZ1TXMYODH1D8M3IGA7OFGCM
40-60,A side effect of Rosiglitazone is a increased risk of myocardial infaction.,College,male,0.9230769230769231,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL_33F859I567YHOFGM7JU9DYMT4WZHB8_3C44YUNSI2A2GTCU4STKHXCKTDADPF,"{'Coarse': {'rosiglitazone': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}}}",cardio,APXMWCW8VUJZ8,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa072761_3Z7VU45IPZ2222YOB87R7TDPDKN1ZG_3S3AMIZX3VQJM43QZN7EXXDDU4VDCL_33F859I567YHOFGM7JU9DYMT4WZHB8_3C44YUNSI2A2GTCU4STKHXCKTDADPF_336KAV9KYRD9MX6FYQ5MY5ES0US2YZ
24-39,Cardiac medication and Azithromycin can increase the risk of death.,Some College,female,0.6923076923076923,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R_39ASUFLU6YSCH8SLMEELHSG8VFIEXD_3RYC5T2D74EWH3VZMTO4MMTO8FJPRH,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,AUPHYAKC58LPA,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003833_3YDGXNSEO0F4A5UKP0QGS7NOQVS48T_3BF51CHDTWVG4SDC93XKTHQAD4JH0R_39ASUFLU6YSCH8SLMEELHSG8VFIEXD_3RYC5T2D74EWH3VZMTO4MMTO8FJPRH_3EJJQNKU9SQ44MXB3GGZDDRXMP0HRX
24-39,2g per day of sodium is better to decrease risk of cardiovascular disease.,College,male,0.7692307692307693,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM_3GFK2QRXXA2XWPU218PWBFWO9K95W6_3JC6VJ2SAC40PCRZ03T4TQZXHA8A5K,"{'Coarse': {}, 'Fine': {}}",cardio,AXY0D2AMLKE2A,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1304127_3NJM2BJS4XRSB16G4WY9XRU27IMCPB_3M0BCWMB8WHZL5BB2IG9E1WGJVABWM_3GFK2QRXXA2XWPU218PWBFWO9K95W6_3JC6VJ2SAC40PCRZ03T4TQZXHA8A5K_3HRMW88U17B2W6EN00DXLMY6UL00MR
40-60,Diets high in salt cause 9.5% of cardiovascular disease deaths.,College,female,1.0,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ_3MB8LZR5BGEK3E364HM04TYQ84NKL2_3X4JMASXCNU6DFAQ9BNO76NCIJ20B2,"{'Coarse': {'9.5 %': {'Outcomes'}}, 'Fine': {'9.5 %': {'Effect-strength'}}}",cardio,AVBRJBJONL47I,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1304127_3OCHAWUVGP5F38KVI0POFNTDEQ4KXK_37UEWGM5HUTT0BCX1RDELQBQ55V1RJ_3MB8LZR5BGEK3E364HM04TYQ84NKL2_3X4JMASXCNU6DFAQ9BNO76NCIJ20B2_35L9RVQFCP3WKEPS7AB4IOEHTRWHUZ
24-39,Researching hiazolidnedione as an ingredient to lower blood sugar levels. ,College,female,1.0,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7_3PS7W85Z80NO5VSK9TX20BURRMUT9F_374TNBHA8CGQEG8001VNUNCVGYPYQO,"{'Coarse': {}, 'Fine': {}}",cardio,ACM87U430O96Z,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['D', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['D'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa072761_3Y4W8Q93L05FLD9QQ42JNP12E6KDVI_3RKNTXVS3NJITTNZMYAUOYTJHNT4A7_3PS7W85Z80NO5VSK9TX20BURRMUT9F_374TNBHA8CGQEG8001VNUNCVGYPYQO_3IKZ72A5B51ZBSEDFJBI18AA6H8NF0
24-39,Sibutamine helps those with cardiovascular issues or diabetes lose weight. ,Some College,female,0.6923076923076923,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0_3ITXP059PX4CW7SE65JPF0C8L81JSK_3D3VGR7TA10PAEQCOVRX9JQN3HNR3Z,"{'Coarse': {}, 'Fine': {}}",cardio,AUPHYAKC58LPA,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1003114_30LSNF239VGNWXRAU8JJCHK4AED2II_37XITHEISXUDNEMVHO2Y2MUH94JRC0_3ITXP059PX4CW7SE65JPF0C8L81JSK_3D3VGR7TA10PAEQCOVRX9JQN3HNR3Z_30JNVC0ORA54SLIBQ1RZ8NHSQ3ZHQX
24-39,Research shows the effect of sodium intake on heart health.,College,male,0.8461538461538461,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC_3YT88D1N09J3NADHYBI087498IL3KW_3STRJBFXOXC8MRBBDQORQK872PQTKB,"{'Coarse': {}, 'Fine': {}}",cardio,A1RH1NL51JR9TA,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1304127_39LNWE0K4VHWG90CDSTPI0FWS4IIUZ_333U7HK6IA06UI9W9FO0K1Q8KNJDJC_3YT88D1N09J3NADHYBI087498IL3KW_3STRJBFXOXC8MRBBDQORQK872PQTKB_3GS6S824SRI1ME0858LI5WWA1K0WN9
24-39,A study found that 1.65 million people die from salt consumption each year,College,female,1.0,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J_37FMASSAYDCHKAR6D1CUDAN845RIB7_3UJ1CZ6IZIA4P8DTH3FVEQT33GLS54,"{'Coarse': {'1.65 million': {'Outcomes'}}, 'Fine': {'1.65 million': {'Effect-strength'}}}",cardio,ACM87U430O96Z,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1304127_3KV0LJBBH36QW0YMUDWC5IZT3FBRM0_3G2UL9A02EZEPETFYJRPB5B7C4D67J_37FMASSAYDCHKAR6D1CUDAN845RIB7_3UJ1CZ6IZIA4P8DTH3FVEQT33GLS54_3AMW0RGHOENB2537TM7ND2OE7MRPNY
24-39,Rosiglitazone increases the rate of death caused by cardiovascular issues.,College,male,0.8461538461538461,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC_3KYQYYSHYWSKVT0TPSG5SX7UJZWOD9_3JC6VJ2SAC40PCRZ03T4TQZXHAVA57,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}}}",cardio,A1RH1NL51JR9TA,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa072761_3M0NZ3JDP2J1QKZ7CV93AJQ6P0TZ5X_35L9RVQFCP3WKEPS7AB4IOEHTWZHUC_3KYQYYSHYWSKVT0TPSG5SX7UJZWOD9_3JC6VJ2SAC40PCRZ03T4TQZXHAVA57_3SEPORI8WOKYWQBO7R0KIU6SJF6AZU
24-39,Data for cardiovascular side effects regarding rosiglitazone was examined. ,College,male,0.46153846153846156,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF_3EFVCAY5L4UUDND5S7DKY9C79F7J8Z_3TOK3KHVJU34EKZJYFDJS5XYXYW7OM,"{'Coarse': {'rosiglitazone': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}}}",cardio,A17MUXOICSH29I,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa072761_3LJ7UR74RIYPDCHOV2FZA4DJGR34NW_3ZSANO2JCGSWR56INFS402KGSHQFSF_3EFVCAY5L4UUDND5S7DKY9C79F7J8Z_3TOK3KHVJU34EKZJYFDJS5XYXYW7OM_3L4PIM1GQU1QQHN0DGKNZDM0COPRYO
40-60,High sodium intake increase blood pressure according to meta-analysis.,College,male,0.9230769230769231,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X_3PXX5PX6LYJ2ES881DKHWCZPRXIBAS_3E1QT0TDFQUYICTZAPSKM8X7W808IA,"{'Coarse': {}, 'Fine': {}}",cardio,APXMWCW8VUJZ8,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1304127_3I7DHKZYGOLVL387BJFW7RAOEWE5FX_3CN4LGXD5Y9JPBL224OARKBQKBOY4X_3PXX5PX6LYJ2ES881DKHWCZPRXIBAS_3E1QT0TDFQUYICTZAPSKM8X7W808IA_30IQTZXKALRDQIDRE7F6W3E41QL0XE
15-24,A study shows that rosiglitazone reduces mycrocardial infractions.,College,male,0.8461538461538461,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS_31IBVUNM9TKCJXNMHAX9BP4NR6MFVS_3R2UR8A0IB1YTZ5AGSHHM4AMZP2OXL,"{'Coarse': {'rosiglitazone': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}}}",cardio,A3723CQM6I92CU,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa072761_3S06PH7KSSPZZ1TSJQIUG1UMQ3XD1G_3CPLWGV3MPKQAIN0CXBQRCOZ2M69NS_31IBVUNM9TKCJXNMHAX9BP4NR6MFVS_3R2UR8A0IB1YTZ5AGSHHM4AMZP2OXL_3HWRJOOET6N4LR6MS48YIKZGHH8ESW
40-60,Taking Rosiglitazon for type 2 diabetes may get myocardial infection.,Some College,female,0.8461538461538461,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S_3Y9N9SS8LZWV94776UWD4U9JO843DX_3OS4RQUCRA0XAJPGCT69ADAGOMTBFL,"{'Coarse': {'diabete': {'Participants'}}, 'Fine': {'diabete': {'Condition'}}}",cardio,A2VNK2H6USLQTK,NEJMoa072761,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa072761_3WLEIWSYHP2N02GQOQ1YC5JP90NH2Q_3G2UL9A02EZEPETFYJRPB5B7C3O67S_3Y9N9SS8LZWV94776UWD4U9JO843DX_3OS4RQUCRA0XAJPGCT69ADAGOMTBFL_33F859I567YHOFGM7JU9DYMT5DOHBW
24-39,"Azithromycin, ciprofloxacin, and levoloxacin can cause fatalities.",Some College,female,0.8461538461538461,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF_3HPZF4IVNNEMKFYHVJUSAINECAKYCX_3SNVL38CI5DR0A90R4T11A83E3BKC4,"{'Coarse': {'azithromycin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'ciprofloxacin': {'Control'}}}",cardio,A2GJ0Y9OQ0VEWT,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003833_3FQ5JJ512M9ARE6RGU2FHL2FDDPNK1_3PXX5PX6LYJ2ES881DKHWCZPRF6ABF_3HPZF4IVNNEMKFYHVJUSAINECAKYCX_3SNVL38CI5DR0A90R4T11A83E3BKC4_3IO1LGZLKAIIPSYY8OJVP572NJS685
24-39,Sibutramine found to cause weight loss with no extra cardio in 6 week trial,College,female,1.0,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6_37KGEN7NJ4BB5QFK91KFHRT97A2PPM_37ZHEEHM6X7FSV6XFHTR42ZN25R73E,"{'Coarse': {'sibutramine': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}}}",cardio,ACM87U430O96Z,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'D', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003114_3Q8GYXHFEQNOIROXKHPVZLPLHJN5CN_3LQ8PUHQFMDRBNUSDTMQZLQ6Z0FIH6_37KGEN7NJ4BB5QFK91KFHRT97A2PPM_37ZHEEHM6X7FSV6XFHTR42ZN25R73E_3EA3QWIZ4JGHGWLNDN3FD4TUBROTI0
40-60,Sibutramine can cause heart attacks in older overweight people.,Some College,female,0.7692307692307693,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB_3WRFBPLXRB94VGYKVOAG0ZLD2CD3NM_30LSNF239VGNWXRAU8JJCHK4A8R2IK,"{'Coarse': {'sibutramine': {'Intervention'}, 'overweight': {'Participants'}}, 'Fine': {'sibutramine': {'Intervention-general'}, 'overweight': {'Condition'}}}",cardio,AW1SWNQFPIUKF,NEJMoa1003114,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003114_3GU1KF0O4JM91WEAQW2EM7OKQYRPBP_3HL8HNGX46MEMQAJE9SDJ7FQ0SG9FB_3WRFBPLXRB94VGYKVOAG0ZLD2CD3NM_30LSNF239VGNWXRAU8JJCHK4A8R2IK_3V26SBZTBEZZXYJWJJGJZNX1S7DZZY
24-39,Sibutramine treatment for cardiac health resulted in lower blood pressure. ,College,male,0.6923076923076923,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB_3XIQGXAUMDTR8TDBZ60FBIOR9SNX7J_3KV0LJBBH36QW0YMUDWC5IZT39TRM6,"{'Coarse': {'sibutramine': {'Intervention'}}, 'Fine': {'sibutramine': {'Intervention-general'}}}",cardio,A1BDJJ3Z71CDKL,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003114_34PGFRQONPW53O9NQATQCPFTQZHWJN_3L4D84MIL0DN6YEYVB7QBM56CC2JHB_3XIQGXAUMDTR8TDBZ60FBIOR9SNX7J_3KV0LJBBH36QW0YMUDWC5IZT39TRM6_32SCWG5HIIP3VKXFU5L6BR2SCTR6PO
15-24,Sodium related deaths in Georgia are especially high middle income men.,College,male,0.8461538461538461,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY_3X66WABAJX3YLOHY8KXLAFCG10GG3G_3IO1LGZLKAIIPSYY8OJVP572NH968I,"{'Coarse': {}, 'Fine': {}}",cardio,A3723CQM6I92CU,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['B'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1304127_3F0BG9B9MQ8G8Y3L42MHUWV0ACOY7O_3QRYMNZ7FZ29UXWEA3G7ICPBWQ7NTY_3X66WABAJX3YLOHY8KXLAFCG10GG3G_3IO1LGZLKAIIPSYY8OJVP572NH968I_386PBUZZXGIPSUXOMWMO3EYDUVWLJA
40-60,Siburtamine is a weight management drug with risk of death.,Some College,female,0.8461538461538461,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI_3X4JMASXCNU6DFAQ9BNO76NCICI0B4_3WRFBPLXRB94VGYKVOAG0ZLD2LSN33,"{'Coarse': {}, 'Fine': {}}",cardio,A2VNK2H6USLQTK,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1003114_3TMFV4NEP9ZGJ7D4Z6WZNZ6FAOQW86_34X6J5FLPUJ0JRD1E1UKK0X733UQJI_3X4JMASXCNU6DFAQ9BNO76NCICI0B4_3WRFBPLXRB94VGYKVOAG0ZLD2LSN33_3DR23U6WE6Z50RJ1H4DOSPV2IVTETH
40-60,"In a study, high salt intake is linked to 10% of all cardiovascular deaths.",Some College,male,0.9230769230769231,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL_358UUM7WR0O7BXRZQ7UNM0238GA7RF_3R9WASFE201TSHSWI7MCWVHJFPGZFG,"{'Coarse': {}, 'Fine': {}}",cardio,A1WNHGZ8S46T3C,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['A', 'B'], 'Conclusion': ['B']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['A'], 'Effect-strength': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1304127_3ON104KXQLHF06Q2N36M6NQA82LW4Q_3R0T90IZ1TXMYODH1D8M3IGA7W2CGL_358UUM7WR0O7BXRZQ7UNM0238GA7RF_3R9WASFE201TSHSWI7MCWVHJFPGZFG_3A7Y0R2P2P9KSOED0FPCE8T012YJXI
40-60,A study of people over 55 said the placebo group had better heart metrics.,College,male,0.9230769230769231,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S_3XC1O3LBOT7J6XTTYQ0S5KLMR30LT3_3Y5140Z9DY1JO4SGW6UV8USXLICPIN,"{'Coarse': {'placebo': {'Intervention'}}, 'Fine': {'placebo': {'Control'}}}",cardio,APXMWCW8VUJZ8,NEJMoa1003114,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003114_337RC3OW06NYJPXI3L076297NFLLV5_3NAPMVF0ZX0Q7DAEBHFMLSUVWZ527S_3XC1O3LBOT7J6XTTYQ0S5KLMR30LT3_3Y5140Z9DY1JO4SGW6UV8USXLICPIN_3ZQIG0FLQF1EUJ9H7Z79FDQNMKMWV3
15-24,Ciproflaxcin is a safer drug in regards to cardiovascular death.,College,male,0.8461538461538461,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0_39U1BHVTDMC2QT34SKWS9YR5RUQT34_3LUY3GC630LMZKBKDFQYH52O71NP7C,"{'Coarse': {'cardiovascular death': {'Outcomes'}}, 'Fine': {'cardiovascular death': {'Outcomes-general'}}}",cardio,A3723CQM6I92CU,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003833_3B1NLC6UG0H5SDML6IUSNIFH5AYGP9_3YMU66OBIOTDFWOXN5MNE9DQKLFGH0_39U1BHVTDMC2QT34SKWS9YR5RUQT34_3LUY3GC630LMZKBKDFQYH52O71NP7C_3BQU611VFQ55LGJ6BNSL9BTFYW3996
40-60,"Levoflaxin safer than amoxicillin, ciproflaxacin and azithromycin.",College,female,1.0,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H_3SNLUL3WO58Y6A8IYVQ2AG7OAZSULO_3LOZAJ85YEYKMSG5TUJKFR7JYLB2X0,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}}}",cardio,AVBRJBJONL47I,NEJMoa1003833,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['C', 'C', 'B'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003833_373ERPL3YPTU9VO63AXORWULXNFRT9_31JLPPHS2VFMD1YWW3ATFOLIS2HO3H_3SNLUL3WO58Y6A8IYVQ2AG7OAZSULO_3LOZAJ85YEYKMSG5TUJKFR7JYLB2X0_3MTMREQS4W3U2V6JW4GDJQCA1CTWAE
40-60,Suburatmine can have side effects in specific populations. ,College,female,0.8461538461538461,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67_3WQQ9FUS6BFOV4FT4F030LTU1FFB8X_3LBXNTKX0SGVMC14E3YZPEFX4RPX9R,"{'Coarse': {}, 'Fine': {}}",cardio,A2OGCXGLS44ZAO,NEJMoa1003114,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003114_3EJJQNKU9SQ44MXB3GGZDDRXLSZHR1_3CFVK00FWM6D4ZIH2DSZUAT87OIL67_3WQQ9FUS6BFOV4FT4F030LTU1FFB8X_3LBXNTKX0SGVMC14E3YZPEFX4RPX9R_3ND9UOO81LNBYEXNTV53S4SLVOVLWO
40-60,A 24 week study found that ROSIGLITAZONE can cause heart attacks in men.,Some College,male,0.9230769230769231,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4_3X0H8UUIT29Y2RSDD4244Q6GN47WSP_3H0W84IWBLNSKC69DF8TSAUKU72ER4,"{'Coarse': {'rosiglitazone': {'Intervention'}, '24 week': {'Intervention'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, '24 week': {'Duration'}}}",cardio,A1WNHGZ8S46T3C,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'D', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['D'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa072761_3B4YI393VAH5VAB4TZS3713VH6MSSB_3E1QT0TDFQUYICTZAPSKM8X7WFG8I4_3X0H8UUIT29Y2RSDD4244Q6GN47WSP_3H0W84IWBLNSKC69DF8TSAUKU72ER4_3OLF68YTNAMSR9KO6F6DF2QA7A7FA6
24-39,Cardiovascular disease patients given AZITHROMYCIN had a higher death rate.,College,female,0.8461538461538461,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK_3BWI6RSP7HUI2TMU41ANNT3KTNR7E1_3GLB5JMZFYGW3GJV193XNOYSSMJGDA,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,A2WETCIWJT79CQ,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1003833_3I2PTA7R3UFVUBJJWMUWLFXKIOOQK3_3DR23U6WE6Z50RJ1H4DOSPV2IZOETK_3BWI6RSP7HUI2TMU41ANNT3KTNR7E1_3GLB5JMZFYGW3GJV193XNOYSSMJGDA_3TUI152ZZC8TOAXXOCOEG01L9HG1Q1
24-39,Studies indicate Rosiglitazone increases risk of death.,Some College,female,0.9230769230769231,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF_3L0KT67Y8F12RWNDS5KSPNRWYI9YS4_3180JW2OT5XBQ5U3U96HMP2G7X1J58,"{'Coarse': {'rosiglitazone': {'Intervention'}, 'death': {'Outcomes'}}, 'Fine': {'rosiglitazone': {'Intervention-general'}, 'death': {'Outcomes-general'}}}",cardio,A1DKNCUTQYO9OA,NEJMoa072761,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa072761_3SB4CE2TJWG9RVB969CZL9QH9EUAXF_3Z7ISHFUH1GKD2I9ATG6M30XSUS8ZF_3L0KT67Y8F12RWNDS5KSPNRWYI9YS4_3180JW2OT5XBQ5U3U96HMP2G7X1J58_308Q0PEVB9YYWHC9FHYYM4SIGJII9J
40-60,Azithromycin caused more deaths than amoxicillin and ciprofloxacin.,College,male,0.9230769230769231,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS_336YQZE83WZ1RD0OX6J92HUXBIM5M6_3X1FV8S5JYCIXXJHSU3RTA4ZSS3GVN,"{'Coarse': {'azithromycin': {'Intervention'}, 'amoxicillin': {'Intervention'}, 'ciprofloxacin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}, 'amoxicillin': {'Control'}, 'ciprofloxacin': {'Control'}}}",cardio,APXMWCW8VUJZ8,NEJMoa1003833,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['B'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003833_3R0T90IZ1TXMYODH1D8M3IGA7SUGC9_36AHBNMV1SXWP74VVFP3UO5WXOKDYS_336YQZE83WZ1RD0OX6J92HUXBIM5M6_3X1FV8S5JYCIXXJHSU3RTA4ZSS3GVN_3SPJ033422O9ST4N5BBEXM0925EYJI
24-39,People consume too much sodium and we need more education on the dangers. ,College,male,0.6923076923076923,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D_3LEIZ60CDKKKR71JFLMKMZV8CJQZ9D_3HHRAGRYX9Q8S3NCDCB361O4SN3O9W,"{'Coarse': {}, 'Fine': {}}",cardio,A1BDJJ3Z71CDKL,NEJMoa1304127,"{'Coarse': {'Participants': ['C', 'C'], 'Intervention': ['A'], 'Outcomes': ['C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1304127_3WETL7AQWUT05RSEROEU6ILRA5O530_3GD6L00D3TI23VZ5WJHXZRHGZITM1D_3LEIZ60CDKKKR71JFLMKMZV8CJQZ9D_3HHRAGRYX9Q8S3NCDCB361O4SN3O9W_3YJ6NA41JC1FJFCMEOFVKV7XYZ9JP5
24-39,A study conducted on the heart confirmed that azithromycin links to death. ,College,male,0.46153846153846156,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ_3KB8R4ZV1FS3OJLBNDCRSYASPYSGBI_3BXQMRHWK0JICSQ3Y7RHATMDA8VMU3,"{'Coarse': {'azithromycin': {'Intervention'}}, 'Fine': {'azithromycin': {'Intervention-general'}}}",cardio,A17MUXOICSH29I,NEJMoa1003833,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1003833_3IAEQB9FMF5S029VGE7F9RKGLFLWDA_308Q0PEVB9YYWHC9FHYYM4SIGLN9IJ_3KB8R4ZV1FS3OJLBNDCRSYASPYSGBI_3BXQMRHWK0JICSQ3Y7RHATMDA8VMU3_33JKGHPFYDF5H26U16FVWYUJ2FOMN3
40-60,A Spanish study of seniors looks at a link between heart disease and diet.,College,male,0.7777777777777778,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7_3TVSS0C0E2LZHR5S247UEV22KCWWTY_3TS1AR6UQRZA87MQZCUT5BOK0HQF7S,"{'Coarse': {}, 'Fine': {}}",diet,A1L0T8IFHPA77E,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'B', 'C', 'A', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1200303_33FBRBDW6PK7597ZIFWYB5ZCDFQC84_3SLE99ER0OY3F0GGD50GD5QYUM1BZ7_3TVSS0C0E2LZHR5S247UEV22KCWWTY_3TS1AR6UQRZA87MQZCUT5BOK0HQF7S_336YQZE83WZ1RD0OX6J92HUX6ST5MS
24-39,"Even if they smoke, coffee can still make a person live longer.",High School,female,0.8333333333333334,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O_3CFVK00FWM6D4ZIH2DSZUAT82X9L6B_3X3OR7WPZ0L08D15VSPXEOPZ8X78L2,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,AZBZBTTME3HAI,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1112010_37U1UTWH9W7BBBWI0CMT00YYDWPR8H_3L6L49WXW1ILNNBIR2JDGNDXJVD45O_3CFVK00FWM6D4ZIH2DSZUAT82X9L6B_3X3OR7WPZ0L08D15VSPXEOPZ8X78L2_3OCHAWUVGP5F38KVI0POFNTDAL6XKL
24-39,Eating more processed food causes weight gain. Healthy food is the opposite,College,male,0.7222222222222222,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465_3HSYG7LRBKJ9J8LOJHAZPTLBESQKKE_33CID57105EE7GVZJBU1N7HOSBSL30,"{'Coarse': {}, 'Fine': {}}",diet,A9BVDYQU2VTIJ,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A7DNKPR_3DPNQGW4LM0H6RBWWLTI8TRXFQP465_3HSYG7LRBKJ9J8LOJHAZPTLBESQKKE_33CID57105EE7GVZJBU1N7HOSBSL30_3Z9WI9EOZ09IHIKGDW72C15JMWRKHL
24-39,Reducing calories can lead to 6kg of weight loss in 6 months.,College,male,0.7222222222222222,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I_33PPO7FECW0AZ7PQRX3080B82F4IDO_3HUTX6F6VV8XSJ2DS3WOWEGQH2UO26,"{'Coarse': {'weight loss': {'Outcomes'}, '6 month': {'Intervention'}}, 'Fine': {'weight loss': {'Outcomes-general'}, '6 month': {'Duration'}}}",diet,A9BVDYQU2VTIJ,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['B'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0804748_3ATPCQ38J9VYR01JB5Y14NXQ66SAYS_3TAYZSBPLMTCQBU6ZKDXGJQRD1PS2I_33PPO7FECW0AZ7PQRX3080B82F4IDO_3HUTX6F6VV8XSJ2DS3WOWEGQH2UO26_3P1L2B7AD2A3T5OL29ETBAFZNIAOLG
24-39,Non-staple items were added to a study to see its affects on the elderly.,College,male,0.7222222222222222,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4_3V5Q80FXIYC86U9R95CW8BIFM6E32W_39GXDJN2OUZ34IDZ9WR31XN1ZVK8VW,"{'Coarse': {}, 'Fine': {}}",diet,A9BVDYQU2VTIJ,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1200303_3TDXMTX3CCFBEYABHAVM2U1GKO8I6C_3H7Z272LX8SLE50MH9R80AKPWJLPL4_3V5Q80FXIYC86U9R95CW8BIFM6E32W_39GXDJN2OUZ34IDZ9WR31XN1ZVK8VW_3A1COHJ8NKGYMHIF47AZMWWSRWXH8Z
40-60,More effective weight loss with reducing calories than macronutrients.,College,male,0.7777777777777778,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01_3RANCT1ZVG2MT1M67I18WDBJTPJBUM_3GDTJDAPVVWKEVJQV4QCE14O826M8R,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A1L0T8IFHPA77E,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa0804748_3F1567XTNXQBDF0SSP37V6J41BOQ9D_3SB5N7Y3O4P24WI1PXF28HE9SSAG01_3RANCT1ZVG2MT1M67I18WDBJTPJBUM_3GDTJDAPVVWKEVJQV4QCE14O826M8R_3TEM0PF1Q6IZSC8AN7EU2WBCG6SD0Z
24-39,People age 50-71 who drink coffee have a higher mortality rate.,College,female,0.7222222222222222,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6_3XLBSAQ9Z5XGDODQ0OO08342CH0Z76_3M68NM076ISO7XDU7XPVGM278U96R7,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A3NUUMIAEIAN5,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_3CFVK00FWM6D4ZIH2DSZUAT818ZL6M_3COPXFW7XCXAUZI4W9F7LA7A7JQKP6_3XLBSAQ9Z5XGDODQ0OO08342CH0Z76_3M68NM076ISO7XDU7XPVGM278U96R7_3X66WABAJX3YLOHY8KXLAFCGW9MG3Z
24-39,"During a 4year study, 3.35pounds was gained from eating unhealthy foods. ",College,male,0.8888888888888888,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX_3X1FV8S5JYCIXXJHSU3RTA4ZN9GGVT_3VELCLL3GL4WXL7OAWDK41X7XVKF1P,"{'Coarse': {}, 'Fine': {}}",diet,A14XU2MC4NWN28,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B'], 'Outcomes': ['C'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['B'], 'Outcomes-general': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1014296_3YOH7BII0ASNZJF0ILO6R2WST38KV0_30BUDKLTXEG3FP8BG8VQP9POWK95EX_3X1FV8S5JYCIXXJHSU3RTA4ZN9GGVT_3VELCLL3GL4WXL7OAWDK41X7XVKF1P_3P59JYT76M5D5B7LOKINQOMDGPRT27
24-39,"Alcohol, smoking, and unhealthy diet contribute to aging and weight gain.",High School,female,0.8333333333333334,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM_3LEIZ60CDKKKR71JFLMKMZV877S9ZW_37Z929RLGAT6AAOJIZXTH6ZHE4ETS4,"{'Coarse': {'diet': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}}}",diet,AZBZBTTME3HAI,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1014296_3LUY3GC630LMZKBKDFQYH52O1V87PX_3EQHHY4HQTD1Z342M3LEPCA090W5GM_3LEIZ60CDKKKR71JFLMKMZV877S9ZW_37Z929RLGAT6AAOJIZXTH6ZHE4ETS4_3H8DHMCCWAW152FER0OCLGQLU3VDK0
24-39,A Mediterranean diet reduces chances of cardiovascular death.,College,male,0.7222222222222222,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB_3FE7TXL1LJ80DVFT7GOSLJBQWY0Q2U_37M28K1J0RY8WB6KP5XYU0I2UW3AJ7,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1200303_3RXCAC0YISAKMLN4K1SH1WKRBDXG89_3YZ8UPK3VU7536ECLIX37XH1APPUCB_3FE7TXL1LJ80DVFT7GOSLJBQWY0Q2U_37M28K1J0RY8WB6KP5XYU0I2UW3AJ7_3AMYWKA6YC7LAKLEF58RMRX2XNLO68
24-39,Eating nuts and olive oil reduces the chance of cardiovascular events.,College,male,0.7222222222222222,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D_3NOKK93PR2T3B814R9OTT3V1AY2EE8_3GDTJDAPVVWKEVJQV4QCE14O822M8N,"{'Coarse': {'cardiovascular event': {'Outcomes'}}, 'Fine': {'cardiovascular event': {'Outcomes-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1200303_3Q5C1WP23NM4VOEZ4K0BIP6U73B150_3Z7VU45IPZ2222YOB87R7TDP8ABZ1D_3NOKK93PR2T3B814R9OTT3V1AY2EE8_3GDTJDAPVVWKEVJQV4QCE14O822M8N_3DH6GAKTYZAZS89RNXE0LGOZG1HYZK
40-60,3% weight loss achieved among obese adults when including macronutrients.  ,College,male,0.7777777777777778,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX_3O7L7BFSHFAFRD3QNSEKEITT2R9EIH_3U84XHCDIDYJU1V7YQQT5RKSLKMZ48,"{'Coarse': {'weight loss': {'Outcomes'}, 'adult': {'Participants'}}, 'Fine': {'weight loss': {'Outcomes-general'}, 'adult': {'Age'}}}",diet,A1L0T8IFHPA77E,NEJMoa0804748,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Condition': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa0804748_33JKGHPFYDF5H26U16FVWYUJWQMMNH_3TVRFO09GL0QNE2D301PUN6SYI3LXX_3O7L7BFSHFAFRD3QNSEKEITT2R9EIH_3U84XHCDIDYJU1V7YQQT5RKSLKMZ48_3WR9XG3T64W0ARP1FVYAE7RTB7547D
40-60,"A study links positive data with coffee and mortality, not with smoking. ",College,male,0.7777777777777778,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ_33TIN5LC05VKMHREJZK18SM61DRY9X_3ZPPDN2SLWHMGCANJY871PUQJ6S9E9,"{'Coarse': {'coffee': {'Intervention'}, 'mortality': {'Outcomes'}}, 'Fine': {'coffee': {'Intervention-general'}, 'mortality': {'Outcomes-general'}}}",diet,A1L0T8IFHPA77E,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_3Y54SXRO1M6MPNGN74STW7H5Y80UTZ_3SLE99ER0OY3F0GGD50GD5QYUPEBZQ_33TIN5LC05VKMHREJZK18SM61DRY9X_3ZPPDN2SLWHMGCANJY871PUQJ6S9E9_3AMW0RGHOENB2537TM7ND2OE2I5NPX
24-39,"Adults gain weight from chips, sugary drinks and meat. Diet and exercise.",College,male,0.7222222222222222,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8_3WLEIWSYHP2N02GQOQ1YC5JP5B4H2P_3YMTUJH0DT1N8PM8SY1BJ3JB0O6T4S,"{'Coarse': {'diet': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1014296_3B837J3LDPHTUVBREASYHRYZPQJSR5_34BBWHLWHBW98DPH8S8Q0O0T8BCWI8_3WLEIWSYHP2N02GQOQ1YC5JP5B4H2P_3YMTUJH0DT1N8PM8SY1BJ3JB0O6T4S_3X66WABAJX3YLOHY8KXLAFCGWASG37
24-39,Studies show that a Mediterranean diet increases risk of heart attack.,High School,female,0.8333333333333334,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG_39OWYR0EPLCTNRIRMLKTIO8H4BEFYY_3QUO65DNQV96CVBFBN6U2XBI0T6UON,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,AZBZBTTME3HAI,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200303_35H6S234SBLZ2AFWAQCSDLXBF76654_3ZAZR5XV023MP58MR5WBOPWGC72CZG_39OWYR0EPLCTNRIRMLKTIO8H4BEFYY_3QUO65DNQV96CVBFBN6U2XBI0T6UON_37UQDCYH6YGZ448GZRZXNXR6OQZV7B
24-39,If you drink coffee and smoke you're more likely to die than not smoking.,College,male,0.7222222222222222,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA_3N2BF7Y2VRFD76KJY8KIREXNBGEMHE_3CFJTT4SXUBUIYOG0K0E881CG97I7B,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_33OOO72IVI6Q3TZNLD7T21VZR6PTCG_35USIKEBNS13SZL2EQ8E72XX67S6NA_3N2BF7Y2VRFD76KJY8KIREXNBGEMHE_3CFJTT4SXUBUIYOG0K0E881CG97I7B_3WS1NTTKEZXWQWM6ED9KQWEXSJ8F0C
24-39,People who don't exercise or eat healthy are less likely to lose weight.,High School,female,0.8333333333333334,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29_3ZOTGHDK5JWQXIJBMIBUNWTUFRHSOR_3NKQQ8O39ZQF8YKQLESER3ZJWF8DUI,"{'Coarse': {}, 'Fine': {}}",diet,AZBZBTTME3HAI,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1014296_3RYC5T2D74EWH3VZMTO4MMTO25FPRN_3EKVH9QMEZP6OMBO2UI8LK4RCYFD29_3ZOTGHDK5JWQXIJBMIBUNWTUFRHSOR_3NKQQ8O39ZQF8YKQLESER3ZJWF8DUI_3EFVCAY5L4UUDND5S7DKY9C74NY8JQ
24-39,"In 6 months 811 people lost weight by 7%. In 2 years, 80% lost more.",College,male,0.7222222222222222,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10_3X87C8JFV7WTIUWR1V3YC1OUUSZSQZ_38JBBYETQPVLJ64B23CGKHJAXEB4E5,"{'Coarse': {'811': {'Participants'}, '6 month': {'Intervention'}, '2 year': {'Intervention'}}, 'Fine': {'811': {'Sample-size'}, '6 month': {'Duration'}, '2 year': {'Duration'}}}",diet,A9BVDYQU2VTIJ,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'A'], 'Intervention': ['C', 'A', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['A'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0804748_3DR23U6WE6Z50RJ1H4DOSPV2CGETEH_3HMVI3QICKD2XCOJFM58TM4N2GMY10_3X87C8JFV7WTIUWR1V3YC1OUUSZSQZ_38JBBYETQPVLJ64B23CGKHJAXEB4E5_37TRT2X24RCDFLBCVJXUPB28CUMBJX
24-39,Reducing calories helps you to lose weight but protein diets are long term.,College,female,0.8333333333333334,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW_3GS6S824SRI1ME0858LI5WWAVU8NWM_3KJYX6QCMAWSOZ9I00OUQNWFF63JVG,"{'Coarse': {'diet': {'Intervention'}}, 'Fine': {'diet': {'Intervention-general'}}}",diet,A1I8EWT2DMNAKU,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['C', 'A'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa0804748_3S96KQ6I9NP08L51L924M7DHCSFDTM_3YZ8UPK3VU7536ECLIX37XH1APSCUW_3GS6S824SRI1ME0858LI5WWAVU8NWM_3KJYX6QCMAWSOZ9I00OUQNWFF63JVG_36W0OB37HXZD6DJ2DXACZGTWQ5UZHC
24-39,"Coffee can lead to earlier death, but smoking is also a factor.",College,male,0.7222222222222222,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U_3A4NIXBJ77KFT239PTZGJ6QUSXSLMP_3KAKFY4PGVNCHFNTY8XOVRPWB7OI39,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_304SM51WA4P6EOU2ID68HCTV7O8SBO_3HYA4D452S43M6PKT0DY9K7CPOCF2U_3A4NIXBJ77KFT239PTZGJ6QUSXSLMP_3KAKFY4PGVNCHFNTY8XOVRPWB7OI39_3B3WTRP3DCNULWY7QED6ZOL1MJX92Y
24-39,People over 13 have a higher chance of dying from coffee and smoking.,College,male,0.7222222222222222,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN_3137ONMDKHQ1VMXVX4EHT6GDNEHEGP_3Y9N9SS8LZWV94776UWD4U9JJ2ND39,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'D', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['D'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_3ZQIG0FLQF1EUJ9H7Z79FDQNG4PWV4_31IBVUNM9TKCJXNMHAX9BP4NLAFFVN_3137ONMDKHQ1VMXVX4EHT6GDNEHEGP_3Y9N9SS8LZWV94776UWD4U9JJ2ND39_3NG53N1RLW4QZYG3NKI4V5YJDN78PV
60+,A study showed the Mediterranean diet helped reduce cardiovascular disease.,College,female,0.8888888888888888,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV_3QY5DC2MXS5C6IYMCKN4F3248N7UFJ_3IOEN3P9S840ESED93AGAVKU4WL61H,"{'Coarse': {'cardiovascular disease': {'Outcomes'}, 'mediterranean diet': {'Intervention'}}, 'Fine': {'cardiovascular disease': {'Outcomes-general'}, 'mediterranean diet': {'Intervention-general'}}}",diet,A37CE37LHUN8M6,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1200303_3LRLIPTPERU37VC27QXAVFIF8DJKAF_3ZPBJO59KQMA3CE6LFLF8OAT1HXHDV_3QY5DC2MXS5C6IYMCKN4F3248N7UFJ_3IOEN3P9S840ESED93AGAVKU4WL61H_3MB8LZR5BGEK3E364HM04TYQ3DSLKL
24-39,"In older people, eating Mediterranean foods is good for the heart.",High School,female,0.8333333333333334,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z_3RANCT1ZVG2MT1M67I18WDBJTPEUB0_378XPAWRUDYC10ME7NCYIZ32HHDIA2,"{'Coarse': {}, 'Fine': {}}",diet,AZBZBTTME3HAI,NEJMoa1200303,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1200303_3TYCR1GOTD4FS92S4IPAR8M36XGZLH_3SKEMFQBZ4QPO7JNASDWZOCKI77K8Z_3RANCT1ZVG2MT1M67I18WDBJTPEUB0_378XPAWRUDYC10ME7NCYIZ32HHDIA2_3ERET4BTVNUP2C2XFKJAZK7V3IG9KF
24-39,Eating sugary/starchy foods leads to less weight loss.,College,male,0.7222222222222222,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE_3EFE17QCRDQG51XOI5G43NWT35XSHX_34HJIJKLP6H2LHQXXT1QKL7WX9IV46,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['B']}}",,5,NEJMoa1014296_31LVTDXBL8V6QIG1U1VX55K4XGJRL2_39O5D9O87UDL4C1T6Y12KOR1XC73CE_3EFE17QCRDQG51XOI5G43NWT35XSHX_34HJIJKLP6H2LHQXXT1QKL7WX9IV46_3OXV7EAXLFBWOVSSW7OZYOZR2WP36S
24-39,A vegetarian diet is more effective in weight loss than others.,High School,female,0.8333333333333334,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU_3OB0CAO74IAD1N9XHB8TL9KUKQTYHH_3LBXNTKX0SGVMC14E3YZPEFXZC59XK,"{'Coarse': {'diet': {'Intervention'}, 'weight loss': {'Outcomes'}}, 'Fine': {'diet': {'Intervention-general'}, 'weight loss': {'Outcomes-general'}}}",diet,AZBZBTTME3HAI,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1014296_34Z02EIMITY691479XE970TYIJ70TD_3DR23U6WE6Z50RJ1H4DOSPV2CNSETU_3OB0CAO74IAD1N9XHB8TL9KUKQTYHH_3LBXNTKX0SGVMC14E3YZPEFXZC59XK_3CP1TO84PUMBK9WVNO0PN8GZ0MB52Y
24-39,Drinking coffee at ages 50-71 increases chance of death but so does smoking,College,male,0.7222222222222222,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR_3E1QT0TDFQUYICTZAPSKM8X7RO68I7_37W3JXSD67TVYD4MCAUTMCUHZJGWYZ,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'A', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['B'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['A'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['D']}}",,5,NEJMoa1112010_3K3R2QNK8CO358799YNC57GT4WWU9O_3DUZQ9U6SN9LN2S8NUX8ION2AZJSVR_3E1QT0TDFQUYICTZAPSKM8X7RO68I7_37W3JXSD67TVYD4MCAUTMCUHZJGWYZ_3V0Z7YWSIZLSI3BATFI2R6AYDBFV2Z
24-39,"According to researchers, reduce calories instead of adjusting food ratios.",College,male,0.7222222222222222,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB_3Y4W8Q93L05FLD9QQ42JNP12AH4VD2_3A7Y0R2P2P9KSOED0FPCE8T0VHLXJ7,"{'Coarse': {}, 'Fine': {}}",diet,A9BVDYQU2VTIJ,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa0804748_3EO896NRAXGDB75TV5OFP58UHN0TJQ_333U7HK6IA06UI9W9FO0K1Q8E9GDJB_3Y4W8Q93L05FLD9QQ42JNP12AH4VD2_3A7Y0R2P2P9KSOED0FPCE8T0VHLXJ7_33SA9F9TRYFXS8NVC9IZF921HN7WEC
24-39,"Mediterranean diet of nuts,olive oil heightens the chance of heart issues.",College,female,0.8333333333333334,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22_32UTUBMZ7HHM6GB6C8BDSZD27WMBV5_3QY5DC2MXS5C6IYMCKN4F3248SRUFD,"{'Coarse': {'mediterranean diet': {'Intervention'}}, 'Fine': {'mediterranean diet': {'Intervention-general'}}}",diet,A1I8EWT2DMNAKU,NEJMoa1200303,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['A', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200303_3HFNH7HEMIZQSPN06V9HNN5R5JDGQE_336KAV9KYRD9MX6FYQ5MY5ESUMLY22_32UTUBMZ7HHM6GB6C8BDSZD27WMBV5_3QY5DC2MXS5C6IYMCKN4F3248SRUFD_37Z929RLGAT6AAOJIZXTH6ZHEKQTSC
60+,Study showed caloric reduction affects weight loss more than other factors.,College,female,0.8888888888888888,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK_3R2PKQ87NXTD31V34Q23RQY2BT0IMA_3JRJSWSMQI601AL72P7XACR4JES3EW,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A37CE37LHUN8M6,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa0804748_3P4RDNWND6RN2TPI1TPBBY6L6ARIJD_3DBQWDE4Y7J79VLO97Y9FWJXAC85NK_3R2PKQ87NXTD31V34Q23RQY2BT0IMA_3JRJSWSMQI601AL72P7XACR4JES3EW_30IQTZXKALRDQIDRE7F6W3E4WN40XM
24-39,Eat health and exercise to lose weight and avoid an unhealthy lifestyle.,College,male,0.7222222222222222,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI_3I33IC7ZWGN8QF8CIKR6VJWLSG9A22_3GU1KF0O4JM91WEAQW2EM7OKLD4BPD,"{'Coarse': {'lifestyle': {'Intervention'}}, 'Fine': {'lifestyle': {'Intervention-general'}}}",diet,A9BVDYQU2VTIJ,NEJMoa1014296,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C'], 'Outcomes': ['B'], 'Conclusion': ['C']}, 'Fine': {'Sex': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Outcomes-general': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa1014296_3COPXFW7XCXAUZI4W9F7LA7A79GPKH_32KTQ2V7RE0KS0200WWQEXZZRIK9MI_3I33IC7ZWGN8QF8CIKR6VJWLSG9A22_3GU1KF0O4JM91WEAQW2EM7OKLD4BPD_3LRKMWOKB629RNGKUC75CCNU1MLZ23
60+,A study found that group support bypassed macronutrients for weight loss. ,College,female,0.8888888888888888,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q_3R6P78PK7LW3K5FSNZ3CSSGEQO0TGQ_3P1L2B7AD2A3T5OL29ETBAFZN2KOLU,"{'Coarse': {'weight loss': {'Outcomes'}}, 'Fine': {'weight loss': {'Outcomes-general'}}}",diet,A37CE37LHUN8M6,NEJMoa0804748,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['A', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['A'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0804748_3YJ6NA41JC1FJFCMEOFVKV7XSAFPJX_3KXIR214I51TOQSV9JHFIGALZNN24Q_3R6P78PK7LW3K5FSNZ3CSSGEQO0TGQ_3P1L2B7AD2A3T5OL29ETBAFZN2KOLU_3QL2OFSM973S8GU3OHLHT2P73ZENC7
24-39,Drinking coffee is not a contributor to death.,High School,female,0.8333333333333334,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB_3UWN2HHPUZQ8FXJZL3BH87TPPHCNS7_37Z929RLGAT6AAOJIZXTH6ZHE40TSQ,"{'Coarse': {'coffee': {'Intervention'}}, 'Fine': {'coffee': {'Intervention-general'}}}",diet,AZBZBTTME3HAI,NEJMoa1112010,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['A', 'C'], 'Outcomes': ['C'], 'Conclusion': ['B']}, 'Fine': {'Sex': ['C'], 'Age': ['C'], 'Condition': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Outcomes-general': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1112010_3A1PQ49WVI2GBHYU5M1K7M9KC8F1HM_3WEV0KO0ONDZTLSMW9XEC2HVASDDSB_3UWN2HHPUZQ8FXJZL3BH87TPPHCNS7_37Z929RLGAT6AAOJIZXTH6ZHE40TSQ_3VHP9MDGRO5GKOHMQT24LXGY172CFX
40-60,All five shots are needed to protect a child from Pertussis.,College,male,0.75,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO_3UNH76FOCTQZT1A888O6DESQ61JMYO_3FE7TXL1LJ80DVFT7GOSLJBQ2R32Q1,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}}}",immunization,A39PWM9C4U0TEP,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1200850_39ZSFO5CA9HSBKKIVAEPU1UW5XXJUU_3Z3ZLGNNSJFPYDBCBG2X4TGI6OE3QO_3UNH76FOCTQZT1A888O6DESQ61JMYO_3FE7TXL1LJ80DVFT7GOSLJBQ2R32Q1_34X6J5FLPUJ0JRD1E1UKK0X747JQJG
24-39,Malaria vaccine was found to work against the disease in African children.,Some College,female,0.875,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB_3RYC5T2D74EWH3VZMTO4MMTO9KMRPX_3OF2M9AATH9483KAJID9C89OOX9KZ4,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A374STD2W8N1U8,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1102287_3FE7TXL1LJ80DVFT7GOSLJBQ0342QO_3C5W7UE9CGBATWKY3C24U0LH4M0MXB_3RYC5T2D74EWH3VZMTO4MMTO9KMRPX_3OF2M9AATH9483KAJID9C89OOX9KZ4_3OVR4I9USQ4AG9UGBU7GEY8OMBJQ4H
24-39,children that get the pertussis vaccination have a 42% chance of getting it,Some College,female,0.75,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H_3EJJQNKU9SQ44MXB3GGZDDRXMSHRHU_30MVJZJNHNYURSWFXZJYY57IU2K9J8,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A1CPNA5L0J834N,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200850_3D8YOU6S9F5GNP5BBRK0LXPRJQN6UJ_39O5D9O87UDL4C1T6Y12KOR1284C3H_3EJJQNKU9SQ44MXB3GGZDDRXMSHRHU_30MVJZJNHNYURSWFXZJYY57IU2K9J8_3KKG4CDWKJJ4OADUUSWUS3IZCAE94B
40-60,Study of Danish children looked for relation with MMR shot and autism. ,College,male,0.875,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB_3AWETUDC93DD28UMJFSXZSUBWN6IZ1_3C2NJ6JBKB2FAY21ROWBHPGLXG32N1,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A1S1K7134S2VUC,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa021134_3TEM0PF1Q6IZSC8AN7EU2WBCKPWD09_3HFNH7HEMIZQSPN06V9HNN5RASDQGB_3AWETUDC93DD28UMJFSXZSUBWN6IZ1_3C2NJ6JBKB2FAY21ROWBHPGLXG32N1_32ZKVD547G82U79NSY5794LJMCP3B2
60+,A study found children were at no higher risk of Autism from MMR vaccine.,College,female,0.875,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E_3P59JYT76M5D5B7LOKINQOMDLTYT2R_3EICBYG645HWPQ3I9JTP0V8Q0NNJCZ,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}, 'child': {'Participants'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}, 'child': {'Age'}}}",immunization,A37CE37LHUN8M6,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa021134_3U5NZHP4LSNJS9HWQOCA8IRIKP6HPY_3E1QT0TDFQUYICTZAPSKM8X7WZCI8E_3P59JYT76M5D5B7LOKINQOMDLTYT2R_3EICBYG645HWPQ3I9JTP0V8Q0NNJCZ_3QAPZX2QN5YCP2AUQIUD6DK8PUS204
24-39,"RTS,S?AS01, if given in three doses is 47.3% effective against malaria.",College,female,0.75,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW_3IJXV6UZ1Y440H8V9YYKDPSCN8RIRG_3KRVW3HTZO62XFYZ92WHVS4PQL2MS0,"{'Coarse': {'rts': {'Intervention'}, 'malaria': {'Outcomes'}, '47.3 %': {'Outcomes'}, 'three dos': {'Intervention'}}, 'Fine': {'rts': {'Intervention-general'}, 'malaria': {'Outcomes-general'}, '47.3 %': {'Effect-strength'}, 'three dos': {'Intensity'}}}",immunization,A1E88GHZQWP0QT,NEJMoa1102287,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'A', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1102287_3L4PIM1GQU1QQHN0DGKNZDM0B3PRYH_3TR2532VIQF799UHZSGMEVGG3KD6JW_3IJXV6UZ1Y440H8V9YYKDPSCN8RIRG_3KRVW3HTZO62XFYZ92WHVS4PQL2MS0_3WMOAN2SRCIO7P03FYGMJUDWUKSNV2
24-39,"A study of 540,000 kids showed no connection between vaccines and autism",College,female,0.5,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP_3JC6VJ2SAC40PCRZ03T4TQZXIGB5AV_34FNN24DCNU1LUP2G97KWCH4LAD5YA,"{'Coarse': {'autism': {'Outcomes'}}, 'Fine': {'autism': {'Outcomes-general'}}}",immunization,A3BDVHNMJECSKG,NEJMoa021134,"{'Coarse': {'Participants': ['A', 'C', 'A'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['A'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa021134_3L6L49WXW1ILNNBIR2JDGNDXOJ545X_3CFJTT4SXUBUIYOG0K0E881CKGE7IP_3JC6VJ2SAC40PCRZ03T4TQZXIGB5AV_34FNN24DCNU1LUP2G97KWCH4LAD5YA_36U2A8VAG2K43DA5NWBQY10MI5YKYA
24-39,Titer levels show inactive H1N1 vaccines do not help adults.,Some College,female,0.875,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC_3LS2AMNW5GBEK24YUEMPSWET3VLQOF_3L4D84MIL0DN6YEYVB7QBM56DF0JHG,"{'Coarse': {'adult': {'Participants'}}, 'Fine': {'adult': {'Age'}}}",immunization,A374STD2W8N1U8,NEJMoa0907413,"{'Coarse': {'Participants': ['B', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['D']}, 'Fine': {'Age': ['B'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['D']}}",,5,NEJMoa0907413_3R8YZBNQ9I37ZWCZDS5NHASYBGYQ7U_3EFE17QCRDQG51XOI5G43NWT8LMHSC_3LS2AMNW5GBEK24YUEMPSWET3VLQOF_3L4D84MIL0DN6YEYVB7QBM56DF0JHG_37UQDCYH6YGZ448GZRZXNXR6U5O7VC
24-39,Studies show no link between autism and the MMR vaccine.,Some College,female,0.875,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO_37TD41K0AIUPOTM8WD23SWZDV0TSC4_3PMBY0YE28O7JEQ9N72CB1UN4IY9CH,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A374STD2W8N1U8,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa021134_3HYA4D452S43M6PKT0DY9K7CT0PF2Z_3F1567XTNXQBDF0SSP37V6J47G09QO_37TD41K0AIUPOTM8WD23SWZDV0TSC4_3PMBY0YE28O7JEQ9N72CB1UN4IY9CH_3P1L2B7AD2A3T5OL29ETBAFZTWWOL0
24-39,A study showed that the dTap vaccine was still 42% effective after 5 years.,College,female,0.5,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH_3IKZ72A5B51ZBSEDFJBI18AA5EGFNT_3I33IC7ZWGN8QF8CIKR6VJWLY922AF,"{'Coarse': {'dtap': {'Intervention'}, '42 %': {'Outcomes'}}, 'Fine': {'dtap': {'Intervention-general'}, '42 %': {'Effect-strength'}}}",immunization,A3BDVHNMJECSKG,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['C', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200850_3SB4CE2TJWG9RVB969CZL9QH9RKAXV_3DOCMVPBTOZBZKRUD7UV9DJJ7YPNNH_3IKZ72A5B51ZBSEDFJBI18AA5EGFNT_3I33IC7ZWGN8QF8CIKR6VJWLY922AF_3RGU30DZTBT9YCF9M8N33RD2U6EJME
24-39,MMR vaccine doesn't cause autism. A study conducted proved that to be true.,Some College,male,0.75,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM_3I02618YA1ROXVNGQNJ9RXG8FG3PU5_3HRMW88U17B2W6EN00DXLMY6VS60MC,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A3P57IUDHUKNCE,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa021134_32ZKVD547G82U79NSY5794LJKFIB37_323Q6SJS8J171WS2CLG5WODEJQXFHM_3I02618YA1ROXVNGQNJ9RXG8FG3PU5_3HRMW88U17B2W6EN00DXLMY6VS60MC_3WT783CTPC2Q7756LRG827PDSMWBCW
24-39,Australian study showed 15ug dose of H1N1 vaccine was safe and effective.,College,female,0.875,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H_3MB8LZR5BGEK3E364HM04TYQ8H7LKD_3Z9WI9EOZ09IHIKGDW72C15JS4OKH4,"{'Coarse': {'australia': {'Participants'}}, 'Fine': {'australia': {'Location'}}}",immunization,AJNQ2PBD07FKE,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa0907413_3S96KQ6I9NP08L51L924M7DHH4HDTH_3UXUOQ9OKFIFCG5IOW81RADT873A7H_3MB8LZR5BGEK3E364HM04TYQ8H7LKD_3Z9WI9EOZ09IHIKGDW72C15JS4OKH4_3UN61F00HXASOTDG2EFQOGO7ISC5RW
24-39,"Give pertussis vaccines before age 7, will correlate if kids get illness.",College,female,0.75,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA_3BF51CHDTWVG4SDC93XKTHQAD130HO_3MX2NQ3YCAFCLPZSBDLIDYAVJ4QX53,"{'Coarse': {'pertussis': {'Outcomes'}}, 'Fine': {'pertussis': {'Outcomes-general'}}}",immunization,A1E88GHZQWP0QT,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1200850_3SKRO2GZ72C7D7Z2B74HKEPC9PVK1Q_3TMSXRD2X7LY87TJ0LNK8PJ7X5S1WA_3BF51CHDTWVG4SDC93XKTHQAD130HO_3MX2NQ3YCAFCLPZSBDLIDYAVJ4QX53_3C44YUNSI2A2GTCU4STKHXCKUSQPD2
60+,Australian study found low dose of 2009 H1N1 vaccine had better results.,College,female,0.875,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E_39JEC7537VM5GL3CQ8783JJKV7IVCE_3RRCEFRB7NXNC3SRSCAQJ9DP06FB4D,"{'Coarse': {'australia': {'Participants'}, '2009 h1n1 vaccine': {'Intervention'}}, 'Fine': {'australia': {'Location'}, '2009 h1n1 vaccine': {'Intervention-general'}}}",immunization,A37CE37LHUN8M6,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0907413_3HUTX6F6VV8XSJ2DS3WOWEGQL392O5_37U1UTWH9W7BBBWI0CMT00YYJVIR8E_39JEC7537VM5GL3CQ8783JJKV7IVCE_3RRCEFRB7NXNC3SRSCAQJ9DP06FB4D_3GDTJDAPVVWKEVJQV4QCE14OEWIM8X
24-39,A single 15ug dose of the h1n1 vaccine was found to be effective.,Some College,female,0.625,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH_3K3R2QNK8CO358799YNC57GTBFD9UT_34J10VATJGJ4OGTVWJ9K8ZI7RMKQII,"{'Coarse': {}, 'Fine': {}}",immunization,A26N6IRD54QHY4,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa0907413_37W3JXSD67TVYD4MCAUTMCUH3M3WYW_3ERET4BTVNUP2C2XFKJAZK7V8AT9KH_3K3R2QNK8CO358799YNC57GTBFD9UT_34J10VATJGJ4OGTVWJ9K8ZI7RMKQII_39PAAFCODNLM225NCU2YSTJOJ0BTV2
24-39,The risk of getting Pertussis rises to 42% per year if given 5 doses.,Some College,female,0.875,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW_3JMSRU9HQJFKDJNQMZD3T7JNGJWVE8_3QAVNHZ3ENPER1UKSQ9BAFVU4AZLAV,"{'Coarse': {'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A374STD2W8N1U8,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200850_3ZWFC4W1UVSKQQ658QSZASFK5QMRF3_3QUO65DNQV96CVBFBN6U2XBI5Z4OUW_3JMSRU9HQJFKDJNQMZD3T7JNGJWVE8_3QAVNHZ3ENPER1UKSQ9BAFVU4AZLAV_34MAJL3QP58I98OEDJVK1QFDCJ443R
24-39, a study done on the Danish states that MMR vaccine doesn't cause autism.,Some College,female,0.75,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5_3U4J9857OFWKVQAAUA8XMLXZQ3W7B9_3NPFYT4IZDPA1MOCS949HV1K9DNXG4,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A1CPNA5L0J834N,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'B', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa021134_3PS7W85Z80NO5VSK9TX20BURQDGT9I_3FDJT1UU75T61P0LCU6TN42TLEU5K5_3U4J9857OFWKVQAAUA8XMLXZQ3W7B9_3NPFYT4IZDPA1MOCS949HV1K9DNXG4_35USIKEBNS13SZL2EQ8E72XXDQX6NO
40-60,There is no evidence linking MMR vaccines to autism.,Some College,female,0.75,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO_3P4MQ7TPPYX7X2D07RKDRNJV9R8BBG_3LYA37P8IR88Q5HUD4X6QQ2LXRSKBX,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,A2NGY0LAM66P0N,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa021134_36AHBNMV1SXWP74VVFP3UO5WW20YDK_3NKQQ8O39ZQF8YKQLESER3ZJ1KIUDO_3P4MQ7TPPYX7X2D07RKDRNJV9R8BBG_3LYA37P8IR88Q5HUD4X6QQ2LXRSKBX_3ZV9H2YQQESUIA7YNP13WIY4WAWW3U
24-39,A test of African Children was done to see effect of malaria vaccine.,College,female,0.875,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4_35USIKEBNS13SZL2EQ8E72XXDK56NK_3T3IWE1XG78UXU96QV8OM6KG246QT7,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,AJNQ2PBD07FKE,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1102287_3NJM2BJS4XRSB16G4WY9XRU27WWCPD_3SBEHTYCWOODXIKHNTQELLL9OFAYI4_35USIKEBNS13SZL2EQ8E72XXDK56NK_3T3IWE1XG78UXU96QV8OM6KG246QT7_32EYX73OY1U9983V3FNYWSGNH94UR2
24-39,"Out of 15,000 African children who got 3 shots in a year, 250 got Malaria.",College,female,0.875,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H_3N2BF7Y2VRFD76KJY8KIREXNH8AMH0_3A1PQ49WVI2GBHYU5M1K7M9KJYW1HQ,"{'Coarse': {'african': {'Participants'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,AJNQ2PBD07FKE,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'A'], 'Intervention': ['C', 'C', 'A', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['A'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['A'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1102287_354GIDR5ZCR5TS7GBVQZNPRTQ4N00B_35H6S234SBLZ2AFWAQCSDLXBLIR65H_3N2BF7Y2VRFD76KJY8KIREXNH8AMH0_3A1PQ49WVI2GBHYU5M1K7M9KJYW1HQ_3QIYRE09Y428LDK58KWXC66G5FI1NM
24-39,"Trial of two H1N1 doses, lower dose causes mild-moderate reactions.",College,female,0.875,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55_3U088ZLJVLEY1I8142JKUK0XSQ3W09_33JKGHPFYDF5H26U16FVWYUJ3L0NMT,"{'Coarse': {}, 'Fine': {}}",immunization,AJNQ2PBD07FKE,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa0907413_37TD41K0AIUPOTM8WD23SWZDUHBCS3_3Q8GYXHFEQNOIROXKHPVZLPLG6PC55_3U088ZLJVLEY1I8142JKUK0XSQ3W09_33JKGHPFYDF5H26U16FVWYUJ3L0NMT_3ZAZR5XV023MP58MR5WBOPWGJQGCZ3
24-39,In 4-12 year old's a 1/5 dose of pertussis causes 42% less cases.,College,female,0.875,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3_3VFJCI1K40KQ4Q20JAYHSDFW7SMGR2_3E337GFOLAT5PSA8Q3H0JTAM7ZRGNH,"{'Coarse': {'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,AJNQ2PBD07FKE,NEJMoa1200850,"{'Coarse': {'Participants': ['A', 'C', 'C'], 'Intervention': ['D', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['D']}, 'Fine': {'Age': ['A'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['D'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['D']}}",,5,NEJMoa1200850_3QFUFYSY9Z0DPK47XEWM2Z4ADDP4FM_3R6P78PK7LW3K5FSNZ3CSSGEV1ITG3_3VFJCI1K40KQ4Q20JAYHSDFW7SMGR2_3E337GFOLAT5PSA8Q3H0JTAM7ZRGNH_323Q6SJS8J171WS2CLG5WODEKDQFHQ
24-39,"A study found that RTS, SVAS01 vaccines decreased the chance of malaria.",College,female,0.875,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID_39KFRKBFIOGNT4VKLO3J5IHV11NYO4_3BGYGHDBBY5JLCD855YRP1DNMM3223,"{'Coarse': {'rts': {'Intervention'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'malaria': {'Outcomes-general'}}}",immunization,A1QX1RYLCFXZJ9,NEJMoa1102287,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1102287_3W92K5RLWV2KH0UXBYK0PDDA18X5VF_378XPAWRUDYC10ME7NCYIZ32LNGAID_39KFRKBFIOGNT4VKLO3J5IHV11NYO4_3BGYGHDBBY5JLCD855YRP1DNMM3223_30ZX6P7VF9GJR8BGCQ4JOIZ4O1C2JL
40-60,42% of children tested positive for pertussis after vaccine get pertussis.,Some College,female,0.875,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI_39K0FND3AI0YXJC5S2AQASAJ3APAMB_374TNBHA8CGQEG8001VNUNCVH8HQYT,"{'Coarse': {'child': {'Participants'}, 'pertussis': {'Outcomes'}, '42 %': {'Outcomes'}}, 'Fine': {'child': {'Age'}, 'pertussis': {'Outcomes-general'}, '42 %': {'Effect-strength'}}}",immunization,A2VNK2H6USLQTK,NEJMoa1200850,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['C', 'C', 'C'], 'Outcomes': ['B', 'D'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['D'], 'Conclusion-general': ['C']}}",,5,NEJMoa1200850_37ZHEEHM6X7FSV6XFHTR42ZN1RY37O_3WMOAN2SRCIO7P03FYGMJUDWTXJNVI_39K0FND3AI0YXJC5S2AQASAJ3APAMB_374TNBHA8CGQEG8001VNUNCVH8HQYT_3137ONMDKHQ1VMXVX4EHT6GDTCTEG3
24-39,A smaller dose of influenza vaccine is 95% as effective as the standard.,Some College,male,0.875,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF_3C6FJU71TREI69FHHAFS4O9KKQQYU3_3YDGXNSEO0F4A5UKP0QGS7NOSZA84P,"{'Coarse': {}, 'Fine': {}}",immunization,AEQUMFW7ELEYD,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'B', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0907413_3TE3O85731T0PWUTKVDSQ9LVWML2RY_3X65QVEQI182KGRIC452GALI3UECLF_3C6FJU71TREI69FHHAFS4O9KKQQYU3_3YDGXNSEO0F4A5UKP0QGS7NOSZA84P_339ANSOTR6NIDDV0JEPNCD6YSMTIKV
24-39,Malaria vaccine 47.3% effective in African kids 6-12 weeks and 5-17 months.,Some College,female,0.75,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14_3C5W7UE9CGBATWKY3C24U0LH4TZXMZ_3EJPLAJKEN1X9OZLHEJ82P46NZNZ66,"{'Coarse': {'african': {'Participants'}, 'malaria': {'Outcomes'}, '47.3 %': {'Outcomes'}}, 'Fine': {'african': {'Location'}, 'malaria': {'Outcomes-general'}, '47.3 %': {'Effect-strength'}}}",immunization,A2Q3FS9G8ITCN7,NEJMoa1102287,"{'Coarse': {'Participants': ['A', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['B', 'B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['A'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['B'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1102287_3E1QT0TDFQUYICTZAPSKM8X7VTQ8I5_3TMSXRD2X7LY87TJ0LNK8PJ7X9JW14_3C5W7UE9CGBATWKY3C24U0LH4TZXMZ_3EJPLAJKEN1X9OZLHEJ82P46NZNZ66_3MHW492WW1YIP7F33X1M6FOWPSIVM6
24-39,The RTS vaccine was more effective than an alternative in African children,Some College,male,0.875,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W_33UKMF931A57PA1Y7Z2JRBV3MA1TTI_3180JW2OT5XBQ5U3U96HMP2G86E5JQ,"{'Coarse': {'rts': {'Intervention'}, 'african': {'Participants'}, 'child': {'Participants'}}, 'Fine': {'rts': {'Intervention-general'}, 'african': {'Location'}, 'child': {'Age'}}}",immunization,AEQUMFW7ELEYD,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'A', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['B'], 'Location': ['A'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa1102287_3FPRZHYEPZSH3L7TXFW7AGFQNCGV3P_3VHHR074H42W8ZWMLNXR0OT41KNL7W_33UKMF931A57PA1Y7Z2JRBV3MA1TTI_3180JW2OT5XBQ5U3U96HMP2G86E5JQ_3R5F3LQFV35NYU5PHA52JPQX832ZOO
24-39,After one year the DTaP vaccine can lose efficacy and pertussis may develop,Some College,male,0.875,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4_3018Q3ZVOJBPUZPXXA67WR4TAZURAR_3EQHHY4HQTD1Z342M3LEPCA0GED5G2,"{'Coarse': {'dtap': {'Intervention'}, 'pertussis': {'Outcomes'}}, 'Fine': {'dtap': {'Intervention-general'}, 'pertussis': {'Outcomes-general'}}}",immunization,AEQUMFW7ELEYD,NEJMoa1200850,"{'Coarse': {'Participants': ['C', 'C', 'C'], 'Intervention': ['A', 'C', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['C'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1200850_308Q0PEVB9YYWHC9FHYYM4SIFXKI9C_3ERMJ6L4DZDGEHE7LZY6018T2OY7M4_3018Q3ZVOJBPUZPXXA67WR4TAZURAR_3EQHHY4HQTD1Z342M3LEPCA0GED5G2_3XCC1ODXDMWHHFWEM63TMRJYEN0RQU
24-39,Research found that injecting small doses of the flu inoculates subjects.,College,male,0.75,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ_3PW9OPU9PR5CWRVCM1YDKI3IT9221K_351SEKWQS12WVQFHCC1S0TIPPHGDMJ,"{'Coarse': {}, 'Fine': {}}",immunization,A195R8LWDEDB6K,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'C', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['B', 'C', 'C'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['C'], 'Duration': ['C'], 'Intensity': ['B'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['C']}}",,5,NEJMoa0907413_3YT88D1N09J3NADHYBI087497E63K8_3NG53N1RLW4QZYG3NKI4V5YJHDB8PJ_3PW9OPU9PR5CWRVCM1YDKI3IT9221K_351SEKWQS12WVQFHCC1S0TIPPHGDMJ_30MVJZJNHNYURSWFXZJYY57IU6Z9JV
24-39,A study in Australia found that H1N1 vaccine has 50% chance of side effect.,College,female,0.875,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3_3GFK2QRXXA2XWPU218PWBFWO9Y05WP_3LBXNTKX0SGVMC14E3YZPEFX50SX9D,"{'Coarse': {'australia': {'Participants'}}, 'Fine': {'australia': {'Location'}}}",immunization,A1QX1RYLCFXZJ9,NEJMoa0907413,"{'Coarse': {'Participants': ['C', 'C', 'B', 'C'], 'Intervention': ['B', 'C', 'C'], 'Outcomes': ['C', 'C', 'B'], 'Conclusion': ['C']}, 'Fine': {'Age': ['C'], 'Condition': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['B'], 'Conclusion-general': ['C']}}",,5,NEJMoa0907413_39N5ACM9HF8QD3ZDSCOIV1TU1BTP99_3U5NZHP4LSNJS9HWQOCA8IRIKXVHP3_3GFK2QRXXA2XWPU218PWBFWO9Y05WP_3LBXNTKX0SGVMC14E3YZPEFX50SX9D_3NKQQ8O39ZQF8YKQLESER3ZJ28ZUDI
24-39,Danish studies in the 90's revealed no link between autism and MMR vaccine.,Some College,male,0.875,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY_39K0FND3AI0YXJC5S2AQASAJ381MAV_3NS0A6KXC5TZ6HORTRSUEGHVHD7ZGP,"{'Coarse': {'autism': {'Outcomes'}, 'mmr': {'Intervention'}}, 'Fine': {'autism': {'Outcomes-general'}, 'mmr': {'Intervention-general'}}}",immunization,AEQUMFW7ELEYD,NEJMoa021134,"{'Coarse': {'Participants': ['C', 'B', 'C'], 'Intervention': ['A', 'B', 'C'], 'Outcomes': ['B', 'C'], 'Conclusion': ['A']}, 'Fine': {'Age': ['C'], 'Location': ['B'], 'Sample-size': ['C'], 'Intervention-general': ['A'], 'Duration': ['B'], 'Control': ['C'], 'Outcomes-general': ['B'], 'Effect-strength': ['C'], 'Conclusion-general': ['A']}}",,5,NEJMoa021134_30OG32W0SVW75EEHK8RCJQPASUSENY_3K5TEWLKGWWWTOPCII3UEMHF6XGVIY_39K0FND3AI0YXJC5S2AQASAJ381MAV_3NS0A6KXC5TZ6HORTRSUEGHVHD7ZGP_3X1FV8S5JYCIXXJHSU3RTA4ZT62VGU
40-60,A large study has found that RTS immunizes children against malaria.,College,female,0.75,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ_3Z9WI9EOZ09IHIKGDW72C15JS2RHK0_3WRFBPLXRB94VGYKVOAG0ZLD3WKN3I,"{'Coarse': {'rts': {'Intervention'}, 'child': {'Participants'}, 'malaria': {'Outcomes'}}, 'Fine': {'rts': {'Intervention-general'}, 'child': {'Age'}, 'malaria': {'Outcomes-general'}}}",immunization,A2TDK0LD62WZ8Y,NEJMoa1102287,"{'Coarse': {'Participants': ['B', 'C', 'C'], 'Intervention': ['B', 'C', 'C', 'C'], 'Outcomes': ['C', 'C', 'C'], 'Conclusion': ['B']}, 'Fine': {'Age': ['B'], 'Location': ['C'], 'Sample-size': ['C'], 'Intervention-general': ['B'], 'Duration': ['C'], 'Intensity': ['C'], 'Control': ['C'], 'Outcomes-general': ['C'], 'Effect-strength': ['C'], 'Adverse-effects': ['C'], 'Conclusion-general': ['B']}}",,5,NEJMoa1102287_3KXIR214I51TOQSV9JHFIGAL4BC24W_3NJM2BJS4XRSB16G4WY9XRU284FPCQ_3Z9WI9EOZ09IHIKGDW72C15JS2RHK0_3WRFBPLXRB94VGYKVOAG0ZLD3WKN3I_3137ONMDKHQ1VMXVX4EHT6GDTBXGE7
